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In atherosclerosis cholesterol accumulation in arterial walls forms plaques which lead 
to associated cardiovascular diseases. High-density lipoprotein (HDL) nanoparticles 
known as “good cholesterol” transport cholesterol from arterial plaques to the liver for 
excretion. Therefore, HDL and its components have been targeted for tackling 
atherosclerosis treatment. Significantly, carriers of the R173C or L144R mutation in the 
major HDL protein apolipoprotein A-I (apoA-I) have low levels of HDL with a low 
atherosclerosis incidence. This suggests the mutations are atheroprotective as wild-type 
(WT) apoA-I carriers have a higher risk of atherosclerosis with low HDL levels. 
However, the mechanism for the mutants atheroprotective function is unknown.  
This work compares the molecular structure of reconstituted HDL (rHDL) nanoparticles 
containing the apoA-I variants using biophysical techniques. To determine if the rHDL 
structure affects the nanoparticle function and aid atherosclerosis treatment 
development. 
The expression and purification of unlabelled and uniformly [13C/15N]-labelled 
recombinant apoA-I variants was established. rHDL nanoparticles were prepared 
containing POPC, ±cholesterol, and apoA-I using detergent-mediated dialysis and 
density-based ultracentrifugation. The rHDL nanoparticle size and morphology were 
iii 
   
analysed with techniques such as NativePAGE gradient gel electrophoresis and 
transmission electron microscopy (TEM). 
A novel morphology characterisation was developed using 31P solid-state NMR 
spectroscopy of oriented rHDL nanoparticles on glass substrates. Three distinct rHDL 
nanoparticle morphologies were identified that were inaccessible by TEM. The rHDL-
L144R nanoparticles showed a different surface curvature when compared to the rHDL-
WT and R173C nanoparticles. Subtle differences in the protein secondary structure 
were identified by circular dichroism and high-resolution 2D 13C-13C NMR spectra of 
PEG-precipitated rHDL-WT and L144R nanoparticles. Consequently, the different 
rHDL nanoparticle morphologies detected could be connected to the atheroprotective 
functional properties of the rHDL-L144R nanoparticles. The morphology 
characterisation technique was applied to a plasma HDL sample which provides a 
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1 Introduction 
Atherosclerosis and associated cardiovascular disease are one of the major causes of 
death in the UK (British Heart Foundation (BHF) statistics factsheet August 2019). A 
low level of high-density lipoprotein cholesterol (HDL-C) is associated with an 
increased risk of atherosclerosis (Lewis and Rader, 2005). Apolipoprotein A-I (apoA-
I) is the major protein component at 70 % of the total protein content in HDL 
(Brouillette et al., 2001; Vance and Vance, 2002). HDL nanoparticles transport 
cholesterol from the tissues to the liver for excretion in the reverse cholesterol transport 
(RCT) system (Fisher et al., 2012).  
ApoA-I Milano (apoA-I R173C) (Weisgraber et al., 1980) and apoA-I Zaragoza (apoA-
I L144R) (Recalde et al., 2001) are considered to be atheroprotective mutations of 
apoA-I, i.e. the mutations are hypothesised to confer protective functional capabilities 
to protect against the accumulation of cholesterol in the arterial wall. This is exhibited 
in the phenotype of the respective mutants carriers that have low levels of HDL-C and 
importantly a low incidence of atherosclerosis (Franceschini et al., 1980; Recalde et al., 
2001).  
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Therefore, the two mutations are of interest to investigate the underlying structure-
function relationship of the atheroprotective mutants compared to wild-type apoA-I 
(apoA-I WT). Carriers of the atheroprotective mutations show the opposite effect to 
HDL containing apoA-I WT as carriers have naturally low levels of HDL-C without the 
associated increased risk of atherosclerosis. This suggests the mutations affect the 
development of atherosclerosis or transport of cholesterol in the RCT system.  
This research aims to establish methodologies for the routine production of the 
atheroprotective apoA-I proteins and reconstituted HDL (rHDL) nanoparticles to enable 
the first detailed comparison of the structural and functional properties of rHDL 
nanoparticles containing apoA-I WT, R173C or L144R. In particular, the molecular 
structure and organisation of the lipids, cholesterol and apoA-I protein in HDL 
combined with functional analysis of the rHDL nanoparticles.  
1.1 Atherosclerosis 
Atherosclerosis is a systemic inflammatory disease of the arterial wall, in which there 
is a build-up of lipids and fibrous components (Lusis, 2000). In atherogenesis plaques 
develop called atheromas in the endothelial cells, the inner lining, of the arteries (Libby 
et al., 2011). The process of atherogenesis is simplified in Figure 1.1. 
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Figure 1.1. The simplified process of atherogenesis in an artery. Adapted from Lusis et 
al. (Lusis, 2000). 
At branch points and major curved regions of arteries blood flow disturbances can occur 
leading to vulnerable regions where atherosclerotic lesions can form (Gimbrone, 1999). 
The subendothelial matrix composition of the arterial wall is altered and the endothelial 
permeability of the arterial wall in the vulnerable regions increases. This allows the 
accumulation of apolipoprotein B (apoB)-containing low-density lipoproteins (LDLs) 
in the subendothelial matrix of the intima layer to occur (Gimbrone, 1999; Lusis, 2000; 
Tabas et al., 2007). The apoB-containing LDLs interact with matrix proteoglycans on 
the subendothelial cell surface (Tabas et al., 2007). LDLs trapped in the subendothelial 
intima layer become oxidised through several mechanisms in vivo such as oxidative 
vascular cell waste and enzymes like myeloperoxidase and lipoxygenase (Lusis, 2000; 
Yoshida and Kisugi, 2010). The build-up of oxidised LDLs initiates the recruitment of 
leukocytes known as white blood cells (monocytes, lymphocytes), via the production 
of pro-inflammatory molecules by the endothelial cells (Lusis, 2000). The monocytes 
migrate from the endothelial cells to the subendothelial space in the intima and 
differentiate to form both macrophages and dendritic-like cells (Galkina and Ley, 2009; 
Libby et al., 2011; Tabas et al., 2007). The differentiated cells ingest highly oxidised 
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LDLs by phagocytosis forming lipid/cholesterol-laden macrophages called foam cells 
(Libby et al., 2011; Lusis, 2000; Tabas et al., 2007).  
As the early lesion progresses the foam cells die, for example by apoptosis, and the dead 
cells are efficiently cleared until the lesion becomes advanced (Tabas, 2010). The 
removal of apoptic cells by efferocytes, a class of phagocytic cells, is known as 
efferocytosis (Tabas, 2010). In advanced lesions insufficient efferocytosis furthers the 
build-up of extracellular lipids and cell debris causing secondary necrosis (Tabas, 2005; 
Tabas, 2010). This accumulation produces the lipid-rich necrotic core, a hallmark of 
advanced atherosclerotic plaques (Lusis, 2000). The necrotic core also contains 
cholesterol crystals, cholesterol ester, proteases, thrombotic material, and extracellular 
debris (Lusis, 2000; Tabas et al., 2007).  
The accumulation of cholesterol is highly pathogenic as there is no direct treatment for 
removing the cholesterol accumulated in arterial wall plaques, only prevention of 
further accumulation with drugs such as statins which act to reduce the levels of LDL 
cholesterol (Ward et al., 2019). Further accumulation of cholesterol in the arterial 
plaques leads to the following pathogenic complications and cardiovascular disease.  
Smooth muscle cells (SMCs) transfer from the media into the intima layer of the arterial 
wall (Lusis, 2000). The SMCs produce extracellular matrix fibrous components such as 
collagen and elastin, that contribute to the formation of fibrous plaques, facilitated by 
macrophages and T-cells (Libby et al., 2011; Lusis, 2000; Tabas et al., 2007). A fibrous 
cap forms surrounding the necrotic core and contains SMCs and extracellular matrix 
components in the intima layer of the artery (Libby et al., 2011; Lusis, 2000; Tabas et 
al., 2007).  
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Small vessels in the lesion can haemorrhage as the plaque progresses, and calcification 
of the plaque and ulceration can occur at the surface of the lumen (Lusis, 2000). 
Advanced atherosclerotic plaques can rupture or erode, and the fibrous cap can become 
thinner (Tabas et al., 2007). Therefore, the ruptured plaques usually contain less SMCs 
and are macrophage-rich, whilst the fibrous cap is thin and contains less collagen (Libby 
et al., 2011). Plaque growth causes flow-limiting stenosis, the narrowing of the artery 
restricting blood flow resulting in tissue ischaemia (Libby et al., 2011).  
Acute thrombotic vascular complications can occur from thrombosis when thrombi 
(blood clots) block blood vessels causing myocardial infarction and stroke (Libby et al., 
2011; Lusis, 2000; Tabas et al., 2007). Thrombi are formed when a fibrous lesion 
ruptures and/or the thin fibrous cap fractures, which releases necrotic core and 
macrophage pro-coagulant components that interact with blood coagulant proteins in 
the arterial lumen (Libby et al., 2011; Lusis, 2000). Further complications such as 
dysfunctional arterial wall repair and the development of aneurysms are caused by 
elevated tension in the plaque affected arterial wall, known as hypertension (Libby et 
al., 2011). 
1.2 Apolipoproteins and HDL 
Apolipoproteins are serum proteins embedded in the lipid surface of lipoprotein 
particles, including LDL and HDL (von Eckardstein et al., 2001). HDL particles are 
heterogeneous as the particles can have different compositions, size, charge, and density 
(Rosenson et al., 2011). The HDL particles in addition to apoA-I (~70 %) contain other 
proteins such as apolipoprotein A-II (apoA-II) (~20 – 25 %), whilst the bulk body of 
the particle consists of phospholipids, as well as cholesterol, cholesteryl ester (CE), and 
triglycerides (Brouillette et al., 2001; Lewis and Rader, 2005). The chemical structures 
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of the bulk body components are in Figure 1.2. The CE, triglyceride, and phospholipid 
structures each contain long hydrophobic hydrocarbon tails and the cholesterol 
molecule is predominantly hydrophobic. The phospholipid molecule is amphipathic due 
to the hydrophilic glycerol-phosphocholine headgroup. The structural arrangement of 
these HDL constituents and apoA-I is described in section 1.6.2.  
 
Figure 1.2. The chemical structures of a phospholipid (14:0 PC, 1,2-dimyristoyl-sn-
glycero-3-phosphocholine, DMPC), 17:0 cholesteryl ester (cholest-5-en-3β-yl 
heptadecanoate), cholesterol, and a triglyceride (1,2,3-trihexadecanoyl-glycerol). 
Obtained from Avanti® polar lipids and (Sud et al., 2007). 
Accumulation and transport of cholesterol, triglycerides, and phospholipids in the blood 
stream is mediated by the protein-lipid complexes (von Eckardstein et al., 2001). Raised 
levels of HDL-C, also known as ‘good cholesterol’, has an atheroprotective effect 
protecting from the development of atherosclerotic coronary heart disease (Fisher et al., 
2012). As there is an inverse correlation between HDL-C and cardiovascular disease 
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(CVD), i.e., low levels of HDL-C correlate with higher incidences of atherosclerosis 
and CVD, and vice-versa (Fisher et al., 2012).  
Reverse cholesterol transport is the main role of HDL which involves the transport of 
cholesterol from tissues to the liver for excretion mediated via HDL particles (Fisher et 
al., 2012; von Eckardstein et al., 2001). The apoA-I bearing HDL particles are 
considered to be atheroprotective as the particles can stimulate cholesterol efflux from 
cells in atherosclerotic lesions for cholesterol transport and excretion (Fisher et al., 
2012; von Eckardstein et al., 2001). This transport of cholesterol by HDL particles is 
considered to be atheroprotective as this prevents the build-up of excess pathogenic 
cholesterol in the arterial wall which accumulates in arterial plaques (Fisher et al., 2012; 
Lusis, 2000; von Eckardstein et al., 2001). Additionally, HDL particles can inhibit LDL 
oxidation and inflammatory events in atherogenesis (Fisher et al., 2012).  
1.3 HDL synthesis and reverse cholesterol transport 
Reverse cholesterol transport is the major process in which HDL containing apoA-I 
transports cholesterol from peripheral tissues or foam cells in atherosclerotic plaques, 
to the liver for recycling in lipoproteins, transport to steroidogenic tissues, catabolism, 
and biliary excretion (Fielding and Fielding, 1995; Fisher et al., 2012). The processes 
of HDL synthesis and RCT are summarised in the following sections.  
1.3.1 The processes of HDL nanoparticle formation 
Initially, apoA-I is secreted into the plasma from the intestines and liver, and 
approximately 5-10 % is lipid-free apoA-I, or apoA-I can interact with lipids to become 
small lipid-poor pre-β-HDL particles, whilst the majority of apoA-I is in a lipid-bound 
state in lipid-rich α-HDL particles (Brouillette et al., 2001; Del Giudice et al., 2011; von 
Eckardstein et al., 2001) (Figure 1.3).  
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Next, ATP binding cassette transporter A1 (ABCA1), a membrane protein, interacts 
with lipid-free apoA-I and lipid-poor pre-β-HDL particles, referred to as “HDL 
precursors” (Sahoo et al., 2004; von Eckardstein et al., 2001). This is an ATP-dependent 
process which regulates cellular cholesterol transport and lipid efflux from the cell 
membrane forming nascent phospholipid-rich cholesterol-poor discoidal HDL (dHDL) 
particles, as the pre-β-HDL and lipid-free apoA-I accumulate lipids and cholesterol 
(Duong et al., 2008; Lewis and Rader, 2005; Sahoo et al., 2004). 
The apoA-I lipidation/relipidation process through interactions with hepatic ABCA1 is 
significant in preventing deterioration of lipid-poor apoA-I before mature α-HDL 
particles are formed (Lewis and Rader, 2005), as well as protecting against cholesteryl 
ester build-up in macrophages (Del Giudice et al., 2011). 
The larger lipid-rich spheroidal α-HDL (sHDL, HDL3 and HDL2) particles have a 
hydrophobic CE-enriched core, and form when the HDL precursors obtain 
phospholipids and cholesterol as the particles circulate in the plasma (Lewis and Rader, 
2005; von Eckardstein et al., 2001). The HDL2 and HDL3 notations refer to the two 
major subclasses of HDL nanoparticles (see section 1.4).  
The hydrophobic core is surrounded by lipids and the particles can contain between 2 – 
5 apoA-I molecules (Duong et al., 2008; Huang et al., 2011) and approximately two-
thirds of HDL can contain apoA-II as they become more complex (Lewis and Rader, 
2005). Initially smaller HDL3 particles are formed and through the following processes 
form larger HDL2 particles (Lewis and Rader, 2005).  
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Figure 1.3. The processes of HDL synthesis (green). The dashed and solid arrows 
indicate the movement of protein and lipids, respectively. Adapted from (von 
Eckardstein et al., 2001).  
The formation of cholesteryl ester is driven by lecithin: cholesterol acyltransferase 
(LCAT) which catalyses the esterification of cholesterol in the sHDL particles, 
therefore most plasma HDL-C is esterified (Lewis and Rader, 2005; von Eckardstein et 
al., 2001). The cholesteryl esters are hydrophobic and move into the particle core in 
mature sHDL particles (Lewis and Rader, 2005). In addition to LCAT, phospholipid 
transfer protein (PLTP) transfers plasma and surface triglyceride phospholipids to HDL, 
as well as facilitating HDL3 particle fusion to form larger HDL2 particles and the by-
product of lipid-poor apoA-I (Lewis and Rader, 2005; von Eckardstein et al., 2001). 
Furthermore, lipoprotein lipase (LPL) is an enzyme bound to endothelial cell surface 
heparan sulphate proteoglycans (Lewis and Rader, 2005). LPL hydrolyses triglycerides 
in triglyceride-rich lipoproteins, such as chylomicrons and very low-density 
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lipoproteins, resulting in the release of surface cholesterol, phospholipids, and 
apolipoproteins to the HDL precursors for the formation of larger HDL particles (Lewis 
and Rader, 2005).  
1.3.2 Catabolism of HDL nanoparticles 
In the RCT system (Figure 1.4), the mature α-HDL particles are affected indirectly by 
cholesteryl ester transfer protein (CETP), and the lipid and triglyceride hydrolysis 
enzymes hepatic lipase (HL) and endothelial lipase (EL) (von Eckardstein et al., 2001).  
 
Figure 1.4. The processes of HDL catabolism and reverse cholesterol transport (red). 
The dashed and solid arrows indicate the movement of protein and lipids, respectively. 
Adapted from (von Eckardstein et al., 2001). 
HL is a hepatic cell enzyme that converts larger HDL2 particles into smaller HDL3 
particles and HDL precursors through hydrolysis of triglycerides and phospholipids in 
Chapter 1: Introduction 
Sophie Lau - July 2021   11 
HDL, with triglyceride lipase and phospholipase A1 activity, respectively (Lewis and 
Rader, 2005; von Eckardstein et al., 2001).  
Endothelial cells produce EL which hydrolyses phospholipids in HDL, with 
phospholipase A1 activity like HL, producing fatty acids at the vascular endothelial 
surface (Lewis and Rader, 2005; von Eckardstein et al., 2001). CETP reduces the size 
of HDL2 to HDL3 particles by mediating the transfer of CE from HDL to triglyceride-
rich apoB-containing lipoproteins, whilst transferring triglycerides to HDL from these 
lipoproteins (Lewis and Rader, 2005; Rigotti and Krieger, 1999; von Eckardstein et al., 
2001). 
The direct HDL catabolism pathways are scavenger receptor B1 (SR-B1) mediated 
lipid, cholesterol and CE uptake from HDL particles, and apolipoprotein E and apoA-I 
receptors mediated holoparticle uptake of HDL for further processing (von Eckardstein 
et al., 2001). The HDL binds to the SR-B1 receptor with high affinity allowing the 
transfer of HDL-C to hepatocytes in the liver and steroidogenic tissues without 
endocytosing the HDL particles and proteins (Lewis and Rader, 2005; von Eckardstein 
et al., 2001). 
Additionally, some of the lipid-free apoA-I and pre-β-HDL particles are processed by 
glomerular filtration and apoA-I is reabsorbed in the proximal tubulus lumen in the 
kidney facilitated by cubilin (von Eckardstein et al., 2001). 
Importantly, the RCT process is relevant to atherosclerosis as the ATP binding cassette 
transporters (ABCA1, ABCG1), and SR-B1 are present in macrophage foam cells and 
interaction with lipid-free apoA-I promotes cholesterol efflux to HDL particles (Fisher 
et al., 2012; Lewis and Rader, 2005; Yvan-Charvet et al., 2010; Zhou et al., 2015).  
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1.3.3 Summary 
Overall, HDL has a direct role in reverse cholesterol transport, in mediating cholesterol 
efflux and the transport of cholesterol to the liver for excretion and recycling. This 
indicates that HDL is a primary target for gaining a greater understanding of how to 
tackle atherosclerosis treatment. To establish structural differences between the 
atheroprotective apoA-I mutants an understanding of HDL structure is required. The 
following sections describe the plasma HDL distribution, structural characterisation 
techniques, and current models of lipid-free apoA-I and HDL nanoparticles. This is 
followed by introducing the atheroprotective apoA-I mutant characteristics, a summary 
of rHDL-infusion therapies and experimental structural techniques that have been used 
to analyse rHDL nanoparticles.  
1.4 Characterisation of HDL 
The function of HDL is determined by the apolipoprotein content, mainly apoA-I and 
by the lipid content of the HDL particle (Vance and Vance, 2002). The properties of 
HDL have been reviewed extensively (Martin et al., 2014; Rosenson et al., 2011; Vance 
and Vance, 2002). Specifically, the characterisation and distinctions between the 
different subclasses of the heterogenous plasma HDL particles using various 
measurement techniques, summarised in Table 1.1 (Martin et al., 2014; Rosenson et 
al., 2011). 
Overall, the HDL particles have densities between approximately 1.063 – 1.21 g/ml, 
and diameters between 7.2 – 12.9 nm as determined by density gradient 
ultracentrifugation (UTC) and non-denaturing gradient gel electrophoresis (NDGGE) 
(Rosenson et al., 2011; Vance and Vance, 2002). Using NDGGE and density gradient 
UTC the major subclasses HDL2 and HDL3 can be further separated into HDL2a and 
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HDL2b, as well as HDL3a, HDL3b and HDL3c, respectively (Chapman et al., 1981; 
Rosenson et al., 2011; Vance and Vance, 2002).  
HDL particles of different size and charge can also be separated using 2-dimensional 
gel electrophoresis and classified as pre-β- or α-HDL, with the respective diameter 
ranges indicated in Table 1.1 (Asztalos et al., 2000; Rosenson et al., 2011). There are 
also large pre-β2 migrating HDL (12.0-14.0 nm), and pre-α-HDL with similar diameters 
to the α-HDL particle subclasses (Rosenson et al., 2011; Vance and Vance, 2002; Zhou 
et al., 2015). However, the pre-α particles relative to the α-HDL particles exist at a low 
concentration in human plasma (Asztalos et al., 2005; Rosenson et al., 2011).  
The dHDL particles α-4 and pre-β1-HDL particles contain lipids and apoA-I with and 
without cholesterol, respectively (Asztalos et al., 2005; Rosenson et al., 2011). In 
addition to the dHDL components the sHDL α-1 to α-3 particles contain cholesteryl 
esters and triglycerides in the hydrophobic core, the α-2 and α-3 particles also contain 
apoA-II, whereas the α-1 particles contain low concentrations of apoA-II (Asztalos et 
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Table 1.1. HDL particle subfractions categorised by physical properties and analysis 












1.063 – 1.087 1.088 – 1.110 1.110 – 1.129 1.129 – 1.154 1.154 – 1.21 
Size Range (nm) 12.9 - 9.7 9.7 – 8.8 8.8 – 8.2 8.2 – 7.8 7.8 – 7.2 
Density Gradient 
Ultracentrifugation 
HDL2b HDL2a HDL3a HDL3b HDL3c 
Density Range 
(g/ml) 





HDL2b HDL2a HDL3a HDL3b HDL3c 
Size Range (nm) 12.9 – 9.7 9.7 – 8.8 8.8 – 8.2 8.2 – 7.8 7.8 – 7.2 
2D Gel 
Electrophoresis 
α-1 α-2 α-3 α-4 Pre-β-1 




Medium HDL particle Small HDL particle 
Size Range (nm) 12.9 – 9.7 9.7 – 8.8 8.8 – 8.2 8.2 – 7.8 7.8 – 7.2 
Ion Mobility HDL2b HDL2a and HDL3 
Size Range (nm) 14.5 – 10.5 10.5 – 7.65 
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1.5 Antiatherogenic properties of HDL 
It has been suggested that HDL has additional anti-atherogenic properties associated 
with the antioxidant and anti-inflammatory properties of HDL acting upon and aiding 
the prevention of atherosclerotic plaque formation (Barter et al., 2004). This further 
emphasises the atheroprotective nature of the HDL particles in addition to cholesterol 
transport in the RCT system.  
The antioxidant functionality of HDL could be due to the inhibition of the oxidation of 
LDLs and transferring oxidation products of LDL to the liver for removal (Barter et al., 
2004; Bowry et al., 1992; Okura et al., 2010). The accumulation of oxidised LDLs 
triggers the recruitment of monocytes leading to the formation of foam cells in 
atherosclerotic plaques (Galkina and Ley, 2009; Lusis, 2000; Tabas et al., 2007). The 
antioxidant properties of HDL can also be attributed to the proteins associated with 
HDL, specifically apoA-I, as well as apolipoprotein A-II and paraoxonase, in the 
transport and breakdown of lipid hydroperoxides (Barter et al., 2004; Bowry et al., 
1992).  
The anti-inflammatory functionality of HDL reduces the recruitment and migration of 
monocytes into the arterial wall through inhibiting the expression of MCP-1, a 
signalling protein involved in recruitment of monocytes, and endothelial cell adhesion 
proteins (Barter et al., 2004; Navab et al., 1991). Additionally, the formation of pro-
inflammatory proteolytic peptides called granulins was inhibited by apoA-I and/or HDL 
binding to a macrophage-derived secretory factor complex containing progranulin, the 
precursor protein of the granulin peptides (Okura et al., 2010). 
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1.6 HDL nanoparticle structure 
The following sections describe the structural models of lipid-free apoA-I WT followed 
by the structural models of discoidal HDL nanoparticles. It is necessary to characterise 
the lipid-free and lipid-bound structure of the apoA-I protein to determine if there are 
structural similarities and/or differences in the protein structure that are related to its 
function.  
1.6.1 Lipid-free apoA-I 
It is important to understand the structure of apoA-I as this relates to its interactions 
with lipids, cholesterol and enzymes, and therapeutic properties. Human apoA-I is a 
243 residue protein that exists in lipid-free, lipid-poor or lipid-bound states (Silva et al., 
2008). The mature protein is formed in the liver and intestine and has a molecular weight 
of ~28 kDa (1-24 signal sequence, residues 25-267) and mature apoA-I is produced 
after cleavage of the signal sequence pre- and pro- peptides, with the amino acid 
sequence shown in Figure 1.5 (Brouillette et al., 2001; Del Giudice et al., 2011; Law 
and Brewer, 1984). 
ApoA-I is a predominantly -helical protein, which adopts different tertiary structures 
dependent upon the protein is lipid-free or lipid-bound. Various techniques have been 
used to analyse the structure of lipid-free apoA-I (see Oda et al. for a review) (Oda, 
2017), however structural analysis of lipid-bound apoA-I particles due to its size and 
resistance to forming crystals are more problematic (see later).  
The apoA-I protein sequence in the exon-4 encoded region (44 – 243) contains 22 amino 
acid repeats consisting of two 11 amino acid sequences, referred to as 11-mer/22-mer 
or as A and B, which form amphipathic helices (Li et al., 1988; Mei and Atkinson, 2011; 
Segrest et al., 1974; Segrest et al., 1992). The amphipathic alpha helices in apoA-I have 
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a polar face containing charged hydrophilic residues interacting with the aqueous 
environment and lipid headgroups, whilst the nonpolar hydrophobic face associates 
with lipid acyl tails or intramolecularly self-associates with the nonpolar faces of other 
helices in a lipid-free environment (Li et al., 1988; Segrest et al., 1974).  
 
Figure 1.5. Human apoA-I WT amino acid sequence with the pre- and pro- signal 
peptides (Law and Brewer, 1984). The full-length protein (1 – 243) predicted secondary 
structure α-helices (H1-H10) are indicated (Li et al., 1988; Nolte and Atkinson, 1992). 
The G* N-terminal helix is labelled, and the type A and Y helices are underlined in 
green and purple, respectively (Segrest et al., 1992). The proline residues are yellow, 
and residues L144 and R173 are in blue and red, respectively. The figure is adapted 
from (Law and Brewer, 1984; Oda, 2017; Roberts et al., 1997; Segrest et al., 1992). 
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In Segrest et al.’s proposed theory the charged residues follow a pattern with the 
cationic residues (Lys, Arg) on either side of the polar face edges meeting the nonpolar 
face, whilst the anionic residues (Glu, Asp) were centred in the polar face (Segrest et 
al., 1974). The “Snorkel” model was suggested in which the cationic residues are 
described as amphipathic and are situated with the charged amine group(s) towards the 
hydrophilic lipid headgroups, and the hydrophobic acyl chains of the residues are 
associated with the hydrophobic lipid acyl chains (Segrest et al., 1992).  
The amphipathic helices of apoA-I were separated into different classes called A, Y and 
G* (Segrest et al., 1992). The alpha helices described with the charge distribution as 
above are class A (Segrest et al., 1992). The class G* helix is encoded by exon-3, and 
the polar face contains randomly distributed positively and negatively charged residues 
(Segrest et al., 1992). Whereas, in the class Y amphipathic helix polar face the charged 
residues are clustered, alternating positive to negative regions, and distributed radially 
containing a total of three positive regions interspersed with two negative regions 
(Segrest et al., 1992). The helices were determined in ascending order of hydrophobicity 
as class A < Y < G, and suggested to facilitate protein-lipid interactions, a mix of both 
interaction types, and protein-protein interactions, respectively (Segrest et al., 1992).  
There are two apoA-I crystal structures produced by Borhani et al. of N-terminally 
truncated apoA-I Δ(1-43) (Borhani et al., 1997), whilst Mei and Atkinson produced a 
structure of C-terminally truncated apoA-I Δ(185-243) (Mei and Atkinson, 2011). The 
N-terminally truncated lipid-bound tetrameric twisted-ring apoA-I Δ(1-43) crystal 
structure at 4 Å resolution is thought to represent lipid-bound apoA-I (Borhani et al., 
1997). Each chain forms a nearly continuous α-helical secondary structure with proline 
residues throughout the chain causing kinks in the α-helical structure (Helices 1-10, 
Chapter 1: Introduction 
Sophie Lau - July 2021   19 
Figure 1.6, left) (Borhani et al., 1997). The individual apoA-I molecules in each dimer 
are arranged in an antiparallel conformation, with hydrophobic residue interactions 
between the nonpolar faces (Borhani et al., 1997).  
 
Figure 1.6. The crystal structure of apoA-I Δ(1-43) chain A (left) and Δ(185-243) 
(right) adapted from (Borhani et al., 1997) and (Mei and Atkinson, 2011), respectively. 
The monomer structures are labelled with the helices (e.g., H1), the residues L144 
(blue), R173 (red), and the prolines (yellow). The apoA-I Δ(1-43) tetramer (chains A-
D) and the apoA-I Δ(185-243) dimer conformation are both shown below the respective 
monomers.  
Mei and Atkinson produced a higher resolution 2.2 Å crystal structure of C-terminally 
truncated apoA-I (Δ185-243) consisting of ~80% α-helical secondary structure (Figure 
1.6, right) (Mei and Atkinson, 2011). Two antiparallel apoA-I (Δ185-243) half circle 
monomers produced a dimer with a diameter of 11.0 nm and height of 1.7 nm (Mei and 
Atkinson, 2011). Each monomer consists of 7 major helices and a minor helix, at the 
junctions between helices are proline residues which cause kinks in the structure similar 
to the apoA-I (Δ1-43) structure (Borhani et al., 1997; Mei and Atkinson, 2011).  
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The central hinge region contains a “leucine-like zipper” between hydrophobic leucine 
residue functional groups in the H5/5 helices (Figure 1.7), and without stabilising salt 
bridges suggesting flexibility, indicated by the arrow in Figure 1.6 (Mei and Atkinson, 
2011). It is suggested that at low apoA-I concentrations in solution that apoA-I will 
convert between monomeric and dimeric conformations, with monomeric apoA-I as a 
closed structure, with the hinge-region allowing the C-terminus to fold forming a 
monomeric apoA-I helical bundle (Mei and Atkinson, 2011). Lipid-free ApoA-I is 
suggested to have two structural domains consisting of an N-terminus helix bundle 
connected to a less structured carboxyl terminus structure containing alpha-helices 
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Figure 1.7. The intermolecular and intramolecular regions that stabilise the apoA-I 
Δ(185-243) dimer: The hydrophobic N- and C- terminal clusters and π-cation 
interactions with the corresponding distances in Å. The central hinge region “leucine-
like” zipper. The α-helical residues are coloured as in the helical assignments of Figure 
1.5: G* helix (green), residues 33 – 43 (orange), H1 (metallic blue), H2/3 (dark green), 
H4 (cyan), H5 (pink), H6 (violet), and H7 (dark purple). Residues L144 and R173 are 
in blue and red, respectively. Adapted from (Mei and Atkinson, 2011). 
The apoA-I dimer is stabilised with intermolecular and intramolecular hydrophobic 
aromatic residue clusters at either end of the helix bundle (N and C termini), including 
π-π interactions at each cluster further stabilising the bundle at either end (Figure 1.7). 
At the C-terminus cluster the interaction is weaker suggesting a susceptibility to lipid 
disruption of the protein structure. Furthermore, π-cation interactions stabilise the 
helical bundle as well as intra- and inter-molecular salt bridges stabilising the backbone 
of the dimer (Mei and Atkinson, 2011). 
Both crystal structures support that the hydrophobic interfaces between monomers of 
apoA-I are key to dimerization and form the apoA-I helical to lipid binding interface 
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providing a backbone in determining the size of HDL particles (Mei and Atkinson, 
2011). The formation of a tetramer of apoA-I (Δ1-43) is suggested to form due to 
interacting hydrophobic surfaces of the dimers exposed due to the lack of residues 1-43 
in the apoA-I structure, suggested to stabilise the lipid-free apoA-I structure and prevent 
the hydrophobic surface interacting and producing tetramers (dimer-dimer) interactions 
(Mei and Atkinson, 2011).  
Borhani et al. suggested that the tetramer formed in the crystal structure is not 
necessarily indicative of apoA-I structure bound to lipids (Borhani et al., 1997). In 
which, the leucine and valine sidechains of each apoA-I monomer are unable to bind 
lipid as they are in the core of the 4-helix bundle formed in the tetramer, and the apoA-
I dimers associate due to lack of lipids and form the tetramer through interaction of the 
respective dimers hydrophobic faces (Borhani et al., 1997). 
There is further evidence that lipid-free apoA-I has a range of structures (Oda, 2017) 
from a two-state equilibrium between a 4- and 2-helix bundle at lower temperatures 
(Roberts et al., 1997; Rogers et al., 1998b) and multiple states at physiological 
temperatures including a molten globular state (Gursky 1996).  
In the 4-helix bundle suggested structure the C-terminal residues (190-243) are in a less 
structured flexible conformation attached to the N-terminal residues (8-189) in compact 
helices (Roberts et al., 1997). The change in structure between the compact 4-helix 
bundle to the elongated 2-helix hairpin in equilibrium was suggested to be through a 
hinge mechanism and associated with apoA-I changing conformation for lipid binding 
(Roberts et al., 1997; Rogers et al., 1997; Rogers et al., 1998a; Rogers et al., 1998b).  
Further research indicated that the N-terminal residues 1-98 are associated with 
structural stability in lipid free apoA-I due to conformational changes in N-terminally 
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truncated apoA-I mutants in particular Δ(1–43) (Rogers et al., 1998a). In contrast, the 
C-terminal truncation mutant overall structure was similar to the full-length 
conformation (Rogers et al., 1997; Rogers et al., 1998b). Both N- Δ(1–65) and C-
terminal Δ(187–243) truncation mutations compared to full-length apoA-I showed 
reduced and greatly reduced lipid affinity, respectively (Rogers et al., 1998a). Rogers 
et al. also suggested that helix 3 could be associated with stabilising the lipid-free apoA-
I conformation due to significant loss in alpha helicity and stability in a helix 3 Δ(88–
98) internal deletion mutant (Rogers et al., 1998b).  
The molten globular state at physiological temperature suggested the apoA-I secondary 
structure was well-defined with highly flexible alpha helices due to weak interhelical 
tertiary interactions (Gursky and Atkinson, 1996). This implied that the flexibility of 
the molten globular protein could aid in lipid binding in the formation of HDL particles 
(Gursky and Atkinson, 1996). More recent lipid-free apoA-I structural models are based 
upon using multiple techniques (Oda, 2017) such as mass spectrometry (MS), 
homology modelling and cross-linking (Pollard et al., 2013; Silva et al., 2005a), electron 
paramagnetic resonance spectroscopy (EPR) (Lagerstedt et al., 2012), combined crystal 
structures and molecular dynamics simulations (MDS) with cross-linking and MS 
(Segrest et al., 2014).  
Silva et al. utilised 17 experimentally determined lysine cross-link distance restraints 
combined with homology modelling to produce an all atom lipid-free apoA-I structure 
(Figure 1.8A) (Silva et al., 2005a). The structure consists of a multiple helical bundle 
with a hydrophobic core including two helices in the C-terminal domain (215-225) 
which was spatially close to the N-terminus (Silva et al., 2005a). Another similar model 
(Figure 1.8B) with different overall structure and structural element arrangement due 
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to differences in cross-links formed compared to Silva et al. (Silva et al., 2005a) 
produced a structure which contained N-terminal residues 1-43, a 4-helix bundle 
between residues 44-186 (H1-7), and C-terminal helices (H8–10) (Pollard et al., 2013). 
In both cross-linking models the termini are in close proximity to each other and the 
helical bundle (Pollard et al., 2013; Silva et al., 2005a).  
 
Figure 1.8. The lipid-free apoA-I structures produced by cross-linking (A) (Silva et al., 
2005a) and (B) (Pollard et al., 2013). The double headed arrows indicate the N- (blue) 
and C- (red) termini proximity, the alpha helices (green), random coil (yellow) and the 
corresponding dimer of structure A is shown faded. Adapted from (Oda, 2017).  
The “beta-clasp” mechanism describes destabilisation of the helical bundle due to C-
terminal conformational changes in apoA-I during lipid binding (Lagerstedt et al., 2012; 
Oda et al., 2003). The C-terminal secondary structure was determined for residues 163-
241, in which the secondary structure was α-helix (163-187), random coil (188-208) 
containing a flexible loop between residues 188-205, β-sheet (209-219), and α-
helix/random coil (221/241) (Oda et al., 2003). In rHDL nanoparticles the flexible loop 
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and β-sheet regions converted to an ordered alpha helical structure suggesting the 
rearrangement of the apoA-I molecule to the “double belt model” conformation was 
initiated by these structural changes during lipid binding (Oda et al., 2003). Specifically, 
the change in conformation of the β-sheet occurred due to the energy provided by the 
conversion of residues 189-200 from random coil to α-helix during lipid binding 
(Lagerstedt et al., 2012; Nagao et al., 2014; Oda, 2017; Oda et al., 2003). 
The “beta-clasp” mechanism was further investigated with EPR to produce a model of 
full-length lipid-free apoA-I structure (Figure 1.9) containing a central loop, an alpha 
helix bundle with a hydrophobic core of four anti-parallel β-strands in the N- and C-
termini (Lagerstedt et al., 2012). The flexible central loop at residue 139 was suggested 
to be formed by the paired β-strands at residues 102-115 and 130-148, and the β-strands 
at residues 20–25 and 214-220 were suggested to stabilise the respective termini in close 
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Figure 1.9. The “beta-clasp” model of lipid-free apoA-I. The termini are spheres N- 
(blue) and C- (red), α-helices (green), β-strands (red), random coil (yellow), the EPR 
spin-coupled residues (violet). the corresponding dimer is shown faded. Adapted from 
(Oda, 2017). 
Segrest et al. produced a “chimera” structure (Figure 1.10) from the C-terminal 
residues 183-243 of apoA-I Δ(1-43) oriented in the hydrophobic cleft present 
throughout the closed hinge form of apoA-I Δ(185-243) (Oda, 2017; Segrest et al., 
2014). The 15 ns MDS structure was described as a molten globule state structure and 
was the best fit to experimental data and models (Chetty et al., 2009; Lagerstedt et al., 
2012; Pollard et al., 2013; Segrest et al., 2014; Silva et al., 2005a).  
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Figure 1.10. The “chimera” lipid-free apoA-I 15 ns structural model. The N- and C-
termini are indicated with arrows, H4 (cyan), H5 (green), H6 (magenta), H10 (red), 
helical bundle helices H1-3 and H7-9 (grey), proline residues (yellow spheres), and the 
helical bundle and folded helical-hairpin motif are indicated. Adapted from (Segrest et 
al., 2014). 
The structure contains termini in close proximity similar to previous models discussed, 
and 10 alpha helices (H1-H10) of varied sizes connected by regions of random coil 
(Segrest et al., 2014). The helical-hairpin motif contains H4 (100-120) in an antiparallel 
conformation with H6 (144-164) connected by H5, which contains two short alpha 
helices (126-129 and 137-141) and random coil (Figure 1.10) (Segrest et al., 2014). At 
15 ns the motif is in a closed conformation compared to a more open helical-hairpin 
motif at later stages in the simulation (Segrest et al., 2014). The more open helical 
hairpin structure suggested a possible conformation for lipid binding in HDL formation 
or protein dimerization, with the movement of H5 outwards from above the enclosed 
C-terminal H10 (226-239) (Segrest et al., 2014).  
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The lipid-free apoA-I structures have similarities such as the amphipathic helical bundle 
and association of the N- and C- termini, and differences such as the helical spatial 
arrangements and assignment of secondary structure elements in the N- (1-43) and C- 
(190-243) terminal residues β-strands (Oda, 2017). Therefore, the lipid-free apoA-I 
structure is dynamic which is suggested to be due to various conformations required for 
the functions of apoA-I in vivo (Oda, 2017). Overall an understanding of how the lipid-
free apoA-I structure relates to the protein function in HDL nanoparticles could inform 
how the atheroprotective mutations influence the apoA-I structure and in turn the HDL 
particle function.  
1.6.2 HDL nanoparticle structure 
It is difficult to study the structure of HDL nanoparticles and apoA-I in HDL directly 
by experimental techniques such as X-ray crystallography and NMR, due to the 
inhomogeneity in particle size and compositions (Phillips et al., 1997). Therefore, a 
combination of experimental (Gogonea, 2016) and computational molecular dynamics 
(MD) simulations (Pan and Segrest, 2016) have been used to determine the structure of 
discoidal and spheroidal HDL particles to various extents. The large size of rHDL 
nanoparticles has been an issue in X-ray crystallography and NMR studies and 
obtaining detailed structural information has remained a problem despite recent 
advances in solution state NMR truncated apoA-I structural determination (Bibow et 
al., 2017). The experimental structural techniques used to study the structure of rHDL 
nanoparticles are summarised in section 1.8.  
The MD simulation types are briefly described below, and studies of HDL structure are 
a mixture of MD simulations and experimental data (Pan and Segrest, 2016). In all-
atom MD (AAMD) each atom in every molecule in the system is represented 
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individually with respect to the force field used and individual atom behaviour is shown 
throughout the simulation (Pan and Segrest, 2016). Whereas, in a coarse-grained MD 
(CGMD) simulation the individual atoms are grouped so that each CG bead contains 
multiple atoms (≤10 atoms) compromising structural precision for increased simulation 
times and decreased computational cost (Pan and Segrest, 2016). In an MD simulated 
annealing (MDSA) simulation multiple structural conformations may be produced 
during the simulation as the system undergoes increases in temperature, using 
temperature jumps to surpass energy barriers, before cooling (Pan and Segrest, 2016).  
1.6.3 Discoidal HDL nanoparticle structure  
Earlier models of dHDL particles consisted of different apoA-I conformations in either 
a “picket fence”, “hairpin” or “double belt” conformation whilst the lipids were in an 
oblate ellipsoid (discoidal), i.e. a lipid bilayer nanodisc (Gogonea, 2016). When apoA-
I interacts with lipids the hydrophobic areas of the various proposed apoA-I dimers 
interact with the hydrophobic lipid regions, and vice-versa for the hydrophilic regions 
of the protein and the polar head groups of the lipids are exposed and interact with the 
aqueous phase (Borhani et al., 1997; Mei and Atkinson, 2011; Nath et al., 2007; Wu et 
al., 2009). Hagn et al. produced phospholipid nanodiscs smaller than 9 nm in diameter 
for structural analysis using high resolution solution-state NMR, with good quality 
spectra of an integral membrane protein embedded in the phospholipid nanodisc matrix, 
suggesting that the structure of apoA-I could be analysed using similar methods (Hagn 
et al., 2013).  
The “picket-fence” (Figure 1.11A) model depicts two apoA-I molecules in which the 
alpha helices alternate in an antiparallel “fence-like” pattern with the helix normal 
parallel with the lipid bilayer nanodisc normal, the respective termini of each monomer 
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are associated either N- to N-terminus, or N to C-terminus (Gogonea, 2016; Jonas et al., 
1989; Nolte and Atkinson, 1992; Phillips et al., 1997; Wald et al., 1990). This model 
has been discredited in the light of subsequent experimental data. 
The “hairpin” model (Figure 1.11B) consists of antiparallel apoA-I monomers with 
each monomer folded back on itself at helix 5 (Rogers et al., 1998a; Silva et al., 2005b; 
Tricerri et al., 2001). The model was suggested to be able to accommodate up to 4 
molecules of apoA-I in a dHDL particle compared to the belt model (Tricerri et al., 
2001). The salt bridge interactions in both the “double-belt” and “hairpin” models are 
the same, however the protein-protein interactions are inter- and intramolecular, 
respectively (Martin et al., 2006; Silva et al., 2005b).  
 
Figure 1.11. Structural models of discoidal HDL. A) The “picket-fence” model 
obtained from (Shih et al., 2007b). The apoA-I monomers (red, blue), lipid headgroups 
are spheres and lipid tails are white. B) The “hairpin” model of apoA-I monomers 
around a nanodisc lipid bilayer shape with the N-terminal residues as a sphere. Obtained 
from (Silva et al., 2005b). C) The “double-belt” model with antiparallel apoA-I Δ(1-43) 
monomers (blue, cyan) wrapped around a lipid bilayer nanodisc (white), obtained from 
(Nath et al., 2007).  
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However, experimental data and MD models indicated evidence for the “double belt” 
(Figure 1.11C) model with apoA-I Δ(1-43) monomers in a dimer that are antiparallel 
relative to each other, and the alpha helix normal is perpendicular to the lipid membrane 
normal (160 POPC molecules) in the dHDL particles (Bibow et al., 2017; Martin et al., 
2006; Nath et al., 2007; Segrest et al., 1999). The “double-belt” model was supported 
by the crystal structure of apoA-I Δ(1-43) which was suggested to represent the lipid-
bound structure of apoA-I (Borhani et al., 1997). The apoA-I Δ(1-43) N-terminally 
truncated protein is also referred to as a membrane scaffold protein 1 (MSP1) (Bayburt 
et al., 2002).  
CGMD simulations supported the “double belt” model including a simulation starting 
with the protein in the “picket fence” conformation showing the protein conformation 
was unstable over a 1 µs timescale (Shih et al., 2007a; Shih et al., 2007b). The alignment 
of the antiparallel apoA-I monomers contained the helix 5 registry between the two 
monomers, where helix 5 of one monomer was aligned with helix 5 of the second 
monomer referred to as LL5/5 (Segrest et al., 1999). Additionally, the hydrophobic face 
of the amphipathic helices faces the lipid acyl chains whilst the polar face is exposed to 
the aqueous media (Segrest et al., 1999).  
In further support of the belt model, Silva et al. showed that in dHDL (9.6 and 7.8 nm 
diameter) the apoA-I dimer contained the LL5/5 registry in the “double-belt” model and 
did not fit the “hairpin” model through comparison of inter- and intra-molecular cross-
links and MS (Silva et al., 2005b). As well as, an alternative LL5/2 registry where the 
monomers in the dimer are moved with respect to each other, with helix 5 associated 
with helix 2 of the second monomer shown by intermolecular cross-links (Silva et al., 
2005b). They also suggested that an apoA-I monomer in the hairpin conformation could 
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exist in particles with a dimer in the “double-belt” model conformation (Silva et al., 
2005b).  
Additional dHDL models contain specific secondary structure conformations for 
residues as random coil loop structures such as the “looped belt” and “solar flares” 
models. Martin et al. in the “looped belt” model of dHDL found evidence for continuous 
alpha helical secondary structure with a loop segment between residues 133-146 in 
lipid-bound apoA-I (Figure 1.12A), with predominantly intermolecular protein to 
protein monomer interactions supporting the “double-belt” model (Martin et al., 2006). 
The central loop in the “looped belt” model of HDL is a structural feature in the “beta-
clasp” model of lipid-free apoA-I (Lagerstedt et al., 2012). The central loop in apoA-I 
was suggested to allow for changes in particle size between 7.2, 9.4 and 10.5 nm 
diameter dHDL particles by increasing or decreasing the size of the loop region (Martin 
et al., 2006).  
Previously, Li et al. suggested the helices (H5/5) in lipid-bound apoA-I protruded 
outwards from the nanodisc edge in a “hinge-domain” (Brouillette et al., 1984; Li et al., 
2004). This led to a proposed mechanism for increasing the particle size with a decrease 
in hinge size from 9.8 to 10.6 nm diameter, followed by the incorporation of the N-
terminal domain (residues 1-43) helices in 11 residue increments as the particle size 
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Figure 1.12. Further structural models of discoidal HDL. A) The “looped belt” model, 
apoA-I monomers (blue, cyan), lipid nanodisc (yellow). Obtained from (Martin et al., 
2006). Residues 133-146 of the loop region are indicated with the central residue 139. 
B) The “solar flares” model, POPC:cholesterol:apoA-I 200:20:2, 9.6 nm diameter, 
POPC (light grey), cholesterol (purple), apoA-I chains (dark orange, orange), solar flare 
regions (blue), N- and C-termini residues (blue and red, respectively). Adapted from 
(Wu et al., 2007). 
Another model called the “solar flares” model of dHDL (Figure 1.12B) was produced 
using hydrogen-deuterium exchange (HDX) MS, MS combined with cross-linking, and 
energy minimisation MD of the structure (Wu et al., 2007). The differences between 
this model and the “double-belt” model were the use of full-length apoA-I residues 1-
243 including the N-terminal residues 1-43, and the “solar flare” random coil loop 
regions between residues 159-180 on each apoA-I monomer (Wu et al., 2007). The 
residues 159-170 were shown to be an LCAT interaction site in the lipid-bound apoA-
I molecules (Wu et al., 2007). However, the “solar flare” model was subjected to 10 ns 
atomistic MD simulation in which the stabilising salt bridges of the solar flare regions 
were shown to collapse and suggested that further investigation was required by Wu et 
al. to test the stability of the atomistic dHDL model (Shih et al., 2008).  
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Figure 1.13. The anti-parallel double super-helix embedded around an ellipsoidal 
shaped lipid core (left) and without lipids (right). The N- and C- termini are indicated 
in the corresponding colour to the monomers, and the H5/H5 registry is indicated in 
orange. Adapted from (Wu et al., 2009). 
An alternative model of lipid-bound apoA-I is the “double superhelix” (DSH) model 
(Figure 1.13) of nascent HDL (POPC:cholesterol:apoA-I 200:20:2 (M/M)) containing 
apoA-I in an anti-parallel double super-helix embedded around micellar lipids in a 
prolate ellipsoidal shape with the helix 5 registry (Gogonea et al., 2010; Wu et al., 2009). 
The model contains the “solar flare” regions between residues 159-180 and was 
produced using low-resolution small angle neutron scattering (SANS) with contrast 
variation and previous experimental data constraints (Wu et al., 2009). It was suggested 
that the DSH model shows a more flexible conformation of the nascent HDL particle 
allowing for maturation of the nascent HDL particles (Wu et al., 2009).  
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The thermodynamic stability of the DSH model was tested using various types of MD 
simulations with opposing results (Gogonea, 2016), as thermodynamically stable 
particles with solar flare regions containing fluctuating salt bridges (AAMD 60 ns) 
(Gogonea et al., 2010; Wu et al., 2009), and later suggesting the salt bridges could be 
viewed as “transient constructs” (Gogonea, 2016). However, this is in contrast to Jones 
et al.’s study that suggested the particle was not thermodynamically stable due to 
particle collapse to an oblate ellipsoid (CGMD 60 µs and MDSA 60 ns) (Jones et al., 
2010).  
Further study of dHDL produced the “Turtle” model using SANS with contrast 
variation with HDX-MS and cross-linking MS (Gogonea, 2016; Gogonea et al., 2013). 
The lipids are not in a bilayer as in the “double-belt” model but contained mainly 
lamellar lipids in an approximately discoidal shape, with the dimer of antiparallel helix 
5 registry apoA-I in an open conformation as the dimer termini ends are spaced apart 
with micellar lipids in between (Gogonea et al., 2013). 
The hairpin extended from the main discoidal lipids contained in chain A helices 2 and 
3, 4, 5 (residues 66-143) aligned with helices 7, 6, and 5 (residues 121-194) in chain B, 
respectively, in particles without cholesterol (DMPC:apoA-I, 160:2, mol/mol) 
(Gogonea et al., 2013). The hairpin was suggested to allow for particle expansion such 
as incorporating lipid and cholesterol as the hairpin was absent in the particles 
containing cholesterol (DMPC:cholesterol:apoA-I, 172:18:2, mol/mol) (Gogonea et al., 
2013). As the DSH and turtle models contained different open protein conformations 
this was suggested to be due to the particle composition, i.e. the use of DMPC or POPC, 
or the lipid:cholesterol:apoA-I molar ratios (Gogonea, 2016).  
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A recent experimentally determined model of truncated apoA-I Δ(1-54, 121-142) in 
discoidal rHDL-like nanodiscs (DMPC:protein 100:2 (M/M)) was produced using high 
resolution solution state NMR restraints combined with EPR spectroscopy (Bibow et 
al., 2017). The anti-parallel dimer conformation was stabilised by interhelical π-cation 
cluster interaction between H4 and H6 (Figure 1.14). Additionally, salt bridges were 
proposed such as the interhelical (H9 and H10) and intrahelical salt bridge interactions 
(H2 – 4) which could have stabilised the dimer (Figure 1.14) (Bibow et al., 2017). 
Helices 4 and 6 are aligned in the LL5/5 registry in the lipid-free apoA-I WT Δ(1-43) 
crystal structure which is thought to represent lipid-bound apoA-I similar to the 
“double-belt” model (Borhani et al., 1997). However, this model does not contain full-
length apoA-I WT therefore it may not accurately represent the apoA-I WT 
conformation in plasma or rHDL nanoparticles. Additionally, there is the absence of 
phospholipid structural information with this solution state NMR method. This is 
explored further in Chapter 6.  
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Figure 1.14. The structural model of apoA-I truncated apoA-I Δ(1-54, 121-142) in 
discoidal rHDL-like nanodiscs (DMPC:protein 100:2 (M/M). The stabilising π-cation 
interactions and proposed salt bridges are shown. The H1 (residues 55-65, violet), H2/3 
(dark green), H4 (cyan), H6 (pink), H7 (dark purple), H8 (orange), H9 (yellow) and 
H10 (green). The monomer termini are labelled as N1/C1 and N2/C2. Adapted from 
(Bibow et al., 2017). 
More recent studies have found further variation of the “double-belt” model to 
accommodate the different compositions of nascent HDL particles using experimental 
and atomistic MD simulations with longer timescales. In particular, nascent dHDL 
particles containing POPC:cholesterol:apoA-I molecule ratios of 160:24:2 (10 nm) and 
200:20:2 (11 nm) were simulated for prolonged times using AAMD for 20 and 10 µs, 
respectively (Pourmousa et al., 2018). The protein monomers showed different 
conformations with respect to each other, and previous dHDL models in which the 
dimers have an approximately symmetrical conformation of both monomers, e.g. 
Figure 1.12A-B (Pourmousa et al., 2018).  
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The common feature of the helix 5 registry was retained in the simulations including 
the structure of helices 2-7 (Pourmousa et al., 2018), whilst some of the key differences 
are further outlined. The C-terminal region (Figure 1.15A, C2) was shifted to the 
particle surface because of the position of the “hinge” region (Figure 1.15, N1, yellow) 
in the 160:24:2 particle (Pourmousa et al., 2018). The secondary structural changes are 
indicated as helical bends and turns (Figure 1.15, blue, cyan), which became folded 
domains in both the N2 and C1 regions in the 160:24:2 particle, as well as the N-termini 
helix association stabilised by salt bridges in both particles (Figure 1.15, red) 
(Pourmousa et al., 2018).  
Additionally, the nanodiscs do not have strictly planar bilayers, this is more prominent 
in the 160:24:2 particle, as the upper leaflet has a convex face compared to the lower 
leaflet concave face, to adapt to the lipid-protein circumference mismatch (Pourmousa 
et al., 2018). A non-planar nanodisc shape was described as “saddle shaped” HDL 
particles, with a more pronounced curvature of the lipids and increased protein twisting 
as the lipid:apoA-I or lipid:cholesterol:apoA-I molar ratio decreased below 160:2 and 
160:24:2, respectively (Catte et al., 2006; Gu et al., 2010; Miyazaki et al., 2009).  
The structures of dHDL produced have developed over numerous studies, and the 
particles are approximately discoidal in shape containing lipid, cholesterol and two 
apoA-I WT molecules. The nascent HDL structures produced by Pourmousa et al. 
(Pourmousa et al., 2018) have the advantage of comparatively longer simulation times, 
and demonstrate the versatility of apoA-I conformation in HDL particles, and the 
significant role apoA-I has in maintaining the structure of dHDL and adapting to 
forming various particles of different sizes (Pourmousa et al., 2018).  
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Figure 1.15. The AAMD simulation structures of nascent HDL containing 
POPC:cholesterol:apoA-I at ratios of A) 160:24:2 after 20 µs, and B) 200:20:2 HDL 
particle structure after 10 µs. Adapted from (Pourmousa et al., 2018). POPC headgroups 
(coloured by heteroatom), lipid tails (grey), cholesterol (purple), apoA-I chains (dark 
orange, orange), termini labelled N1 C1 and N2 C2, for chain 1 and 2, respectively. 
Structural features are helical bends and turns (blue), N-terminal residues 1-21 (red), 
hinge region residues 26-43 (yellow), and C-terminal bend residues 197-202 (cyan).  
1.6.4 Spheroidal HDL nanoparticle structure 
The structure of sHDL has been researched to a lesser extent than dHDL particles and 
is briefly described as understanding the structure of reconstituted discoidal HDL 
particles with the atheroprotective mutants was the primary focus in this research (see 
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reviews (Gogonea, 2016; Pan and Segrest, 2016) for more detail). The sHDL particles 
have a hydrophobic core containing triglycerides, cholesterol, cholesteryl ester and free 
cholesterol, surrounded by lipids with apoA-I molecules on the particle surface (Pan 
and Segrest, 2016). Various conformations of the apoA-I molecules have been proposed 
containing between 2-5 apoA-I molecules such as the “trefoil” model (Huang et al., 
2011; Silva et al., 2008), the “helical-dimer-hairpin” model (Wu et al., 2011), and the 
“double-belt hairpin” model (Segrest et al., 2013). Figure 1.16 A, B and C show the 
general conformations of the apoA-I molecules in each model, respectively.  
 
Figure 1.16. Structural models of sHDL. A) The “trefoil” model, 3 symmetrical helical 
apoA-I molecules surrounding a hypothetical lipid sphere, obtained from (Silva et al., 
2008). B) The “helical-dimer-hairpin” model. The SANS lipid shape (green), apoA-I 
dimer (red, blue) and “folded-back hairpin” monomer (cyan), obtained from (Wu et al., 
2011). C) The “double-belt-hairpin” model, the apoA-I dimer and hairpin monomer are 
wrapped around a hypothetical lipid sphere, obtained from (Segrest et al., 2013).  
1.7 Atheroprotective apoA-I mutants 
ApoA-I R173C (Milano) and apoA-I L144R (Zaragoza) are both considered to be 
atheroprotective mutants of apoA-I as carriers of either apoA-I mutant have low levels 
of HDL-C without cardiovascular disease or atherosclerosis (Franceschini et al., 1980; 
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Recalde et al., 2001). There are significantly more studies of the apoA-I R173C mutant 
compared to apoA-I L144R. The difference in amino acid structure in each 
atheroprotective mutant is shown in Figure 1.17 for apoA-I R173C and L144R. These 
single amino acid changes affect the apoA-I structure in different ways, for apoA-I 
R173C the formation of cysteine-cysteine disulphide bonded dimers (Weisgraber et al., 
1980). ApoA-I L144R may have different monomeric or lipid-bound conformation(s) 
(Fiddyment et al., 2011) possibly by additional intra- or intermolecular interactions due 
to the additional positive charge of the arginine residue.  
 
Figure 1.17. The structures of the amino acids arginine, cysteine, and leucine with the 
functional group (R) differences indicated as cationic, sulphydryl and nonpolar, 
respectively. The amino acid changes are indicated by the labelled arrows for apoA-I 
R173C (red) and L144R (blue). 
The apoA-I Milano (R173C) mutation was discovered by Franceschini et al. in an 
Italian family from Northern Italy in 3 heterozygous carriers with hypertriglyceridemia 
(Franceschini et al., 1980), with the point mutation identified as R173C by Weisgraber 
et al. characterisation of the isolated mutated plasma apolipoprotein A-I (Weisgraber et 
al., 1980; Weisgraber et al., 1983). The plasma apoA-I R173C monomer molecular 
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weight was determined as ~28 kDa, a cysteine disulphide bond linked dimer ~55 kDa, 
and a mixed disulphide heteromer with apoA-II ~35 kDa (Weisgraber et al., 1980). 
Gualandri et al. determined that 33 carriers with ages between 2-81 years old were 
heterozygous carriers of the apoA-I R173C autosomal dominant trait (Gualandri et al., 
1985). Additionally, the proportion of plasma apoA-I WT to apoA-I R173C in the 
mutation carriers was approximately 25 and 75 %, respectively (Weisgraber et al., 
1983).  
Recently, in a Spanish family 4 heterozygous carriers of the apoA-I Zaragoza variant 
were discovered between the ages of 13-37, a single amino acid missense point mutation 
at the 144th residue from leucine (L) to arginine (R) (L144R) (Recalde et al., 2001). The 
characteristics of the apoA-I R173C and L144R carrier phenotypes compared to apoA-
I WT carriers are summarised in Table 1.2.  
Both atheroprotective mutants exhibit phenotypes with reduced levels of plasma HDL, 
apoA-I, HDL-C and HDL CE, and increased HDL triglyceride (Franceschini et al., 
1982; Franceschini et al., 1980; Recalde et al., 2001). The plasma HDL L144R particles 
were smaller than the control HDL particles (Recalde et al., 2001), whereas the HDL 
R173C particles also contained larger 12.0 nm diameter particles compared to 9.4 nm 
diameter measured by TEM (Franceschini et al., 1980). Further analysis of the plasma 
HDL R173C particles showed less HDL2 particles and more HDL3 particles with 
diameters between approximately 8.8-11.7 nm, compared to normal particle proportions 
(Franceschini et al., 1982). Enhanced CETP activity was suggested as a possible reason 
for the triglyceride enrichment and CE depletion of the HDL L144R particle core, and 
changes in the HDL composition overall (Recalde et al., 2001).  
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Table 1.2. The characteristics of the atheroprotective apoA-I R173C (Franceschini et 
al., 1982; Franceschini et al., 1980; Weisgraber et al., 1980; Weisgraber et al., 1983) 
and L144R (Recalde et al., 2001) carriers relative to apoA-I WT (normal) carriers. The 
↑ and ↓ arrows indicate an increased or reduced level compared to normal apoA-I 
carriers, respectively. Triglycerides (TRL). Where available, the numbers are the 
percentage of the “normal” carrier levels the factor was reduced to, or approximate 
increase x2 i.e. 2-fold increase. 
 Level/amount relative to apoA-I WT carriers in human carriers 
apoA-I 
mutation 




















The phenotype characteristics of 4 carriers between ages 43-62, of the apoA-I L144R 
mutation from the Copenhagen City Heart Study were measured and consistent with 
Recalde et al.’s findings of lower levels of total cholesterol, HDL-C, apoA-I levels and 
increased triglycerides compared to apoA-I WT carriers (Haase et al., 2011). This was 
supported by apoA-I L144R expression in apoA-I deficient mice showing low HDL-C 
levels, and the mouse plasma HDL particles were characterised as predominantly small 
HDL3 (pre-β- and α4-HDL) in the approximately 5-7.5 nm diameter range (Haase et al., 
2011).  
This suggested a decrease in LCAT activity due to a reduced ratio of cholesteryl ester: 
total cholesterol in the apoA-I L144R expressing mice (Haase et al., 2011), which 
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Recalde et al. observed in human carriers but they concluded that as the LCAT activity 
was normal this was unlikely (Recalde et al., 2001). ApoA-I L144R and LCAT 
expressing apoA-I deficient mice showed a similar ratio of cholesteryl ester: total 
cholesterol and a HDL particle size distribution (pre-β-, α1- to α4-HDL) to apoA-I WT 
expressing mice (Haase et al., 2011). The deletion of helix 6 (residues 143-164) in 
apoA-I WT resulted in a significantly inhibited LCAT activation (~97%) showing this 
region is important for LCAT activation (Sorci-Thomas et al., 1993). Therefore, further 
research could be required to conclusively determine if HDL L144R interacts 
differently with LCAT compared to HDL WT.  
Helix 7 (residues 165-186) was deleted from apoA-I WT producing a ~98% LCAT 
activation inhibition suggesting the apoA-I R173C containing region of residues could 
also affect LCAT activation (Sorci-Thomas et al., 1993). Reconstituted HDL R173C 
relative to rHDL-WT particles had a decreased capability in LCAT activation, 40 and 
70% reduction for 7.8 and 12.5 nm diameter rHDL, respectively, suggested to be a result 
of an altered conformation in the disulphide bond region in the rHDL-R173C particles 
(Calabresi et al., 1997a).  
The apoA-I R173C mutation cysteine residue was suggested to destabilise the helix 
bundle domain conformation (Figure 1.8-9), as the cationic arginine residue may form 
an intrahelical salt bridge with the anionic glutamic acid residue 169 in apoA-I WT in 
the lipid-free or lipid-bound states (Alexander et al., 2009; Mei and Atkinson, 2011). 
There are also intermolecular salt bridges (D89-R173-E92) between the N-terminal 
helix bundle residues (D89, E92) and helix 7 (R173) of the respective monomers in the 
dimeric apoA-I Δ(185-243) crystal structure (Figure 1.6) (Mei and Atkinson, 2011). 
The apoA-I R173C mutation was suggested to prevent the formation of dimeric apoA-
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I in a similar conformation to the lipid-free apoA-I WT Δ(185-243) dimer crystal 
structure due to destabilisation of the salt bridges (Mei and Atkinson, 2011). 
Dimeric apoA-I R173C was suggested to affect rHDL particle size distribution with 
only dimers or multiple dimers associating with the HDL, so there could be limits upon 
the possible conformations of dimeric apoA-I R173C compared to apoA-I WT 
(Alexander et al., 2009; Calabresi et al., 1997b). A “double-belt” model of dimeric 
apoA-I R173C Δ(1-43) protein conformation was described as “locked” in a shifted 
helix-helix registration compared to the lipid-bound apoA-I WT LL5/5 registration, by 
the intermolecular covalent disulphide bond between adjacent monomer cysteine 
residues (Klon et al., 2000). The R173 residue was mutated to cysteine in both apoA-I 
monomers using PyMol software (Schrodinger, 2015) to visualise the shifted registry 
between the disulphide bonded monomers (Figure 1.18). It can clearly be observed that 
the interhelical registry of the apoA-I R173C monomers changes which could result in 
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Figure 1.18. (Left) The apoA-I WT Δ(1-43) crystal structure monomers, chains A and 
B (1AV1 PDB) (Borhani et al., 1997). Selected helices are labelled to indicate the LL5/5 
registry in apoA-I WT with the L144 (blue) and R173 (red) residue positions indicated. 
(Right) The R173 residue was mutated to cysteine in both of the apoA-I WT Δ(1-43) 
monomers and oriented with the C173 residues in anti-parallel proximity relative to 
each other. The distance between the -SH groups of the cysteine residues is indicated to 
show where the disulphide bond would align the monomers. 
Significantly, the carriers of HDL R173C and L144R have a low incidence of 
atherosclerosis or CVD, with an altered HDL particle composition and size (Recalde et 
al., 2001; Weisgraber et al., 1980). This could be due to enhanced RCT, however the 
mechanism through which this could occur, or if the particles have a different structure 
affecting the particle functional capabilities (e.g., interactions RCT enzymes, cell 
receptors) compared to HDL WT particles is yet to be completely understood. This in 
turn, could be applied to future development of HDL-infusion therapies to treat 
atherosclerosis.  
The structure of dimeric lipid-bound apoA-I R173C Δ(1-43) has been predicted with 
molecular modelling (Klon et al., 2000) based upon the belt model of apoA-I WT Δ(1-
43) (Segrest et al., 1999). Structural models have been proposed for discoidal HDL 
Chapter 1: Introduction 
Sophie Lau - July 2021   47 
nanoparticles containing dimeric apoA-I R173C structure based upon lysine cross-
linking combined with mass spectrometry distance restraints of 7.8 and 12.5 nm 
diameter rHDL-R173C nanoparticles has been studied (Bhat et al., 2010). Structural 
“double belt” apoA-I HDL models based upon this data (Bhat et al., 2010) and the 
apoA-I WT Δ(185-243) crystal structure (Mei and Atkinson, 2011) have been proposed 
for HDL R173C nanoparticles (Gursky et al., 2013).  
Although, structural models have been proposed for the apoA-I R173C dimer 
conformation in discoidal rHDL nanoparticles there is a lack of high-resolution 
structural information from techniques such as solid-state NMR.  
Little is known about the structural conformation of lipid-free or lipid-bound apoA-I 
L144R, with minimal studies demonstrating the feasibility of producing rHDL 
POPC:cholesterol:apoA-I L144R 200:20:2 (M/M) nanoparticles (Fiddyment et al., 
2011). Therefore, there is a need to address the lack of structural information of the 
lipid-free apoA-I L144R protein and in rHDL nanoparticles. The advantageous 
phenotype observed in carriers of the apoA-I L144R mutation suggests that the apoA-I 
L144R protein could have better functional properties relative to apoA-I WT in the 
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1.8 Structural techniques used to study rHDL nanoparticles  
This section briefly summarises the experimental techniques that have been used to 
characterise rHDL nanoparticles. Table 1.3 shows the structural information provided 
by the experimental technique and the limitations with example references indicated.  
Previous experimental techniques have focussed upon determining the apoA-I protein 
structure. However, the lipid and cholesterol component organisation within the rHDL 
nanoparticles could affect the particle function. A thorough comparison of the rHDL 
nanoparticle constituents could provide clues to determine why the apoA-I mutants are 
atheroprotective.  
A lack of high-resolution solid-state NMR studies of full-length apoA-I proteins in 
rHDL nanoparticles indicated that further study of apoA-I WT and the mutants was 
required. The apoA-I proteins can be uniformly labelled with 15N/13C to produce solid-
state 2D 13C-13C CP-MAS dipolar correlation and 1H-15N PISEMA spectra to study the 
apoA-I protein conformations. 31P oriented solid-state NMR could be used to study the 
lipid organisation within the rHDL nanoparticles.  
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Table 1.3. A summary of the structural techniques used to characterise rHDL apoA-I WT nanoparticles.  
Technique Structural Information Limitations References 
Circular dichroism 
Average secondary structure estimations, 
thermal stability 
Not residue secondary structure 
assignment specific 
(Giudice et al., 2017) 
Cross-linking with mass 
spectrometry 
Inter- and intrahelical distance restraints Cross-linker arm length (Silva et al., 2005b) 
EPR spectroscopy Tertiary and secondary structure information  (Martin et al., 2006) 
Solution NMR 
High-resolution protein structural restraints, 
secondary and tertiary conformations 
Truncated apoA-I Δ(1-54, 121-142), 
limited by HDL particle size 
(Bibow et al., 2017) 
Solid state NMR 
Overall secondary structure conformation, some 
residue-specific information 
Truncated apoA-I Δ(1-43), an 
abundance of cross-peaks due to large 
protein size 
(Li et al., 2006) 
X-ray crystallography High resolution secondary structure assignment 
Truncated lipid-free proteins, limited by 
apoA-I and HDL particle size 
(Borhani et al., 1997) 
DLS Hydrodynamic diameter 
Assumes an ideal spherical particle 
shape 
(Wu et al., 2009; Wu 
et al., 2007) 
NDGGE Hydrodynamic diameter Broad bands lead to estimated diameters 
(Cavigiolio et al., 
2008) 
TEM Diameter 
Dried nanoparticles, limited morphology 
detection 
(Zhang et al., 2011) 
Cryo-em Morphology Limited contrast (Zhang et al., 2011) 
SANS Average protein and lipid conformations 
Low-resolution, time-averaged 
conformation 
(Wu et al., 2009) 
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1.9 rHDL infusion therapy  
Currently, there are no direct treatments for patients with atherosclerosis to remove 
accumulated cholesterol and induce plaque regression. There is an inverse relationship 
between HDL-C levels and the risk of cardiovascular disease (Lewis and Rader, 2005). 
There has been considerable interest in the development of HDL-infusion therapies 
(Darabi et al., 2016; Kingwell et al., 2014), which are the intravenous injection of 
reconstituted HDL nanoparticles to increase HDL-C levels to increase RCT and reduce 
arterial plaque size (Darabi et al., 2016; Kingwell et al., 2014). 
Importantly, the development of an rHDL-infusion therapy could have the potential to 
directly treat atherosclerotic plaques, and it is of great interest to analyse the structure-
function relationship of the rHDL constituents to inform the production of future 
atherosclerosis treatments.  
There are rHDL-infusion therapies that have progressed from animal models to clinical 
trials in human patients (Darabi et al., 2016; Kingwell et al., 2014) which are discussed 
in the following sections for apoA-I WT and R173C rHDL-infusion therapies. The 
rHDL-infusion therapies differ in phospholipid composition, apoA-I type (plasma or 
recombinant apoA-I WT or recombinant apoA-I R173C), and the lipid:apoA-I molar 
ratio. Due to the abundance of phosphatidylcholine (PC) containing lipids in plasma 
HDL, lipids such as POPC and soy-PC have been predominantly used to form rHDL 
for infusion therapy studies (Darabi et al., 2016).  
1.9.1 ApoA-I WT infusion therapy 
An earlier study directly infused plasma HDL-VHDL into cholesterol-fed rabbits and 
induced the regression of atherosclerotic lesions, specifically aortic fatty streaks, and 
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lipid deposits. This was suggested to be through stimulation of RCT by the infused HDL 
particles (Badimon et al., 1990). A magnetic resonance imaging (MRI) clinical trial 
study of statin-treated patients undergoing existing atherosclerosis treatment with 
nicotinic acid over a year found a statistically significant elevation of HDL-C levels and 
reduction in LDL-cholesterol with reduced atherosclerosis progression (Lee et al., 
2009). The nicotinic acid was used to increase the plasma HDL-C levels of the patients. 
This highlighted in a human study that elevated levels of HDL-C can reduce the 
progression of atherosclerosis.  
The main clinical intravenous rHDL apoA-WT formulations are CSL111 and CSL112 
from CSL Behring (Australia). CSL111 contained rHDL prepared from soy-PC:human 
apoA-I WT at a 300:2 molar ratio. rHDL-infusion treatments were trialled in human 
patients with acute coronary syndrome (ACS) (Tardif et al., 2007), peripheral vascular 
disease (Shaw et al., 2008), type 2 diabetes (Calkin et al., 2009; Patel et al., 2009), and 
in a mouse model (Chen et al., 2012). Positive differences in plaque morphology were 
observed such as a decrease in lipid content, macrophage-containing lipids cell size and 
inflammation of CSL111 treated plaques (Shaw et al., 2008), despite no significant 
decrease in the atheroma plaque volume (Tardif et al., 2007).  
In comparison, the CSL112 rHDL formulation formed from soy-PC:plasma apoA-I WT 
at the 110:2 molar ratio rHDL-infusion therapy has been extensively researched (2013 
– ongoing) from pre-clinical testing in animals (Diditchenko et al., 2013), to clinical 
trials in human patients (Easton et al., 2014; Gibson et al., 2019; Gille et al., 2018; Gille 
et al., 2019; Gille et al., 2014; Tricoci et al., 2015). The most recent trials are the large 
phase 2 AEGIS-I trial (Gibson et al., 2016) and a large phase 3 AEGIS-II trial 
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(NCT03473223, ongoing patient recruitment, expected completion 2022) (Karalis and 
Jukema, 2018).  
CSL112 increases ABCA1 mediated cholesterol efflux (Diditchenko et al., 2013) for 
the treatment of ACS and post-ACS cardiovascular events in patients with stable 
atherosclerotic disease (Tricoci et al., 2015). In the various studies and clinical trials 
there was an increase in reverse cholesterol transport, apoA-I levels, and pre-β-HDL 
formation (Easton et al., 2014; Gille et al., 2014; Tricoci et al., 2015).  
1.9.2 ApoA-I R173C infusion therapy 
The primary rHDL-infusion therapy formulations containing apoA-I R173C are called 
ETC-216 (Esperion, USA) and MDCO-216 (Medicines Company, USA). The ETC-216 
rHDL infusions contained POPC:recombinant apoA-I R173C at a 1:1 weight ratio 
(Kingwell et al., 2014). ETC-216 infusions showed significant regression in atheroma 
plaque volume in patients with ACS (Nissen et al., 2003), and in rabbits with advanced 
aortic lesions (Ibanez et al., 2008). Further study in rabbits with atherosclerosis showed 
the ETC-216 and apoA-I WT complexes produced similar plaque regression, but the 
apoA-I R173C rHDL showed greater anti-inflammatory, plaque stabilising, and 
antioxidant effects, as well as a decreased plaque macrophage density (Ibanez et al., 
2012). Ibanez et al. suggested the changes in the “molecular footprint” of the 
atherosclerotic lesions produced a more stable phenotype with differences in the protein 
and gene expression in the aortic lesions treated with ETC-216 (Ibanez et al., 2008). 
Therefore, the apoA-I R173C complexes could produce rapid regression and 
atherosclerotic plaque stabilisation.  
Manufacturing problems, side-effects and expensive production costs affected the ETC-
216 and CSL111 rHDL formulations halting further studies (Darabi et al., 2016; Karalis 
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and Jukema, 2018; Kingwell et al., 2014). The ETC-216 manufacturing was optimised 
to reduce the side-effects observed in clinical trials (Karalis and Jukema, 2018; Reijers 
et al., 2017), and further researched as MDCO-216 in monkeys (Kempen et al., 2013) 
and human patient trials (Kallend et al., 2016; Kempen et al., 2016a; Kempen et al., 
2016b; Nicholls et al., 2018) with each trial indicating MDCO-216 was well-tolerated. 
The results suggested MDCO-216 could potentially be used to treat patients with 
atherosclerosis as suggested by the increase in pre-β-1 HDL levels and ABCA1 
mediated cholesterol efflux, and lipoprotein composition changes (Kallend et al., 2016; 
Kempen et al., 2016a; Kempen et al., 2016b; Nicholls et al., 2018). However, the drug 
was discontinued by the Medicines company due to the lack of clinical efficacy in the 
regression of atherosclerotic plaques (Nicholls et al., 2018) despite the complex being 
well tolerated in animals and human patients (Li et al., 2019).  
1.9.3 Adaptations of rHDL infusion therapy composition 
Optimisation of rHDL based upon the structure function relationship of the components 
within the formulation has been called “smart” rHDL therapy to optimise the 
atheroprotective effects of rHDL (Darabi et al., 2016). Different lipids or lipid ratios 
could affect the particle function, such as in CER-001 egg-sphingomyelin:DPPG in a 
wt ratio of 97:3 combined with recombinant human apoA-I at protein:lipid wt ratio of 
1: 2.7 (Barbaras, 2015; Tardif et al., 2014), similar to how changing the apolipoprotein 
could affect the particle function.  
For example, sphingomyelin lipids have a high affinity to cholesterol, stabilise rHDL 
particles, regulate plasma HDL enzymes, and are a substrate for potent signalling 
mediators (Darabi et al., 2016). PC containing lipids stabilise rHDL, are a substrate for 
potent signalling mediators, have anti-inflammatory and anti-apoptic effects, ABCA1 
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mediated cholesterol uptake, and modulate particle uptake and clearance (Darabi et al., 
2016). Additionally, phosphatidylglycerol containing lipids have similar effects to PC 
lipids, without anti-inflammatory/anti-apoptic effects, and aid in the regulation of apoA-
I level and function, and regulation of plasma HDL enzymes (Darabi et al., 2016).  
An interesting approach to rHDL formulations was as a dual-therapy with statin-loaded 
rHDL nanoparticles in apoE knockout mice with atherosclerosis (Duivenvoorden et al., 
2014). The discoidal rHDL complexes were 25-30 nm diameter and contained lipids 
(lyso-PC, DMPC): human apoA-I: simvastatin at a ratio of 80.7: 7.7: 11.6 wt % of the 
nanoparticle (Duivenvoorden et al., 2014). The complexes in vitro had an anti-
inflammatory effect in J774 macrophages and accumulated in plaques with a decreased 
macrophage plaque content in vivo in the mice model (Duivenvoorden et al., 2014).  
Another study demonstrated that rHDL nanoparticles with approximately 10 nm 
diameter were combined with an MRI imaging agent which binds to collagen to monitor 
changes in arterial plaques in a mouse model (Chen et al., 2013). The use of statins and 
an imaging agent in the rHDL nanoparticles demonstrates further possibilities of rHDL-
infusion therapies (Di Bartolo et al., 2018).  
1.9.4 Limitations of rHDL-infusion therapies  
The studies of rHDL infusion therapies discussed have limits such as small study 
population sizes, the short time period of assessment following treatment, and a need to 
assess how plaque vulnerability is affected by rHDL infusions which atheroma volume 
does not include (Kingwell et al., 2014). As well as improvements in choosing primary 
efficacy end points, and choice of patients as the trials focussed on potent statin treated 
patients with ACS which could have affected the effectiveness of the HDL infusions 
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due to the improved prognosis of ACS patients treated with these statins (Karalis and 
Jukema, 2018).  
1.9.5 Summary 
Overall, there is evidence of pre-clinical atheroprotective functions and properties in 
rHDL-infusion therapies despite the mixed results of clinical trials suggesting a greater 
understanding is required of HDL functionality and properties in stimulation of RCT 
compared to only increasing the HDL-C levels (Karalis and Jukema, 2018). 
Additionally, the combined approach of determining plaque stability, factors which 
affect plaque vulnerability, and the use of multiple imaging techniques could allow for 
greater characterisation than plaque size and regression to determine the success of an 
rHDL therapy in the treatment of atherosclerosis (Di Bartolo et al., 2018).  
Taken together, there is evidence for both apoA-I WT and R173C rHDL-infusion 
therapy atheroprotective effects indicated by the regression in the size of atheroma 
plaques in animal models and human patient studies. Therefore, there is a benefit to 
continuing research which could provide mechanistic information informing the 
development of future rHDL-infusion treatments. A greater understanding of the 
differences and comparison of the molecular features which enhance the 
atheroprotective properties of rHDL containing apoA-I WT, apoA-I R173C and apoA-
I L144R could inform future rHDL therapy approaches. 
Furthermore, the adaptation of the rHDL nanoparticle compositions and the potential as 
a combined therapy for atherosclerosis for cholesterol efflux and as a drug delivery 
system demonstrate that rHDL-infusion therapy is versatile with many options to 
explore.  
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1.10 Aims 
The overall aim of this thesis is to understand how the structure of the apoA-I R173C 
and L144R mutants is related to their atheroprotective function. This is key to 
understanding how the HDL nanoparticles in vivo can transport cholesterol effectively 
to gain an enhanced understanding of the low atherosclerosis incidence in the mutant 
carriers. Importantly, the direct structural comparison between rHDL nanoparticles 
containing the atheroprotective apoA-I mutants and apoA-I WT will inform possible 
rHDL-infusion treatments for atherosclerosis.  
To establish if there are significant differences or similarities in the respective particle 
structure that affect the HDL particle function in cholesterol transport, through the 
following objectives: 
• To implement a methodology for the expression of the atheroprotective apoA-I 
mutants with a sufficient yield for the routine expression of unlabelled, and dual 
or mono-isotopically (13C and/or 15N) labelled protein for NMR studies.  
 
• Establish a working protocol for preparing rHDL nanoparticles incorporating 
apoA-I WT and the atheroprotective mutations for biophysical characterisation. 
This will enable the detection of structural differences or similarities that could 
affect the rHDL nanoparticle function.  
 
• Use a combination of characterisation techniques, solid-state NMR, combined 
with computational modelling, to examine the molecular structure and 
organisation within the particles of the protein, phospholipid, and cholesterol 
constituents. To produce structural models of the respective rHDL nanoparticles 
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and search for molecular level structural clues to establish a structure-function 
relationship.  
 
• To test the capability of the lipid-free and lipid-bound apoA-I proteins in rHDL 
nanoparticles to induce cholesterol efflux in vitro from cholesterol-loaded 
macrophages. 
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2 Theory 
This chapter is an introduction to the main techniques used for analysis of the 
reconstituted HDL (rHDL) nanoparticles. Both circular dichroism (CD) and solid-state 
NMR (SS NMR) were used to examine the structure of apoA-I within the rHDL 
nanoparticles. SS NMR was also used to characterise the structure of the lipids in the 
rHDL nanoparticles.  
2.1 Circular dichroism  
CD is a widely used technique to study the overall secondary structure conformations and 
thermal stability of proteins (Greenfield, 2006a; Greenfield, 2006b). The definition of CD 
is the “unequal absorption of left-handed and right-handed circularly polarised light” 
(Greenfield, 2006b). At the wavelength λ with the left-handed ( 𝐿) and right-handed ( 𝑅) 
circularly polarised light extinction coefficients, this is represented by (Sreerama and 
Woody, 2004a): 
 ∆ (𝜆) = 𝐿(𝜆) − 𝑅(𝜆)  [1]  
The following units are typically used for CD called molar CD (M-1 cm-1) and can be 
interconverted with molar ellipticity [θ] (deg cm2 dmol-1) (Equation [2]) (Sreerama and 
Woody, 2004a).  
 ∆ =  
[𝜃]
3298
 𝑎𝑛𝑑 [𝜃] =
100 ∙ 𝜃
𝐶 ∙ 𝑙
 [2]  
The concentration (𝐶) in g/L of the sample is taken into account with the pathlength 𝑙 in 
cm (Sreerama and Woody, 2004a). The difference between the absorption of the two 
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opposing circularly polarised light beams occurs when there are chiral centres present 
in the sample molecule(s) (Wallace and Janes, 2009).  
To understand how chiral centres in a molecule enable CD signal detection the electric 
vector model is shown in Figure 2.1. Where the opposing beams of circularly polarised 
light are of equal magnitude and form a plane polarised light beam (Wallace and Janes, 
2009). When the polarised light passes through an achiral sample no CD signal is 
detected as 𝐿(𝜆) = 𝑅(𝜆) which results in a linear path of the vector (Figure 2.1, left).  
A CD signal occurs, either positive or negative as in Figure 2.2, when the sample 
contains chiral centre(s) which absorb left- or right-handed circularly polarised light in 
varied amounts at different wavelengths in the far UV range (180 – 250 nm) 
(Greenfield, 2006b; Wallace and Janes, 2009). This absorption changes the magnitude 
of the vectors with respect to each other, e.g. greater absorption of the right-handed 
circularly polarised light in Figure 2.1 (right), and results in an elliptically polarised 




 (Wallace and Janes, 2009). 
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Figure 2.1. A comparison of circularly polarised light absorption in an achiral and a 
chiral centre containing sample, the field of view is down the direction of the light 
source (Wallace and Janes, 2009). Left- (blue) and right- (green) handed circularly 
polarised light vectors and the individual rotations (red arrows). The resultant linear and 
elliptical vectors (black) for the achiral and chiral samples, respectively. The ellipticity 
angle θ (orange). Adapted from (Wallace and Janes, 2009).  
The primary chiral chromophores in proteins are peptide bonds in the polypeptide backbone 
that have specific electronic transitions that enable structural studies of proteins with CD 
(Wallace and Janes, 2009; Whitmore and Wallace, 2008). The transitions in the peptide 
bond chromophore are between the 𝑛 → 𝜋∗ and 𝜋 → 𝜋∗ electron molecular orbitals with 
the maximum absorption wavelengths at approximately 220 and 190 – 200 nm, respectively 
(Figure 2.2) (Wallace and Janes, 2009; Whitmore and Wallace, 2008).  
Characteristic CD spectra (Figure 2.2) are produced when analysing proteins as the 
chromophores become aligned in specific arrangements in secondary structures such as α-
helices or β-sheets (Greenfield, 2006b). In a protein with a predominantly α-helical 
Chapter 2: Theory 
Sophie Lau - July 2021   61 
structure, such as apoA-I, the 𝜋 → 𝜋∗ transition produces two negative minima at ~222 
and 206 nm, and the 𝑛 → 𝜋∗ transition has a positive maxima at ~190 nm (Holzwarth 
and Doty, 1965).  
 
Figure 2.2. (Left) The peptide bond chiral chromophore electronic transitions which 
occur when circularly polarised light is absorbed during CD. The transition dipoles of 
the 𝒏 → 𝝅∗  and 𝝅 → 𝝅∗  molecular orbital transitions (blue arrows). Adapted from 
(Whitmore and Wallace, 2008). (Right) Example characteristic secondary structure CD 
spectra obtained from (Greenfield, 2006b). Poly-L-lysine, (1) α-helical at pH 11.1, (2) 
anti-parallel β-sheet at pH 11.1, and (3) extended conformation (random coil) at pH 5.7. 
Placental collagen, (4) triple-helix native, and (5) denatured.  
The secondary structure components in a protein sample can be estimated with various 
deconvolution algorithms combined with fitting to a reference data set including 
proteins with known structures (Greenfield, 2006b; Sreerama and Woody, 2004a; 
Wallace and Janes, 2009). Therefore, CD spectroscopy can be used to determine the 
molecular structure of proteins. Furthermore, changes in the CD spectra can be used to 
determine important thermal stability and denaturation properties (Greenfield, 2006a).  
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2.2 Solid-state NMR 
Important aspects of SS NMR analyses are focussed upon that were used to observe 
high-resolution spectra such as magic-angle spinning, cross-polarisation, proton 
decoupling and broadline SS NMR. To understand these concepts the basic principles 
of primarily SS NMR are briefly explained.  
Nuclei have intrinsic angular momentum called spin (I) which produces a nuclear 
magnetic moment (μ) and the ratio between I and μ is called the gyromagnetic ratio (γ) 
(Apperley et al., 2012). In this study, I = ½ nuclei were observed in apoA-I and POPC 
(i.e., 15N, 13C, and 31P), and the following description will therefore be limited to spin 
½ nuclei. Nuclear spins precess about the magnetic field at an angular frequency  = 
B0, called the Larmor precession frequency, where /2 is in the MHz (radiofrequency 
(RF)) range for typical magnetic field strengths of 7 – 20 T.  
The nuclear magnetic moment can exist in 2I+1 projections on an axis and the magnetic 
component quantum number (mI) defines the number of spin states under B0 (Apperley 
et al., 2012). In terms of energy levels, spin ½ nuclei can exist in two energy states 
where mI equals +½ or -½ known as the α and β states, respectively. The splitting into 
energy levels in the presence of a magnetic field is called the Zeeman effect with the 
nuclear magnetic moments in a low (α) or high (β) energy state aligned with or opposing 
B0 (Apperley et al., 2012). A slight excess in the population of spins in the low energy 
state gives rise to bulk magnetization, which can be represented by a vector. The energy 
difference between the two states is given by E = h/2. 
The vector model can be used to describe what occurs during an NMR experiment. The 
nuclei in a sample possess an overall net magnetisation of the nuclear magnetic 
moments under an applied magnetic field (B0) at equilibrium, and the magnetisation 
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vector is aligned along B0, which corresponds to the z-axis in the laboratory frame 
(Figure 2.3). A perturbation of the nuclear spins away from equilibrium occurs when 
oscillating electromagnetic radiation is applied at frequencies close to the Larmor 
frequency. 
In the vector model, this perturbation is represented as a rotation of the bulk 
magnetization (M) about either the x-axis or y-axis. An RF pulse of defined duration 
and strength is applied. In order to observe an NMR signal, a pulse of sufficient length 
and strength is required to rotate the magnetization into the x-y, or transverse, plane; 
this is called a 90° or /2 pulse, referring to the tip-angle of the magnetisation. The 
magnetisation vector then precesses in the transverse plane about the z-axis at the 
Larmor frequency and generates an oscillating signal in the RF coil, which is detected 
as a free- induction decay (FID) (Keeler, 2010).  
The frequency domain spectrum is produced when the time domain FID signal is 
converted to the frequency domain by Fourier transformation. The precession 
frequencies of spins in different chemical environments is determined by chemical 
shielding of the nuclei by the circulating electrons, which may enhance or reduce the 
overall magnetic field experienced by the nuclei. Chemical shielding is anisotropic, but 
for small molecules undergoing rapid reorientation in the magnetic field the shielding 
effect around each nucleus is averaged to produce a single isotropic chemical shift. 
Nuclear spins also couple to one another through bonds (J-coupling) or through space 
as a result of the interactions between the nuclear dipoles.  
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Figure 2.3. The vector model of an NMR experiment. The direction of the bulk 
magnetisation (M) of the nuclei in a sample at equilibrium under B0 (left). After an RF 
pulse is applied, e.g., 90° or π/2 radians, the bulk magnetisation moves outwards as 
indicated by the dashed line towards the xy-plane. Adapted from (Keeler, 2010). 
After the RF pulse the magnetisation vector of the nuclei reverts to the overall net 
magnetisation aligned with B0 at the equilibrium position, this is known as relaxation 
(Keeler, 2010). There are two types of relaxation called longitudinal (T1) and transverse 
(T2) relaxation. T2 relaxation concerns the loss of coherence of the spins, which 
dampens the oscillating signal. T1 relaxation concerns the re-establishment of the 
Boltzmann distribution.  
An example pulse sequence of a 13C NMR experiment with proton decoupling is shown 
in Figure 2.4. The nuclei in a sample are initially at equilibrium under B0. A 
radiofrequency pulse is applied, e.g., at 90° or 180° in tp. The following period tacq is 
when the FID signal is acquired with simultaneous proton decoupling (Keeler, 2010). 
This pulse sequence is repeated multiple times to improve the signal-to-noise ratio and 
each repeat is known as a transient. A delay tr, called the recycle delay, between each 
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pulse-acquisition step is required to allow the spins to relax to their equilibrium 
populations. The transients are averaged before conversion of the FID to an NMR 
spectrum using Fourier transformation (Keeler, 2010).  
 
Figure 2.4. An example NMR experiment pulse sequence for 13C nuclei with 1H 
decoupling. The period the nuclei in a sample reach equilibrium is the relaxation delay 
tr. The RF pulse is applied during tp and the FID is acquired in the acquisition period 
(tacq). During tacq proton decoupling is applied. The ellipses represent n repeats of the 
pulse sequence. Adapted from (Keeler, 2010). 
2.2.1 Magic-angle spinning 
In the solution NMR analysis of small-to-medium size molecules (100-20,000 Da), 
effects from dipolar coupling and chemical shift anisotropy (CSA), i.e. orientation 
dependence of the chemical shielding, are observed minimally due to the rapid isotropic 
tumbling of molecules in solution (Duer, 2004). During the timescales used in solution 
NMR this results in an averaging of the CSA orientation dependence to zero (Duer, 
2004). In solids, or semi-solid materials, these effects are not averaged to zero and can 
result in broad lineshapes in the NMR spectrum (Bothwell and Griffin, 2011). The 
lineshapes contain information about molecular dynamics and can provide orientational 
information as will be shown later. However, it is often necessary to apply measures to 
narrow the NMR lines in order to obtain high-resolution spectra.  
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
66  Sophie Lau - July 2021 
Magic-angle spinning (MAS) is frequently used in SS NMR to produce high-resolution 
spectra with narrow lineshapes by removing the effects of the CSA and heteronuclear 
dipolar coupling (Duer, 2004). Typically, the sample is packed into a zirconium rotor 
and rotated at high frequencies (2 kHz to > 100 kHz) around the spinning axis (Figure 
2.5). The spinning axis is at the magic-angle θR = 54.736° relative to B0 (Duer, 2004). 
The shielding tensor principal z-axis orientation relative to B0 is described by the angle 
θ (Figure 2.5) and the molecular orientation dependence is defined as 3 cos2 𝜃 − 1 
(Duer, 2004). The principal z-axis and the spinning axis are separated by angle β (Duer, 
2004). 
 
Figure 2.5. The magic-angle spinning experiment (left), at the magic-angle θR = 54.7° 
relative to B0, the rotor is spun rapidly about the spinning axis (Duer, 2004). The 
shielding tensor principal z-axis is oriented at angle θ and β relative to B0 and the 
spinning axis, respectively. The chemical shift shielding tensor components (right). An 
ellipsoid representation of the chemical shielding tensor with the separate components 
δ11, δ22 and δ33. Adapted from (Duer, 2004).  
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The principle of MAS can be explained with a powder sample containing all molecular 
orientations where θ and β can be all possible values. The interaction tensor for each 
molecule in a solid sample is in a fixed position with multiple molecules in different 
orientations in the sample (Duer, 2004). The angle θ changes with time as the solid 
sample is rapidly spun at θR. The average of the nuclear spin interaction orientation 
dependence (3 cos2 𝜃) with the angles θ, β, and θR as described above (Duer, 2004) is: 
 〈3 cos2 𝜃 − 1〉 =
1
2
(3 cos2 𝜃𝑅 − 1)(3 cos
2 𝛽 − 1)  [3] 
At the magic-angle 3 cos2 𝜃𝑅 − 1 = 0 , hence the average interaction anisotropy 
〈3 cos2 𝜃 − 1〉  = 0 and only the isotropic component of the chemical shielding is 
observed (Duer, 2004). This produces SS NMR spectra which have narrow bands and 
removes the effects of anisotropic lineshape broadening (Bothwell and Griffin, 2011; 
Duer, 2004). A centre band is flanked on either side by spinning side-bands, separated 
by the MAS frequency. If the MAS frequency exceeds the CSA, then a single peak at 
the isotropic chemical shift is observed (Duer, 2004). 
2.2.2 Dipolar coupling and proton decoupling 
In solution NMR the J-coupling (“through bond”), provides bond connectivity 
information in a molecule and is observed as multiplets in the spectrum (Apperley et 
al., 2012; Keeler, 2010). Indirect spin-spin coupling occurs through the polarisation of 
electrons in the bond between the connected nuclei (Mlynarik, 2017). However, J-
coupling is not usually observed in SS NMR as it is small relative to dipolar coupling 
in solid samples, e.g. <1 kHz for light elements (Apperley et al., 2012). Dipolar coupling 
is anisotropic and has the 3 cos2 𝜃 − 1 dependence on the magnetic field, where in this 
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
68  Sophie Lau - July 2021 
case  is the angle between the vector linking the positions of two dipolar coupled nuclei 
and B0. 
Dipolar (“through space”) coupling between two nuclei is important in SS NMR and 
results in significant line broadening (Apperley et al., 2012; Bechinger et al., 2004). It 
is the interaction between two magnetic dipole moments of the nuclei μi and μs, 
separated by the internuclear distance r (Figure 2.6A) (Apperley et al., 2012; Duer, 
2004). The dipolar interaction strength is affected by the orientation of the spins with 
respect to B0 (Figure 2.6B), and the internuclear distance by 
1
𝑟3
 (Equation [4]) (Duer, 
2004).  
 
Figure 2.6. A) A representation of two nuclei I and S with magnetic moments μi and μs 
separated by the internuclear distance r. Obtained from (Apperley et al., 2012). B) The 
internuclear vector (red dashed line) between nuclei I and S, with the angles θ and ϕ 
defining the vector orientation relative to B0. Adapted from (Duer, 2004).  
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The dipolar coupling constant can be calculated with  






(3 cos2 𝜃 − 1) [4]  
where ℏ  is Planck’s constant/2π, μ0 is the vacuum permeability constant, r is the 
internuclear distance, and the nuclei gyromagnetic ratios are γI and γS (Bechinger et al., 
2004; Duer, 2004). In organic solids, 1H-1H dipolar coupling constants can exceed 70 
kHz, whereas 15N-1H bonds can have a dipolar coupling interaction between 
approximately -20 ≤ Δv ≤ 10 kHz (Bechinger et al., 2004). 
Dipolar coupling between nuclei complicates and broadens the NMR spectrum 
(Apperley et al., 2012). To obtain a high-resolution spectrum, the sample must be 
rotated at frequencies much greater than the dipolar coupling constant (Duer, 2004). 
This is straightforward for weaker couplings (e.g., 13C-13C), but technically more 
demanding for removing stronger (e.g., 1H-1H) couplings (Apperley et al., 2012). 
Consequently, many NMR experiments on organic solids rely on the observation of 13C 
or 15N signals whilst removing heteronuclear couplings (13C-1H, 15N-1H) with either 
continuous wave or a broadband decoupling sequence, which is used to irradiate the 
protons in a sample (Apperley et al., 2012; Keeler, 2010). 
The continuous wave irradiation at the Larmor frequency of the protons in a sample 
removes the heteronuclear dipolar coupling between the measured nuclei and the 
protons, such as 15N and 13C in the sample (Keeler, 2010). A broadband decoupling 
sequence is a set of pulses with specific phases and flip angles with continuous 
irradiation of protons in the sample (Keeler, 2010). An example of a broadband 
decoupling sequence for SS NMR samples is called small phase incremental alternation 
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containing 64 steps (SPINAL-64) which was developed by Fung et al. (Fung et al., 
2000). 
2.2.3 Cross-polarisation 
An important method in SS NMR for increasing sensitivity and reducing measurement 
times is cross-polarisation (CP) at the Hartmann-Hahn condition. CP is mediated by the 
heteronuclear dipolar interaction and is the transfer of magnetisation from an abundant 
and sensitive nuclei to less abundant, less sensitive nuclei (X) in a sample, such as 1H 
to 13C or 15N (Apperley et al., 2012; Duer, 2004).  
CP improves the spectrum signal-to-noise ratio for the measured FID of the less 
abundant nuclei, and reduces the overall experiment time (Duer, 2004). The experiment 
time is reduced as the relaxation time (T1) is dependent on the 
1H nuclei magnetisation 
which has a more rapid recovery of equilibrium magnetisation compared to nuclei X 
(Apperley et al., 2012). This is due to the presence of both strong homonuclear and 
heteronuclear dipolar interactions for the protons in the sample. Whereas, nuclei X has 
predominantly weaker heteronuclear dipolar interactions which result in longer 
relaxation times (Duer, 2004). The X nuclei such as 13C/15N have relatively low natural 
abundance compared to 1H in proteins. Therefore, CP is used to increase the signal 
intensity of the observed X nuclei (Apperley et al., 2012). 
The basic pulse sequence for a CP NMR experiment is shown in Figure 2.7. Firstly, the 
1H nuclei magnetisation moves to the -y axis with a 90𝑥
°  pulse (Duer, 2004). Next, the 
1H magnetisation is maintained due to the formation of the spin-lock field with an on-
resonance 1H contact pulse (-y) (Apperley et al., 2012; Duer, 2004). At the same time 
the contact pulse (-y) at the X nuclei frequency is applied (Figure 2.7) (Apperley et al., 
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2012; Duer, 2004). The contact time is the period in which the contact pulses are applied 
and the magnetisation transfer occurs (Apperley et al., 2012).  
 
Figure 2.7. An example of the CP pulse sequence. After the RF pulse (𝟗𝟎𝒙
° ) CP occurs 
when the contact pulses are applied. During the X nuclei signal acquisition proton 
decoupling is applied. Adapted from (Duer, 2004), example FID from Figure 2.4.  
To achieve CP the amplitudes of the contact-pulses are changed to meet the Hartmann-
Hahn match condition (Duer, 2004), originally discovered by (Hartmann and Hahn, 
1962), defined as: 
 𝛾𝐻𝐵1( 𝐻
1 ) = 𝛾𝑋𝐵1(𝑋) [5] 
This results in CP when both nuclei have equal energy gaps between the nuclei spin 
states described as equal nuclei nutation frequencies (Apperley et al., 2012; Duer, 
2004). The theoretical enhancement of the signal from nucleus X by cross-polarisation 
from H is H/X, although this is rarely achieved in practice because of nuclear relaxation 
(Apperley et al., 2012). 
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2.2.4 Homonuclear decoupling experiments 
Two-dimensional (2D) correlation cross-polarisation magic-angle spinning (CP-MAS) 
NMR experiments between 13C-13C nuclei can be used to produce spectra containing 
site-specific cross-peaks, which indicate nuclei close in space and can be used in protein 
structural analyses (Duer, 2004; Takegoshi et al., 2001). To obtain higher resolution 
spectra the sample is spun at the magic-angle to remove dipolar coupling before re-
establishment of the dipolar coupling with a recoupling sequence (Duer, 2004), such as 
dipolar-assisted rotational resonance condition (DARR) recoupling (Takegoshi et al., 
2001).  
The DARR recoupling can be used to recouple the 13C-13C nuclei mediated by the 13C-
1H heteronuclear dipolar interaction (Takegoshi et al., 2001). During MAS, continuous 
wave proton irradiation re-establishes the heteronuclear dipolar coupling with a 1H RF 
field intensity under the DARR condition (Takegoshi et al., 2001). The rotational 
resonance condition is when the proton RF field intensity is equal to the sample rotation 
field intensity multiplied by an integer (n = 1 or 2) (Oas et al., 1988; Takegoshi et al., 
2001).  
In the mixing period of the pulse sequence the magnetisation is transferred between the 
proton and 13C nuclei (Duer, 2004). Proton homonuclear and heteronuclear dipolar 
interactions broaden the spectrum, which produces an heteronuclear dipolar coupling 
pattern (Takegoshi et al., 2001). The heteronuclear dipolar coupling pattern of a 13C 
spin and another 13C spin spinning sideband overlap (Takegoshi et al., 2001) to form 
cross-peaks in the spectrum when the nuclei are close in space (Duer, 2004).  
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2.2.5 NMR of oriented molecules 
As stated earlier, the nucleus is surrounded by electrons that produce a secondary 
opposing field to B0 which shields the nucleus and affects the chemical shift detected 
(Duer, 2004; Mlynarik, 2017). The extent of chemical shielding and therefore a decrease 
in the resonance frequency of the nuclei depends on the chemical environment of the 
nuclei, i.e. the surrounding atoms in the molecule (Mlynarik, 2017).  
The CSA interaction is a second rank tensor that contains three principal components 
referred to as σ11, σ22 and σ33 and shows that the chemical shielding is not homogeneous 
around a nucleus (Figure 2.5) (Bechinger et al., 2004). The CSA in a static sample is 
therefore orientation dependent and the measurable chemical shielding constant σ of a 
nucleus can be calculated from the tensor components relative to B0 (Bechinger et al., 
2004) using  




The position of B0 relative to the principal axes of the chemical shift tensor is defined 
by the angles Θ and Φ as in Figure 2.8C (Bechinger et al., 2004; Duer, 2004). To 
convert to the chemical shift 𝛿𝑎𝑎 = 𝜎𝑟𝑒𝑓 − 𝜎𝑎𝑎 for each interaction tensor component 
separately where aa = 11 or 22 or 33 (Duer, 2004). The chemical shift is measured 
relative to a reference compound such as tetramethylsilane (TMS) and calculated from 
the measured nuclei shielding constant σ relative to σref as described above (Duer, 2004). 
If a molecule has a restricted range of orientations relative to B0, such as a single crystal 
or a protein in an oriented lipid bilayer, the chemical shift tensors (δ11, δ22 and δ33) can 
be readily used in Equation [6] to determine relevant interaction tensor orientations 
such as the amide bond (N-H) for residues in a protein (Bechinger et al., 2004). The 15N 
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chemical shift (δi) can be calculated for the amide (i) groups in a protein backbone with 
Equation [7] 
 𝛿𝑖 = 𝛿11𝑠𝑖𝑛
2Θ𝑐𝑜𝑠2Φ + 𝛿22𝑠𝑖𝑛
2Θ𝑠𝑖𝑛2Φ + 𝛿33𝑐𝑜𝑠
2Θ [7]  
The amide 15N chemical shift tensor can be described by the main components δ11, δ22 
and δ33 which have the chemical shift values of 60, 75 and 222 ppm, respectively 
(Bechinger et al., 2004). The isotropic chemical shift is defined as δiso = (δ11 + δ22 + 
δ33)/3 and the tensor components are defined as (δ33 - δiso) ≥ (δ11 - δiso) ≥ (δ22 - δiso) 
(Apperley et al., 2012; Duer, 2004). δ33 is directed along the plane of the peptide bond 
at ~18° from the N-H bond in an α-helical protein which are aligned along the helix axis 
(Figure 2.8A) (Bechinger et al., 2004).  
 
Figure 2.8. A) The alignment of N-H bonds throughout a right-handed alpha helix with 
the main helix axis indicated. B) The 15N chemical shift tensors (δ33, δ22 and δ11) in 
relation to the peptide bond and B0. δ33 is aligned in the peptide bond plane (dashed blue 
outline). C) The Φ and Θ angles represent the position of B0 relative to the 
15N chemical 
shift tensors. Adapted from (Bechinger et al., 2004). 
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The 1H-15N dipolar coupling constant (Di) for each residue (i) can be calculated using 
Equation [8] (Chen and Tjandra, 2012), as dipolar coupling occurs between the N and 
H nuclei in the N-H bond (Figure 2.8B) (Bechinger et al., 2004).  
 𝐷𝑖 = 𝐷𝑚𝑎𝑥(3𝑐𝑜𝑠
2𝜃 − 1)/2  [8] 
The N-H bond vector and B0 are separated by the angle θ, and the largest dipolar 
coupling value is Dmax (Chen and Tjandra, 2012).  
An example of α-helical protein alignment with respect to an oriented lipid bilayer has 
been shown with [15N]-labelled Vpu, an 81 residue protein associated with HIV-1 
(Marassi et al., 1999) in Figure 2.9. The observed 15N chemical shifts at ~200 and 70 
ppm indicated alignment of the N-H bond within the helices (Figure 2.8A) as parallel 
and perpendicular to the bilayer normal, respectively (Figure 2.9) (Marassi et al., 1999).  
 
Figure 2.9. The 15N NMR spectra of [15N]-labelled Vpu and truncated Vpu (residues 2-
51 and 28-81) in oriented phospholipid bilayers (A). The α-helix N-H bond alignment 
is indicated as parallel (blue) or perpendicular (red) to the bilayer normal. The position 
of the corresponding amphipathic (red) and hydrophobic (blue) Vpu helices is shown 
in (B). Obtained and adapted from (Marassi et al., 1999).  
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2.2.6 PISEMA 
The 2D SS NMR methods used in this study are described further such as polarisation 
inversion spin exchange at the magic-angle (PISEMA) (Wu et al., 1994) and the 2D 
13C-13C CP-MAS spectrum.  
To obtain site-specific information from a SS NMR experiment dipolar couplings which 
can cause significant line broadening need to be taken into account (Ramamoorthy et 
al., 1999). PISEMA acts to decrease the spin-diffusion effects between 1H nuclei, i.e. 
homonuclear dipolar couplings, without an increase in heteronuclear dipolar coupling 
utilising the spin-lock phase (Ramamoorthy et al., 1999; Yamamoto et al., 2005). 
Therefore, PISEMA can be used to produce high resolution spectra in the heteronuclear 
dipolar frequency dimension (Ramamoorthy et al., 1999; Wu et al., 1994).  
PISEMA can be applied to [15N]-labelled proteins in oriented phospholipid bilayers to 
determine the protein orientation relative to B0 (Marassi et al., 1997; Ramamoorthy et 
al., 1999). This utilises the heteronuclear dipolar coupling between 15N-1H in the amide 
bonds present in the protein backbone as described earlier, and the respective nuclei 
chemical shift frequencies (Marassi et al., 1997; Ramamoorthy et al., 1999). 
In the SEMA phase (Figure 2.10) double (or triple) resonance pulse sequences with 
spin-exchange at the magic angle are used (Ramamoorthy et al., 1999). At the magic 
angle (θm) an effective field is formed through application of off-resonance RF 
1H 
irradiation in the t1 period, i.e., the 
1H magnetisation spin-lock for magnetisation 
transfer (Ramamoorthy et al., 1999; Yamamoto et al., 2005). The suppression of the 1H 
homonuclear dipolar couplings is achieved with the flip-flop Lee-Goldburg (LG) pulse 
sequence (Lee and Goldburg, 1965). During this the effective field is phase- (X to -X), 
and frequency-switched at each 2π rotation (Figure 2.10) (Ramamoorthy et al., 1999). 
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Figure 2.10. The stages of the PISEMA SS NMR experiment. The preparation stage: 
The initial 90° pulse (π/2). The quadrature phases are represented by X, -X, Y, -Y. The 
SEMA stage: The LG condition frequencies are shown as positive (+LG) and negative 
(-LG), and the θm is the magic-angle pulse at 54.74°. (Ramamoorthy et al., 1999). Proton 
decoupling is applied during the FID acquisition phase. Adapted from (Yamamoto et 
al., 2005), and example FID from Figure 2.4.  
A 2D PISEMA spectrum is produced with the 1H-15N dipolar couplings correlated with 
the 15N chemical shifts. The cross-peaks in the PISEMA spectra correspond to 
individual amide sites (N-H) in the protein studied (Marassi et al., 1999). In the Vpu 
protein example, a 2D PISEMA Vpu experimental spectrum contained a “wheel-like” 
pattern in the transmembrane α-helix region (Figure 2.11A) (Marassi et al., 1999). The 
transmembrane α-helix of Vpu (Figure 2.9, blue) was suggested to have a tilt of ~15° 
relative to B0 as the observed Vpu cross-peaks were similar to the simulated α-helix 2D 
PISEMA spectrum peaks (Figure 2.11B, D) (Marassi et al., 1999). 
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Figure 2.11. (A) The experimentally observed 2D PISEMA spectrum of [15N]-labelled 
Vpu. (B-F) The simulated 2D PISEMA spectra of an α-helix containing 17 amino acid 
residues with tilt angles between 0 – 30° with respect to the bilayer normal/B0. The 
transmembrane α-helix region is highlighted by the blue box. Obtained and adapted 
from (Marassi et al., 1999).  
This is a powerful technique in SS NMR as the orientation of a protein in a phospholipid 
bilayer can be determined, as well as helical residue secondary structure assignment 
(Marassi and Opella, 2000). The α-helix wheel pattern can be shown by the pattern of 
resonances in the PISEMA spectrum (Figure 2.11) (Marassi and Opella, 2000). This is 
aided by narrow spectrum lines due to the reduction of the heteronuclear dipolar 
coupling in the SEMA period by 18.4 % (Yamamoto et al., 2005). Additionally, several 
factors influence the resonance frequencies such as the α-helix orientation, the CSA of 
the amide tensor, the amide bond length, and the backbone dihedral angles (Marassi and 
Opella, 2000).  
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3 Atheroprotective apoA-I 
mutant expression and 
characterisation 
3.1 Introduction 
This section (3.1.1-3.1.3) gives an overview of the strategy for expressing recombinant 
apoA-I WT and the atheroprotective mutants, apoA-I R173C and L144R.  
3.1.1 Recombinant protein expression 
E. coli cells are used widely to express recombinant proteins for further study in a 
variety of cell types such as BL21(DE3) cells that are used for initial protein expression 
tests (Rosano and Ceccarelli, 2014). In this work, BL21(DE3) cells are used for the 
development and optimisation of recombinant protein expression, and XL1-Blue cells 
are used to store the expression vector.  
XL1-Blue cells do not express Endonuclease I due to the endA1 mutation in the E. coli 
cell genotype. This mutation increases the quality of the plasmid preparations for 
sequencing by reducing the amount of nonspecific cellular plasmid DNA digestion 
(Samuelson, 2011) (Agilent).  
The stability of plasmid inserts is improved due to the recA1 mutation in the XL1-Blue 
cell genotype which removes homologous DNA recombination (Samuelson, 2011; 
Studier et al., 1990) (Agilent). Additionally, the BL21 (DE3) cells were used for 
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recombinant protein expression as the recA1 mutation can slow cell growth (Samuelson, 
2011). 
Previously, recombinant his6-tagged apoA-I WT (E2D) was expressed to a yield of 100 
±20 mg/L of cell culture media in BL21(DE3)pLysS E. coli cells. The pNFXex vector 
contained an optimised apoA-I cDNA sequence for expression in E. coli cells (Ryan et 
al., 2003) with further details in section 3.2.1. The expression was further optimised to 
produce the apoA-I WT (E2D) protein with a yield up to 100 mg/L of culture media 
(Townsend, 2016). Therefore, this expression method was used to express apoA-I WT 
(E2D) to provide enough apoA-I to study as a comparison to the atheroprotective apoA-
I mutant proteins, in the lipid-free and lipid-bound protein rHDL nanoparticle structure. 
Laboratory protein recombinant apoA-I protein expression can produce yields as low 
as 0.1 ug/L up to 100 mg/L of cell culture media (Brouillette and Anantharamaiah, 
1995; Panagotopulos et al., 2002; Pyle et al., 1996; Ryan et al., 2003; Schmidt et al., 
1995; Townsend, 2016). In comparison an industrial scale batch-fed expression of 
apoA-I R173C has produced a yield of 2 - 4.9 g/ L of culture media (Calabresi et al., 
1994; Caparon et al., 2010). 
Briefly, the his-tagged apoA-I (E2D) protein expression was induced using isopropyl-
β-D-thiogalactoside (IPTG) in the BL21(DE3) cells (section 3.2.5), and immobilised 
metal ion affinity chromatography (IMAC) was used to separate the fusion protein from 
E. coli proteins after cell lysis. Before the cleavage of the his6-tag using formic acid to 
produce apoA-I WT (3-243). 
Chapter 3: Atheroprotective apoA-I mutant expression and characterisation 
Sophie Lau - July 2021   81 
3.1.2 Atheroprotective mutant recombinant protein expression 
The development of procedures to express the atheroprotective mutants of apoA-I 
Milano (R173C) and apoA-I Zaragoza (L144R) to a sufficient yield and purity was 
required to produce the proteins for further study. The aim was to produce the 
atheroprotective mutants on a similar scale to apoA-I WT, up to 100 mg/L of cell culture 
media. Methods development was also required for producing rHDL nanoparticles. The 
scale of recombinant protein expression required for the characterisation of the rHDL 
nanoparticles is discussed further in Chapter 4, section 4.3.4.2. The atheroprotective 
apoA-I mutant expression was adapted for apoA-I R173C whilst apoA-I L144R was 
expressed under similar conditions as apoA-I WT (E2D). Dimeric apoA-I R173C can 
form through formation of a disulphide bond between two apoA-I R173C cysteine 
residues (Weisgraber et al., 1980). Therefore, it is important to confirm if the 
recombinant apoA-I R173C can also form dimeric apoA-I R173C.  
3.1.3 Labelled protein expression 
For expression of apoA-I WT and the atheroprotective apoA-I mutants for solid-state 
NMR analyses it is necessary to uniformly 13C and/or 15N label the protein. The apoA-
I WT (E2D) minimal media expression conditions (Townsend, 2016) were used to 
produce dual [13C,15N]-labelled apoA-I R173C and L144R. Additionally, dual-labelled 
apoA-I WT, [13C]-apoA-I WT and [15N]-apoA-I WT were expressed for solid-state 
NMR analyses. To achieve this, apoA-I R173C and L144R apolipoproteins were 
expressed in E. coli using a minimal growth medium containing either 13C glucose or 
15N NH2Cl as the sole carbon and nitrogen sources, or both sources for dual-labelled 
[13C,15N]-protein expression. 
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This chapter discusses the first application of expressing unlabelled and dual-labelled 
recombinant apoA-I L144R using the established apoA-I WT expression method. As 
well as adaptation of the apoA-I WT methodology with a TCEP reduction stage to form 
a mixture of monomeric and dimeric disulphide bonded apoA-I R173C.  
3.1.4 Aims 
This chapter describes the methodology developed to express the atheroprotective 
apoA-I Milano (R173C) and apoA-I Zaragoza (L144R) proteins to a sufficient yield 
and purity for structural and functional analyses.  
3.2 Materials and methods 
3.2.1 Plasmid design 
Previously, Dr. M. Oda of the Children’s Hospital Oakland Research Institute USA, 
kindly provided the pNFXex vector for apoA-I (E2D) expression stated earlier (Oda et 
al., 2001; Ryan et al., 2003; Townsend, 2016). Oda et al. altered the human cDNA of 
apoA-I WT to include a his6-tag for affinity chromatography protein purification and a 
proteolytic cleavage site (Appendix 1A).  
The bacterial expression vector phAIex was formed by subcloning the altered WT 
apoA-I cDNA into the pET-20b+ bacterial expression vector. The phAIex expression 
plasmid was transformed into BL21(DE3)pLysS E. coli cells for his-tagged apoA-I 
recombinant protein expression (Oda et al., 2001). To optimise the bacterial expression 
of apoA-I WT Ryan et al. altered the cDNA of human apoA-I in the pBluescript KS (+) 
vector (Stratagene) using site-directed mutagenesis (Oda et al., 2001; Ryan et al., 2003).  
The E2D mutation was produced to form an acid labile D-P peptide bond between 
residues 2 and 3 to allow formic acid cleavage of the N-terminal his6-tag after affinity 
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column chromatography (Ryan et al., 2003). Additionally, silent mutations were used 
to mutate the cDNA sequence for proline, arginine, leucine, and glycine amino acids to 
more abundant codons (frequency per one thousand) present in E. coli cells to optimise 
the apoA-I (E2D) protein expression. For example, the arginine 188 codon AGA at 2.7 
frequency per thousand was mutated to CGC with a 21.1 frequency per thousand. 
Further silent mutations were introduced to produce 13 new restriction endonuclease 
sites for further changes to the protein sequence if required (Ryan et al., 2003). 
After the cDNA manipulations were confirmed via sequencing the apoA-I (E2D) cDNA 
sequence was subcloned into the high copy number pET20b+ plasmid to form the 
pNFXex expression vector (Ryan et al., 2003). The pNFXex vector contains an 
ampicillin resistance gene and an IPTG-inducible promoter for IPTG induced protein 
expression (Ryan et al., 2003). The pET20b+ plasmid and recombinant his-tagged 
apoA-I (E2D) modified cDNA and amino acid sequence are in Appendix 1.  
3.2.2 Atheroprotective mutant construct production using SLIM-
PCR 
The site-directed ligase-independent mutagenesis polymerase chain reaction (SLIM-
PCR) method is used for rapid and efficient mutagenesis to form sequence 
modifications such as insertion, deletion and substitution (Chiu et al., 2004). Previously, 
the apoA-I R173C protein was expressed (Townsend, 2016), consequently the apoA-I 
R173C plasmid was isolated and sequenced again as outlined below. However, the 
apoA-I R173C nucleotide sequence compared to the apoA-I WT (E2D) sequence was 
a 477/579 nucleotide 82 % match producing an inconclusive amino acid sequence 
(Appendix 1). Therefore, the SLIM-PCR reaction was repeated to produce the apoA-I 
R173C mutant plasmid. To form the apoA-I R173C and apoA-I L144R point mutations 
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the following primers were designed with the desired mutation on complementary 
overhangs (Figure 3.1).  
 
Figure 3.1. ApoA-I R173C (Townsend, 2016) and apoA-I L144R SLIM-PCR forward 
(F) and reverse (R) primer designs. The primers were produced by Sigma-Aldrich®. The 
sequences are 5’ to 3’, the 5’ adaptor sequence of the tailed primer complementary 
nucleotide overhang (red), and the mutated nucleotides are also shown in red. 
The respective mutations for apoA-I R173C and apoA-I L144R were formed by 
changing the nucleotides coding R173 from CGC to TGC (C173), and nucleotides 
coding L144 from CTG to CGC (R144). The respective codons were chosen with a 
relatively high abundance in E. coli cells following the process of Ryan et al. (Ryan et 
al., 2003). A comparison of the codon frequency per thousand for cysteine and arginine 
residues in E. coli. from various sources is summarised in Table 3.1. There was a 
marginal difference between the frequency of cysteine codons in E. coli from either 
source therefore the cysteine codon TGC was used. The most abundant codons for 
arginine in E. coli are CGC and CGT with varied difference between sources for both 
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codons (Table 3.1). The codon CGC was used as this was the most abundant arginine 
codon used in the pNFXex vector apoA-I WT (E2D) cDNA sequence (Ryan et al., 
2003).  
Table 3.1. The relative abundance (frequency per thousand) of the most abundant 
cysteine and arginine codons in E. coli cells.  
  Abundance in E. coli cells (frequency per thousand) 
Amino acid Codon (GenScript, 2019) 
(Komar, 2016; 




Cysteine TGC 6.1 5.5  
 TGT 5.2 5.9  
Arginine CGC 19.7 14.0 21.1 
 CGT 20.0 15.9 20.7 
3.2.3 SLIM-PCR reaction 
Initially, the original expression PNFXex vector for apoA-I WT (E2D) was isolated 
from the XL1-Blue plasmid storage cells and a mutation was induced using the SLIM-
PCR method (Chiu et al., 2004). 
The SLIM-PCR reaction is described in Figure 3.2 (Chiu et al., 2004). The L144R and 
R173C forward tailed (FT) primer and reverse short (RS) primer were added to a PCR 
tube labelled as L144R and R173C reaction 1, respectively. The L144R and R173C 
reverse tailed (RT) primer and short forward (FS) primer were added to a separate PCR 
tube labelled as L144R and R173C reaction 2, respectively. The remaining reaction 
reagents were prepared as a master mix and aliquoted together into each primer reaction 
mix, and the control reaction. 
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Figure 3.2. The process of SLIM-PCR reactions 1 and 2 for both atheroprotective 
mutant plasmid DNA formation, adapted from (Chiu et al., 2004).  
In the first PCR reaction the primers annealed to the denatured plasmid DNA (double 
stranded to single stranded) and formed mixed PCR products with the required mutation 
in the complementary overhangs. The second PCR cycle combined the products of 
reaction 1 and 2 in which the DNA was denatured and reannealed to form heteroduplex 
hybridised double stranded PCR products. The heteroduplex products with the 
respective complementary overhangs spontaneously circularised to form the plasmid 
DNA containing the R173C and L144R mutations, respectively.  
Each 25 µL reaction contained 5 µL of Phusion HF buffer (Mg2+ concentration of 1.5 
mM, Thermo Scientific™), 200 µM dNTP’s (2 µL of 2 mM stock, Novagen), 2.5 µL 
betaine, ~10 pmol (0.5 µM) of the respective primers (0.5 µL of 25 µM stocks), ~1 ng 
of template plasmid pNFXex ApoA-I (E2D) DNA, 1 U (0.5 µL) of Phusion™ Hot Start 
II High-Fidelity DNA Polymerase (Thermo Scientific™), and 12.5 µL Milli-Q® 
Ultrapure (MQ) H2O to a final volume of 25 µL. The control reaction mix contained 1 
µL of MQ H2O instead of 2x 0.5 µL of the two primers in the reaction mixes. 
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In the PCR amplification cycle the PCR machine plate was preheated to 98°C for 2 
minutes (step 1). The following cycle was used, with initial denaturation at 98°C for 30 
seconds (step 2), at 61°C for 30 seconds (step 3), at 72°C for 8 minutes (step 4), 35 
cycles of steps 2-4 (step 5), a final extension at 72°C for 5 minutes (step 6) and held at 
4°C (step 7). After the first PCR cycle 5 µL of each reaction was run on a 0.8% (w/v) 
agarose gel with a 1 kb DNA ladder (NEB®, Thermo Scientific™). If the PCR was 
successful a strong band would appear at approximately 4.5 kb on the agarose gel 
corresponding to the plasmid. DpnI a restriction enzyme, used to digest the methylated 
template DNA, was added to each reaction (1 µL of 20 U stock concentration, NEB®) 
and incubated at 37°C for 1 hour. To stop the DpnI digestion 30 µL of H-buffer (300 
mM NaCl, 50 mM tris, pH 9.0, 20 mM EDTA, pH 8) was added to each PCR reaction.  
Before SLIM hybridisation was initiated the PCR products from reaction 1 and 2 were 
combined for each mutation L144R and R173C. The second PCR cycle began with an 
initial denaturation at 99°C for 3 minutes (step 1), 65°C for 5 minutes (step 2), 30°C for 
15 minutes (step 3), 2 cycles of steps 2-3 (step 4) and held at 4°C (step 5). After the 
SLIM hybridisation PCR cycle a 5 µL sample of each reaction was run on a 0.8 % (w/v) 
agarose gel. The PCR products were stored at -20°C prior to XL1-Blue cell 
transformation. 
3.2.4 Gel electrophoresis 
3.2.4.1 Agarose gel electrophoresis 
To prepare a 0.8 % (w/v) agarose gel, 0.8 g of agarose was dissolved in 100 mL of TAE 
buffer and 10 µL of SYBR™ Safe DNA stain (Invitrogen™) was added to the solution. 
The gel was poured into the gel cast and allowed to set with a 1.5 mm 10 well gel comb. 
To 5 µL aliquots of each sample for both SLIM-PCR reactions 1 µL of 6x sample buffer 
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was added. The samples run in the 0.8% (w/v) agarose gels were the control, L144R 1 
and 2, R173C 1 and 2, L144R PCR products and the R173C PCR products. Both the 
GeneRuler 1 kb DNA Ladder (Thermo Scientific™) and the 1 kb DNA ladder (NEB®) 
were diluted and used to the appropriate concentration for 1.5 mm wells following the 
manufacturer’s instructions (Figure 3.3). In each agarose gel 1.8 µL of marker was 
loaded per well.  
 
Figure 3.3. GeneRuler 1 kb DNA Ladder (Thermo Scientific™) (left). 1 kb DNA 
Ladder (NEB®), ethidium bromide staining on a 0.8% TAE agarose gel. Mass values 
0.5 µg/lane (Right). Images obtained from Thermo Scientific™ and NEB®, 
respectively. 
After the samples were loaded into the respective wells, 1x TAE buffer (10x stock 0.4 
M tris base, 12.1 mL acetic acid, 10 mM EDTA) was used to fill the buffer dam and the 
gels were run at 100 V until the dye front had run past the halfway point of the total gel 
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length for band separation. The gels were imaged using the Molecular Imager® 
ChemiDoc™ XRS+ Imaging System and the Image Lab™ 4.0 Software (Bio-Rad).  
3.2.4.2 SDS-PAGE electrophoresis 
To analyse the protein content of samples throughout the apoA-I WT, R173C and 
L144R protein expressions sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was used. SDS, an anionic detergent, was added to samples to break down 
the tertiary structure of proteins combined with a heat shock at 95°C to denature and 
linearize the protein structure. The negatively charged proteins under a constant voltage 
migrated towards the anode and were compared to a marker with bands corresponding 
to known molecular weights (Figure 3.4). 
 
Figure 3.4. PageRuler™ Broad Range (left) and Low Range (right) Protein Ladders 
(ThermoFisher Scientific) on a 4 – 20 % tris-glycine gel and an 18 % tris-tricine gel, 
respectively. Image obtained from ThermoFisher Scientific. 
The SDS-PAGE gels were prepared with a 15% resolving gel and a 4 % stacking gel. 
The 15 % resolving gel contained 3.75 mL of 40 % solution of acrylamide: bis-
acrylamide 37.5:1 (Fisher Scientific™), 2.5 mL of 1.5 M tris HCl buffer pH 8.8, 3.6 
mL of dH2O and 100 µL of 10% (w/v) SDS solution. The 4 % stacking gel contained 1 
mL of 40% solution of acrylamide: bis-acrylamide 37.5:1, 2.5 mL of 0.5 M tris HCl 
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buffer pH 6.8, 6.3 mL of dH2O, and 100 µL of 10% (w/v) SDS solution. Just prior to 
pouring 75 µL of 10% (w/v) APS and 7.5 µL of TEMED were added to the resolving 
and stacking gel solutions. 
The gel plates were cleaned using methanol and placed into the gel casting frames. The 
15% resolving gel solution was prepared and pipetted to just below the 10-well comb 
mark. A layer of water saturated n-butanol was pipetted onto the upper resolving gel 
surface to produce an even gel surface. Once the gel was set the butanol was rinsed 
away with dH2O before the 4% stacking gel was pipetted above the resolving gel. The 
10-well comb was inserted into the stacking gel and allowed to set. The SDS-PAGE 
gels in the plates were rinsed with dH2O and stored at 4°C wrapped in water saturated 
paper towel until used. The 1x running buffer contained 100 mL of 10x running buffer 
diluted to 1 L with dH2O. The 10x running buffer contained 250 mM tris base, 1.92 M 
glycine, and 1% (w/v) SDS. 
The ‘fix’ solution contained 25% (v/v) isopropanol, and 10% (v/v) acetic acid made up 
to 250 mL with dH2O. The ‘stain’ solution contained 10% (v/v) acetic acid and 0.006% 
(w/v) Coomassie Blue R250 made up to 500 mL with dH2O. The ‘destain’ solution 
contained 10% (v/v) acetic acid and 40% (v/v) methanol made up to 250 mL with dH2O. 
The SDS-PAGE gel was inserted into the buffer dam with 1x running buffer in the 
buffer dam. For each SDS-PAGE gel 5 µL of the PageRuler™ Broad Range Protein 
Ladder marker (Figure 3.4) was loaded into the gel using a micro-syringe (Hamilton). 
Each SDS-PAGE sample was mixed with 10x sample buffer (SB) to a final ratio of 1x 
SB, vortexed and heated at 95°C for 5 minutes. The samples were loaded into the 
stacking gel wells using a micro-syringe with a total volume of 20 µL. The sample 
volumes and concentrations loaded into the SDS-PAGE gels were sample dependent.  
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The gels were run at 200 V using the Mini-PROTEAN® Tetra Cell and PowerPac™ 
Basic Power Supply (Bio-Rad) until the dye front approached the end of the gel. The 
SDS-PAGE gel was removed from the glass slides and placed in ‘fix’ solution for 30 
minutes, ‘stain’ solution overnight and ‘destain’ on a rotary shaker until the background 
stain was removed. The gels were imaged using the same imaging system as described 
for the agarose gels.  
3.2.4.3 Non-denaturing gradient gel electrophoresis 
Non-denaturing gradient gel electrophoresis (NDGGE) was used to examine the 
formation of dimeric apoA-I R173C. The 4-16% NativePAGE™ bis-tris protein gels 
(Invitrogen™) were used, and the marker was the High Molecular Weight (HMW) 
calibration kit for native electrophoresis (Amersham™, GE Healthcare) (Cavigiolio et 
al., 2008; Dalla-Riva et al., 2015). The HMW marker kit contains thyroglobulin 669 
kDa, ferritin 440 kDa, catalase 250 kDa, lactate dehydrogenase 140 kDa and bovine 
serum albumin 66 kDa. The corresponding protein Stokes’ diameters are 17.0 nm, 12.2 
nm, 10.0 nm, 9.2 nm, and 7.1 nm, respectively (Cavigiolio et al., 2008; Suurkuusk and 
Singh, 2000). 
The samples were prepared to contain 1x NativePAGE™ sample buffer (4x stock, 
Invitrogen™) and pipetted into the respective sample wells. The NativePAGE™ anode 
and cathode running buffers were prepared from the 20x running buffer and cathode 
additive (Invitrogen™). The gels were run at 150 V until the dye front approached the 
end of the gel in the Bolt Mini Gel Tank (Novex Life Technologies). InstantBlue™ 
(Expedeon) stain was used to stain the gels for 1 hour and the gels were imaged as 
described previously.  
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3.2.5 Plasmid transformation into E. coli cells 
The features of various types of E. coli competent cells used for protein expression are 
summarised by Rosano and Ceccarelli (Rosano and Ceccarelli, 2014). BL21(DE3) E. 
coli competent cells are the most widely used strain for protein expression and initial 
protein expression tests (Rosano and Ceccarelli, 2014). The BL21 strain of E. coli cells 
is derived from the parental B strain B834 which contains the mutation hsdSB to prevent 
DNA methylation, DNA degradation and loss of the plasmid from the cells (Rosano 
and Ceccarelli, 2014).  
In the BL21(DE3) chromosome the λDE3 prophage was inserted into the genome 
containing the genes for the lacUV5 promoter and T7 RNA polymerase (RNAP) for 
protein expression (Rosano and Ceccarelli, 2014; Studier et al., 1990). IPTG initiates 
T7 RNAP production by inhibiting the lac repressor repression of the lacUV5 promoter 
in the BL21(DE3) genome (Studier et al., 1990). The T7 RNAP can then transcribe the 
recombinant protein gene sequence as the pET20b+ vector contains the T7 promoter 
system (Rosano and Ceccarelli, 2014; Studier et al., 1990). Additionally, BL21(DE3) 
cells do not contain the genes for OmpT (Grodberg and Dunn, 1988) and lon 
(Gottesman, 1996) proteases which degrade extracellular and non-native proteins, 
respectively.  
To explore the possibility of expressing predominantly dimeric apoA-I R173C and 
tuneable IPTG induced expression, the R173C plasmid was transformed into Origami™ 
B(DE3) competent cells which have the features of BL21(DE3), Tuner™ (lacZY 
mutant, lac permease) and Origami™ (trxB/gor mutations) cells (Novagen). The lac 
permease lacY deletion mutation enables IPTG induced concentration dependent 
protein expression as the IPTG enters the cell homogeneously across the cell population 
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without lac permease (Khlebnikov and Keasling, 2002; Rosano and Ceccarelli, 2014). 
In cells without the mutation the amount of lac permease membrane proteins per cell 
can vary resulting in non-homogenous IPTG induction as IPTG enters the cell with and 
without lac permease (Khlebnikov and Keasling, 2002; Rosano and Ceccarelli, 2014). 
The cytoplasm in E. coli cells is a reducing environment therefore proteins expressed 
intracellularly in the cytoplasm are usually present in their reduced form (Bessette et 
al., 1999; Stewart et al., 1998). In the context of cysteine residues this refers to a free 
thiol (SH) group preventing the formation of disulphide bonds (R-S-S-R) in proteins 
expressed intracellularly (Bessette et al., 1999; Derman et al., 1993). The thioredoxin 
and glutaredoxin pathways in E. coli cells are involved in reducing disulphide bonds of 
proteins expressed in the cytoplasm (Prinz et al., 1997). Consequently, the trxB and gor 
mutations aid disulphide bond formation in cytoplasmic proteins corresponding to the 
deletion mutations of genes for the expression of the enzymes thioredoxin reductase 
and glutathione reductase, respectively (Derman et al., 1993; Stewart et al., 1998). 
3.2.5.1 Plasmid transformation protocol  
The plasmid was initially transformed into XL1-Blue competent E. coli cells (Agilent 
Technologies) for plasmid storage and any further DNA manipulation required if SLIM-
PCR was unsuccessful. After cDNA sequence confirmation to confirm the presence of 
the L144R and the R173C mutations the respective plasmids were transformed into 
BL21(DE3) competent E. coli cells (Agilent Technologies) for protein expression. Both 
types of competent cells follow the transformation protocol provided by Agilent 
Technologies described below.  
LB agar, total volume of 500 mL was autoclaved and cooled to below 55°C before 500 
µL of 10 % (w/v) ampicillin was added to a final concentration of 100 µg/mL ampicillin. 
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
94  Sophie Lau - July 2021 
Under sterile conditions the LB agar containing 100 µg/mL ampicillin was poured into 
petri dishes and allowed to set for approximately 30 mins. The LB agar plates containing 
100 µg/mL ampicillin were stored inverted at 4°C and pre-warmed at 37°C for at least 
1 hour prior to the cell transformation.  
Sterile SOB medium was prepared containing 5.0 g tryptone, 1.25 g yeast extract and 
0.125 g NaCl. The volume was adjusted to 250 mL with dH2O and autoclaved. After 
the solution was autoclaved, 2.5 mL of 1 M MgCl2 and 2.5 mL of 1 M MgSO4 were 
filter sterilised using a 0.22 µm syringe filter into the 250 mL SOB medium before use. 
A 20 % (w/v) glucose solution was filter-sterilised and prepared just before use, with a 
total volume of 10 mL. To prepare the sterile SOC media with a total volume of 1 mL 
per aliquot, 200 µL of the filter-sterilised 20 % (w/v) glucose was added to 0.8 mL of 
SOB media.  
The SOC media 1 mL aliquots were pre-heated to 42°C in a water bath and sterile 
eppendorfs were pre-chilled on ice. The competent cells were thawed on ice. The cells 
were gently mixed and 100 µL was aliquoted into the sterile Eppendorf tubes for each 
PCR product reaction L144R, R173C and for the positive control plasmid pUC18. To 
each aliquot 1.7 µL of β-mercaptoethanol was added and the tubes were swirled gently 
and incubated on ice for 10 minutes. The tubes were swirled every 2 minutes. Aliquots 
of 2 and 5 µL of the R173C and L144R PCR products were added to individual 100 µL 
cell aliquots. To the positive control cell aliquot 1 µL of pUC18 control DNA was 
added. The various aliquots were named apoA-I M2 and M5, and apoA-I Z2 and Z5. 
The cells were incubated on ice for 30 minutes. After the incubation on ice the cells 
were heat shocked at 42°C for 45 seconds. The cells were incubated on ice for 2 
minutes. To each cell aliquot 900 µL of pre-heated SOC media was added drop-by-
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drop. The cells were incubated at 37°C for 1 hour at 200 rpm. Under sterile conditions 
100 µL of each respective cell aliquot was spread onto separate LB agar plates 
containing 100 µg/mL carbenicillin. The plated cell cultures were inverted and 
incubated at 37°C overnight. A single colony from each plate was selected and 
overnight cell cultures were prepared using approximately 15 mL of sterile LB media 
containing 100 µg/mL carbenicillin. The cell cultures were incubated overnight at 37°C 
with shaking. The GenElute™ Plasmid Miniprep Kit (SIGMA®) was used to isolate the 
respective plasmid DNA for cDNA sequencing. The plasmid samples were sent to 
Source Bioscience Lifesciences for sequencing.  
Glycerol stocks were prepared from the overnight cell cultures to store the cells 
containing the apoA-I R173C and L144R plasmids. Glycerol was diluted to form a 50 
% (v/v) solution with dH2O and filter-sterilised with a 0.22 µm syringe filter before use 
under sterile conditions. In cryogenic storage vials 500 µL of 50 % (v/v) glycerol and 
500 µL of overnight cell cultures (XL1-Blue or BL21(DE3)) for apoA-I R173C and 
L144R, were mixed and frozen at -80°C to preserve the E. coli cells for future use.  
During optimisation of the apoA-I R173C protein expression, the R173C plasmid was 
transformed into Origami™ B(DE3) (Novagen) cells to facilitate the formation of 
disulphide bonds during protein expression (Prinz et al., 1997; Rosano and Ceccarelli, 
2014) using the following transformation protocol as provided by Novagen.  
The Origami™ B(DE3) cells were thawed on ice in 20 µL aliquots for up to 5 minutes 
and gently mixed before pipetting into pre-chilled 1.5 mL Eppendorf tubes. The R173C 
plasmid (1 µL of 10 ng/µL stock) and the positive control plasmid (1 µL of 0.2 ng/µL 
stock) were added to the respective 20 µL cell aliquots, gently mixed, and incubated on 
ice for 5 minutes. The cells were heat-shocked at 42°C for 30 seconds in a water bath 
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and the cells were incubated on ice for 2 minutes. Pre-heated SOC medium was slowly 
added to each cell aliquot whilst on ice until 80 µL SOC medium was added. The cells 
were incubated at 37°C for 1 hour at 250 rpm before plating onto pre-warmed LB agar 
plates containing 100 µg/mL carbenicillin. The following plates were incubated 
overnight at 37°C; a negative control plate without cells, 10 µL of the test plasmid 
plated, and two plates with 25 and 50 µL of the R173C plasmid test cells plated. 
Overnights were prepared from a single colony as described earlier of the R173C 
plasmid containing cells and after an overnight incubation glycerol stocks were 
prepared. 
3.2.6 Expression of apoA-I WT (E2D) 
3.2.6.1 Cell growth and induction 
The following recombinant apoA-I WT (E2D) expression protocol was established 
(Townsend, 2016) and adapted from the previous expression methods (Oda et al., 2001; 
Ryan et al., 2003). LB media was prepared with 25 g of LB (Millers) in 1 L of dH2O 
and autoclaved to sterilise. Once the LB cooled to less than 55°C, 1 mL of 10 % (w/v) 
carbenicillin was added to 1 L of LB to a final concentration of 100 µg/mL. Under 
sterile conditions overnight cultures of the BL21(DE3) cells containing the apoA-I WT 
(E2D) plasmid were prepared by inoculating 15-20 mL of LB media containing 100 
µg/mL ampicillin with a scraping of the BL21(DE3) apoA-I WT glycerol stocks. The 
cell cultures were incubated overnight at 37°C with shaking at 200 rpm.  
The overnight cell culture was used to inoculate 1 L of LB containing 100 µg/mL 
ampicillin and incubated at 37°C at 200 rpm until the OD600 ≥ 0.6 indicating cell growth 
in the logarithmic phase. Protein expression was induced by the addition of 1 mL of 1 
M IPTG to a final concentration of 1 mM to the cell culture (1 L). The induced cell 
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culture was incubated at 37°C for 5 hours at 200 rpm to allow protein expression. A 1 
mL pre-induction sample was taken prior to IPTG addition and a 1 mL post-induction 
sample was taken for SDS-PAGE. The SDS-PAGE samples were centrifuged at 13.4 
krpm for 3 minutes. The supernatant was discarded, and the pellet was resuspended in 
1 mL dH2O. 
3.2.6.2 Cell lysis 
The cells were centrifuged at 5000 x g for 20 minutes at 4°C. The growth media was 
discarded, and the pelleted cells were resuspended in minimal volume of lysis buffer (6 
M guanidine HCl, 20 mM NaPO4, 0.5 M NaCl) pH 7.4, and frozen at -20°C overnight. 
For example, a maximum of 10 mL lysis buffer for a 1 L protein expression. The cells 
were sonicated on ice for 5 cycles of 15 seconds on, 60 seconds off, at an amplitude of 
approximately 20 microns. Phenylmethylsulphonyl fluoride (PMSF) at a stock 
concentration of 200 mM was added before and after sonication to a final overall 
concentration of 1 mM. The lysed cells were centrifuged at 43 000 x g for 30 minutes 
at 4°C. The lysis supernatant was retained, and the pellet discarded. The lysis 
supernatant was diluted by adding an equal volume of lysis buffer pH 7.4 before further 
purification. A 100 µL supernatant and a pellet sample were taken for SDS-PAGE. 
3.2.6.3 His-trap chromatography 
The apoA-I WT (E2D) protein amino acid sequence contains a hexahistidine (his6) tag 
used to isolate the fusion protein apoA-I (E2D) using his-trap chromatography. The 
column used was the 5 mL HisTrap FF™ pre-packed Ni Sepharose column (GE 
Healthcare). The his6-tag in the fusion protein has a high binding affinity for the Ni
2+ 
metal ions and binds to the column resin. Imidazole competes with the fusion protein 
his6-tag for binding to the nickel ions, as the imidazole binds at a higher affinity. The 
concentration of imidazole was increased to remove non-specific binding proteins in 
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wash steps and to elute the fusion protein. The ÄKTA Start chromatography system and 
UNICORN™ Start 1.0 software (GE Healthcare) were used for the separation of the 
fusion protein from the cell lysis proteins.  
An example to show the process of IMAC is shown in Figure 3.5, the Ni2+-nitriloacetic 
acid (Ni2+-NTA) matrix is attached to a support resin, usually cross-linked agarose 
beads, and the Ni2+ metal ion has 4 coordinate bonds with the NTA matrix atoms 
(Bornhorst and Falke, 2000). As the lysis sample flows through the column the his-
residues in the poly-histidine fusion protein tag form 2 coordinate bonds with the Ni2+ 
ion immobilising the protein attached to the matrix in the resin (Bornhorst and Falke, 
2000). 
 
Figure 3.5. An example of interactions between the poly-histidine tag of a fusion 
protein and the Ni2+-NTA matrix attached to a support resin inside a chromatography 
column during IMAC. The R1 group indicates the additional histidine residues in the 
poly-histidine tag, e.g., a His6-tag contains 6 histidine residues in total. The R2 group 
represents the link to the recombinant protein. The red box outlines the structure of 
imidazole. Adapted from (Bornhorst and Falke, 2000). 
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Imidazole is an analogue of the histidine residue R group structure (Figure 3.5, red) 
and competitively binds to the IMAC resin Ni2+ metal ion with a higher affinity than 
the poly-histidine residues to displace and elute the fusion protein at high imidazole 
concentrations (≥100 mM for Ni2+-NTA) (Bornhorst and Falke, 2000). As the post-
induction cell lysis sample contains expressed E. coli proteins and his6-tagged-apoA-I 
(E2D), the his6-tag is an important addition to the apoA-I cDNA sequence enabling the 
isolation of the fusion protein from the E. coli protein impurities (Oda et al., 2001; Ryan 
et al., 2003). 
All buffers and solutions used for his-trap chromatography were filtered and degassed 
using a vacuum pump prior to use with the column. The column was stored in 20 % 
(v/v) ethanol and prepared by washing the column with dH2O at a flow rate of 5 mL/min 
until the UV and conductivity were constant values which indicated the column was 
equilibrated with dH2O. The column was equilibrated with lysis buffer pH 7.4 at a flow 
rate of 5 mL/min.  
Fractionation was started, and 10 mL fractions were collected unless stated otherwise. 
The diluted lysis supernatant sample was loaded at a flow rate of 1 mL/min and the 
volume loaded per chromatography purification run was equivalent to half a litre of cell 
culture. The column was washed with lysis buffer pH 7.4, to remove any non-specific 
binding proteins at a flow rate of 3 mL/min.  
To further remove non-specific binding proteins the imidazole concentration was 
increased using a step gradient. The column was washed with binding buffer (20 mM 
NaPO4, 0.5 M NaCl, 20 mM imidazole) pH 7.4, at a flow rate of 3 mL/min. At a flow 
rate of 3 mL/min, the column was washed with 95 % binding buffer pH 7.4, and 5 % 
elution buffer (20 mM NaPO4, 0.5 M NaCl, 500 mM imidazole) pH 7.4, with a final 
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concentration of 45 mM imidazole. The fusion protein was eluted with 100 % elution 
buffer pH 7.4, 500 mM imidazole concentration, and 1 mL fractions were collected at 
a flow rate of 1 mL/min. In-between runs the column was washed with dH2O then lysis 
buffer, pH 7.4. For storage the column was washed with dH2O then 20 % (v/v) ethanol 
at 5 mL/min.  
The 1 mL elution fractions samples corresponding to the protein peak on the 
chromatogram protein concentrations were tested using the Nanodrop™ 2000c 
(Thermo scientific™) protein A280 measurement. Fractions with a protein concentration 
above 1 mg/mL were pooled for dialysis. A 100 µL SDS-PAGE sample was taken of 
the flow-through, lysis buffer wash, 20 mM imidazole wash, and the 45 mM imidazole 
wash. A 50 µL pooled fusion protein elution sample was also taken for SDS-PAGE. 
The samples in lysis buffer contained guanidine hydrochloride which required ethanol 
precipitation as the guanidine hydrochloride interferes with running the samples in an 
SDS-PAGE gel.  
3.2.6.4 His-tag formic acid cleavage 
The pooled his-tagged apoA-I column fractions were incubated at 55°C with 45 % (v/v) 
formic acid for 5 hours in a water bath to cleave the his-tag from the apoA-I via the acid 
labile D2-P3 bond. The formic acid and his-tag were removed by dialysis over 2 days 
with 1 buffer change at 4°C in 50 mM tris base, 1 mM EDTA, 1 mM benzamidine, pH 
≥ 8.0. After dialysis a 50 µL post-cleavage apoA-I (E2D) sample was taken for SDS-
PAGE to check the protein purity and concentration.  
3.2.7 Atheroprotective apoA-I mutant expression  
After confirmation of protein sequence via gene sequencing the apoA-I R173C and 
apoA-I L144R plasmids were transformed into BL21(DE3) cells for initial protein 
Chapter 3: Atheroprotective apoA-I mutant expression and characterisation 
Sophie Lau - July 2021   101 
expression tests. The apoA-I WT (E2D) protein expression conditions were used to 
express both apoA-I R173C and L144R to test if the conditions were sufficient and 
comparable to routinely express both proteins at acceptable yields and purity.  
As described earlier BL21(DE3) cells are not tuneable to IPTG concentration dependent 
induction of protein expression (Rosano and Ceccarelli, 2014). Therefore, the protein 
expression levels were analysed using SDS-PAGE of hourly post-induction samples of 
a 0.5 L cell culture for each mutant under the apoA-I WT (E2D) conditions for cell 
growth and IPTG induction. A 1 mL pre-induction sample and post-induction samples 
at 2, 3, 4 and 5 hrs, and after the overnight incubation were taken for SDS-PAGE 
analysis.  
Overall, the apoA-I WT (E2D) protocol was used as described previously in section 
3.2.6, for protein expression, purification, and isolation to produce apoA-I R173C and 
apoA-I L144R post-his-tag cleavage.  
3.2.7.1 ApoA-I R173C cysteine reduction 
Mass spectrometry was used to analyse the post his-tag cleavage sample of apoA-I 
R173C, and the mass was greater than expected, under the conditions described in 
section 3.2.7.3. Additionally, NDGGE gels did not show evidence of dimer formation 
as expected via the 173rd cysteine residue. Dr. F. Benson (Faculty of Health and 
Medicine, Lancaster University) helpfully suggested that the cysteine residue could 
have a post-translational modification such as the glutathione modification in the 
protein expression by Sengupta and Udgaonkar (Sengupta and Udgaonkar, 2017). 
Therefore, the modification of the cysteine residue by glutathione preventing the 
formation of disulphide bonded dimeric apoA-I R173C was investigated.  
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Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) (Sigma-Aldrich) was used to 
reduce the cysteine residue in apoA-I R173C and analyse the mass of monomeric and 
dimeric apoA-I R173C without the suspected glutathione modification (Li et al., 2012; 
Sengupta and Udgaonkar, 2017).  
The method of TCEP removal and apoA-I R173C incubation time were tested. Initially, 
apoA-I R173C was incubated with 5 mM TCEP reducing agent for ≥ 12 hours at 4°C 
with inverting to mix. The glutathione and TCEP removal methods were tested using 
dialysis and a PD-10 desalting column (GE Healthcare). The apoA-I R173C pre-TCEP 
stock solution was 0.75 mg/mL in 50 mM tris base, 1 mM benzamidine, 1 mM EDTA, 
pH 8.0 buffer. The final protein concentration was 0.65 mg/mL containing 5 mM TCEP 
at 25°C for 24 hrs, total sample volume of 3 mL per sample.  
To remove the TCEP 2.5 mL aliquots of the sample were dialysed with 2 buffer 
changes, dialysis and desalting (PD-10) column, and PD-10 column only. The samples 
were incubated at 37°C for 8 days with samples taken for NDGGE at 0, 24, 120 and 
192 hours. After the initial TCEP removal tests, apoA-I R173C was incubated at 0.5 
mg/ml with 5 mM TCEP at 37°C. After TCEP removal by dialysis as previously 
described and incubation at 37°C to form dimeric apoA-I R173C a sample for NDGGE 
analysis was taken every 24 hours and stored at -20°C. The samples were filtered using 
a 0.22 µm syringe filter (Corning®) to remove precipitated protein.  
The following apoA-I R173C TCEP reduction conditions were used after optimisation 
tests. All incubation periods including dialysis and dimer formation were at 4°C at 
approximately 0.5 mg/mL to reduce protein precipitation. The post-formic acid cleaved 
apoA-I R173C (E2D) was incubated for 24 hours with 5 mM TCEP. The TCEP and 
cleaved glutathione were removed by dialysis over 2 days with at least 2 buffer changes. 
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To form apoA-I R173C dimer the protein was incubated for 48 hours post-TCEP 
removal.  
3.2.7.2 Size exclusion chromatography for mass spectrometry 
Before the apoA-I R173C post-TCEP incubation sample was loaded onto the column 
the protein concentration was increased using a Corning® Spin-X UF6 Concentrator 
Polyether sulfone (PES) membrane (Sigma-Aldrich). The spin concentrator was loaded 
with 6 mL of dH2O to pre-rinse the membrane and spun at 3200 x g for 20 minutes at 
room temperature. The flow-through was discarded and the concentrator was loaded 
with 6 mL of apoA-I R173C at 0.8 mg/mL and centrifuged as above until the total 
volume was 1 mL. The expected apoA-I R173C concentration was 4.8 mg/mL in a 1 
mL volume and the measured concentration was 3.16 mg/mL. Therefore, the 
concentrator yield was approximately 66 % of the total protein in the dilute stock 
solution.  
Size exclusion chromatography (SEC) was used to separate apoA-I monomer and dimer 
for mass spectrometry analysis using the HiLoad™ 16/600 Superdex™ 75 pg, 120 mL 
column volume (CV), connected to the ÄKTA Start chromatography system and 
UNICORN™ Start 1.0 software (GE Healthcare). The SEC was washed at a flow rate 
of 1 mL/min with four CVs of dH2O and equilibrated with four CVs of 10 mM tris base, 
1 mM EDTA, 0.15 M NaCl, 1 mM NaN3, pH 8.0. After the TCEP reduction and 
incubation to form apoA-I R173C dimer, a sample of 3.7 mg/mL with a total volume of 
1 mL was loaded onto the column at a flow rate of 1.0 mL/min. The SEC buffer was 
run for 1 CV for dimer and monomer separation. When the protein UV absorbance 
increased above 5 mAU 1 mL fractions were collected and the concentration was 
measured using the Nanodrop™ 2000c. The fractions were run on an NDGGE gel as 
described earlier to determine the purity and amount of separation.  
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3.2.7.3 Mass spectrometry of atheroprotective mutants 
The samples were outsourced to Liverpool University where the initial protein samples 
were run, and the data was deconvoluted by Mr M. Prescott at the Institute of Integrative 
Biology using electrospray ionisation time-of-flight mass spectrometry (ESI-TOF MS) 
using the Q-ToF Micro mass spectrometer (Waters/Micromass). The SEC separated 
apoA-I R173C monomer and dimer samples were run, and data was deconvoluted by 
Dr. P. Brownridge at the Centre for Proteome Research using C4 based reversed phase 
liquid chromatography (LC) ESI-TOF MS for full-length intact mass analysis. The SEC 
fractions were confirmed to contain only monomer or dimer using NDGGE.  
The apoA-I R173C and apoA-I L144R samples were sent as 100 µL stock solutions in 
30 % (v/v) acetonitrile in MQ H2O at 1 mg/mL each for ESI-TOF MS. The apoA-I 
R173C monomer and dimer samples analysed by C4 based reversed phase LC-MS were 
in 10 mM tris, 1 mM EDTA, 1 mM NaN3, pH 7.4 containing 5 % (v/v) acetonitrile. The 
monomer sample also contained 5 mM TCEP to ensure reducing conditions and prevent 
dimer formation before the sample was analysed. The apoA-I R173C monomer and 
dimer (fractions T50/51) stock concentrations were 100 µL at 1.6 and 1.8 mg/mL, 
respectively.  
3.3 Results 
3.3.1 Evidence of plasmid mutations using SLIM-PCR  
3.3.1.1 Plasmid construct PCR products 
The SLIM-PCR reaction was used to generate mutations in the apoA-I WT (E2D) 
sequence for expression of the atheroprotective mutants, apoA-I L144R and R173C. 
Therefore, it was necessary to confirm the estimated mass of the plasmids following the 
SLIM-PCR reaction before sequencing the plasmid cDNA recombinant protein 
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sequence. The PCR amplification (Figure 3.6) and the SLIM hybridisation (Figure 
3.7–3.8) agarose gels contained strong bands labelled as the PCR products at 
approximately 4.5 kb which corresponded to the approximate number of bases as the 
apoA-I (E2D) pNFXex vector. The SLIM-PCR products were transformed into XL1-
Blue cells and the respective plasmids were isolated from overnight cultures grown 
from single colonies of the transformed cells. The purified plasmids were sequenced 
prior to protein expression tests.  
 
Figure 3.6. The SLIM-PCR amplification products from the L144R and R173C 
reactions 1 and 2 in a 0.8 % (w/v) agarose gel including a control PCR sample.  
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Figure 3.7. The SLIM-PCR hybridisation products from both the L144R and R173C 
reactions in a 0.8 % (w/v) agarose gel including a control PCR sample.  
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Figure 3.8. The SLIM-PCR hybridisation products from both the L144R and R173C 
reactions in a 0.8 % (w/v) agarose gel. 
3.3.1.2 Gene sequencing 
After confirmation of the estimated plasmid masses for apoA-I R173C and L144R by 
agarose gel electrophoresis, the plasmids were sequenced to confirm the mutation of the 
173rd and 144th residues occurred, respectively. The expected cDNA nucleotide 
sequence of apoA-I WT (E2D) is shown in Appendix 1B. The sequence of the mutated 
plasmids containing the expected R173C and L144R mutation respectively were 
compared to the apoA-I WT (E2D) cDNA sequence to confirm the presence of the 
mutation in the plasmid DNA before protein expression tests using BLAST® blast-n 
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suite (Zhang et al., 2000). The ExPASy Translate tool was used to convert the cDNA 
nucleotide sequence to amino acids (Artimo et al., 2012).  
The cDNA sequences of both the R173C and L144R mutants (Appendix 1) were 
compared to the apoA-I WT cDNA sequence using BLAST® sequence and showed the 
expected nucleotide changes of 1 and 2 nucleotides, respectively. As the BLAST® data 
showed a 99 % match for both R173C at 776/777 (CGC to TGC) nucleotides and L144R 
at 775/777 (CTG to CGC) nucleotides indicating that the codon mutations specified in 
the SLIM-PCR primers occurred. The nucleotide sequence when converted to amino 
acid sequence also showed the R173C and L144R mutations at the correct residue 
number in the protein sequence.  
3.3.2 ApoA-I (E2D) and atheroprotective mutant protein expression 
and purification 
3.3.2.1 Protein expression  
To confirm the overexpression of the fusion proteins of apoA-I WT, R173C and L144R, 
SDS-PAGE gels were used to determine the relative amount and estimate the molecular 
weight (MW) of the fusion protein compared to the E. coli proteins. The fusion protein 
N-terminally his6-tagged apoA-I (E2D) has a molecular weight of 29798.57 Da (~30 
kDa) as calculated by inputting the amino acid sequence (Appendix 1B) into the 
ExPASy Compute pI/MW tool (Artimo et al., 2012). The approximate molecular weight 
of 28 kDa is used for the fusion protein as the migration of the fusion protein in the gel 
compared to the marker bands indicates the band is less than approximately 30 kDa 
(Figure 3.9). 
In each SDS-PAGE gel for the pre- and post-induction protein expression samples of 
apoA-I WT (Figure 3.9), R173C (Figure 3.10) and L144R (Figure 3.11), the pre-
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induction sample does not have a strong band at approximately 28 kDa. This suggests 
that basal expression of the fusion protein does not occur allowing the cells to grow to 
an optimal density before IPTG is added, as basal ‘leaky’ expression of recombinant 
proteins can lead to slow cell growth rates (Rosano and Ceccarelli, 2014). After IPTG 
addition overall E. coli protein expression occurred as indicated by the bands over the 
range of 10 – 250 kDa. The fusion protein at approximately 28 kDa for each mutant and 
apoA-I WT was expressed after 2-5 hours and overnight post-induction incubation at 
37°C.  
The expression of apoA-I WT increased from 2 – 5 hours post-induction (Figure 3.9). 
The apoA-I R173C expression increased from 2 – 4 hours, with a similar intensity 
expression band at 5 hours to 3 hours post-induction (Figure 3.10). After an overnight 
induction there was a decrease in the apoA-I R173C expression. The apoA-I L144R 
expression increased over time with no significant increase after an overnight induction 
period (Figure 3.11).  
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Figure 3.9. ApoA-I WT (E2D) pre- and post-induction hourly samples over 2 – 5 hours 
on a 15 % SDS-PAGE gel.  
 
Figure 3.10. ApoA-I R173C pre- and post-induction hourly samples (2-5 hours) and 
overnight (ON) sample on a 15 % SDS-PAGE gel.  
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Figure 3.11. ApoA-I L144R pre- and post-induction hourly samples (2-5 hours) and 
ON sample on a 15 % SDS-PAGE gel.  
3.3.2.2 Nickel ion affinity chromatography 
To separate the fusion protein from the proteins expressed by the E. coli cells nickel ion 
affinity chromatography was used and the samples at each wash step were visualised 
on an SDS-PAGE gel to check for the removal of impurities. In Figure 3.12, the apoA-
I WT +his-tag protein band is indicated on the SDS-PAGE gel and the fusion protein 
band is present in the post-induction, lysis supernatant, and final elution (500 mM 
imidazole) lanes.  
In the corresponding chromatogram a peak in the UV absorbance indicated the presence 
of protein eluted from the nickel column. The flow-through (FT), lysis buffer (wash 1), 
20 mM, 45 mM and 500 mM imidazole washes are as indicated. In the purification for 
apoA-I WT the wash 1 and 45 mM imidazole bands are faint with a band at 
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approximately 28 kDa indicating that minimal amounts of the fusion protein were eluted 
at these stages. The bands are faint due to low concentration as indicated on the 
chromatogram at 45 mM imidazole with a minimal increase in UV absorbance at 
approximately 130 mL. The wash 1 and 20 mM imidazole samples were prepared 
through EtOH precipitation to remove the protein from guanidine HCl which interferes 
with samples running effectively in an SDS-PAGE gel. It appears the guanidine was 
not completely removed and/or the precipitated protein did not fully resuspend therefore 
only some faint impurity bands are visible.  
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Figure 3.12. 15 % SDS-PAGE gel of the apoA-I WT lysis pellet, lysis supernatant, 
flow-through (FT), wash 1 (W1), 20 mM imidazole, 45 mM imidazole, 500 mM 
imidazole fractions. The UV protein absorbance chromatogram of His-trap 
chromatography purification of apoA-I WT. 
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The peaks on the chromatogram confirmed the removal of non-specific binding proteins 
in the flow-through and wash 1 fractions, and the binding of the majority of the fusion 
protein to the nickel resin. The fusion protein in the 500 mM imidazole lane is indicated 
as a large band at approximately 28 kDa with some faint impurities only present at a 
high concentration as the sample was > 1.5 mg/mL on the gel. The chromatogram peak 
at 500 mM imidazole also shows a high UV absorbance up to the maximum of 2000 
mAU indicating protein elution.  
ApoA-I L144R was purified under the same conditions with each lysis and wash step 
shown in the SDS-PAGE gel (Figure 3.13). The lysis supernatant contained a larger 
amount of fusion protein at approximately 28 kDa compared to the lysis pellet and post-
induction sample. The flow-through, wash 1, 20 mM and 45 mM imidazole samples in 
the chromatogram (Figure 3.13) show UV absorbance peaks indicating the elution of 
non-specific binding E. coli proteins.  
However, similar to the apoA-I WT 20 and 45 mM imidazole wash steps (Figure 3.12) 
the apoA-I L144R fusion protein band in the corresponding samples was faint (Figure 
3.13). The eluted fusion protein at 500 mM imidazole at this high concentration at 
approximately 1 mg/mL shows some smaller impurities indicated by faint bands 
comparable to apoA-I WT and R173C. The elution fusion protein peak also reached a 
maximum of 2000 mAU.  
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Figure 3.13. 15 % SDS-PAGE gel of the apoA-I L144R pre-induction, post-induction, 
lysis pellet, lysis supernatant, FT, 20 mM imidazole, 45 mM imidazole, 500 mM 
imidazole fractions. The UV protein absorbance chromatogram of His-trap 
chromatography purification of apoA-I L144R. 
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ApoA-I R173C expressed in BL21(DE3) cells fractions are shown at each stage in the 
chromatogram (Figure 3.14) whilst the fusion protein expressed with OrigamiTM 
B(DE3) cells is shown with the respective chromatogram (Figure 3.15). The SDS-
PAGE gel of apoA-I R173C BL21(DE3) chromatogram fractions indicated fusion 
protein in the lysis supernatant, flow-through, and 500 mM elution (Figure 3.14). The 
flow-through and wash stages (wash 1, 20 mM and 45 mM imidazole) show peaks in 
the UV absorbance in the chromatogram indicating the removal of non-specific binding 
proteins, like apoA-I WT and L144R. The SDS-PAGE imidazole wash steps only show 
faint bands on the gel. The elution fraction at 500 mM imidazole is comparable with the 
apoA-I WT and L144R with faint impurities below the concentrated 1-2 mg/mL apoA-
I R173C +his-tag band. The overall apoA-I R173C +his-tag fusion protein elution peak 
maximum was lower than apoA-I WT and L144R at approximately 1200 mAU.  
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Figure 3.14. 15 % SDS-PAGE gel of the apoA-I R173C lysis pellet, lysis supernatant, 
FT, W1, 20 mM imidazole, 45 mM imidazole, 500 mM imidazole fractions. The UV 
protein absorbance chromatogram of His-trap chromatography purification of apoA-I 
R173C. 
The apoA-I R173C fusion protein expressed with OrigamiTM B(DE3) cells was purified 
and an SDS-PAGE gel was run of the final elution fraction for mass spectrometry 
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(Figure 3.15). The eluted fusion protein had a peak maximum at approximately 600 
mAU and no impurity bands as indicated on the SDS-PAGE gel. The wash stages 
contained peaks similar to the chromatograms of apoA-I WT, L144R and R173C 
(BL21(DE3)) indicating the removal of non-specific binding proteins.  
 
 
Figure 3.15. 15 % SDS-PAGE gel of the pooled apoA-I R173C + His-tag elution 
fraction protein expressed with OrigamiTM B(DE3) E. coli cells. The UV protein 
absorbance chromatogram of His-trap chromatography purification of apoA-I R173C 
expressed with OrigamiTM B(DE3) E. coli cells. 
3.3.2.3 His-tag cleavage and protein dialysis 
After separation of the fusion protein for apoA-I WT, R173C and L144R expressed 
with BL21(DE3) cells the his-tag was cleaved during incubation with formic acid. The 
SDS-PAGE gels in Figure 3.16 correspond to apoA-I WT (A), R173C (B) and L144R 
(C). Each gel shows only the fusion protein band at approximately 28 kDa (apoA-I +his-
tag) in the pre-cleavage sample lane and a lower molecular weight post-his-tag cleavage 
protein band in the post-cleavage lane.  
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Figure 3.16. 15 % SDS-PAGE gels of the pre- and post-His-tag cleavage of A) apoA-I 
WT, B) apoA-I R173C and C) apoA-I L144R, at 0.2 mg/mL protein per lane. For the 
purposes of showing the pre- and post-his-tag cleavage samples for apoA-I L144R and 
R173C, empty lanes and duplicate samples were cropped from the gel images, and the 
gels without cropping are in Appendix 1.  
3.3.3 Protein identification 
3.3.3.1 Confirmation of protein mass 
The purified post-cleavage protein samples of the atheroprotective apoA-I mutants were 
analysed by mass spectrometry to confirm their molecular masses. Initially, apoA-I 
R173C and L144R post-cleavage proteins expressed with BL21(DE3) cells were 
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analysed using ESI-TOF MS. The expected masses of apoA-I WT, R173C and L144R 
proteins residues 3-243 (post-his-tag cleavage) were predicted using the ExPASy 
compute pI/MW tool (Artimo et al., 2012) for comparison to the observed masses from 
ESI-TOF MS sample analysis.  
The expected and observed molecular masses, and the adducts for each protein are 
summarised in Table 3.2. Previously, the mass of the apoA-I WT (E2D) protein was in 
close agreement with the expected mass (Townsend, 2016). Similarly, the apoA-I 
L144R observed mass (27878 Da, Figure 3.17) is the expected mass of apoA-I L144R 
+1H atom (Table 3.2).  
The apoA-I R173C mass (28088 Da, Figure 3.18) was greater than expected by 307 
Da, therefore further investigation was required to produce the protein with the expected 
molecular mass. Before the identification of the glutathione adduct the apoA-I R173C 
+his-tag fusion protein was expressed with OrigamiTM B(DE3) cells and analysed by 
ESI-TOF MS (Figure 3.19). The measured masses were below the expected mass of 
the apoA-I R173C fusion protein suggesting that the protein expressed was modified at 
some stage in the expression.  
Table 3.2. The expected and observed masses of apoA-I WT (Townsend, 2016), L144R 
and R173C as analysed by ESI-TOF MS.  












WT 27834 27837 3 3H 
L144R 27877 27878 1 1H 
R173C 27781 28088 307 glutathione 
OrigamiTM 
B(DE3) 
R173C +His 29614 
24693 4921  
27272 2342  
28284 1330  
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Figure 3.17. The mass spectrum of apoA-I L144R by ESI-TOF MS, observed mass 27878 Da. 
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Figure 3.18. The mass spectrum of apoA-I R173C + glutathione cysteine modification by ESI-TOF MS, observed mass 28088 Da. 
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Figure 3.19. Mass spectrum of apoA-I R173C +His (OrigamiTM B(DE3) cells), by ESI-TOF MS , observed masses 24693, 27272, and 28284 Da. 
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3.3.3.2 Identification and cleavage of the apoA-I R173C glutathione moiety 
The observed mass of the apoA-I R173C post-his-tag cleavage protein was greater than 
the expected mass by 307 Da, so it was suspected that the free cysteine thiol groups 
were modified with glutathione. Therefore, the apoA-I R173C protein was reduced 
using TCEP to remove any post-translational modifications via the reduction reaction 
in Figure 3.20. ApoA-I WT does not contain cysteine residues and so the mutation 
allows for dimerization of the protein through intermolecular disulphide bridge 
formation (Weisgraber et al., 1980). This may be responsible for the atheroprotective 
properties of this mutant, and so it was necessary to regenerate free thiol groups for 
subsequent disulphide formation.  
 
Figure 3.20. The TCEP disulphide bond reduction reaction of apoA-I R173C + 
glutathione moiety. The apoA-I R173C cysteine (X1, red) contains residues 3-172 and 
174-243 in R1 and R2, respectively, and is bonded through a disulphide bond to the 
glutathione moiety (X2, purple). The reduction reaction oxidises TCEP and regenerates 
the cysteine and glutathione thiol (-SH) groups.  
After reduction, three methods were tested for removal of TCEP: dialysis only, dialysis 
and desalting (PD-10) column, and PD-10 column only. The samples were taken of 
apoA-I R173C + 5 mM TCEP at 0 and 192 hours, post-TCEP removal for each method 
at 0, 24, 120 and 192 hour incubation periods (Figure 3.21). Successful removal of 
Chapter 3: Atheroprotective apoA-I mutant expression and characterisation 
Sophie Lau - July 2021   125 
glutathione could be monitored by mass spectrometry (see later) and inferred by the 
formation of dimeric protein. Both apoA-I R173C samples in the presence of the 
reducing agent showed a singular band at approximately 28 kDa for apoA-I R173C 
monomer. Similarly, the presence of only monomeric apoA-I R173C is indicated at 
each timepoint for the samples using dialysis and the PD-10 column, and only the PD-
10 column for TCEP removal. The apoA-I R173C dimer and monomer bands are 
indicated in the TCEP dialysis only removal method. 
 
Figure 3.21.A 4 – 16 % NativePAGE gel of apoA-I R173C samples +5 mM TCEP and 
without TCEP removed by three different methods: dialysis, dialysis and PD-10, and 
PD-10 only at 0, 24, 120 and 192 hours. 
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The TCEP was removed by dialysis and a sample was taken at 24 hour intervals over 7 
days (Figure 3.22). ApoA-I R173C dimer and monomer were present at relatively equal 
amounts at each time point except for 0 hr after TCEP removal, at approximately 56 
and 28 kDa, respectively. The apoA-I R173C sample containing 5 mM TCEP also 
contained dimeric and monomeric apoA-I R173C possibly due to formation of dimer in 
the presence of TCEP in an equilibrium or partial oxidation of the TCEP reducing agent.  
 
Figure 3.22. A 4-16 % NativePAGE gel of ApoA-I R173C with 5 mM TCEP and 
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Size exclusion chromatography fractions run on a NativePAGE gradient gel of the 
separation of apoA-I R173C monomer and dimer post-TCEP reduction and the UV 
absorbance chromatogram are in Figure 3.23. The fractions labelled in the gel were 
eluted during the SEC and correspond to peak 1 (blue) and peak 2 (green) in the 
chromatogram. Fractions T47 – T54 show a band at approximately 56 kDa indicating 
dimeric apoA-I R173C only. Monomeric apoA-I R173C was in fractions T56 – T60 at 
approximately 28 kDa. Fractions T47-48 and T55 contained a lower concentration of 
dimeric apoA-I R173C than T49-T54 shown by the faint band intensity. The SEC was 
used to separate monomeric and dimeric apoA-I R173C protein for mass spectrometry 
analysis only and the separation was not further optimised. 
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Figure 3.23. A 4 – 16 % NativePAGE gradient gel of post-TCEP apoA-I R173C SEC 
fractions T47-T54 (peak 1, blue) and T55-T60 (peak 2, green) indicated in the UV 
protein absorbance chromatogram. 
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The post-TCEP treated apoA-I R173C monomer and dimer SEC separated samples 
were analysed using mass spectrometry to confirm the molecular masses and if the 
suspected glutathione adduct was removed. The expected and observed masses are in 
Table 3.3 of the apoA-I R173C post-TCEP treated monomer and dimer, and the 
previous pre-TCEP monomer mass for comparison.  
Table 3.3. The expected and observed masses of apoA-I R173C monomer and dimer 











Pre-TCEP 27781 28088 307 glutathione 
Monomer 27781 27783 2 2H 
Dimer 55560 55563 3 3H 
 
After TCEP treatment post-glutathione cleavage apoA-I R173C monomer and dimer 
separated by SEC expected masses are 27781.37 and 55560.74 Da, respectively. The 
measured mass of monomeric apoA-I R173C was 27783.45 Da (Figure 3.24) and 
dimeric apoA-I R173C was 55563.43 Da, with another peak at lower intensity at 
27781.21 Da (Figure 3.25). The smaller mass at 27781.21 Da despite the similar mass 
to monomeric apoA-I R173C was probably a processing artefact as the NativePAGE 
gel of fractions T50/51 combined for MS indicated that only dimeric apoA-I R173C 
was present in the sample (Figure 3.23). The mass difference of apoA-I R173C 
monomer and dimer was 2 and 3 Da, corresponding to +2H and +3H atoms, 
respectively. Therefore, the MS masses confirmed the correct masses of apoA-I R173C 
monomer and dimer protein expressed.  
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Figure 3.24. ApoA-I R173C monomer mass spectrum deconvoluted mass 27783.45 Da using C4 based reversed phase LC-MS for intact mass 
samples. 
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Figure 3.25. ApoA-I R173C dimer mass spectrum, deconvoluted mass of 55563.43 Da using C4 based reversed phase LC-MS for intact mass 
samples.  
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The apoA-I WT, R173C and L144R proteins were run on a NativePAGE gradient gel 
(Figure 3.26) to confirm if monomeric or dimeric protein was present in the stock 
protein solutions (>2.0 mg/mL). Each protein contained monomer and dimer at 
approximately 28 and 56 kDa, respectively.  
 
Figure 3.26. A 4 – 16 % NativePAGE gradient gel of lipid-free apoA-I WT, R173C 
and L144R under non-denaturing conditions at 8 ug protein per lane (0.4 mg/mL), with 
dimeric and monomeric protein bands indicated. 
This suggests that the apoA-I WT and L144R mutant do not require a cysteine residue 
to form dimers, as the dimers cannot form through the formation of an intermolecular 
disulphide bond like apoA-I R173C. This can be expected as the apoA-I proteins have 
the capability to form dimers for discoidal HDL nanoparticle formation (Fiddyment et 
al., 2011; Giudice et al., 2017). Lipid-free apoA-I WT structural models show the 
formation of dimeric apoA-I due to the intermolecular interactions between monomers 
(Oda, 2017). ApoA-I dimers can form at > 0.1 mg/mL concentrations as lipid-free 
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apoA-I multimer formation is concentration dependent (Davidson et al., 1996; Giudice 
et al., 2017; Oda, 2017; Petrlova et al., 2016). Additionally, a comparison of the 
observed masses (Table 3.2-3.3) for each apoA-I protein shows that only the apoA-I 
R173C forms a stable dimer under MS conditions. Taken together, this suggests that 
the formation of an intermolecular covalent bond in the apoA-I WT and L144R dimers 
is not critical to dimer formation but that the disulphide bond in dimeric apoA-I R173C 
could stabilise the apoA-I R173C dimer under MS conditions.  
3.3.3.3 Protein expression yield 
The average unlabelled and labelled protein expression yields for apoA-I WT, R173C 
and L144R are given in Table 3.4. ApoA-I WT expressions had the highest average 
yield at 56 mg/L. Whereas apoA-I R173C and L144R average yields were similar to 
each other but lower than achieved for apoA-I WT, being 33 and 32 mg/L respectively. 
The dual-labelled apoA-I L144R had a high yield of 53 mg/L in comparison to apoA-I 
WT at 19 mg/L but the yield of dual-labelled apoA-I R173C was considerably lower at 
7 mg/L post-TCEP treatment. The singular isotopically labelled [13C]- and [15N]-apoA-
I WT protein yields were 24 and 29 mg/L, respectively. Further optimisation of the 
expression on minimal media was not attempted as sufficient quantities of protein were 
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Table 3.4. ApoA-I WT, R173C and L144R average protein expression yield (mg per 
Litre of LB) ±SD, the number of expressions averaged = n, and the range (mg/L).  
Protein Average Yield (mg/L) ±SD Range (mg/L) 
apoA-I WT 55.6 ±25.8 23.1 – 99.0 (n = 6) 
apoA-I R173C 33.4 ±8.2 24.5 – 44.4 (n = 4) 
apoA-I L144R 32.3 ±13.2 21.1 – 49.0 (n = 4) 
[13C, 15N]-apoA-I WT 19.2 (n = 1) 
[13C]-apoA-I WT 24.4 (n = 1) 
[15N]-apoA-I WT 29.0 (n = 1) 
[13C, 15N]-apoA-I R173C 7.3 ±0.4 7.0 – 7.7 (n = 2) 
[13C, 15N]-apoA-I L144R 52.5 (n = 1) 
 
The protein expression range is shown as an indicator of a low yield compared to a high 
yield for the unlabelled protein expressions. Each expression minimum yield was at 
least 20 mg/L indicating a usable yield if an anomalous expression occurred. Whilst the 
maximum yields of apoA-I R173C, L144R and WT were 44, 49 and 99 mg/L indicating 
that the protein yields over these ranges were sufficient for routine use.  
3.4 Discussion 
3.4.1 Comparison of expression conditions of native and 
atheroprotective apoA-I  
The conditions for expressing atheroprotective apoA-I mutants were identical to those 
used for apoA-I WT (E2D) expression, except that apoA-I R173C required the 
additional reduction step to remove the glutathione moiety from the cysteine residue to 
form disulphide bonded dimeric apoA-I R173C. This is the first use of TCEP as a 
reducing agent to form dimeric apoA-I R173C. The apoA-I R173C and L144R plasmid 
masses at approximately 4.5 kb were at the expected number of bases of the pNFXex 
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vector. Additionally, the protein cDNA gene sequences were determined to be 99 % 
accurate compared to apoA-I WT (E2D) indicating a single residue mutation for both 
R173C and L144R cDNA sequences within the pNFXex vector.  
The apoA-I R173C expression presented some difficulties in determining the post-
translational modification glutathione moiety and removal with an adaptation of the 
TCEP reduction method of a prion protein with the glutathione adduct (Sengupta and 
Udgaonkar, 2017). The OrigamiTM B(DE3) cells were used containing the apoA-I 
R173C pNFXex vector, however the mass spectrum of apoA-I R173C +his-tag 
indicated the presence of multiple incorrect molecular species with masses below the 
expected mass, therefore the expression using OrigamiTM B(DE3) cells was not further 
optimised. 
To confirm the masses of the monomeric and dimeric apoA-I R173C SEC was used to 
separate the monomer and dimer post-glutathione cleavage (Figure 3.23) for mass 
spectrometry analysis. The minor mass differences between the expected and measured 
masses of the monomer and dimer confirmed the masses to be correct of the expressed 
recombinant protein apoA-I R173C monomer and dimer. 
Both apoA-I R173C and L144R expressions were optimised with similar yields and 
purity to apoA-I WT for comparative structural and functional studies at 33 and 32 mg/L 
of culture media, respectively. Additionally, apoA-I L144R was expressed with similar 
purity and yield to Fiddyment et al. at approximately 30 mg/L of culture media 
(Fiddyment et al., 2011).  
The minimal media expression of dual-labelled apoA-I R173C required optimisation 
indicated by the low yield of 7 mg/L of media. The dual-labelled apoA-I WT minimal 
media expression produced 19 mg/L. In comparison, the dual-labelled apoA-I L144R 
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yield was as high as the maximum expression yield for unlabelled apoA-I L144R at 52 
mg/L and 49 mg/L, respectively. The labelled apoA-I R173C protein yield was low due 
to precipitation during the TCEP incubation and dialysis stages to remove the reducing 
agent and incubation to form dimeric apoA-I R173C. However, improvements were 
made to the unlabelled apoA-I R173C TCEP protocol with a maximum protein 
concentration of 0.5 mg/mL used to reduce the protein precipitation during the TCEP 
reduction and dimer formation.  
The purified apoA-I proteins when run on a NativePAGE gel at a concentration of 0.4 
mg/mL showed monomeric and dimeric apoA-I diluted from concentrated stock 
solutions > 2.0 mg/ml. This in agreement with previous studies on apoA-I in solutions 
at a concentration > 0.1 mg/ml has been shown to form multimers (dimeric, tetrameric 
or greater) as the protein concentration increased (Davidson et al., 1996; Giudice et al., 
2017; Oda, 2017; Petrlova et al., 2016). Therefore, the apoA-I WT and L144R proteins 
formed an approximately similar ratio of monomeric to dimeric apoA-I as apoA-I 
R173C. 
The apoA-I R173C in the presence of TCEP did not form approximately equal amount 
of dimer and monomer as shown in the NativePAGE gels (Figure 3.21-3.22) whilst 
samples without TCEP after 24 hours showed approximately equal amounts of 
monomeric and dimeric apoA-I R173C. This suggests that the formation of apoA-I 
R173C dimer was a result of the formation of a disulphide bond between two monomer 
cysteine residues rather than a concentration dependent effect of dimer/multimer 
formation.  
Overall, a combination of the protein yields of the atheroprotective apoA-I mutants at 
approximately 30 mg/L, the high level of protein purity as assessed by SDS-PAGE gels 
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and the confirmation of accurate mass using mass spectrometry indicated that 
expression and purification conditions developed here were suitable for providing the 
proteins as required throughout the study.  
The apoA-I R173C and L144R mutants yields at ~30 mg/L of culture media were 3-
fold less than comparative apoA-I WT yields of up to 120 mg/L (Del Giudice and 
Lagerstedt, 2018; Ryan et al., 2003; Townsend, 2016). As a comparison early bacterial 
expressions of apoA-I WT produced low yields between 0.1 – 650 µg/L, and relatively 
higher yields up to 5 – 20 mg/L (Brouillette and Anantharamaiah, 1995; Panagotopulos 
et al., 2002; Pyle et al., 1996; Schmidt et al., 1995).  
In a laboratory scale expression ~100 mg/L of culture media for apoA-I WT is a high 
amount of protein for routine expression needs. A direct comparison of laboratory-scale 
recombinant apoA-I R173C yields was not available at this time. Previous industrial-
scale batch-fed E. coli expressions of the apoA-I R173C mutant yielded between 2 – 
4.9 g/L of culture media (Calabresi et al., 1994; Caparon et al., 2010). The large-scale 
expression demonstrated it is feasible to produce higher yields of apoA-I R173C. 
Further optimisation of the apoA-I R173C and L144R expression methodology would 
be required to optimise the expression yields on a non-industrial scale. For example, 
another optimised expression protocol high-cell density culture system produced yields 
of unlabelled ~ 17 - 34 mg and [13C,15N, 2H]-labelled apoA-I WT 14 – 25 mg/ 50 mL 
of culture media (Sivashanmugam et al., 2009). 
Recent reviews have discussed progress of recombinant protein expression in E. coli 
cells such as the strain genotype, plasmid design, expression on an industrial scale, and 
selection of overexpressing cells to obtain optimal yields (see reviews for more detail 
and refs therein) (Rosano et al., 2019; Tripathi and Shrivastava, 2019). Therefore, there 
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are other options to consider for future optimisation of the expressions of apoA-I R173C 
and L144R to obtain a similar or higher yield to apoA-I WT (~100 mg/ L).  
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4 Production of reconstituted 
High-Density Lipoproteins 
4.1 Introduction 
A protocol for producing rHDL nanoparticles comprising phospholipids and apoA-I 
with and without cholesterol for structural and functional comparisons of rHDL 
containing WT and mutant proteins was required. The following section is a summary 
of the process of rHDL nanoparticle formation. Henceforth, rHDL particles containing 
WT apoA-I will be referred to as rHDL-WT, and likewise rHDL containing the mutant 
proteins will be termed rHDL-R173C and rHDL-L144R.  
4.1.1 Discoidal rHDL nanoparticle formation  
Discoidal rHDL nanoparticles are similar in shape to nascent plasma HDL nanoparticles 
as in the “double-belt” model (Segrest et al., 1999). The rHDL nanoparticles are 
prepared in vitro using the now widely-used detergent-mediated reconstitution method 
with physiologically relevant lipids containing unsaturated bonds such as egg-PC and 
saturated DPPC established by Matz and Jonas (Jonas, 1986; Matz and Jonas, 1982).  
The sodium cholate detergent-mediated dialysis method is described in the methods 
section 4.2.1 for rHDL nanoparticle formation (Jonas, 1986). The temperature at each 
stage of the sodium cholate dialysis method is close to and above the lipid gel to liquid 
phase transition temperature (Tc) to improve rHDL formation. The Tc of DMPC is 24°C 
and for POPC Tc is -2°C, and preparation temperatures of 25°C and 4°C, have been 
reported (Jonas, 1986; Pownall et al., 1978). The detergent is removed by extensive 
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dialysis in excess of 500-fold buffer (Jonas, 1986). During dialysis the concentration of 
the detergent molecule decreases to below the critical micellar concentration (CMC) 
which results in the dissociation of detergent micelles to detergent monomers for 
removal (Seddon et al., 2004). The CMC is the minimum concentration of a molecule, 
lipid or detergent, required to form a micelle (Seddon et al., 2004). 
The lipid/detergent mixed micelles and amphipathic apoA-I interact to form discoidal 
rHDL nanodiscs. The hydrophobic interactions in the lipid-lipid and protein-lipid 
interface are principally formed by the hydrophobic effect and are a major factor in the 
assembly and stability of rHDL nanoparticles as shown in previous discoidal HDL self-
assembly coarse grained molecular dynamics (CGMD) simulations (Shih et al., 2007a; 
Shih et al., 2007b), and in the discoidal HDL “double-belt” model (Nath et al., 2007). 
The hydrophobic effect acts upon the hydrophobic groups to minimise the exposure to 
the aqueous environment, i.e., the hydrocarbon lipid tails, referred to as the attractive 
force enabling aggregation/association of the nonpolar groups in an amphiphile 
(Luckey, 2014; Tanford, 1973). There is also a repulsive force between the polar groups 
of the amphiphile, i.e. the same charge on the lipid headgroup(s) causes ionic 
electrostatic repulsion and limits size in amphiphile micelle formation (Tanford, 1973).  
Cholesterol can be incorporated into discoidal rHDL in the reconstitution process by 
adding cholesterol in the initial lipid drying and resuspension of the lipid film (Jonas, 
1986). In discoidal rHDL the majority of cholesterol is not in the boundary layer of 
lipids interacting with apoA-I (Jonas, 1986), but is located in the central region of the 
bilayer leaflet similar to the model of nascent HDL containing POPC:cholesterol:apoA-
I molar ratios of 160:24:2 and 200:20:2 produced by Pourmousa et al. (Pourmousa et 
al., 2018). The cholesterol molecules in the model are oriented with the hydroxyl moiety 
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facing the aqueous solution with the lipid headgroups, and the cholesterol molecules 
are intercalated between lipids in the nanodisc lipid bilayer (Pourmousa et al., 2018).  
4.1.2 The structure of lipids, cholesterol, and sodium cholate 
Phospholipids are amphipathic containing the hydrophobic hydrocarbon fatty acid tails 
connected to a hydrophilic glycerol-phospho-choline or phosphatidylcholine head 
group (Figure 4.1). The lipid used to prepare rHDL nanoparticles was 1-palmitoyl-2-
oleoyl-glycero-3-phosphocholine (16:0-18:1 PC or POPC) as this lipid is 
physiologically relevant (Figure 4.1) (Jonas, 1986; Matz and Jonas, 1982). 
Additionally, the majority of phospholipids in native HDL particles contain PC at 
approximately 33-45 wt% of total HDL lipid, including POPC (Kontush et al., 2013; 
Wiesner et al., 2009). The 16:0-18:1 ratio refers to the fatty acid acyl chain length: the 
number of unsaturated bonds within the tail at positions sn-1 and sn-2, and sn refers to 
the stereospecific numbering (Figure 4.1).  
 
Figure 4.1. The structure of POPC (16:0-18:1 PC) with sn numbers 1-3 (magenta), the 
hydrophobic fatty acid hydrocarbon tails (black), and the hydrophilic glycerol-phospho-
choline (blue-red-green). The structures of sodium cholate (bile salt), and cholesterol.  
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Cholesterol is similar in structure to sodium cholate with a rigid steroid ring and a single 
hydroxyl group (Figure 4.1). Sodium cholate is a bile salt commonly used to form 
rHDL and consists of rigid steroid rings with 3 hydroxyl groups, attached to an acyl 
carboxyl chain (Figure 4.1). In comparison to sodium cholate cholesterol is 
considerably less polar and therefore more hydrophobic. Sodium cholate is also ionic, 
readily soluble in aqueous buffers, and a mild non-denaturing detergent (Seddon et al., 
2004). 
4.1.3 Size fractionation of HDL 
Reconstituted HDL nanoparticles are heterogeneous in particle size, and restricted size 
ranges can be separated using size exclusion chromatography (SEC) or the particle 
density using density gradient ultracentrifugation (UTC) (Jonas, 1986). Native HDL 
particles have a density between 1.063 – 1.21 g/mL and can be separated based upon 
the particle density by flotation UTC (Fl-UTC) to separate from lipid-free apoA-I (Jonas 
et al., 1984; Schumaker and Puppione, 1986), or gradient density UTC (linear or 
discontinuous) to separate the rHDL particles from liposomes and free apoA-I 
(Cavigiolio et al., 2008; Jonas, 1986; Kelley and Kruski, 1986).  
Non-denaturing gradient gel electrophoresis (NDGGE) with NativePAGE gels are used 
to estimate the rHDL particle size (Cavigiolio et al., 2008; Dalla-Riva et al., 2015). 
Negative stain transmission electron microscopy (TEM) (Cavigiolio et al., 2008; Zhang 
et al., 2011) and dynamic light scattering (DLS) (Del Giudice et al., 2017; 
Schwendeman et al., 2015; Wu et al., 2009; Wu et al., 2007) have also been used to 
measure particle size. In this work the rHDL particle separation techniques were 
compared, and the particle size was measured using NDGGE, TEM, and DLS (Figure 
4.2).  
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Figure 4.2. The stages of rHDL nanoparticle preparation for further structural and 
functional characterisation. 1. Sodium cholate dialysis. 2. rHDL nanoparticle size 
fractionation with SEC or density-based ultracentrifugation (step gradient or flotation). 
3. Size characterisation by NDGGE, DLS, or TEM. The final rHDL nanoparticle 
component compositions were determined with concentration assays.  
4.1.4 Plasma HDL nanoparticle molar ratios 
In this section the size distributions of plasma HDL nanoparticles of previous in vitro 
and in vivo studies are described for each apoA-I protein. A comparison of the different 
plasma HDL sizes informed the decision to produce rHDL nanoparticles with a 
predominant diameter between 8-11 nm in this work.  
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The plasma HDL WT nanoparticle subclasses (see Chapter 1, Table 1.1), as 
characterised by NDGGE are HDL3c (7.2-7.8 nm), HDL3b (7.8-8.2 nm), HDL3a (8.2-8.8 
nm), HDL2a (8.8-9.7), and HDL2b (9.7-12.9 nm) (Nichols et al., 1986). Native HDL WT 
nanoparticles formed in vitro by incubation of apoA-I with various cell types and in 
human or murine plasma have diameters between ~7.3-12.2 nm (Table 4.1, see 
references therein), with major particles in each NDGGE subclass. 
Additionally, the all atom MD (AAMD) model of Pourmousa et al. (2018) had particle 
molar ratios and diameters of 160:24:2 (10 nm) and 200:20:2 (11 nm) similar to the 
nascent HDL particles characterised by Duong et al. at ~196:24:2 (9 nm) from J774 
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Table 4.1. Nascent HDL WT, R173C and L144R particle hydrodynamic diameter with 
major particles in bold (SEC, NDGGE and 2D-NDGGE), and diameter by TEM. The 
cell line in vitro models are J774 (murine) or THP-1 (human) macrophages, human skin 
fibroblasts (HSF) or Chinese hamster ovary (CHO) cells. The subject plasma types are 
human or murine with the protein(s) expressed in vivo indicated.  
Diameter (nm) 
Model Reference 
SEC  TEM NDGGE 





8.5, 12, 14 (2D) J774 
(Duong et al., 2006) 
8 ±0.4 
11 ±0.6 
 7.5, 11, 13 (2D) HSF 
  
7.4, 9-9.2,  
10.8-11 
THP-1 (Bielicki et al., 1999) 
 13.6 ±2.9 
7.3 ±0.05  
9.3 ±0.08  
11.1 ±0.09 
14.2 ±0.16 and 
16.3 ±0.12  
CHO (Forte et al., 1995) 
 9.4 ±1.7 




(Franceschini et al., 1987; 
Franceschini et al., 1980) 
  
7.8, 8.5-13  
(2D antibody) 
human (Favari et al., 2007) 
  
8.8-12.9 
7.9, 8.7, 9.4, 10.0 
apoA-I/A-
II murine 
(Bielicki et al., 1997) 








(Franceschini et al., 1987; 
Franceschini et al., 1982; 
Franceschini et al., 1980) 
  7.8, 8.5-13 (2D) human (Favari et al., 2007) 
  10, 12 murine (Alexander et al., 2009) 
  
 
7.6, 8.3 (55%) 
 9.5 (45 %) 
 







(Bielicki et al., 1997) 
apoA-I L144R     
  
5-6 and 7-7.5(2D) 
7.8-8.2, 8.2-8.8  
8.8-9.7 
murine (Haase et al., 2011) 
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In comparison, the atheroprotective mutants have a shifted plasma HDL distribution 
compared to plasma HDL WT particles, with reduced HDL2 (8.8-12.9 nm) particles in 
human carriers for apoA-I R173C (Franceschini et al., 1987; Franceschini et al., 1982) 
and a reduced overall size in human apoA-I L144R carrier plasma (Recalde et al., 2001) 
and in a mouse model for apoA-I L144R (Haase et al., 2011). Therefore, rHDL infusion 
therapy has focussed on smaller rHDL nanoparticles which mediate ABCA1 cholesterol 
efflux with lower lipid:apoA-I molar ratios such as CSL112 soy-PC:apoA-I WT at 
110:2 (M/M) with a 7.5-8.0 nm in diameter (Diditchenko et al., 2013) and MDCO-216 
POPC:apoA-I R173C at 78:2 (M/M) with an 8 nm particle diameter (Kempen et al., 
2013).  
However, there is evidence of larger rHDL nanoparticles between 8.5-13 nm in 
diameter in the HDL2 subclasses as detected in human apoA-I R173C plasma (Favari 
et al., 2007), and in murine mouse models (Alexander et al., 2009; Bielicki et al., 1997). 
The major 7.6 nm diameter HDL nanoparticle in an apoA-I R173C/A-II murine model 
suggested an increase in apoA-I R173C dimer formation without apoA-I WT decreased 
the particle size population (Bielicki et al., 1997).  
Additionally, the murine plasma HDL L144R particle distribution contained minor 
populations of larger particles between 8.8-9.7 nm in diameter (Haase et al., 2011). An 
established human plasma HDL distribution for apoA-I L144R carriers has yet to be 
established to the extent of apoA-I WT or R173C carriers. Moreover, larger rHDL 
nanoparticles were utilised for diversifying rHDL infusion therapy, for example, as a 
statin carrier (25-30 nm) (Duivenvoorden et al., 2014) and as an MRI plaque imaging 
agent carrier (~10 nm) (Chen et al., 2013). Therefore, this chapter has focused upon 
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producing discoidal rHDL atheroprotective mutant particles with a similar diameter to 
the nascent HDL WT nanoparticles between approximately 8 – 11 nm.  
4.1.5 Discoidal rHDL nanoparticle size and molar ratios 
Discoidal rHDL nanoparticles prepared with POPC:±cholesterol:apoA-I form different 
sizes of rHDL nanoparticles based upon the molar ratio of the components used (Jonas, 
1986). The rHDL nanoparticle sizes from previous studies are summarised in the 
discussion for a direct comparison to rHDL nanoparticles produced in this work (see 
section 4.4.2, Table 4.9, and references therein). The range of rHDL nanoparticles 
was between ~7.3-17.0 nm dependent upon the start molar ratio (Table 4.9).  
This study focused on the POPC:apoA-I WT 100:1 molar ratio to produce rHDL apoA-
I WT (rHDL-WT) nanoparticles as the predominant band in the rHDL nanoparticle 
preparations was between 9.7-10.2 nm diameter and appeared to form regardless of the 
molar ratio used (Chen et al., 2009; Gu et al., 2010; Sparks et al., 1992b). Hereafter, the 
discoidal rHDL nanoparticle molar ratios will be referred to as POPC:±cholesterol: 2 
apoA-I molecules per nanoparticle, e.g. 200:2. This is based on current knowledge of 
chemical cross-linking of apoA-I in discoidal rHDL nanoparticles within the diameter 
range of ~8-11 nm (Cavigiolio et al., 2008; Han et al., 2005; Silva et al., 2005b; Silva 
et al., 2008).  
rHDL nanoparticles containing cholesterol can form between ~7.8-17.0 nm in diameter 
at various molar ratios (Table 4.9). Cavigiolio et al. produced particles with average 
diameters within the five subclasses of plasma HDL nanoparticles (Cavigiolio et al., 
2008). The intermediate particle size between 9.2-10.0 nm (182:8:2 mol/mol) is similar 
in size and molar ratio to the 200:20:2 molar ratio, which as discussed earlier resembles 
nascent plasma HDL WT nanoparticles (Duong et al., 2006; Pourmousa et al., 2018). 
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Wu et al. produced rHDL nanoparticles prepared at the 200:20:2 molar ratio with an 
average diameter of ~9.6 nm by NDGGE and produced the discoidal HDL solar flare 
(Wu et al., 2007) and DSH HDL models (Wu et al., 2009).  
rHDL-WT nanoparticles previously prepared at the 200:20:2 molar ratio were used in 
functional studies with binding via apoA-I WT to the murine SR-B1 cell receptor in 
vitro (Xu et al., 1997), and in mediating ABCA1- (Chroni et al., 2003) and ABCG1- 
(Daniil et al., 2013) mediated cholesterol efflux in vitro from murine J774 macrophages. 
Reconstituted HDL R173C nanoparticles prepared at the 190:10:2 molar ratio were 
between 9.8-10.0 nm in diameter with a final molar ratio of 100 ±10: 5: 1 and infusion 
resulted in lesion regression in an atherosclerotic mouse model (Cho and Kim, 2009). 
Additionally, rHDL-WT nanoparticles produced at the 190:10:2 molar ratio were used 
as LCAT enzyme reaction substrates which demonstrated the particles can be used to 
determine cholesteryl ester formation (Han et al., 2005).  
The previous literature of functional studies with rHDL nanoparticles at these molar 
ratios indicated that further study combined with structural characterisation of the rHDL 
bearing the atheroprotective mutants could provide mechanistic information in how 
these particles transport cholesterol or interact with enzymes in reverse cholesterol 
transport. To determine if the atheroprotective mutant containing rHDL nanoparticles 
are atheroprotective due to the presence of the mutant protein(s) only rHDL 
nanoparticles of comparable size and composition were prepared to the rHDL-WT 
nanoparticles.  
To show the current scale of rHDL nanoparticle yields, the preparation of rHDL-C WT 
160:8:2 nanoparticles is briefly described. The rHDL-C nanoparticles of various sizes 
were prepared using the sodium cholate dialysis method followed by ultracentrifugation 
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and size exclusion chromatography purification (Cavigiolio et al., 2008). The rHDL-C 
WT 160:8:2 nanoparticles had a diameter of ~9.6 nm and the highest yield at ~32.8 
±11.3 % relative to the starting apoA-I concentration. In comparison the rHDL-C ~8.4 
and 12.2 nm diameter particle yields were ~8.2 – 9.2 %. Whereas the 7.8 and 17.0 nm 
diameter particle yields were ~19.1 and 12.5 %, respectively (Cavigiolio et al., 2008). 
The less than 50 % and varied yields suggested that there are improvements required to 
optimise the yield of rHDL nanoparticle production.  
This work is the first preparation of rHDL-L144R nanoparticles for routine production 
and further characterisation. As well as a direct comparison between the rHDL 
nanoparticles containing apoA-I WT, R173C or L144R produced using the sodium 
cholate dialysis method. Three different methods were tested for the purification of the 
rHDL nanoparticles size exclusion chromatography, flotation, and step-gradient density 
ultracentrifugation.  
4.1.6 Aims 
It was necessary to develop a reliable method to produce rHDL nanoparticles bearing 
apoA-I WT of defined composition and size. After the method was developed rHDL 
particles containing the atheroprotective mutants apoA-I R173C and L144R were 
produced for direct comparison to the rHDL-WT particles. The rHDL nanoparticles of 
known composition and size were produced for further characterisation in later 
chapters.  
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4.2 Materials and methods 
4.2.1 Production of rHDL via sodium cholate dialysis 
Initially, lipids are dissolved in chloroform and the solvent is evaporated with a stream 
of nitrogen to form a thin lipid film. Mixed micelles of lipid and sodium cholate are 
formed when the film is resuspended in buffer containing sodium cholate up to a lipid: 
sodium cholate molar ratio of 1:2. After the formation of mixed micelles of lipid and 
sodium cholate as indicated by the change from an opaque to translucent solution 
(Walter et al., 1991), apoA-I is added to the solution and incubated for at least 12 hours 
(Jonas, 1986). 
Sodium cholate detergent mediated dialysis was used to form rHDL with the more 
physiologically relevant phospholipid POPC adapted from the method described and 
implemented by Jonas et al. (Jonas, 1986; Matz and Jonas, 1982). To form a 
concentrated POPC/sodium cholate stock solution to form rHDL with apoA-I, typically 
> 30 mg of POPC was weighed into a round bottom flask and dissolved in chloroform 
in a fume hood. A thin lipid film was formed in the flask by evaporation of the 
chloroform under a stream of N2 whilst rotating the flask. The lipid film was placed 
under high vacuum for a minimum of 4 hours or overnight before resuspending in 
aqueous buffer. The sample buffer was 10 mM tris HCl, 1 mM EDTA, 1 mM NaN3, pH 
7.4. Henceforth this is referred to as rHDL buffer. A minimum volume of 0.5 mL rHDL 
buffer, pH 7.4, was used to resuspend the lipids.  
Sodium cholate (bovine) was dissolved in rHDL buffer pH 7.4, to a final concentration 
of 232.2 mM (100 mg/mL) to form a concentrated stock solution. Initially, the sodium 
cholate was added to the lipid film at an equimolar concentration to a final volume of 
0.5 mL. The POPC/sodium cholate 1:1 (M/M) was incubated above the Tc of POPC (-
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2°C) at 4°C for 1-2 hours until the solution became clear indicating the formation of 
POPC/sodium cholate micelles. If the solution remained turbid, sodium cholate was 
added up to a 1:2 lipid: sodium cholate molar ratio with the sample volume increased 
to 1 mL.  
Samples were prepared to the final POPC/ apoA-I molar ratio of 200:2 (M/M) with 
apoA-I WT, apoA-I R173C and apoA-I L144R, expressed and purified as described in 
Chapter 3, section 3.2.6. Some samples were prepared with uniformly [13C, 15N]-
labelled apoA-I for NMR analysis. The initial lipid concentration was typically 3 or 5 
mM dependent upon the protein stock concentration used as this limited the maximum 
lipid concentration. After protein expression the protein concentration was usually 
between 1 – 2 mg/mL, which is equivalent to 36 – 72 µM for WT apoA-I, apoA-I R173C 
and apoA-I L144R. Therefore, to minimise the protein volume added a concentrated 
protein solution was prepared as described below, usually ≥ 6 mg/mL equivalent to 0.22 
mM.  
Initially lyophilisation was used to concentrate the apoA-I protein solutions. The 
proteins were dialysed at 4°C using the 12-14 kDa molecular weight cut-off (MWCO) 
membrane dialysis tubing into 50 mM ammonium bicarbonate, pH 8.0, with at least 1 
buffer change over 2 days. The protein was aliquoted and flash frozen using liquid N2 
over a large surface area such as a round bottom flask and lyophilised for 24 hours in a 
freeze-dryer. The cycle was repeated if the solvent was not completely sublimated and 
lyophilised protein. The protein was then resuspended in a smaller volume of sample 
buffer to ≥ 6 mg/mL.  
However, there were issues with precipitation of the protein during dialysis and 
incomplete resuspension after lyophilisation. Therefore, to concentrate the protein or 
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buffer exchange, Corning® Spin-X UF 6 PES membrane spin concentrators were used 
as described previously to prepare a concentrated apoA-I solution at ≥ 6 mg/mL for 
rHDL nanoparticle formation. An example of a typical rHDL sample POPC, sodium 
cholate and apoA-I stock concentrations (conc.) and volumes used is shown in Table 
4.2.  
Table 4.2. Typical rHDL sample preparation conditions. The preparation of the 
POPC/sodium cholate mixed micelle stock solution concentrations, and apoA-I addition 
to the mixed micelles.  
Stock Conc. 
(mM) 





- POPC Film 78.9 
1:1 
232.2 Sodium cholate 170.0 78.9 
 rHDL buffer, pH 7.4 330.0   
 Total volume (µL) 500   
Incubation period for lipid/detergent micelle formation 
78.9 POPC/sodium cholate 63.4 5 
200:2 
0.22 apoA-I WT 227.3 0.05 
 rHDL buffer, pH 7.4 709.4   
 Total volume (µL) 1000   
 
The POPC/apoA-I 200:2 (M/M) sample was incubated for at least 12 hours (overnight) 
at 4°C with mixing. To remove the sodium cholate the rHDL sample was extensively 
dialysed against rHDL buffer pH 7.4 (500-fold excess), using 12 – 14 kDa MWCO 
dialysis tubing, with at least 5 buffer changes over 3 days. The samples were then run 
on a 4 – 16 % NativePAGE gel to determine if rHDL formed at this molar ratio of 
Chapter 4: Production of reconstituted High-Density Lipoproteins 
Sophie Lau - July 2021   153 
lipid/apoA-I and were further purified using SEC or density gradient 
ultracentrifugation.  
4.2.2 Production of rHDL containing cholesterol 
The detergent mediated sodium cholate dialysis method used to produce discoidal rHDL 
containing cholesterol was the same as described previously, except for the initial steps 
up to the solvent evaporation with N2 to form a lipid/cholesterol film. POPC and 
cholesterol were weighed and resuspended in chloroform separately to form stock 
solutions. Aliquots of POPC and cholesterol were transferred to a round bottom flask 
to a final molar ratio of POPC: cholesterol 10:1 (M/M). ApoA-I was added to the final 
POPC/ apoA-I molar ratios of 160:2, 200:2, 240:2, and 300:2. Samples were also 
prepared at a start POPC:cholesterol:apoA-I molar ratio of 190:10:2 for apoA-I WT, 
L144R and R173C. After sodium cholate removal by dialysis, the samples were 
analysed by NDGGE. The cholesterol quantitation kit (MAK043, Sigma-Aldrich®) was 
used to measure the cholesterol concentration in duplicate.  
4.2.3 Purification of rHDL nanoparticles  
4.2.3.1 Sodium bromide density ultracentrifugation  
Two types of NaBr density UTC were used to separate the rHDL nanoparticles from 
liposomes and lipid-free apoA-I to restrict the size distribution of the nanoparticles. The 
discontinuous step gradient sodium bromide density ultracentrifugation (SG-UTC) 
method was previously used in the separation of plasma lipoproteins (Chapman et al., 
1981; Kelley and Kruski, 1986) and rHDL nanoparticles to separate the rHDL from free 
apoA-I, lipids, and heterogenous rHDL nanoparticles (Jonas, 1986). Sequential 
flotation UTC has been used as method to separate plasma HDL (Schumaker and 
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Puppione, 1986) and single-step flotation UTC was used to separate rHDL 
nanoparticles from lipid-free apoA-I (Cavigiolio et al., 2008; Jonas et al., 1984).  
The approximate NaBr density in g/mL was calculated by interpolation of the salt table 
data (Appendix 2) as suggested by Schumaker and Puppione (Schumaker and 
Puppione, 1986). The interpolated values were used to determine the corresponding 
mass in grams for each density layer of NaBr used (Appendix 2). The buffer used 
throughout UTC was rHDL buffer, pH 7.4.  
In SG-UTC, in a 13.2 mL Ultraclear tube (Beckman Coulter), the NaBr density (g/mL) 
solutions were under-layered, a total volume of 2.5 mL per layer, starting with the 1.04 
g/mL solution, in increasing density order, with the following layers 1.09, 1.15, and 
1.21 g/mL (Figure 4.3). The sample density was increased to > 1.21 g/mL by mixing 
1.5 mL of 38 % (w/v) NaBr solution with 0.5 mL of the rHDL sample post sodium 
cholate removal by dialysis. If a control balance tube was used the final 1.5 mL layer 
was 1.30 g/mL density NaBr instead of sample. The tube was gently filled up to 
approximately 2-3 mm of the tube opening before UTC with the density layers of NaBr 
solution. 
After the sample was under-layered below the 1.21 g/mL density layer, the sample was 
centrifuged at 41 krpm for 24 hrs at 4°C in the SW41 Ti rotor (Beckman Coulter) at the 
slowest acceleration rate and no brake setting for deceleration. Immediately after the 
run ended 0.5 mL samples were carefully taken, to avoid disturbing the layers, from the 
top of the tube. The fractions were dialysed to remove the NaBr and analysed by 
NDGGE. The fractions containing the rHDL were pooled and concentrated using an 
Amicon Ultra-4 device with a 10 kDa MWCO (Merck). The spin concentrator was pre-
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rinsed with dH2O before the sample was loaded (up to 4 mL) and centrifuged at 4000 x 
g for 30 minutes.  
 
Figure 4.3. A diagram of the density layers in discontinuous SG-UTC NaBr (left) and 
Fl-UTC (right). The NaBr density is indicated in each layer in g/mL, and the arrows 
indicate the direction of separation of the rHDL nanoparticles and protein during UTC. 
Flotation UTC is a single NaBr density layer, in which the sample was prepared the 
same as in step gradient UTC, and the solutions were under-layered as before. In a 10.4 
mL polycarbonate centrifuge tube with a cap (Beckman Coulter), 0.5 mL rHDL buffer 
was layered, then 7.9 mL of 1.21 g/mL density NaBr solution, and finally the sample 
density > 1.21 g/mL (0.5 mL sample + 1.5 mL 38 % (w/v) NaBr), with the layers shown 
in Figure 4.3. The prepared rHDL sample Fl-UTC tubes were centrifuged at 65 krpm 
for 22 hrs at 4°C in a 70.1 Ti rotor (Beckman Coulter). A total volume of 2.5 mL was 
collected from the top of the tube in 0.5 mL fractions, and dialysed at 4°C against rHDL 
buffer, pH 7.4, with two buffer changes over 2 days to remove the NaBr. As before the 
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fractions were analysed by NDGGE before the fractions were pooled and concentrated 
for analyses and characterisation.  
Further purification of rHDL from free lipids and free apoA-I, and size-fractionation of 
rHDL were undertaken using size exclusion chromatography. In SEC the HiPrep 16/60 
Sephacryl S-300 HR column (S-300 SEC) was used connected to the ÄKTA Start 
chromatography system and UNICORN™ Start 1.0 software (GE Healthcare). This size 
exclusion column was compatible with the chromatography system and had been used 
to purify rHDL previously (Wu et al., 2009). 
4.2.3.2 Size exclusion chromatography of rHDL nanoparticles 
SEC was explored as an alternative method for size fractionation. The S-300 SEC 
manual showed a separation of a 0.5 mL sample containing the protein standards, IgG 
160 000 Da, BSA 67 000 Da, β-lactoglobulin 35 000 Da, cytochrome C 12 400 Da and 
cytidine 240 Da. The peaks of interest in relation to apoA-I are β-lactoglobulin eluting 
at ~85 mL, and cytochrome C at ~95 mL. Therefore, lipid-free apoA-I with a 28 kDa 
MW would be expected to elute between 85 – 95 mL running buffer volume if present 
in the sample. The S-300 SEC was equilibrated with filtered and degassed dH2O, before 
equilibrating the column in 10 mM tris base, 1 mM EDTA, 1 mM benzamidine, 0.15 M 
NaCl, pH 7.0.  
The rHDL was prepared using the detergent-mediated dialysis method as described 
earlier and the initial rHDL sample concentration was POPC/apoA-I WT sample 200:2, 
13.3/0.13 mM (M/M) (+sodium cholate), 1 mL total volume. After dialysis to remove 
sodium cholate, the sample volume was approximately 2 mL and a 20 µL sample was 
taken for NDGGE. The POPC/WT apoA-I 200:2 (M/M) rHDL post-sodium cholate 
removal sample was centrifuged for 10 minutes at 13.4 krpm to remove any unreacted 
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or precipitated POPC. The sample was loaded onto the column at a flow rate of 1.6 
mL/min and a total volume of 1.6 mL, and 1 mL fractions were collected over 1 CV of 
running buffer. The fractions were stored at 4°C until further analysis for protein 
concentration and NDGGE.  
4.2.4 Particle size analysis 
4.2.4.1 Native PAGE gradient gel electrophoresis 
The rHDL samples were run under the conditions described in Chapter 3, section 
3.2.4.3. FIJI software (Schindelin et al., 2012) was used to determine the relative 
mobility (Rf) values of the standard molecular weight marker and sample bands. The Rf 
is the migration distance of the unknown band divided by the migration distance of the 
dye front. The log(diameter) vs the Rf values of the standards were plotted and values 
were interpolated to produce a standard curve and fitted with an exponential fitting 
function for the estimated diameter using OriginPro 2018 following the method of 
Cavigiolio et al. (Cavigiolio et al., 2008).  
4.2.4.2 Dynamic light scattering 
The rHDL nanoparticle samples were measured post-sodium cholate removal with DLS 
to determine the particle diameter with a Zetasizer Nano ZSP (Malvern) at B23 
Diamond Light Source, Oxford, UK. Prior to measurement the samples were 
centrifuged at 2000 x g for 10 minutes to remove precipitated lipids or MLVs. The 50 
µL rHDL samples were scanned in triplicate at 25°C and a 173° scattering angle in a 
ZEN0040 micro cuvette cell. The protein concentration was 36 µM (1 mg/mL) in rHDL 
buffer, pH 7.0. The intensity-weighted population distribution was used to determine 
the mean particle size, and the volume-weighted population distribution was used to 
represent the major particles present in the sample. This is explained further in the 
results section 4.3.1.1. 
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Note – The DLS measurements of the rHDL-R173C samples were performed before 
the glutathione adduct of apoA-I R173C was identified in Chapter 3. This could 
explain why the rHDL-R173C 200:2 (M/M) DLS measurement did not show particles, 
or this could be due to a low particle concentration.  
4.2.4.3 Transmission electron microscopy 
Transmission electron microscopy (TEM) has been used to determine the diameter of 
rHDL nanoparticles (Zhang et al., 2011). Here, TEM using two different staining 
methods was employed to visualise the rHDL nanoparticles.  
Initially, phosphotungstic acid (PTA) was used to negatively stain and image rHDL 
nanoparticles. A 10 µL aliquot of post sodium cholate removal rHDL POPC/WT apoA-
I 200:2 (M/M) was pipetted onto a carbon coated copper grid and the excess was blotted 
after 3 minutes. To stain the rHDL 5 µL of 2 % (w/v) PTA pH 7.0 was pipetted onto 
the grid and incubated for 2 minutes, blotted, and dried before imaging. The sample was 
kindly imaged by Dr. N. Fullwood (Biomedical and Life Sciences, Lancaster 
University, UK) using a Jeol JEM-1010 transmission electron microscope and further 
developed in the dark room by Dr. D. Townsend (Chemistry, Lancaster University, 
UK).  
To further optimise the protocol and promote the formation of individual rHDL 
nanoparticles as opposed to rouleaux, a method was adapted from the optimised 
negative staining method of rHDL developed by Zhang et al. (Zhang et al., 2011). 
Before the sample was pipetted onto the TEM grid, 3 drops at 35 µL each of dH2O were 
pipetted next to 3 drops of 2 % (w/v) uranyl acetate (UA) on parafilm in a line. The 
sample, 3 µL, was pipetted onto a glow-discharged carbon coated copper grid (Agar 
scientific) and after 2 minutes clean filter paper was used to blot the excess sample.  
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The grid was quickly washed by inverting and blotting in sequence along the 3 drops of 
dH2O to remove buffer salts. The rHDL particles on the TEM grid were negatively 
stained by two quick stain and blot steps on the UA drops followed by a 2-minute 
incubation on the final UA drop. The excess stain was blotted, and the sample grid was 
left to dry under a heat lamp. The samples were imaged, and the materials were provided 
at the Astbury Centre for Structural Molecular Biology at the University of Leeds, UK. 
The microscope used was the FEI Tecnai T12 transmission electron microscope with a 
120 keV Lab6 electron source, and a Gatan US4000/SP 4 k x 4 k CCD camera. The 
microscope was funded by the Wellcome Trust (090932/Z/09/Z). The images were 
processed using FIJI software (Schindelin et al., 2012).  
Initially, the rHDL sample protein concentration was varied of POPC:apoA-I WT 200:2 
(M/M) rHDL to see if the stacking/formation of rouleau was affected by sample 
concentration, of a concentration range between 9 – 36 µM (0.25 – 1.0 mg/mL). TEM 
samples of POPC:apoA-I R173C and POPC:apoA-I L144R were imaged at 9 and 36 
µM, respectively. The rHDL nanoparticles with the start molar ratio of 
POPC:cholesterol:apoA-I of 190:10:2 (M/M) containing apoA-I WT or R173C were 
imaged with TEM. FIJI software was used to measure 150 nanoparticles, comprised of 
50 random particles measured three times, for a particle size distribution in the sample 
when the particles were definable.  
4.2.5 Sample concentration determination  
The molar ratios of protein, lipid and where appropriate, cholesterol were determined 
at different stages of the procedure. To determine the protein concentration of the rHDL 
samples the NanoDropTM 2000c (ThermoFisher Scientific) (Desjardins et al., 2009) was 
used with minimal contribution of the lipids to light scattering. If light scattering 
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occurred, as shown by a noisy UV absorbance signal at 260/280 nm, the sample was 
centrifuged to remove unreacted or precipitated lipids and diluted to decrease the effect 
of the light scattering.  
To measure the lipid concentration of the rHDL samples a phospholipid quantification 
assay kit was used (CS0001, Sigma-Aldrich) following the protocol provided in a 
colorimetric 96-well plate assay. The assay uses the enzyme phospholipase D which 
releases choline from the lipid head group which is oxidised by the enzyme choline 
oxidase. The oxidation reaction produces hydrogen peroxide which reacts with the 
substrates in the development mix and probe for detection at 570 nm. The 
phosphocholine standards and samples were assayed in duplicate. The rHDL samples 
were run in various dilutions to produce an absorbance value within the standard curve. 
The cholesterol quantitation kit (MAK043, Sigma-Aldrich®) was used to measure the 
rHDL sample cholesterol concentration in duplicate following the protocol provided in 
a colorimetric 96-well plate assay. The assay measured the total cholesterol in a sample 
through a coupled enzyme assay similar to the lipid assay kit, the reaction product reacts 
with the cholesterol probe for detection at 570 nm (MAK043, technical bulletin, Sigma-
Aldrich®). 
4.3 Results 
4.3.1 Sodium cholate detergent mediated analysis 
Reconstituted HDL WT nanoparticles were produced using the sodium cholate dialysis 
method (Jonas, 1986). The rHDL-WT nanoparticles were used to compare the different 
methods of size fractionation of SEC, SG-UTC and Fl-UTC. After selecting the best 
procedure, the rHDL nanoparticles containing apoA-I R173C or L144R were prepared. 
The rHDL POPC:apoA-I WT 200:2 (M/M) particles were run on a NativePAGE gel 
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and compared to lipid-free apoA-I WT to determine if rHDL particles had formed after 
sodium cholate removal by dialysis (Figure 4.4). 
 
Figure 4.4. A 4-16% NativePAGE gradient gel of A) Lipid-free (LF) apoA-I WT and 
rHDL-WT POPC:apoA-I WT after sodium cholate removal, ~1 mg/mL apoA-I. B) 
rHDL-WT post-sodium cholate removal at a concentration < 1 mg/mL apoA-I.  
The lipid-free apoA-I WT lane indicated the presence of apoA-I monomers and dimers, 
the latter probably formed as a result of the concentrated protein stock solutions used to 
prepare the rHDL nanoparticles (see section 3.3.3.2, section 3.4). The overloaded rHDL 
sample (apoA-I WT 1 mg/mL) showed rHDL nanoparticles indicated by the broad 
protein stain between approximately 7.5 – 17.0 nm diameter, most intense at around 10 
nm (Figure 4.4A), and a broad band below 66 kDa showing unreacted LF apoA-I WT. 
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The rHDL-WT 200:2 sample was diluted to a protein concentration < 1 mg/mL and the 
predominant band indicated rHDL nanoparticles between 8.2 – 10.0 nm in diameter 
(Figure 4.4B). The size range of rHDL-WT nanoparticles detected required further size 
fractionation to produce a homogenous rHDL nanoparticle population for structural 
characterisation.  
4.3.1.1 Dynamic light scattering of crude rHDL nanoparticles 
DLS diffusivity measurements were taken of the rHDL nanoparticle samples to 
determine the particle hydrodynamic diameter. The translational diffusion constant of a 
particle is inversely related to its hydrodynamic radius according to the Stokes-Einstein 
relation, assuming the particle is spherical. The intensity percentage indicates the mean 
particle size in a sample, but larger particles can be overrepresented as the major particle 
in the sample as the intensity percentage scales with the size of the particle (Stetefeld et 
al., 2016). The volume percentage population distribution for each measurement is 
shown to indicate the proportion of the particles represented in the sample (Stetefeld et 
al., 2016).  
Each sample was measured between a 0 – 10000 nm diameter scale, however larger 
particles (which represent a small fraction of the total population) are not shown above 
50 nm, as the region of interest for the rHDL nanoparticles is between 0 – 50 nm. The 
peaks above 50 nm in the intensity-weighted distribution “disappeared” in the volume-
weighted distribution indicating the particles above 50 nm were present in insignificant 
proportions to the main particle size peak in the sample (Stetefeld et al., 2016). The 
polydispersity index (PdI) was used to determine if the sample was suitable to be 
measured using DLS and is indicated in the figure description. If the PdI was > 0.7 the 
sample is more polydisperse with a broad particle size distribution. A PdI < 0.7 indicates 
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a sample approaching a monodisperse particle distribution at < 0.1 (Stetefeld et al., 
2016).  
The DLS measurements determined the average particle diameter and PdI as an average 
of 3 scans. The rHDL-WT 200:2 (M/M) nanoparticle post-sodium cholate dialysis size 
distribution is shown in Figure 4.5. The full diameter range of 0 – 10000 nm is shown 
in both the intensity- and volume-weighted distributions to show the negligible 
contribution of the large intensity particle size peaks.  
 
Figure 4.5. The intensity- and volume-weighted particle population distributions of 
rHDL-WT nanoparticles at the POPC:apoA-I WT 200:2 molar ratio. The average 
particle diameter was 11.3 ±0.2 nm with a PdI of 0.55 ±0.02. 
The predominant rHDL-WT particle size was 11.3 nm according to the intensity-
weighted peak (Figure 4.5). 
The large peaks above approximately 100 nm were not present in the volume 
distribution and therefore the large particles could be liposomes or contaminants such 
as dust, but these did not represent a significant number of particles in the sample. 
Additionally, the particle peak at approximately 10 nm is similar in both particle 
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distributions indicating the homogeneity of the particles between the two different 
distributions (Stetefeld et al., 2016). Hereafter the DLS particle size measurement 
figures will show only the volume-weighted distribution with a linear scale between 0-
50 nm, the intensity-weighted mean particle size and PdI. 
Overall, the range of possible rHDL particle sizes in the overloaded gel lane and the 
presence of LF apoA-I WT (Figure 4.4A) prompted further separation of the particles 
produced to form a more homogenous particle population for rHDL particle 
characterisation. It was particularly important to remove LF apoA-I WT for solid-state 
NMR studies in Chapter 5 using labelled protein to ensure any protein signals were 
from lipid-bound apoA-I only. The purpose of the fractionation was to isolate the 
predominant rHDL nanoparticle band discussed in section 4.1.5 between approximately 
9.7 – 10.2 nm.  
Different methods were compared to separate the rHDL-WT nanoparticles from LF 
apoA-I WT and different rHDL nanoparticle sizes: size-exclusion chromatography, step 
gradient UTC, and flotation UTC. Henceforth, the rHDL-WT nanoparticles post-
sodium cholate dialysis are referred to as unfractionated whilst the further purified 
particles are described as fractionated with respect to the technique used. The size 
exclusion chromatography, step gradient UTC and flotation UTC separation techniques 
will be abbreviated to SEC, SG-UTC, and Fl-UTC fractionated, respectively.  
4.3.2 Size exclusion chromatography 
Size exclusion chromatography of unfractionated rHDL POPC:apoA-I WT 200:2 
(M/M) nanoparticles was tested to see if the rHDL could be separated by size and from 
LF protein and liposomes.  
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The peaks in the UV absorbance chromatogram of the SEC-fractionated rHDL-WT 
200:2 (M/M) nanoparticles (Figure 4.6) corresponded to protein in the 1 mL elution 
fractions. The LF and lipid-bound apoA-I WT tryptophan and tyrosine aromatic amino 
acids absorbed UV light at the 280 nm wavelength as the sample was eluted from the 
size exclusion column and flowed through the UV detector. This is similar to the 
NanoDropTM 2000c which utilises the Trp and Tyr residue 280 nm UV light wavelength 
absorbance to determine the protein concentration (Desjardins et al., 2009).  
 
Figure 4.6. UV absorbance chromatogram of the SEC separation of rHDL-WT 200:2 
(M/M) nanoparticles. The approximate positions of the 1 mL fractions measured with 
DLS are labelled and indicated with the black arrows.  
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In the UV chromatogram the main peak was at an elution volume between 65 – 100 mL 
with a peak maximum at approximately 32.5 mAU. The 1 mL fractions indicated in 
Figure 4.6 were examined by DLS measurements to determine if the particles were 
separated by size.  
The protein concentration of the crude rHDL-WT 1.6 mL sample loaded onto the 
column was ~65 µM, equivalent to a total mass of 2.9 mg. However, only ~48 % of the 
protein mass was detected in fractions 24-36 in a total volume of 13 mL. The difference 
in protein mass was unlikely to be accounted for by fractions 1-24 due to the low 
absorbance values (<12 mAU), i.e., the concentration of the 1 mL fraction 25 was 0.061 
mg/mL (2.2 µM) at ~12 mAU. Furthermore, the protein mass in fraction 35 near the 
peak maximum was ~0.1 mg. Hence, the total mass of the fractions 1-24 and 37-48 
would not equate to 1.5 mg of apoA-I WT. 
The loss of sample could be due to possible protein aggregation with lipids in the 
centrifugation step prior to column loading. Therefore, the overall yield of fractions 
containing protein and hence rHDL nanoparticles was low under these SEC conditions 
as the sample was diluted across a large volume at low concentrations overall.  
4.3.2.1 Dynamic light scattering of size exclusion chromatography fractions 
SEC fractions 2-48 were measured using DLS and examples are shown in Figure 4.7. 
The intensity-weighted average particle sizes and PdI values are in Table 4.3. After 50 
mL, the void volume, the SEC column fraction 2 indicated particles with an average 
hydrodynamic diameter of ~11.3 nm. This suggested a relatively small loss in the 
separation yield as the small UV absorbance at 2.5 mAU corresponded to a ~0.2 µM 
apoA-I concentration.  
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Figure 4.7. DLS volume-weighted particle population distributions of SEC fractions 2, 
25, 35, and 45, scans 1-3, corresponding to the peaks in the SEC chromatogram (Figure 
4.6). The average particle hydrodynamic diameter (nm) and PdI values are in Table 4.3.  
Fraction 25 contained particles with a hydrodynamic diameter of 12.3 nm. Whilst the 
fractions 35, 38, 39 and 41 showed particles with a hydrodynamic diameter of 10.1, 9.6, 
9.9, and 10.9 nm, respectively. The standard deviation (SD) of the particle size 
measurements was within the range of each respective measurement which suggested 
the predominant particle size was approximately ~10 nm between the elution volume 
83-89 mL. The progressive decrease in particle hydrodynamic diameter from ~12 nm 
(#25), to ~10 nm (#35-41), to ≤ 7.8 nm (#45) combined with the corresponding increase 
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in the UV absorbance in the SEC chromatogram suggested the separation of particles 
of different sizes. 
Table 4.3. The intensity-weighted (%) distribution of the particle population in the 
unfractionated rHDL-WT 200:2 (M/M) sample and 1 mL SEC fractions. Each 
measurement was an average of 3 scans, the average PdI and particle size are ±SD. The 
individual peak particle sizes for fractions 2, 45 and 46 are indicated, as the DLS 
measurements were dissimilar in scans 1-3.  
Fraction # Particle size (nm) PdI 
Unfractionated 11.3 ± 0.2 0.55 ± 0.02 
2 2.3 and 9.9, 10.9, 13.0 0.47 ±0.20 
15 815.7 ±46.3 0.13 ±0.02 
25 12.3 ±0.2 0.36 ±0.05 
35 10.1 ±0.3 0.49 ±0.24 
38 9.6 ±0.4 0.56 ±0.03 
39 9.9 ±0.4 0.26 ±0.06 
41 10.9 ±1.7 0.43 ±0.09 
45 0.8, 7.8, 4.2 0.30 ±0.20 
48 460.8, 0.9, 0.8,  0.37 ±0.22 
 
The polydispersity index values were < 0.7 (Table 4.3) of the unfractionated (PdI 0.55) 
and the SEC 25-41 fractions (PdI 0.26-0.56) suggesting the particles were suitable for 
DLS measurements (Malvern Instruments Ltd, 2011; Stetefeld et al., 2016). However, 
fraction 41 had a large SD with a range between 9.2-12.6 nm and a similar PdI (0.43) 
to fractions 35-39 (0.49, 0.56, 0.26) which indicated the particles may not have eluted 
completely in size order, i.e., larger particles have a shorter retention time in the size 
exclusion column and are eluted first. 
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The two important limitations of the SEC separation were low sample recovery and 
sample dilution. Therefore, individual fractions would require spin concentration before 
screening by DLS and NativePAGE gels to confirm particle size and separation from 
lipid-free apoA-I. Furthermore, there was a limited availability of the DLS equipment, 
and the NativePAGE gel protocol was not optimised at this point. Therefore, it was 
difficult to determine if the SEC rHDL-WT nanoparticle was successful with DLS 
measurements alone.  
However, the range of SEC fraction(s) nanoparticle hydrodynamic diameters measured 
by DLS (7.8 – 12 nm) confirmed the presence of various sizes of rHDL-WT 
nanoparticles. This provided additional evidence of nanoparticle characterisation for 
future experiments.  
4.3.3 Density-based ultracentrifugation rHDL purification  
NaBr or KBr density-based ultracentrifugation methods are routinely used to isolate 
plasma HDL particles (Chapman et al., 1981; Huang et al., 2011; Kelley and Kruski, 
1986; Rosenson et al., 2011; Schumaker and Puppione, 1986). In the plasma HDL 
density-based particle separation the various HDL subclasses have defined density 
ranges between 1.063 – 1.21 g/mL (Chapman et al., 1981; Rosenson et al., 2011), (see 
Chapter 1, Table 1.1). Examination of the methods used to purify plasma HDL and 
rHDL nanoparticles of different sizes and from lipid-free apoA-I indicated that SG-
UTC or Fl-UTC can be used (Cavigiolio et al., 2008; Chapman et al., 1981; Jonas, 1986; 
Jonas et al., 1984; Kelley and Kruski, 1986; Schumaker and Puppione, 1986). 
Therefore, the purification of rHDL-WT nanoparticles using SG-UTC and Fl-UTC was 
tested. 
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4.3.3.1 Step-gradient density ultracentrifugation 
For discontinuous SG-UTC, multiple layers of NaBr solution were layered above the 
sample (> 1.21 g/mL) at the densities of 1.21, 1.15, 1.09 and 1.04 g/mL as in Figure 
4.3, to separate the rHDL particles based upon the particle density. After 
ultracentrifugation 0.5 mL fractions were dialysed to remove NaBr and analysed by 
DLS and NativePAGE to confirm the presence of protein and rHDL nanoparticles. 
DLS was used to measure the particle diameter of the rHDL POPC:WT apoA-I 200:2 
(M/M) nanoparticles in the pooled fractions of the 1.09, 1.15 (Figure 4.8) and 1.21 g/ml 
NaBr density layers (2.5 mL total volume). The sample PdI and mean peak diameters 
are in Table 4.4. The DLS peaks for the pooled 1.09 and 1.21 g/mL fractions are not 
shown as the particle diameters were very large at 414 and 304 nm, respectively, which 
suggested the presence of liposomes. The 1.15 g/mL fractions major particles average 
diameter was 12.8 ±0.9 nm, indicating a particle size range between 11.9 – 13.7 nm 
(Figure 4.8).  
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Figure 4.8. DLS volume-weighted particle population distributions of pooled 1.15 
g/mL fractions of rHDL POPC/WT 200:2 (M/M) nanoparticles. The average particle 
hydrodynamic diameter (nm) and PdI values are in Table 4.4. 
 
Table 4.4. Intensity DLS measurements of the rHDL POPC/apoA-I 200:2 (M/M) 
fractions separated by discontinuous SG-UTC. The PdI and mean particle diameter 
(nm) ±SD for each sample DLS intensity peak. 
Density fraction Particle size (nm) PdI 
Post-dialysis 11.3 ±0.2 0.55 ±0.02 
1.09 g/mL 414.2 ±13.2 0.27 ±0.03 
1.15 g/mL 12.8 ±0.9 0.42 ±0.09 
1.21 g/mL 304.3 ±14.9 0.34 ±0.07 
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NativePAGE gradient gels were used to determine the hydrodynamic diameters of the 
unfractionated and SG-UTC fractionated rHDL nanoparticles. The SG-UTC fractions 
were pooled by density layer (2.5 mL) or as 0.5 mL fractions and run on a NativePAGE 
gradient gel in Figure 4.9 and Figure 4.10, respectively. In the NativePAGE gels the 
rHDL nanoparticle sizes in each lane are indicated by the arrows followed by the 
approximate particle size as determined using the relative mobility of the particle bands. 
For example, the predominant particle band in the 1.15 g/mL 2.5 mL pooled fractions 
sample lane (Figure 4.9) indicated the presence of particles with a diameter of 9.1 nm 
and is labelled as rHDL-9.1 WT.  
In Figure 4.9 the major rHDL band appears between the 8.8 – 11.5 nm in the 
unfractionated sample lanes with and without sodium cholate, and pre-UTC. The pre-
UTC bands showed staining indicating rHDL nanoparticles with diameters at ~7.4-8.8, 
12.1 and 16.2 nm.  
The rHDL-12.1 and -16.1 nm diameter particles in the 1.09 g/mL fraction lane indicated 
some separation of the larger rHDL particles from the predominant rHDL-9.1 WT 
particles. Faint bands in the 1.15 g/mL pooled rHDL at ~ 12.2 and 17.0 nm in the 1.15 
g/ml fraction indicated partial separation from the rHDL-9.1 nm particle. The rHDL-
9.1 WT particles were separated from the rHDL-7.4-8.8 nm particles which showed 
bands only in the 1.21 g/mL pooled fractions.  
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Figure 4.9. A 4-16 % NativePAGE gradient gel of the different stages of the rHDL 
nanoparticle POPC:apoA-I WT 200:2 (M/M) preparation using SG-UTC. The sample 
lanes contain: LF apoA-I WT, rHDL containing sodium cholate, rHDL without sodium 
cholate, rHDL pre-UTC after storage at 4°C, and each 2.5 mL pooled NaBr SG-UTC 
fractions at 1.04, 1.09, 1.15, 1.21 and 1.30 g/mL density. The labels indicate the bands 
corresponding to monomeric and dimeric lipid-free WT apoA-I, and rHDL particles 
7.4-8.8, 9.1, 12.1 and 16.2 nm in diameter.  
The 1.30 g/mL fractions contained a strong intensity band of monomeric lipid-free 
apoA-I. This suggested the ultracentrifugation conditions separated LF apoA-I from the 
rHDL nanoparticles. The relative position (8.6-9.8 nm) of the predominant rHDL-9.1 
WT nanoparticle band in the 1.15 g/mL lane remained similar to the unfractionated 
sample band which suggested the lipid-free apoA-I WT band in the 1.30 g/mL lane was 
not due to loss of apoA-I from the rHDL nanoparticles but due to unreacted apoA-I.  
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To further separate the rHDL-9.1 WT particles the 0.5 mL fractions were examined by 
NativePAGE before pooling together for further characterisation (Figure 4.10). 
Representative fractions of layers 1.04, 1.09 and 1.21 g/mL NaBr density did not show 
bands for rHDL particles or LF apoA-I WT. The 1.15 g/mL fractions 11-14 showed a 
prominent band at ~8.7 nm. If a fraction contained additional bands, such as fraction 14 
at ~8.0 nm, it was not pooled for further characterisation. The isolated 0.5 mL fractions 
rHDL-8.7 nm particles (Figure 4.10) was similar to the approximate diameter of the 
1.15 g/mL (2.5 mL) fraction major band between 8.6-9.8 nm (Figure 4.9).  
 
Figure 4.10. A 4-16 % NativePAGE gradient gel of the different stages of the rHDL 
POPC/WT 200:2 (M/M) preparation using SG-UTC. The sample lanes contain: LF 
apoA-I WT, and separate 0.5 mL fractions from the NaBr density gradient layers at 
1.04, 1.09, 1.15, and 1.21 g/mL density. The labels indicate the bands corresponding to 
monomeric and dimeric LF apoA-I WT and rHDL nanoparticles.  
Chapter 4: Production of reconstituted High-Density Lipoproteins 
Sophie Lau - July 2021   175 
The apoA-I concentrations of the pooled (2.5 mL) density layers at 1.04, 1.09, 1.21, 
1.30 g/mL NaBr density were 0.2, 8.5, 4.9, and 7.7 µM, respectively. The 1.15 g/mL 
fractions containing the predominant rHDL-9.1 WT had a concentration of 15.9 µM. 
An approximate mass of protein 3.5 mg was in the unfractionated rHDL sample, and 
the total protein mass of the SG-UTC fractions was ~2.4 mg. The loss in sample could 
be due to precipitation of protein with lipids and interaction with the spin concentrator 
membrane pre-UTC, or dilution of the sample during UTC and NaBr removal dialysis.  
Both NativePAGE gels (Figure 4.9-4.10) showed a predominant particle with a 
diameter of ~8.7-9.1 nm, whereas the DLS measurements of the unfractionated rHDL-
WT sample and pooled 1.15 g/mL (2.5 mL) fractions indicated particles with a larger 
diameter of 11.3 and 12.8 nm, respectively. This difference could be due to the DLS 
measurement of the pooled 1.15 g/mL density layer rather than selected 0.5 mL 
fractions. In the DLS measurement the 1.15 g/mL pooled fraction rHDL-12.1 particle 
faint band (Figure 4.9) could produce an increase in the intensity-weighted average 
particle diameter.  
The absence of bands in the 0.5 mL fractions for the rHDL-12.1 and -16.2 WT particles 
in Figure 4.10 in the 1.04 and 1.09 g/mL density layers and the lack of DLS particle 
detection in the 1.09 g/mL layers (Table 4.4) suggested the use of these density layers 
may not be necessary for isolation of the rHDL-9.1 WT particles. Therefore, the use of 
single-step flotation density ultracentrifugation was tested.  
4.3.3.2 Flotation density ultracentrifugation 
Flotation density ultracentrifugation was used to determine if particle separation and 
separation from lipid-free apoA-I could be achieved compared to SG-UTC. In Fl-UTC 
the sample (> 1.21 g/mL density) was layered beneath a 1.21 g/mL NaBr density layer, 
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with a 0.5 mL layer of rHDL buffer, pH 7.4 (Figure 4.3). After centrifugation fractions 
were taken from the tube (0.5 mL each) from low to high density. The fractions 8-14 
and 20-21 were pooled as rHDL-9.1 WT nanoparticles were not expected in these 
fractions due to the SG-UTC fraction results (Figure 4.9-4.10). The rHDL nanoparticles 
had a density > 1.21 g/mL therefore were expected to be in the upper layers “floated”.  
In Figure 4.11 fractions 1, 4 and 5 showed a band for rHDL-8.1 and -9.1 nm WT 
particles, which were similar to the diameter of the particles isolated in the 0.5 mL SG-
UTC 1.15 g/mL fractions (Figure 4.10). Fractions 2 and 3 showed only the 9.1 nm 
diameter particles and were pooled for further analyses. The rHDL-9.1 WT predominant 
band particle diameter range was between ~8.7-9.5 nm. The Fl-UTC fraction 1-3 lanes 
appeared to contain faint staining above 10 nm which could indicate the presence of 
larger rHDL nanoparticles. Fraction 1 also contained a partial band at ~8.1 nm 
indicating a degree of incomplete separation of particles in the fractions. The Fl-UTC 
conditions were sufficient for the separation of unreacted apoA-I WT as indicated by 
the monomer apoA-I WT band in the final fractions 20-21. 
The protein concentrations of fractions 1, 2, 3, 4 and 5 were 6.7, 6.5, 6.5, 5.2, and 5.4 
µM, respectively. Fraction 1 contained a faint band for the rHDL-8.1 WT particles at 
the same protein concentration (6.7 µM) as fractions 2 and 3 (6.5 µM), which indicated 
that with Fl-UTC as in SG-UTC the 0.5 mL fractions should be checked by NDGGE. 
The unfractionated sample protein mass in 0.5 mL was ~1.4 mg and the Fl-UTC fraction 
concentrations of fractions 1-21 contained a total mass of apoA-I of ~1.3 mg. Therefore, 
based upon the protein mass the loss of sample during the protocol was reduced 
compared to SEC and SG-UTC.  
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Figure 4.11. A 4-16 % NativePAGE gradient gel of the different stages of the rHDL 
POPC/WT 200:2 (M/M) Fl-UTC fractions. The sample lanes contain: LF apoA-I WT, 
and separate 0.5 mL fractions shown by the fraction number. The labels indicate the 
bands corresponding to monomeric and dimeric LF apoA-I WT and rHDL-8.1 and -9.1 
nm WT particles.  
4.3.4 Transmission electron microscopy of rHDL-WT 
Initially, rHDL POPC/apoA-I WT 200:2 nanoparticles post-sodium cholate removal 
were negatively stained with 2 % (w/v) PTA for TEM (Figure 4.12). The rHDL 
nanoparticles are indicated by the black arrows, and are in the well-known rouleaux 
formation (Silva et al., 2008).  
The rouleaux commonly form when the rHDL nanoparticles are negatively stained with 
phosphotungstic acid and are considered to be an artefact of the TEM sample 
preparation (Chen et al., 2009; Duong et al., 2006; Zhang et al., 2011). The particles 
stack with the lipid headgroups of the nanoparticles facing the headgroups of the next 
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rHDL nanoparticle, with the disc face perpendicular to the TEM grid plane (Figure 
4.12). However, the sample staining background significantly obscured the rHDL 
nanoparticles to sufficiently measure the nanoparticle diameter, as well as the sample 
concentration as the rouleau are layered upon other rouleau.  
 
Figure 4.12. A TEM image at x 80 k magnification of POPC:apoA-I WT 200:2 (M/M) 
unfractionated rHDL nanoparticles post-sodium cholate removal stained with 2 % (w/v) 
PTA. The scale bar is 100 nm, and the black arrows indicate stacked rouleau of rHDL 
nanoparticles. The discoidal rHDL nanoparticle model image was obtained from (Nath 
et al., 2007). 
Due to the lack of individual particles using the PTA stain, a protocol was adapted from 
the optimised negative stain method produced by Zhang et al. (Zhang et al., 2011) and 
used to image the rHDL POPC:apoA-I 200:2 (M/M) nanoparticles after Fl-UTC at the 
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protein concentrations of 9 (Figure 4.13) and 36 µM (Figure 4.14). At 9 µM the 
nanoparticles were imaged as separate nanodiscs with the lipid headgroups of the disc 
associated with the TEM grid surface and did not show rouleau formation.  
Fifty particles were measured in triplicate for a total of 150 particle measurements to 
check the reproducibility of using FIJI to measure the particle diameter in the TEM 
images. The average diameter of the nanoparticles was 10.7 ±2.3 nm. The distribution 
of the particle diameters is shown by the histogram in Figure 4.13B.  
 
Figure 4.13. A) A TEM image at x 68 k magnification of POPC/apoA-I WT 200:2 
(M/M) rHDL, 9 µM protein concentration, post-flotation UTC stained with 2 % (w/v) 
UA. The scale bar is 100nm. B) A histogram of 150 rHDL-WT nanoparticle diameter 
measurements at 9 µM apoA-I concentration. 
At 36 µM protein concentration the rHDL nanoparticles were more concentrated and 
closely packed together (Figure 4.14A), with randomly distributed particles in shorter 
rouleaux compared to the extended rouleaux in Figure 4.12. The advantage of the 36 
µM concentration of particles was that the edges of the particles were visible, enabling 
the particle thickness to be determined. The concentrated regions of rHDL nanoparticles 
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at the 36 µM protein concentration provided more particles to measure Figure 4.14A. 
The average diameter of 150 nanoparticles was 10.7 ±2.0 nm. The average thickness 
was 5.6 ±0.7 nm.  
 
Figure 4.14. A) A TEM image at x 68 k magnification of POPC/apoA-I WT 200:2 
(M/M) rHDL, 36 µM protein concentration, post-flotation UTC stained with 2 % (w/v) 
UA. The scale bar is 100 nm. The corresponding histograms of 150 rHDL-WT 
nanoparticle (B) diameter and (C) thickness measurement. 
The thickness (~5.6 nm) of the particles was greater than that of a lipid bilayer ~4 nm 
(Kucerka et al., 2005) suggesting there was systematic error in the measurements or 
overestimation of the particle measurements. This could include user error in measuring 
the TEM images using FIJI software in defining the particle edge for each measurement. 
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Additionally, DLS and NDGGE measure the hydrodynamic diameter of the particles 
whilst TEM measures negatively stained dried particles. 
At both protein concentrations the majority of particles were between 8 – 13 nm 
diameter at 81 and 83 % of the 150 particles at 9 and 36 µM, respectively. Therefore, 
the Fl-UTC fractionated POPC:apoA-I WT rHDL sample showed a similar size 
distribution with some heterogeneity in particle diameter. 
The DLS average rHDL-WT diameter particle of the SG-UTC 1.15 g/mL pooled 
fractions was 12.8 ±0.9 nm compared to the pre-UTC diameter of 11.3 ±0.2 nm. The 
Fl-UTC rHDL-WT nanoparticle TEM diameter measurements (10.7 ±2.0 nm) were 
within the ranges of the pre-UTC measurements and the SG-UTC pooled fractions.  
However, the TEM measurements indicated that the Fl-UTC rHDL-WT sample 
contained nanoparticles of various sizes despite appearing as the predominant rHDL-
9.1 WT band on the NativePAGE gel (Figure 4.11) in fractions 2 and 3. This could be 
due to low concentrations of the particles in the sample or low sample concentration 
loaded into the gel resulting in minor particle populations below the detection limit of 
the NativePAGE gel protein stain. Therefore, the samples showed some variability in 
the nanoparticle diameter and were not completely homogenous, but Fl-UTC was 
successful in the removal of lipid-free apoA-I WT.  
4.3.4.1 A comparison of the rHDL-WT fractionation methods 
SEC and density-based UTC were compared to determine which method best isolated 
the major rHDL-WT nanoparticles between 8.2 – 10 nm in diameter as observed by 
NDGGE (Figure 4.4). The percentage yield and sample recovery were estimated for 
each fractionation method (Table 4.5). Overall, the SG-UTC method had higher 
fraction concentrations and yield compared to SEC and Fl-UTC. The Fl-UTC method 
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had the highest sample recovery which suggested the reduced number of density layers 
could have minimised the sample losses during the protocol stages. 
Table 4.5. The percentage yield of the rHDL-9.1 WT particles purified by SEC, Fl-
UTC and SG-UTC, i.e., the mass of apoA-I in the pooled fractions relative to the start 
mass (mg) in parentheses, the fractions used, total fraction volume, apoA-I WT mass 














35-40 6.0 0.39 2.3 13.4 66.3 
Fl-UTC 
(1.4 mg) 
2-3 1.0 0.18 6.5 13.0 87.4 
SG-UTC 
(3.5 mg) 
11-15 2.5 1.11 15.9 31.9 68.1 
 
The SEC fractionated particles showed size separation by DLS only and had limitations 
such as dilute fractions and lower sample recovery. The SG-UTC and Fl-UTC methods 
were characterised with NativePAGE which confirmed the separation of rHDL from 
lipid-free apoA-I WT. The removal of lipid-free apoA-I by ultracentrifugation was 
highly important for labelled apoA-I solid-state NMR rHDL samples and secondary 
structure analysis by circular dichroism.  
It was concluded that the particles isolated by Fl-UTC were reasonably homogenous for 
further study based upon the average TEM rHDL-WT diameter (~10.7 nm) and the 
predominant NDGGE band of rHDL-9.1 WT nm particles. The NativePAGE gel bands 
of the rHDL-8.7-9.1 WT particles between the UTC methods were similar (Figure 4.10-
4.11) and suggested the SG-UTC and Fl-UTC methods isolated similar sized particles. 
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Additionally, the SG-UTC method separated some of the larger diameter particles (12.2 
and 17.0 nm) from the rHDL-8.7-9.1 WT 1.15 g/mL density layer (Figure 4.9).  
Henceforth, the SG-UTC and Fl-UTC methods were used for isolating the rHDL-8.7-
9.1 nm nanoparticles dependent upon the structural characterisation technique used. The 
SG-UTC method had benefits such as the high sample yield and separation from the 
larger diameter rHDL nanoparticle. In comparison, the Fl-UTC method isolated 
nanoparticles of a similar size with a greater sample recovery and simpler preparation 
procedures.  
4.3.4.2 Scale of rHDL nanoparticle preparation for characterisation techniques 
This is an approximate guide to scale the rHDL nanoparticle preparation using the SG-
UTC fractionation method for the three main characterisation techniques used in this 
work: CD, SS NMR of oriented and polyethylene glycol (PEG)-precipitated samples. 
An example starting sample POPC/apoA-I concentration was ~5/0.05 mM (Table 4.2) 
and contained ~6.76 mg of apoA-I in 4 mL rHDL buffer, pH 7. The concentration of 
apoA-I was used as an indicator of yield at each stage of the preparation as the protein 
concentration was routinely estimated using the A280 UV absorbance.  
The apoA-I concentration required for circular dichroism was 0.1 mg/mL in a total 
volume of 300 µL. The final oriented SS NMR samples contained an apoA-I 
concentration of 0.21 mg/mL in 1 mL total volume. Therefore, the sample preparation 
for the CD (~14-fold dilution) and SS NMR oriented samples (~7-fold dilution) required 
dilution after SG-UTC. Hence, the single unlabelled apoA-I WT and mutant(s) protein 
expression yields at approximately 56 and 32 mg /L of culture media, respectively, were 
suitable for preparation of the circular dichroism and oriented 31P SS NMR samples.  
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In comparison, the PEG-precipitated rHDL samples required a scaled preparation as a 
minimum pellet mass of 5 mg was desirable. The obtained PEG-precipitated rHDL mass 
was between 2 – 5 mg for the samples in this work. The final mass of apoA-I in the 
example sample in Table 4.6 (in bold) was ~1.1 mg. Therefore, to produce a final PEG-
precipitated rHDL apoA-I mass between 2 – 5 mg, a starting mass of apoA-I between 
12.2 – 30.5 mg was required. The [13C, 15N]-labelled apoA-I WT/R173C/L144R protein 
expression yields were ~19, 7, and 53 mg/L of culture media, respectively. Therefore, 
multiple labelled apoA-I WT and R173C expressions were required to prepare the PEG-
precipitated samples.  
This provides an estimate of the amount of apoA-I and POPC that is required using the 
SG-UTC rHDL nanoparticle protocol for the three different characterisation methods.  
Table 4.6. Example sample preparation of rHDL-WT 200:2 nanoparticles. The apoA-I 
concentration is indicated at each stage including the percent protein compared to the 
starting apoA-I mass. *spin-concentrated samples.  













Start 1.69 4 6.76 - 
After sodium 
cholate removal 
1.39 3.5 4.87 72.0 
Before SG-
UTC* 




4.44 0.25 1.11 16.4 
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Overall, 16.4 % of apoA-I was retained in the rHDL-WT 200:2 nanoparticles between 
~8 – 10 nm in diameter as determined by NDGGE. The total percentage of apoA-I 
detected in the 1.04 – 1.09 and 1.21 – 1.30 g/mL NaBr density fractions at ~18.8 % did 
not account for the remaining apoA-I. The possible causes of apoA-I loss could be 
apoA-I interaction with the cellulose membrane during the spin concentration, 
precipitation during dialysis or high protein concentration precipitation.  
4.3.5 Preparation of rHDL-R173C and rHDL-L144R nanoparticles 
Detergent mediated dialysis method followed by SG-UTC or Fl-UTC was chosen as the 
best method for size fractionation of the rHDL-WT nanoparticles and separation from 
lipid-free apoA-I (see section 4.3.4.1). Therefore, the same method was applied to 
isolate rHDL nanoparticles with a similar diameter to the rHDL-9.1 WT nanoparticles 
containing apoA-I R173C or L144R at the molar ratio of POPC:apoA-I mutant 200:2 
(M/M). DLS, NDGGE and TEM were used as before to determine if rHDL 
nanoparticles were formed. It was important to produce the atheroprotective mutant 
nanoparticles at a similar size to the rHDL-WT nanoparticles to compare structural 
features.  
4.3.5.1 rHDL-R173C nanoparticles 
In the following sections, as with the rHDL-9.1 WT nanoparticles, the apoA-I mutant 
particles are referred to by the predominant diameter size in nm, such as rHDL-9.4 
R173C or rHDL-8.9 L144R.  
The rHDL-R173C nanoparticles prepared at the POPC:apoA-I R173C 200:2 molar ratio 
were analysed by NativePAGE. Before fractionation the major band was between ~9.1 
– 9.7 nm, the rHDL-9.4 R173C nanoparticles (Figure 4.15). Faint bands for separate 
minor particle populations at ~7.5-8.8 nm and 12.2 nm were also observed (Figure 4.15, 
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rHDL pre-UTC). After SG-UTC, in the 1.15 g/mL layer, the major particle population 
diameter was between ~8.8-10.1 nm (Figure 4.15, 2.5 mL pooled fractions) and ~8.6-
9.2 nm (Figure 4.16, 0.5 mL fractions). The rHDL-9.4 R173C band indicated particles 
with an equivalent diameter to the purified rHDL-9.1 WT particles (Figure 4.9). 
A comparison of the three pooled density layers 1.09 – 1.21 g/mL sample lanes showed 
partial separation of the predominant rHDL-9.4 R173C particle population from the 
rHDL-7.5-8.8 and -12.2 R173C nanoparticles (Figure 4.15). The 1.09 g/mL fractions 
contained very faint staining between 12.2 – 17.0 nm, and the 1.21 g/mL fractions 
contained a faint broad band between 7.5-8.8 nm (Figure 4.15). The 1.15 g/mL pooled 
fractions (2.5 mL) contained the predominant rHDL-9.4 R173C particle population. As 
well as faint bands that indicated the presence of minor rHDL-R173C nanoparticle 
populations at ~12.2 nm and between 7.5-8.8 nm.  
The 1.30 g/mL fraction sample lane did not show clearly defined bands but there was 
some staining indicating the presence of monomeric lipid-free apoA-I R173C and 
rHDL-7.5 R173C particles. The LF apoA-I R173C showed bands indicating the 
presence of monomeric and dimeric protein. This was expected as apoA-I R173C can 
form a disulphide bonded dimer confirmed by mass spectrometry and in the presence 
of a reducing agent (TCEP) was monomeric (see Chapter 3).  
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Figure 4.15. A 4 – 16% NativePAGE gradient gel of rHDL POPC:apoA-I R173C 200:2 
(M/M) preparation using SG-UTC. The sample lanes contain: LF apoA-I R173C, rHDL 
containing sodium cholate, rHDL without sodium cholate, rHDL pre-UTC after storage 
at 4°C, and each 2.5 mL pooled NaBr SG-UTC fractions, at 1.04, 1.09, 1.15, 1.21 and 
1.30 g/ml density. The labels indicate the bands corresponding to monomeric and 
dimeric lipid-free apoA-I R173C, and rHDL between 7.5 – 12.2 nm diameter. 
It was expected that upon TCEP and glutathione removal the monomeric apoA-I R173C 
which contained reduced cysteine residues would become fully oxidised to form 
disulphide bonded dimeric apoA-I R173C. The presence of monomer suggested that the 
apoA-I R173C was not completely converted to dimer. The monomer could be in 
equilibrium with the dimer formation after TCEP removal. The apoA-I R173C lipid-
free conformation is unknown however apoA-I WT has exhibited a variety of lipid-free 
structures (see section 1.6.1). Therefore, the cysteine residue in the monomer may not 
be completely accessible to form the disulphide bonded dimer.  
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The individual 1.15 g/mL (0.5 mL) fractions 12-14 (Figure 4.16) showed rHDL-R173C 
particles with an ~8.9 nm diameter similar to the 0.5 mL rHDL-8.7 WT particle 
fractions at the same NaBr density (Figure 4.10), and a diameter range of ~8.6-9.2 nm. 
This suggested that before pooling together for further characterisation the individual 
fractions should be analysed by NativePAGE. 
 
Figure 4.16. A 4-16 % NativePAGE gradient gel of the different stages of the rHDL 
POPC/R173C 200:2 (M/M) SG-UTC fractions. The sample lanes contain: LF apoA-I 
R173C, and separate 0.5 mL fractions shown by the fraction number at the NaBr density 
layers of 1.04, 1.09, 1.15, and 1.21 g/mL density. The labels indicate the bands 
corresponding to monomeric and dimeric LF apoA-I R173C and rHDL-8.9 R173C 
particles.  
The DLS measurement of the 1.15 g/mL pooled 2.5 mL layer of rHDL-R173C 
nanoparticles was an average of 2 scans as the PdI of scan 1 was ~0.79 and therefore 
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not included. The average particle diameter was 13.8 ±0.30 nm and a PdI of 0.57 ±0.01 
nm, with the volume-weighted distribution in Figure 4.17B. The DLS rHDL-R173C 
average particle diameter at 13.8 nm was larger compared to rHDL-WT 1.15 g/mL 
fractions at 11.3 nm and the rHDL-8.9-9.4 R173C NativePAGE diameter particles. The 
intensity-weighted diameter DLS measurement was affected by impurities present 
within the 50 nm diameter range which could cause the intensity peak average to shift 
higher (Figure 4.17A).  
 
Figure 4.17. rHDL-R173C POPC:apoA-I 200:2 (M/M) nanoparticles SG-UTC 
fractionated DLS A) intensity- and B) volume-weighted particle population 
distributions between 0 – 50 nm. C) A TEM image at x 98 k magnification of Fl-UTC 
fractionated rHDL-R173C nanoparticles at the 9 µM protein concentration and stained 
with 2 % (w/v) UA. The scale bar is 50 nm. 
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An attempt was made to image the POPC/apoA-I R173C 200:2 (M/M) rHDL 
nanoparticle sample at 9 µM protein concentration (Figure 4.17C) to obtain planar 
particles with the lipid bilayer parallel to the TEM grid surface as with rHDL-WT 
nanoparticles at the 9 µM apoA-I concentration (Figure 4.13). The image showed the 
characteristic rouleaux of the rHDL nanoparticles as indicated by the arrows. However, 
the image resolution was not sufficient to measure the particle diameter as it appears 
the particles did not disperse across the TEM grid surface but appeared concentrated 
with the stain. Due to time constraints the resolution and sample imaging could not be 
improved, and the sample was not imaged at the 36 µM protein concentration. 
4.3.5.2 rHDL apoA-I L144R nanoparticles 
The rHDL-L144R nanoparticles were prepared at the POPC:apoA-I L144R 200:2 molar 
ratio using the same methods as described for the rHDL-WT and R173C nanoparticles. 
The SG-UTC fractionation NativePAGE gel of the 2.5 mL pooled density layer 
fractions (Figure 4.18) showed LF apoA-I L144R contained monomeric and dimeric 
protein similar to apoA-I WT and R173C.  
The major unfractionated rHDL-L144R nanoparticle population was between 8.2 – 10.0 
nm with sodium cholate, and ~8.8 – 9.0 nm without sodium cholate (Figure 4.18). The 
presence of faint bands also showed nanoparticle populations at ~11.6 nm and between 
~7.6–8.3 nm. The major nanoparticle population in the SG-UTC fractionated rHDL-
L144R 200:2 (M/M) sample was at ~9.0 nm with a range between 8.8 – 9.4 nm (Figure 
4.18, 1.15 g/mL sample lane). The rHDL-9.0 L144R nanoparticle population was 
similar in size to the rHDL-9.1 WT and rHDL-9.4 R173C nanoparticle populations.  
The rHDL-7.6-8.3 L144R particle population was separated from the major rHDL-9.0 
L144R particles population as indicated by a broad band between 7.6 – 9.0 nm in the 
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1.21 g/mL density layer (Figure 4.18). Additionally, the separation of lipid-free apoA-
I L144R by SG-UTC from the rHDL-L144R nanoparticles was indicated by the broad 
stain in the 1.30 g/mL density layer.  
 
Figure 4.18. A 4 – 16% NativePAGE gradient gel of rHDL POPC:apoA-I L144R 200:2 
(M/M) nanoparticle preparation. The sample lanes contain: LF apoA-I L144R, rHDL 
containing sodium cholate, rHDL without sodium cholate, rHDL pre-UTC after storage 
at 4°C, and each 2.5 mL pooled NaBr SG-UTC fractions, at 1.04, 1.09, 1.15, 1.21 and 
1.30 g/ml density. The labels indicate the bands corresponding to monomeric and 
dimeric lipid-free apoA-I L144R, and rHDL particles with a diameter between 7.6 – 
11.6 nm. 
The separate 0.5 mL fractions were run on a NativePAGE gel and at the 1.15 g/mL 
density layer fractions 12 and 13 faint bands showed particles with a diameter of ~8.9 
nm (Figure 4.19). The gel was stained for an extended period but the rHDL-L144R 
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
192  Sophie Lau - July 2021 
bands appeared faintly and did not image well. Therefore, the gel contrast after imaging 
was altered (not shown) to view the rHDL bands before the fractions were pooled. The 
bands appeared at approximately the same diameter as the rHDL-8.7-9.1 WT and 
rHDL-8.9-9.4 R173C samples. The lipid-free apoA-I L144R band was faint compared 
to the dark blue staining at the dye front with the approximate position of the monomeric 
protein indicated in Figure 4.19. 
 
Figure 4.19. A 4-16 % NativePAGE gradient gel of the different stages of the rHDL 
POPC/L144R 200:2 (M/M) SG-UTC fractions.  The sample lanes contain: LF apoA-I 
L144R, and separate 0.5 mL fractions shown by the fraction number for the NaBr 
density layers 1.09, 1.15 and 1.21 g/mL. The labels indicate the bands corresponding to 
monomeric LF apoA-I L144R and rHDL-L144R nanoparticles. The dashed box (black) 
outlines the position of the faint rHDL bands in fractions 12 and 13. The dashed box 
(red) indicates the approximate position of monomeric lipid-free apoA-I L144R.  
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The rHDL POPC:apoA-I L144R 200:2 (M/M) sample particle size was measured using 
DLS of the unfractionated nanoparticles (Figure 4.20A) but not the 1.15 g/mL pooled 
fractions due to samples produced at the time of DLS equipment availability. The 
average intensity-weighted particle diameter was 6.2 ±0.45 nm with a PdI of 0.78 ±0.04. 
This was significantly smaller in comparison to the NDGGE major particle band 
between 8.8-9.4 nm. The PdI of each measurement was >0.7 indicating the sample was 
quite polydisperse and not as suitable for DLS measurements as the SG-UTC 
fractionated nanoparticles of rHDL-WT and R173C. The larger PdI may be due to 
possible liposome formation at approximately 100 nm and dust contamination at 
approximately 5000 nm in the intensity-weighted particle distribution.  
The TEM image of the rHDL-L144R fractionated Fl-UTC nanoparticles at the 36 µM 
protein concentration showed short rouleaux formation in a concentrated region of 
rHDL nanoparticles for diameter and thickness measurements (Figure 4.20B). The 
average diameter and thickness of the total 150 nanoparticles was 11.8 ±1.9 nm (Figure 
4.20C) and 5.6 ±0.7 nm (Figure 4.20D), respectively.  
The majority of the rHDL-L144R nanoparticles showed 74 % of particles between 8-
13 nm in diameter, which was slightly lower than the rHDL-WT particle diameter 
distribution (81-83 %). The rHDL-L144R diameter histogram (Figure 4.20C) indicated 
a shifted distribution of larger rHDL particles 7.0-17.0 nm compared to the rHDL-WT 
of 6.5-14.0 nm. The thickness of the rHDL-L144R nanoparticles at 5.6 ±0.6 nm was the 
same as the rHDL-WT nanoparticles at 5.6 ±0.7 nm.  
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
194  Sophie Lau - July 2021 
 
Figure 4.20. rHDL-L144R nanoparticle size measurements at the POPC:apoA-I L144R 
molar ratio of 200:2 (M/M). A) DLS of unfractionated rHDL nanoparticles, scans 1-3 
of the volume-weighted particle distribution. B) A TEM image at 36 µM protein 
concentration of Fl-UTC fractionated nanoparticles stained with 2 % (w/v) UA. The 
scale bar is 100 nm at x 68 k magnification. Histograms of 150 rHDL-L144R 
nanoparticle C) diameter and D) thickness measurements at the 36 µM apoA-I 
concentration. 
 
The diameter DLS measurement of the unfractionated rHDL-L144R was significantly 
smaller at ~6.2 nm. As the sample was unfractionated this could have contributed to a 
different particle diameter, but there was no observed band in the NativePAGE gel <7.6 
nm diameter. The overall major rHDL-L144R nanoparticle distribution as imaged by 
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NDGGE (8.8-9.4 nm) and TEM (11.8 nm) showed similar particle sizes to the rHDL-
WT NDGGE (8.6-9.8) and TEM (10.7 nm). 
4.3.6 rHDL nanoparticles containing cholesterol 
Discoidal rHDL-WT nanoparticles containing cholesterol (rHDL-C) were reconstituted 
with an initial POPC:cholesterol molar ratio of 10:1 (M/M), and varied POPC:apoA-I 
WT molar ratios of 300, 240, 200, and 60:2. The rHDL-C particles were characterised 
by NDGGE and cholesterol content was confirmed by a cholesterol concentration assay 
and calculated as the mol % of the total lipid in the sample.  
The rHDL-C nanoparticles were characterised using NativePAGE to determine the 
particle sizes after sodium cholate removal (Figure 4.21). Across the various 
phospholipid:cholesterol:apoA-I WT ratios five different rHDL-C nanoparticles were 
produced and are indicated by the average diameter for each band. At each lipid:apoA-
I ratio 300-160:2 the rHDL-C-9.7 WT nanoparticle population was predominant despite 
an increase in the total lipid + cholesterol:apoA-I ratio. The diameter range of the major 
rHDL-C-9.7 WT nanoparticle population was between ~9.0-10.1 nm.  
Each lane was absent of lipid-free apoA-I indicating the apoA-I WT in each sample was 
completely lipid-bound. The higher lipid:cholesterol:apoA-I WT ratios 300:30:2 and 
240:24:2 showed faint bands indicating the presence of rHDL-C-17.4 and -12.7 WT 
particle populations. In comparison, the lower phospholipid:apoA-I ratios at 200:20:2 
and 160:16:2 showed the rHDL-C-8.4 WT nanoparticle population, whilst the 160:16:2 
molar ratio also showed a faint band for the rHDL-C-7.5 WT nanoparticle population.  
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Figure 4.21. A 4-16% NativePAGE gradient gel of unfractionated 
POPC:cholesterol:apoA-I WT at the start molar ratios of 300:30:2, 240:24:2, 200:20:2, 
and 160:16:2 (M/M). The rHDL-C nanoparticles formed are indicated with the 
corresponding diameter (nm), and the lipid-free apoA-I WT monomer and dimer.  
Unfractionated rHDL-C L144R and WT particles at the molar ratio of 
POPC:cholesterol:apoA-I of 200:20:2 were produced and analysed by NativePAGE 
(Figure 4.22). Both rHDL-C nanoparticle preparations with apoA-I WT and L144R 
showed bands at ~8.3 and 9.1 nm diameter. The major rHDL-L144R and WT 
nanoparticle band diameter range was between ~8.8-9.4 nm.  
The lipid-free apoA-I WT protein showed approximately equal monomer to dimer 
shown by the comparable band size and band intensity. In comparison the LF apoA-I 
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L144R protein appeared predominantly monomeric with less intense dimer band 
staining relative to the apoA-I WT dimer band. Both proteins were stored at 
concentrations above 1.0 mg/mL which for apoA-I WT results in the formation of 
predominantly dimeric protein (Davidson et al., 1996; Giudice et al., 2017; Oda, 2017; 
Petrlova et al., 2016). This suggested that the apoA-I L144R may not have as strong a 
concentration dependent multimer formation relative to apoA-I WT. This was not 
explored further because this did not affect the rHDL nanoparticles formed which were 
comparable to the apoA-I WT and R173C rHDL nanoparticles.  
 
Figure 4.22. A 4-16% NativePAGE gradient gel of unfractionated 
POPC:cholesterol:apoA-I L144R/WT at the start molar ratio of 200:20:2 (M/M). The 
rHDL-C nanoparticles formed are indicated with the corresponding diameter (nm), and 
lipid-free monomeric and dimeric apoA-I WT and L144R.  
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The POPC:cholesterol:apoA-I molar ratio of 190:10:2 (M/M) (5 mol % cholesterol) was 
used to prepare rHDL-C WT, R173C and L144R nanoparticles and the particle size was 
analysed by NDGGE (Figure 4.23). The unfractionated rHDL-C WT 190:10:2 (M/M) 
sample showed rHDL with a major band at ~9.3 nm, with a diameter range of 8.8-9.6 
nm. Minor faint bands indicated possible larger rHDL-WT nanoparticles at ~17.4 and 
12.0 nm and a smaller particle at ~8.3 nm. The rHDL-C L144R sample contained rHDL 
of similar sizes and band intensity to rHDL-C WT, with the major rHDL-C L144R band 
between 8.7-9.3 nm. The rHDL-C R173C sample did not show any strongly stained 
bands suggesting the sample concentration was too low for NDGGE analysis but SG-
UTC fractionation showed bands indicating rHDL-C nanoparticles were formed 
(Figure 4.26A).  
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Figure 4.23. A 4-16% NativePAGE gel of unfractionated POPC:cholesterol:apoA-I 
WT/R173C/L144R at the molar ratio of 190:10:2 (M/M) post-sodium cholate removal, 
and lipid-free apoA-I WT.  
Each sample was fractionated with SG-UTC and the separation of the particles showed 
rHDL-C-9.1 WT particles in the 1.15 g/mL density fractions between 8.6-9.4 nm in 
diameter (Figure 4.24). Fractions were pooled (11-12) for further analyses which did 
not contain the rHDL-C-8.1 WT particles indicated by a faint band in fractions 13-14.  
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Figure 4.24. A 4-16 % NativePAGE gradient gel of the different stages of the rHDL 
POPC:cholesterol:apoA-I WT 190:10:2 (M/M) 1.09 and 1.15 g/mL SG-UTC fractions 
(0.5 mL). The labels indicate the bands corresponding to LF apoA-I WT monomer and 
dimer, and the rHDL-C-8.1 and -9.1 nm WT particles in the fractions.  
The rHDL-C WT 190:10:2 (M/M) nanoparticles post-Fl-UTC at 36 µM protein 
concentration (Figure 4.25A) were analysed by TEM and showed the rHDL-C WT 
nanoparticles in concentrated dense regions. The rHDL-C WT nanoparticle average 
diameter and thickness were 11.8 ±1.8 nm and 5.8 ±0.7 nm, respectively. The size 
distribution indicated rHDL-C nanoparticles between ~8.5-15 nm diameter and ~4-8 
nm thickness. The majority of particles were between 8-13 nm at 78 % of the total 
particles measured. The TEM diameter size distribution of the Fl-UTC fractionated 
rHDL-C WT nanoparticles suggested the sample contained the minor particle 
population at ~12.0 nm detected by NativePAGE before UTC (Figure 4.23). The 
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particles in TEM were larger than those indicated by NativePAGE analysis (Figure 
4.24) due to difficulties in defining particle edges which could have led to an 
overestimation of the nanoparticle diameter. As a result of limited time, only the rHDL-
C WT 190:10:2 nanoparticles were visualised by TEM.  
 
Figure 4.25. Fl-UTC pooled (2.5 mL) rHDL-C nanoparticles at the molar ratio of 
POPC:cholesterol:apoA-I WT 190:10:2 (M/M), A) A TEM image at x68 k 
magnification and 36 µM protein concentration. The corresponding diameter (B) and 
thickness (C) rHDL-C WT nanoparticle histograms of a total of 150 nanoparticles.  
The NativePAGE gels of the 190:10:2 rHDL-C nanoparticles with apoA-I R173C 
(Figure 4.26A), and L144R (Figure 4.26B) show the predominant species in the 1.15 
g/mL 0.5 mL fractions as rHDL-C-9.3, respectively. The major band particle diameter 
range for rHDL-C-9.3 R173C was between 8.7-9.7 nm and the rHDL-C-9.3 L144R 
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diameter range was between 8.7-9.3 nm. The 1.15 g/mL fractions showed faint bands 
of ~11.5 nm rHDL-C R173C particles, whilst the rHDL-C L144R fractions also 
contained particles ~15.9 nm in diameter. This suggested that with the 5 mol % 
cholesterol rHDL-R173C and L144R preparations the separation of fractions was not 
as defined in the 1.15 g/mL layer and in future the 1.21 g/mL fractions could contain 
more fractions to pool for rHDL-C-9.3 L144R particles.  
 
Figure 4.26. A 4-16 % NativePAGE gradient gel of the different stages of the rHDL 
particles at the molar ratio of POPC:cholesterol:apoA-I 190:10:2 (M/M) 1.15 g/mL SG-
UTC fractions 1-5 (0.5 mL). A) apoA-I R173C with bands for LF apoA-I R173C 
monomer and dimer, and the rHDL-C-9.3 and -11.5 nm R173C particles in the fractions. 
B) apoA-I L144R with bands for LF apoA-I L144R monomer, and the rHDL-C-9.3, -
11.6 and 15.9 nm L144R particles in the fractions.  
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4.3.7 Sample concentration of rHDL nanoparticles 
The POPC:apoA-I 200:2 (M/M) rHDL protein and lipid concentration were measured 
before and after sodium cholate removal by dialysis, and after SG-UTC isolation of the 
predominant particles in each preparation in the 1.15 g/mL pooled fractions (Table 4.7). 
The start and final POPC:cholesterol:apoA-I molar ratios are in Table 4.8 for the 
unfractionated rHDL-C WT, R173C and L144R nanoparticles. The lipid and cholesterol 
concentrations of the rHDL and rHDL-C nanoparticles were quantified using enzyme 
concentration assays measured in duplicate. The protein concentration was determined 
in triplicate using the NanoDropTM A280 absorbance measurements.  
For the rHDL-WT, and L144R nanoparticle POPC:apoA-I 200:2 (M/M) samples the 
final molar ratios were similar before and after sodium cholate removal (Table 4.7). In 
comparison, the rHDL-R173C 200:2 sample molar ratio after dialysis was significantly 
lower at 44.7 ±2.3: 2 (M/M). Additionally, after SG-UTC and spin concentration the 
rHDL-WT and R173C 200:2 sample POPC measurements had a large relative standard 
deviation at 186.6 ±27.0 and 268.0 ± 107.0, respectively.  
The respective NativePAGE gels did not detect a change in the estimated diameter range 
of the rHDL-WT, R173C or L144R nanoparticles between ~8.6 – 10.1 nm at each stage 
in the rHDL protocol (see sections 4.3.3.1 and 4.3.5). Therefore, the fractionated 
rHDL-WT and rHDL-R173C molar ratios, and post-dialysis rHDL-R173C values were 
considered anomalous. Whereas the rHDL-L144R 200:2 nanoparticle POPC molar ratio 
showed a lower POPC:apoA-I molar ratio with a smaller relative SD at 140.5 ±4.7: 2.  
The final POPC:apoA-I molar ratios with the lowest relative SD were used as the overall 
estimated molar ratio for the rHDL-WT, R173C and L144R samples. Henceforth, the 
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rHDL-WT, R173C and L144R samples will be referred to as the estimated molar ratio 
at ~200:2 for reference. 
Table 4.7. The rHDL-WT/R173C/L144R 200:2 (M/M) POPC: apoA-I sample 
concentrations (mM) and final molar ratios ± relative SD. The POPC sample 
concentration (n = 2) ± SD and the apoA-I concentration (n = 3) SD were all ≤0.001. 
Sample 
Concentration (mM) ±SD 
Molar ratio (M/M) ± relative SD 
POPC apoA-I 
apoA-I WT    
Before dialysis 6.0 ±0.059 0.061 197.7 ±2.1:2 
After dialysis 5.0 ±0.032 0.050 202.2 ±3.6:2 
1.15 g/mL spin conc.  14.9 ±2.151 0.159 186.6 ±27.0 :2 
apoA-I R173C    
Before dialysis 5.0 ±0.009 0.051 197.5 ±0.9:2 
After dialysis 1.0 ±0.052 0.045 44.7 ± 2.3:2 
1.15 g/mL spin conc.  14.4 ±5.754 0.108 268.0 ± 107.0:2 
apoA-I L144R    
Before dialysis 5.3 ±0.037 0.052 202.9 ±2.1:2 
After dialysis 4.7 ±0.027 0.045 207.6 ±1.7 :2 
1.15 g/mL spin conc.  9.4 ±0.312 0.134 140.5 ±4.7:2 
 
The unfractionated rHDL-C WT, R173C and L144R nanoparticle final 
POPC:cholesterol:apoA-I molar ratios and mol % cholesterol are summarised in Table 
4.8.  
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Table 4.8. The rHDL-C WT/R173C/L144R nanoparticle POPC and cholesterol 
concentration (mM) (n = 2) are ±SD post sodium cholate removal by dialysis. The 
apoA-I protein concentration (n = 3) SD for each sample was ≤0.001. The cholesterol 
mol % is in parentheses.  
  Concentration (mM) ±SD 
Final molar ratio 













264.7 ±12.1:  








241.6 ±2.1:  


























16.4 ±0.6: 2  

























23.7 ± 1.9: 2  
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In the 10 mol % cholesterol rHDL-C WT sample the final POPC:cholesterol:apoA-I 
WT molar ratio decreased from ~265:38:2 to 150:17:2 as the start 
POPC:cholesterol:apoA-I WT molar ratio decreased (300:30:2 to 160:16:2). This 
coincided with a decrease in the predominant rHDL-C WT nanoparticle diameter range 
as estimated by NDGGE from 9.3 – 10.1 nm to 8.7 – 9.3 nm (Figure 4.21-4.22). The 
rHDL-C L144R 200:20:2 (10 mol % cholesterol) final molar ratio of 172.4 ±2.6: 23.7 
± 1.9: 2 was slightly lower than the rHDL-C WT 186.1 ±6.9: 25.2 ±0.6: 2 final molar 
ratio. The rHDL-C WT and L144R 200:20:2 samples both contained ~13.5 mol % 
cholesterol, with a slightly lower overall POPC content in the rHDL-C L144R 
nanoparticles.  
In the rHDL-C WT and L144R 190:10:2 (5 mol % cholesterol) samples the final molar 
ratios were similar at 193.6 ±8.9: 16.4 ±0.6: 2 (8.5 mol % cholesterol) and 205.6 ±17.4: 
16.3 ± 0.2: 2 (7.9 mol % cholesterol), respectively. However, the rHDL-C R173C final 
molar ratio was 166.3 ±24.4: 8.9 ±1.0: 2 which suggested the rHDL-C R173C 
nanoparticles contained less cholesterol at ~5.4 mol %. The differences detected in the 
rHDL-C WT, R173C and L144R 190:10:2 nanoparticle final molar ratios did not reflect 
a change in the predominant diameter detected by NDGGE of crude and fractionated 
samples between 8.6 – 9.7 nm (Figure 4.23, 4.24, 4.26).  
Similar to the rHDL samples without cholesterol the rHDL-C nanoparticles in this work 
will be referred to by the estimated start molar ratio such as 200:20:2 for reference in 
further chapters.  
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4.4 Discussion 
The primary purpose of this chapter was to develop a method to produce homogenous 
rHDL nanoparticles of similar size containing apoA-I WT, R173C or L144R at the 
molar ratios of POPC:±cholesterol:apoA-I of 200:2, 200:20:2 and 190:10:2.  
4.4.1 rHDL nanoparticle fractionation 
The reliability of two methods for preparing size-fractionated rHDL particles, density-
based UTC and SEC, were assessed, using the POPC:apoA-I WT 200:2 molar ratio as 
the test system. To isolate the predominant rHDL-WT nanoparticles between ~8.6-9.8 
nm according to NDGGE.  
SEC was limited by the relatively low rHDL apoA-I WT protein concentrations 
recovered in fractions, which prevented size measurements by NDGGE. The 
predominant rHDL-WT population SG-UTC yield was approximately 2-fold higher 
than the Fl-UTC and SEC fractionation methods. Whereas Fl-UTC fractionation had 
the highest overall sample recovery at ~20 % higher than both SEC and SG-UTC, due 
to the reduction in density layers in the preparation.  
rHDL-C WT 160:8:2 nanoparticles of a similar diameter at ~9.6 nm have been produced 
with a yield of ~32.8 % relative to starting apoA-I concentration (Cavigiolio et al., 
2008). In this work, the yield of rHDL nanoparticles was ~13 % using both the Fl-UTC 
and SEC purification methods. Interestingly, the SG-UTC purified rHDL nanoparticle 
yield was similar to the literature comparison at ~32 %. However, it is clear from this 
yield that further optimisation would be beneficial to scaling up rHDL nanoparticle 
preparation for further characterisation.  
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The density-based UTC fractionation of the rHDL-WT 200:2 nanoparticles indicated 
the successful removal of unreacted lipid-free apoA-I from the rHDL nanoparticles. 
This was important for future characterisation as lipid-free apoA-I could interfere with 
labelled-protein NMR measurements or lipid-bound protein secondary structure 
analyses such as circular dichroism. Therefore, it was decided that rHDL nanoparticles 
preparation by sodium cholate detergent mediated dialysis, followed by SG- or Fl-UTC, 
was the more efficient method. 
A challenge of the rHDL nanoparticle preparation was the loss of apoA-I in the rHDL 
SG-UTC method (section 4.3.4.2), specifically for the preparation of 13C-CP-MAS SS 
NMR PEG-precipitated rHDL samples containing dual-labelled apoA-I. Stages during 
which sample loss could occur were sample spin concentration or during dialysis. 
Alternatives to spin concentration could be lyophilisation or a buffer exchange column 
to remove sodium cholate and unreacted lipids initially, or NaBr after SG-UTC. 
Additionally, optimisation of the unlabelled and labelled protein expression yields 
would be beneficial to scale up the rHDL nanoparticle sample preparation.  
4.4.2 Evaluation of the rHDL nanoparticle size 
The unfractionated and UTC fractionated rHDL (200:2 POPC:apoA-I) size 
distributions with and without cholesterol are summarised in Table 4.10 and Table 
4.11, respectively. The previously published rHDL/rHDL-C WT diameters, as analysed 
by NDGGE and TEM, are summarised in Table 4.9 for a direct comparison to the rHDL 
nanoparticles produced in this work. 
The unfractionated rHDL containing apoA-I WT or the atheroprotective apoA-I 
mutants R173C and L144R showed a similar rHDL nanoparticle size range according 
to NDGGE with a major band between 8.2 – 10.0 nm in diameter in each case. The 
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NativePAGE gels indicated the presence of minor rHDL populations between 
approximately 7.4 – 8.8, ~11.6-12.2 and 16.2 nm, and the presence of lipid-free apoA-
I.  
Previously, rHDL-R173C nanoparticles produced with 100 % dimeric apoA-I R173C 
produced particles 7.8 and 12.5 nm in diameter only (Calabresi et al., 1997b). In this 
study, the recombinant apoA-I R173C expression was a mixture of monomer and dimer 
as determined by NativePAGE (see Chapter 3, section 3.3.3.2, Figure 3.26) which 
suggested the major rHDL-R173C nanoparticles formed could be between 7-12 nm, 
rather than predominantly small particles or at the restricted sizes of 7.8 or 12.5 nm. 
The rHDL-WT nanoparticle diameters were similar to previously published particle 
diameters at the POPC:apoA-I WT 200:2 molar ratio measured by NDGGE of ~9.8 nm 
and 10.2 nm (Table 4.9) (Chen et al., 2009; Gu et al., 2010).  
The TEM measurements of the rHDL-WT and L144R nanoparticle average diameters 
and thicknesses were ~11 and 5.6 nm, respectively. The rHDL-R173C nanoparticles 
were not measured by TEM as the nanoparticles appeared concentrated with the stain 
which resulted in low image resolution. Additionally, rouleaux formation occurred at 
the higher rHDL-WT protein concentration of 36 µM, and a lower concentration (9 µM) 
was necessary to observe individual particles with their faces exposed. This suggested 
the rHDL-WT nanoparticles stained with uranyl acetate form rouleaux dependent upon 
the rHDL sample concentration (Lau and Middleton, 2020). This observation will be 
central to the interpretation of the NMR results in Chapter 6. 
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Table 4.9. The range of previous discoidal rHDL-WT nanoparticle sizes produced in 
sample preparations containing POPC:±cholesterol:apoA-I WT at different molar 
ratios. In preparations of mixed particles, the major band by NDGGE is highlighted in 
bold. 
POPC:±cholesterol:apoA-I WT Diameter (nm) Reference 



































7.3, 9.3-9.5, 10.2 
9.3-9.5, 10.2 
10.2, 12.2, 17.0 
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(Gu et al., 
2010) 
60: 4: 2 
 
160: 8: 2  
320:16:2 
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105: 6: 2 
181: 8: 2 
281: 9: 2 
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(Xu et al., 
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200: 20: 2 
 
 
218: 17: 2 








(Wu et al., 
2007) 
(Wu et al., 
2009) 
190:10:2 200: 10: 2 9.6-9.7, 12.2-17.0  
(Han et al., 
2005) 
 
The standard deviation of the TEM measurements indicated the rHDL nanoparticles 
fractionated by Fl-UTC contained greater heterogeneity than the size range indicated 
on the NativePAGE gel between 8.7 – 9.5 nm in diameter (Table 4.10). The TEM 
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measurements of dried nanoparticles were probably an overestimate as the particle 
thickness was greater than an average hydrated POPC bilayer at ~4.1 nm (Kucerka et 
al., 2005; Lau and Middleton, 2020). In NDGGE the estimated Stokes diameter was 
calculated from the relative mobility of globular (i.e., spherical) protein standards which 
has been suggested to result in an underestimated diameter as the rHDL nanoparticle 
shape is discoidal (Forte et al., 1995).  
Table 4.10. The unfractionated and SG-UTC fractionated major particle size diameters 
of the POPC: apoA-I WT/R173C/L144R rHDL nanoparticles prepared at the 200:2 
molar ratio. The TEM rHDL particles were Fl-UTC fractionated particles. 
 Diameter (nm) 
ApoA-I 
Unfractionated Fractionated 
NDGGE DLS NDGGE DLS TEM 
WT 8.2 – 10.0 11.3 ±0.2 8.6 – 9.8 12.8 ±0.9 
10.7 ±2 x 
5.6 ±0.7 
R173C 8.8 – 10.0   8.6 – 10.1 13.8 ±0.3  
L144R  8.8 – 9.0  6.2 ±0.45 8.8 – 9.4  
11.8 ±1.9 x 
5.6 ±0.7 
 
The rHDL-WT 200:2 nanoparticle DLS average diameter at ~11 nm was similar to the 
TEM measured diameter and greater than the NDGGE estimated diameter range. The 
rHDL-WT 200:2 nanoparticle hydrodynamic diameter range according to NDGGE was 
between 8.2 – 10 nm (Table 4.10). In comparison the hydrodynamic diameter 
determined by DLS was 11.3 nm. A difference in the hydrodynamic diameter of rHDL 
measured by NDGGE versus DLS has been observed elsewhere (Wu et al., 2009; Wu 
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et al., 2007), rHDL-C WT 200:20:2 nanoparticles had diameters of 9.5 – 9.7 nm 
according to NDGGE and 10.8 – 11.5 nm determined by DLS.  
The rHDL-L144R DLS hydrodynamic diameter was ~6.2 nm which was significantly 
smaller than both TEM (11.8 nm) and NDGGE (8.8 – 9.4 nm) measured diameters of 
the same particles and the rHDL-WT/R173C nanoparticles. The reason for this 
difference in the rHDL-L144R nanoparticle size measured by DLS is unclear, but, as 
will be shown in Chapter 6, is probably related to the shapes of the particles in the two 
preparations.  
The rHDL-C WT nanoparticles containing 10 mol % cholesterol between the molar 
ratios of POPC:apoA-I WT of 300-160:2 showed a similar major particle size 
distribution between 8.7 – 10.1 nm overall (Table 4.11). The rHDL-WT/L144R 
nanoparticles at the 200:20:2 molar ratio produced major rHDL nanoparticles of similar 
diameter between ~8.8 – 9.7 nm. This was analogous to the ~9.5 – 9.7 nm diameter of 
the rHDL-C WT 200:20:2 nanoparticles produced by Wu et al. (Wu et al., 2009; Wu et 
al., 2007).  
Additionally, the 190:10:2 rHDL-C WT/R173C/L144R nanoparticles NDGGE 
diameters showed similar diameters with respect to the different apoA-I protein (8.7 – 
9.7 nm). The rHDL-C 190:10:2 nanoparticle diameters were comparable to previous 
study rHDL-C WT nanoparticle diameters with similar molar ratios of 9.2 – 10.0 nm 
and 9.6 – 9.7 nm (Cavigiolio et al., 2008; Han et al., 2005).  
In the rHDL nanoparticle preparations there was a degree of heterogeneity in the 
unfractionated and UTC fractionated rHDL nanoparticles detected by DLS and TEM. 
The NativePAGE gel diameter range estimates showed the major rHDL nanoparticles 
with and without cholesterol particle populations were comparable.  
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Table 4.11. The unfractionated major particle size diameters by NDGGE of the 
POPC:cholesterol:apoA-I WT/R173C/L144R rHDL-C nanoparticles prepared at the 





apoA-I WT L144R R173C 
300:30:2 9.3 – 10.1   
240:24:2 9.0 – 9.7   
200:20:2 9.0 – 9.7 8.8 – 9.4   
160:16:2 8.7 – 9.3   
190:10:2 
8.8 – 9.6, 8.6 – 9.4a 
11.8 ±1.8 x 5.8 ±0.7b 
8.8 – 9.6, 
8.7 – 9.3a 
8.7 – 9.7a 
 
This variation was expected to an extent as previous studies of density-based UTC 
fractionated rHDL-WT particles prepared at similar molar ratios (200:2, 160:2) 
diameters were 11.2 ± 1.5 nm (Sparks et al., 1992b) and 9.8 ±1.7 nm (Chen et al., 2009). 
Both studies utilised these discoidal rHDL nanoparticles (Table 4.9) for solution state 
NMR apoA-I WT structural studies of the lysine conformation “microenvironment” 
variation (Sparks et al., 1992b) and tertiary apoA-I conformation differences (Chen et 
al., 2009).  
In contrast, previous studies of nanodisc diameters determined with TEM of 
DMPC:MSP1D1 (apoA-I Δ(1-54)) 160:2 (mol/mol) and DMPC:MSP1ΔH5 100:2 
(mol/mol) rHDL nanoparticles were 9.5 ±1.1 and 8.2 ±0.6 nm, respectively, after SEC 
fractionation (Hagn et al., 2013). The latter particles were characterised by solution-
state NMR to produce a discoidal nanodisc structure model (Figure 1.14) (Bibow et al., 
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2017). This suggested the heterogeneity could be further reduced by SEC however due 
to limited time this method was not tested further. 
4.4.3 Summary 
In conclusion, the rHDL and rHDL-C WT/R173C/L144R nanoparticle major diameters 
(Table 4.10 and Table 4.11) were similar to the literature plasma HDL WT and rHDL-
WT nanoparticle diameters (Table 4.1 and Table 4.9). The SG-UTC fractionated rHDL 
nanoparticles by NDGGE showed separation from lipid-free apoA-I with partial 
separation of the particle sizes outside of the major band range (~8 – 10 nm). The TEM 
particle diameter measurements confirmed partial separation from the minor 
nanoparticle sizes. Furthermore, the yield of the rHDL nanoparticle preparation 
required further optimisation.  
Overall, the formation of rHDL nanoparticles of a similar size distribution containing 
the apoA-I R173C and L144R mutants allowed for a direct comparison to rHDL-WT 
nanoparticles. The nanoparticles were suitable for further structural and functional 
characterisation as previous solution-state NMR studies contained a similar level of 
heterogeneity, and the UTC fractionation separated the rHDL nanoparticles from lipid-
free apoA-I. Additionally, this is the first preparation of rHDL-L144R nanoparticles for 
structural analyses at the POPC:±cholesterol:apoA-I L144R molar ratios of 200:2 and 
200:20:2, with only a NativePAGE gel previously run of rHDL-L144R nanoparticles at 
the 190:10:2 molar ratio (~10 nm) (Fiddyment et al., 2011). Hence the molar ratios of 
rHDL-WT were used as a basis for producing rHDL-L144R nanoparticles of similar 
size and composition in this study.  
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5 ApoA-I structure in rHDL 
5.1 Introduction 
The atheroprotective apoA-I mutants, L144R and R173C, could contain structural 
differences in the apoA-I conformation compared to apoA-I WT in rHDL nanoparticles. 
The mutation in apoA-I R173C enables the formation of disulphide bonded dimers and 
has been suggested to exist in a “locked” shifted registry in rHDL-R173C nanoparticles 
(Klon et al., 2000). ApoA-I L144R contains an additional positive residue compared to 
apoA-I WT in the residue region 143-164 suggested to be key to interactions with the 
enzyme LCAT in RCT (Sorci-Thomas et al., 1993). Therefore, structural differences in 
the rHDL nanoparticle protein constituent could affect functionality in reverse 
cholesterol transport, e.g., in cholesterol incorporation/transport, and interaction with 
enzymes.  
This chapter focuses on the apoA-I structural comparison of the rHDL nanoparticles 
characterised in Chapter 4, by varying the lipid:protein molar ratio e.g., 200:2, the 
respective apoA-I protein WT, R173C or L144R, and introducing cholesterol rHDL-C. 
The aim of the work is to find molecular clues, either in the structure of apoA-I or in 
the morphology (Chapter 6) of the rHDL particles, that may explain the functional 
differences between apoA-I WT and the atheroprotective mutants. 
There have been a variety of experimental techniques used to analyse the structure of 
apoA-I WT in rHDL nanoparticles as described in Table 1.3 (Chapter 1, section 1.8) 
such as CD, solution and SS NMR. In comparison, experimental structural analysis of 
apoA-I R173C in solution and HDL has been limited to lysine cross-linking with MS, 
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HDX MS and CD (Bhat et al., 2010; Calabresi et al., 1997b; Chetty et al., 2012; Giudice 
et al., 2017). Furthermore, the structure of apoA-I L144R in rHDL nanoparticles has 
not been studied by structural techniques such as SS NMR or CD. At the time of writing, 
a structure-function study comparing LF apoA-I WT to L144R and respective rHDL 
200:20:2 nanoparticles was published containing comparative CD data 
(Gkolfinopoulou et al., 2020).  
Earlier solution NMR studies of apoA-I WT in discoidal rHDL nanoparticles of 
different sizes focussed on lysine residue conformation (Sparks et al., 1992b). The 
discoidal rHDL lysine residue conformations were suggested to be in different 
“microenvironments” such as in a nonpolar or polar α-helix face dependent on particle 
size 9.3 - 12.1 nm diameter (Sparks et al., 1992b). Additionally, 1H-15N apoA-I cross-
peak differences were observed in 2D solution NMR spectra of apoA-I residues in 7.8 
and 9.8 nm diameter discoidal rHDL nanoparticles (Chen et al., 2009). This suggested 
the overall tertiary apoA-I conformation differed between the nanoparticles of different 
sizes (Chen et al., 2009).  
Solution NMR has been used for structural analysis of membrane proteins embedded in 
membrane scaffold protein 1 (MSP1) or apoA-I Δ(1-43), and truncations of MSP1 
nanodiscs (Bayburt et al., 2002), which mimic a membrane environment (Hagn et al., 
2013). Interestingly, Bibow et al. produced an advanced structural model of lipid-bound 
apoA-I Δ(1-54, and 121-142) in nanodiscs using high resolution solution NMR with 
EPR (Bibow et al., 2017) (see Chapter 1, section 1.6.3, Figure 1.14). This included 
residue-specific truncated apoA-I secondary structure assignment with inter- and 
intramolecular distance constraints (Bibow et al., 2017). However, solution NMR 
studies of rHDL with full-length apoA-I are challenging because the larger size of the 
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particles, and slower rotational diffusion, gives rise to line broadening and loss of 
resolution. Higher resolution can be obtained using 13C and 15N SS NMR with magic-
angle spinning.  
SS NMR has been used to analyse the structure of truncated apoA-I in PEG-precipitated 
nanodiscs, with analysis by CP-MAS 2D 13C-13C correlation spectra (Li et al., 2006; 
Mors et al., 2013). The PEG-precipitated nanodiscs have been established as a viable 
option for structural studies of embedded proteins such as human CYP3A4 (Kijac et al., 
2007) and proteorhodopsin (Mors et al., 2013). CP-MAS SS NMR and the 
corresponding 2D 13C-13C correlation spectra of dual-labelled MSP1 (apoA-I Δ(1-43)) 
can be used to determine the overall protein secondary structure in large molecular 
weight nanodiscs (Li et al., 2006).  
The solution and SS NMR studies have focussed on the structure of truncated apoA-I 
WT rather than discoidal rHDL nanoparticles containing full-length apoA-I WT. 
Therefore, high-resolution SS NMR of full-length apoA-I in rHDL nanoparticles could 
validate previous HDL models based on lipid-free truncated apoA-I crystal structures 
(e.g. see Chapter 1, section 1.6.1-1.6.2) (Bhat et al., 2010; Gursky, 2013; Gursky et 
al., 2013). 
Another technique that has been used to analyse apoA-I secondary structure in rHDL is 
CD spectroscopy (see Chapter 2, section 2.1). The secondary structure and thermal 
stability of LF and rHDL bound apoA-I WT and R173C have been estimated using CD 
spectroscopy (see Table 5.4 – 5.5, and refs therein). Interestingly, Giudice et al. used 
synchrotron radiation CD (SRCD) to examine the secondary structure and thermal 
stability of ~9.6 nm diameter ~200:2 (M/M) DMPC WT and R173C rHDL 
nanoparticles (Giudice et al., 2017). SRCD has a significantly better signal-to-noise 
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ratio at wavelengths below 200 nm (Giudice et al., 2017; Wallace and Janes, 2009). 
Therefore, the SRCD analysis was used as a comparison for the SSE and melting 
temperatures measured for the rHDL nanoparticles prepared in this work.  
Another aspect to consider is the prolonged atomistic MD simulations of nascent HDL 
at the POPC:cholesterol:apoA-I WT 200:20:2 and 160:24:2 molar ratios on multi-
microsecond timescales (10 and 20 μs) (Pourmousa et al., 2018). The simulations 
revealed deviations from a strictly planar discoidal lipid bilayer and belt-like apoA-I 
morphology (see Chapter 1, Figure 1.15) (Pourmousa et al., 2018), but experimental 
verification is needed.  
To summarise, knowledge of the intact protein structure of WT apoA-I in HDL particles 
is incomplete. The effective combination of experimental and computational studies 
could aid in understanding the structure of rHDL nanoparticles. Furthermore, less is 
known about the structural origins of the atheroprotective properties of the L144R and 
R173C apoA-I mutants. Therefore, it was necessary to compare the apoA-I WT with 
the apoA-I mutants structure to search for structural evidence of the atheroprotective 
function.  
5.1.1 Aims 
The aim of the work described in this chapter is to detect structural differences in apoA-
I WT, L144R and R173C when incorporated into rHDL nanoparticles. This was 
addressed using CP-MAS SS NMR and CD to determine structural properties of the 
rHDL nanoparticle apoA-I proteins. To search for hints in the atheroprotective apoA-I 
protein structures which could affect the rHDL nanoparticle functions.  
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5.2 Material and methods 
The rHDL nanoparticles characterised in this chapter were prepared as described in 
Chapter 4. The following methods for rHDL nanoparticle apoA-I structural 
characterisation are published in (Lau and Middleton, 2020).  
5.2.1 CD of lipid-free and rHDL bound apoA-I  
The lipid-free (LF) and fractionated rHDL apoA-I WT/R173C/L144R sample protein 
secondary structure was investigated using CD with a Chirascan plus qCD spectrometer 
(Applied Photophysics). In each sample loaded into a quartz cuvette (Starna scientific) 
the apoA-I concentration was 3.6 µM with a total volume of 300 µL in rHDL buffer, 
pH 7.4. The following conditions were used for measurement: temperature 37oC, path 
length 1 mm, bandwidth 1 nm, time per point 0.5 s, step size 1 nm, and wavelength 
range of 180 – 260 nm.  
The background CD signal scans in triplicate (n = 3) were subtracted from CD spectra 
before sample analysis. The rHDL and LF sample backgrounds were POPC small 
unilamellar vesicles diluted to the sample lipid concentration in rHDL buffer pH 7.4 or 
rHDL buffer only, respectively. Preliminary scans (n = 3) at varied protein 
concentration (1.8, 3.6, 7.2, 18 µM) determined the appropriate apoA-I sample 
concentration was 3.6 µM to detect a CD signal whilst minimising noise (data not 
shown). 
Preparations of rHDL containing apoA-I WT or R173C or L144R, and the lipid-free 
proteins were incubated with agitation at 3.6 μM protein concentration for 24 hours at 
37°C. The protein concentration was taken before and after to determine the amount of 
apoA-I precipitation. CD spectra were taken at 0 and 24 hours at 37°C. However, after 
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24 hours the protein concentration was below 3.6 μM and resulted in too much noise 
therefore only the before incubation spectra are shown.  
Each sample was scanned in triplicate for secondary structure estimation (SSE). To 
determine if the samples were stable for multiple UV measurements the samples were 
scanned 50 times. The CDApps software was generously provided by Drs G. Siligardi, 
R. Hussain, and T. Javorfi at B23, Diamond Light Source (Oxford, UK) (Hussain et al., 
2015) to analyse the CD spectra for SSE. In the SSE analysis the CONTINLL algorithm 
(Provencher and Gloeckner, 1981; Sreerama and Woody, 2000) with the SMP56 (43 
soluble + 13 membrane proteins) basis set was used between the wavelength range 190 
– 240 nm. Note – the rHDL-L144R 190:10:2 sample SSE was also analysed using the 
CDSSTR algorithm and SMP56 basis set due to anomalous SSE with the CONTINLL 
algorithm.  
Thermal CD spectra of the samples were collected as the temperature was increased in 
1°C increments from 25 to 95°C at a rate of 1°C/min with a tolerance of 0.1°C, and a 
final CD spectra collected once the sample cooled to 25°C (Giudice et al., 2017). The 
Global 3 thermal global analysis software (Applied Photophysics) was used to 
determine the melting temperature(s) (Tm) from the collected thermal CD spectra and 
has previously been used for thermal CD analysis of lipid-free apoA-I WT (Townsend 
et al., 2017). The thermodynamic analysis uses sigmoidal unfolding curve fitting across 
multiple wavelengths based upon the Gibbs-Helmholtz (Equation [9]) (Greenfield, 
2006a) (Applied Photophysics).  
  ∆𝐺 = ∆𝐻 (
1 − 𝑇
𝑇𝑚
) − ∆𝐶𝑝 ((𝑇𝑚 − 𝑇) + 𝑇𝑙𝑛 (
𝑇
𝑇𝑚
))  [9] 
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Where, in the thermal transition from a folded to an unfolded protein state, ΔG is the 
Gibbs free energy, ΔH is the van’t Hoff enthalpy, ΔCp is the change in heat capacity, T 
is the temperature (K), Tm is the melting temperature (K) (Greenfield, 2006a) (Applied 
Photophysics).  
To confirm the number of transitions, i.e. Tm’s, the unfolding curves at 222 nm and the 
unfolding curve first derivatives were plotted between 25 – 95°C (Greenfield, 2006a). 
A peak maximum in the first derivative plot corresponds to a Tm which in turn 
corresponds to the midpoint Tm of the inflection in a sigmoidal unfolding curve 
(Greenfield, 2006a). The Tm(s) from each analysis were similar with respect to each 
other. This revealed the number of transitions as monophasic (lipid-free apoA-I) or 
biphasic (rHDL apoA-I) during the thermal temperature ramp. The OriginPro 2018 
software Boltzmann (sigmoidal) and BiDoseResponse (double sigmoidal) fitting 
functions were used to fit the respective unfolding curves. The r2 values of the sigmoidal 
fitting for the monophasic unfolding curves of lipid-free apoA-I WT, R173C and L144R 
were 0.9976, 0.9991, and 0.9987, respectively. The biphasic unfolding curve double 
sigmoidal fitting r2 values were 0.9991, 0.9988, and 0.9982 for rHDL-WT, R173C and 
L144R, respectively. 
The CD data was too noisy below 200 nm in the thermal denaturation samples to analyse 
for SSE using the CONTINLL algorithm and SMP56 basis set. For example, 
CONTINLL SMP56 basis set (190-240 nm) SSE analysis for LF apoA-I WT at 25°C 
was 48.5 % α-helix (α), 5.9 % β-strand (β), 17.3 % turns (T), 28.2 % unordered (U), and 
at 95°C was 75.6 % α-helix and 24.4 % β-strand. At 95°C this contradicted the thermal 
CD spectra which was characteristic of a shift from α-helical to predominantly random 
coil.  
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Therefore, the approximate α-helical content was estimated using the molar ellipticity 
[θ] at 222 nm [θ222] from the observed CD data in the following equation (Morrisett et 
al., 1973):  




Equation [10] is an approximation as it assumes the secondary structure in the protein 
consists of α-helix and random coil, and the α-helix estimated error was ~7.7 % as 
determined from [θ222] = 0. The molar ellipticity at 222 nm values of a 100 % α-helical 
or random coil protein (poly-L-lysine) used were -36000 and 3000 deg cm2 dmol-1, 
respectively, (Greenfield and Fasman, 1969; Morrisett et al., 1973), and have previously 
been used to approximate the α-helical content of apoA-I WT and R173C (Alexander 
et al., 2009; Fang et al., 2003b; Suurkuusk and Singh, 2000). 
5.2.2 rHDL nanoparticle PEG precipitation 
For solid-state NMR analysis, the rHDL nanoparticles were precipitated using PEG-
6000 for 13C CP-MAS NMR (Mors et al., 2013). A 40 % (w/v) PEG-6000 stock solution 
was prepared and added to the rHDL samples to a final concentration of 24 % (w/v). To 
allow for rHDL precipitation the samples were incubated for 48 hours at 4°C and 
inverted to mix. After the rHDL PEG precipitate formed the samples (0.8 mL) were 
centrifuged in an SW 55 Ti rotor (Beckman Coulter) at 41 krpm, 4°C for 2 hours. The 
supernatant was removed, and the rHDL nanoparticle precipitate was stored at 4°C 
before transferring to a 3.2 mm diameter magic-angle spinning rotor.  
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5.2.3 Oriented rHDL nanoparticle preparation 
Glass cover slips (Paul Marienfeld GmbH & Co. KG, Germany; 8 x 22 mm, thickness No. 
0 (0.08-0.12mm)) were cleaned with successive rinses of MeOH, EtOH and MilliQ 
grade water before the slides were dried over 24 – 48 hours at 37°C. A 1 mL sample of 
rHDL-WT 200:2 nanoparticles in rHDL buffer (10 mM tris, 1 mM EDTA, 1 mM NaN3) 
pH 7.4 was pipetted in equal aliquots onto 24 glass cover slips and placed in a desiccator 
until the sample was completely dried (≥12 hours). The dried sample was rehydrated at 
99 % humidity for 16 hours inside a glass desiccator chamber containing 100 mL MQ 
H2O placed inside a 37°C incubator. Just prior to NMR analysis the hydrated sample 
glass slides were stacked and wrapped in cling film.  
5.2.4 Solid-state NMR of apoA-I in rHDL nanoparticles 
A Bruker Avance 400 spectrometer was used to perform the SS NMR measurements 
using an 89 mm bore magnet at a magnetic field strength of 9.3 T and a temperature of 
25°C. The stacked oriented rHDL [15N]-apoA-I WT 200:2 nanoparticle sample was 
placed into the coil (9 x 3 x 3 mm) of a double resonance (H/F and X, the latter tuned 
to 161 MHz for 31P observation) static flat-coil probe (Bruker).  
The pulse sequence for the 1H-15N PISEMA spectrum was as described by Wu et al. 
(Wu et al., 1994), and began with a 2.5 µs 90° pulse on 1H. Then ramped cross-
polarisation (1H to 15N) was used with a time period of 2 ms and at the proton nutation 
frequency of 40 kHz. Subsequently, frequency-switched Lee-Goldburg cross-
polarisation was used at the magic-angle to obtain spin-exchange between 1H to 15N 
nuclei with the 1H and matched 15N fields of 62.5 and 76 kHz, respectively. This was 
followed by the signal acquisition period with simultaneous proton decoupling at a field 
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
224  Sophie Lau - July 2021 
of 62.5 kHz. Each increment contained an average of 10 000 transients in a total of 32 
t1 increments in the indirect dimension which represents the 
1H-15N dipolar coupling. 
The precipitated rHDL [13C]-labelled apoA-I samples were packed into a 3.2 mm 
zirconium rotor. A HFXY probe in double-resonance mode and a magic-angle spinning 
frequency of 8 kHz were used to obtain the 2D 13C-13C spectra. Before signal acquisition 
Hartmann-Hahn cross-polarisation with a contact time of 2 ms was used. Throughout 
signal acquisition at 63 kHz SPINAL-64 1H decoupling was applied (Fung et al., 2000). 
This was followed by a mixing time of 100 ms in which the dipolar-assisted rotational 
resonance DARR condition (Takegoshi et al., 2001) was satisfied by changing the 1H 
nutation frequency to the MAS frequency of 8 kHz, and the spectra were recorded. Each 
increment contained an average of 400 – 600 transients in a total of 480 t1 increments 
in the indirect dimension. The detection in the indirect dimensions was phase-sensitive 
as the States-TPPI (time proportional phase incrementation) method was used. The 
measurement period for each sample was between 2 – 7 days due to differences in rotor 
packing efficiency. Each chemical shift in the spectra was relative to the reference 
compound tetramethylsilane. 
5.2.5 Two-dimensional NMR spectra calculations 
SS NMR spectra of the AAMD-simulated POPC:cholesterol:apoA-I 200:20:2 nascent 
HDL nanoparticle model (Pourmousa et al., 2018) were calculated including 1H-15N 
PISEMA and 2D 13C-13C NMR spectra (Lau and Middleton, 2020). The atomic 
coordinates of the HDL particle were rotated in the final frame of the MD simulation 
so 𝐼𝑧
𝐻𝐷𝐿 was aligned with B0 for the PISEMA spectrum. The 
15N chemical shift (δi) was 
calculated for the amide (i) groups in the apoA-I protein backbone with Equation [7] 
(Chapter 2, section 2.2.5). The amide 15N chemical shift tensor can be described by 
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the main components δ11, δ22 and δ33 and the chemical shift values used were 60, 75 and 
222 ppm, respectively (Lau and Middleton, 2020). The 1H-15N dipolar coupling 
constant (Di) for each residue (i) was calculated using Equation [8] (Chapter 2, section 
2.2.5), as dipolar coupling occurs between the N and H nuclei in the N-H bond, as 
described earlier. The observed Dmax at 11 kHz was the maximum value of the dipolar 
coupling (Lau and Middleton, 2020). 
The protein coordinates from the final frame of the AAMD 200:20:2 simulation in a 
PDB file (Pourmousa et al., 2018) were submitted to the SHIFTX2 server (Han et al., 
2011) which used the protein secondary structure to predict the 13C chemical shifts (Lau 
and Middleton, 2020). The backbone amide carbon (C’) and Cα chemical shifts were 
correlated with the chemical shifts for Cβ and further sidechain carbon atoms to produce 
the 2D spectrum from the predicted frequencies (Lau and Middleton, 2020). The 
purpose of the simulated spectrum was to predict the position of cross-peaks only. 
Therefore, every cross-peak and diagonal peak had the same intensity, as factors that 
can affect the cross-peak intensity like the dipolar coupling strength and spin-diffusion 
were not considered.  
In both dimensions the time domain signal with the appropriate frequencies were 
produced. An exponential line broadening function of 25 Hz was combined with Fourier 
transformation to generate the spectrum (Lau and Middleton, 2020). Both types of 
simulated spectra, the 1H-15N PISEMA and 2D 13C-13C NMR spectra were generated 
with C programs written by Prof. David Middleton for this purpose (Lau and Middleton, 
2020).  
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5.3 Results 
5.3.1 CD analysis of apoA-I secondary structure 
The UV stability of LF and lipid-bound apoA-I WT, R173C and L144R was tested by 
50 repeat scans at 37°C. The repeated scans were used to determine if the apoA-I WT 
or atheroprotective mutant structure denatured under the CD experiment conditions. All 
samples have a spectrum characteristic of a high α-helical content, as evident in the 
maxima at ~190 nm and the two minima at ~206 and 222 nm (Figure 5.1) (Holzwarth 
and Doty, 1965). The lipid-free and rHDL-bound apoA-I proteins were stable and did 
not denature under multiple UV scans. This is shown by the reproducibility of the CD 
scans in each sample between ~195 – 240 nm. Therefore, the proteins retained their 
predominantly α-helical conformations, and the samples were analysed further using 
CD spectroscopy. 
Another test of the LF and lipid-bound apoA-I WT protein stability compared to the 
atheroprotective mutants was incubation of the samples at 37°C for 24 hours (Table 
5.1). To determine if precipitation of the protein occurred the protein concentration was 
taken before and after incubation. The LF and rHDL-WT and R173C samples showed 
similar amounts of protein aggregation. The LF and rHDL-L144R samples aggregated 
approximately 18 – 23 % and 25 % more, respectively than the apoA-I WT/R173C 
samples. This suggested the apoA-I L144R protein was less stable and more prone to 
aggregation. The protein concentration after 24 hours was below 3.6 μM therefore the 
secondary structure was estimated for the 0 hr time point samples only.  
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Table 5.1. The average concentration (µM) after incubation and percent precipitation 
of LF and lipid-bound apoA-I WT/R173C/L144R in rHDL POPC:apoA-I 200:2 (M/M) 
nanoparticles. The 3.6 μM samples were incubated for 24 hours at 37°C. 
Sample 
Average 
concentration (µM)  
% precipitated 
apoA-I WT 2.3 36.0 
apoA-I R173C 2.1 41.3 
apoA-I L144R 1.5 59.0 
rHDL-WT 200:2 3.0 17.3 
rHDL-R173C 200:2 3.0 16.3 
rHDL-L144R 200:2 2.1 41.7 
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Figure 5.1. UV stability CD spectra of lipid-free apoA-I (left) and rHDL POPC: apoA-
I WT/R173C/L144R 200:2 (M/M) (right) samples. Each spectrum shows a total of 50 
repeat scans at 37°C, and 3.6 µM protein concentration. 
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The CD spectra for the LF and rHDL POPC:±cholesterol:apoA-I 200:2 (Figure 5.2) 
and rHDL-C 190:10:2 WT/R173C/L144R samples (Figure 5.3) showed the 
characteristic CD spectrum for a predominantly α-helical protein.  
 
Figure 5.2. The average CD spectra (n = 3) of LF (left) and rHDL POPC:apoA-I 
WT/R173C/L144R 200:2 (M/M) (right) samples. At 37°C and 3.6 µM apoA-I 
concentration. The measured data (black line) and the CONTINLL algorithm and 
SMP56 basis set fit (dashed red line). 
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Figure 5.3. The average CD spectra (n = 3) of the rHDL-C WT/R173C/L144R 190:10:2 
(M/M) samples. At 37°C and 3.6 µM apoA-I concentration. The measured data (black 
line) and the CONTINLL algorithm and SMP56 basis set fit (dashed red line). The 
rHDL-C L144R sample CDSSTR SSE fit is in blue (dashed-dot line).  
To determine the reason for the noise in the CONTINLL algorithm spectra fits between 
~230 – 240 nm (Figure 5.2–5.3) the residuals and SSE for the rHDL-WT 200:2 
nanoparticle sample were compared for the CONTINLL, SELCON3, and CDSSTR 
SSE algorithms. Each algorithm produced a CD spectrum fit for a predominantly α-
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helical protein between 190 – 240 nm with the maxima at ~190 nm, and minima at ~206 
and 222 nm (Figure 5.4).  
 
Figure 5.4. A comparison of SSE analysis of the rHDL-WT 200:2 sample. The average 
CD spectra (n = 3) at 37°C and 3.6 µM apoA-I concentration. The measured data (black 
line) and the (A) CONTINLL (B) SELCON3, and (C) CDSSTR algorithm and SMP56 
basis set fit (dashed lines). (D) The residuals for each algorithm.  
The RMSD and residuals (Figure 5.4D, Table 5.2) were used as an indicator for the 
“goodness of fit” between the SSE fit and the observed CD data (Whitmore and 
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Wallace, 2008). The SELCON3 SSE algorithm was not used due to the larger overall 
difference in the residuals between 190 – 240 nm, hence a larger overall RMSD (~0.22). 
This was observed in the difference between the experimental spectra and the 
SELCON3 fit (Figure 5.4B).  
Table 5.2. The corresponding SSEs of rHDL-WT 200:2 (M/M) SSE algorithm 
comparison estimated with the SMP56 basis set, including normalised mean residual 
standard deviation (NMRSD).  
Algorithm 
Secondary structure estimation (%)  
α-helix β-strand turns unordered Total NRMSD 
CONTINLL 66.6 1.9 11.1 20.3 99.9 0.103 
SELCON3 61.1 4.1 15.3 21.2 101.7 0.218 
CDSSTR 77.7 8.1 9.4 5.4 100.6 0.031 
 
The CDSSTR algorithm fit was the most similar to the experimental spectrum (Figure 
5.4C) with the corresponding low RMSD (0.031) value. In comparison the CONTINLL 
SSE algorithm fit contained noise between ~230 – 240 nm with an RMSD of ~0.1 
(Figure 5.4A). The differences in the 230-240 nm region between CONTINLL and 
CDSSTR were observed in the residual plot (Figure 5.4D). This suggested the 
CDSSTR algorithm was the most “ideal” for SSE of the lipid-bound apoA-I based upon 
the RMSD and residuals.  
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The higher resolution SRCD analysis of apoA-I WT in rHDL 200:2 nanoparticles 
produced an SSE estimation of α - 69 %, β - 4.5 %, T - 8% and U - 18 % (Giudice et 
al., 2017) (see section 5.4.1, Table 5.5). ApoA-I is a primarily α-helical protein when 
lipid-free or lipid-bound (see section 1.6, and refs therein). The CONTINLL algorithm 
provided the most similar SSE (±2 – 3 %) for each secondary structure component when 
compared to the SRCD SSE (Table 5.2). In comparison the CDSSTR SSE values 
compared to the SRCD SSE were α - +8.7, β - +3.6, T - +1.4, and -12.6 % - U. This 
suggested that despite the lower RMSD value the CDSSTR SSE was overestimated. 
Furthermore, the CDSSTR usually produces a low RMSD due to differences in SSE fit 
calculations compared to the CONTINLL algorithm fits (Greenfield, 2006b; Whitmore 
and Wallace, 2008).  
In the CONTINLL analysis the noise in the 230 – 240 nm region could be due to the 
type of reference protein(s) and the corresponding reference CD spectra in the SMP56 
basis set. The SMP56 basis set contained 43 soluble proteins and 13 membrane proteins 
(Sreerama and Woody, 2004b). In comparison lipid-bound apoA-I is in a discoidal 
nanodisc shape wrapped around the lipid nanodisc bilayer (see section 1.6.2). 
Therefore, the reference proteins CD spectra in this region compared to experimental 
spectra from conventional CD may not truly represent the lipid-bound apoA-I in the 
230 – 240 nm region.  
Overall, the SSE was similar to the high-resolution SRCD data for rHDL-WT 200:2 
nanoparticles, which suggested the noise in the 230 – 240 nm region of the CONTINLL 
fits did not interfere with the SSE of lipid-bound apoA-I. It appeared that the reference 
proteins used to calculate the SSE with CONTINLL do not completely fit the 
experimental spectra between 230 – 240 nm.  
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The region of interest for calculating the SSE in particular the α-helix content at 222 
nm using CONTINLL or Equation [10] was suitable for determining the apoA-I SSE 
when compared to the literature SRCD CONTINLL SSE. Therefore, the CONTINLL 
and SMP56 basis set were used for each sample in this work despite the noise present 
in the SSE fit between 230 – 240 nm.  
The secondary structure was estimated for each sample at 37°C (Table 5.3) using the 
CONTINLL algorithm and SMP56 basis set. The LF apoA-I samples each contained 
similar SSEs overall. The rHDL-WT and R173C α-helical content was greater than the 
respective LF protein structure estimations. In apoA-I R173C this appears to be due to 
conversion of the unordered content to β-strand and α-helix when lipid-bound. The 
rHDL-WT SSE indicated smaller structural changes following a similar pattern except 
for a decrease in β-strand content. Surprisingly, the LF and lipid-bound apoA-I L144R 









Chapter 5: ApoA-I structure in rHDL 
Sophie Lau - July 2021   235 
Table 5.3. The corresponding SSEs of LF apoA-I and rHDL-WT/R173C/L144R 200:2 
(M/M), and rHDL-C 190:10:2 samples estimated using the CONTINLL algorithm and 
SMP56 basis set, including normalised mean residual standard deviation (NMRSD). 
*CDSSTR algorithm 
Sample 
Secondary structure estimation (%)  
α-
helix 
β-strand turns unordered NMRSD 
apoA-I WT 51.6 6.1 15.7 26.6 0.035 
apoA-I R173C 46.2 5.3 17.9 30.6 0.052 
apoA-I L144R 54.9 6.3 18.3 20.5 0.171 
rHDL-WT 200:2 66.6 1.9 11.1 20.3 0.103 
rHDL-R173C 200:2 73.8 19.1 7.1 0 0.296 
rHDL-L144R 200:2 54.3 3.1 12.1 30.6 0.223 
rHDL-C WT 190:10:2 60.7 8.5 8.4 22.4 0.051 
rHDL-C R173C 190:10:2 64.7 4.4 10.5 20.4 0.047 
rHDL-C L144R 190:10:2 0 0 100 0 0.224 
rHDL-C L144R 
190:10:2* 
43.5 25.8 15.5 15.0 0.095 
 
The rHDL-C WT 190:90:2 apoA-I SSEs contained relatively small structural changes 
compared to the rHDL-WT 200:2 nanoparticles. There was only a small decrease in α-
helical content (-5.9 %) with an increase in the β-strand secondary structure (+6.6 %). 
The rHDL-C R173C 190:90:2 nanoparticles apoA-I contained a large increase in 
unordered secondary structure content (+20.4 %) compared to the rHDL-R173C 200:2 
nanoparticles. This corresponded with a decrease (-14.7 %) in β-strand content. The 
rHDL-C R173C 190:90:2 SSEs were similar to the rHDL-WT 200:2 SSE nanoparticles. 
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This suggested the apoA-I R173C protein could adopt an overall similar secondary 
structure conformation in rHDL-C 190:90:2 nanoparticles despite the shifted registry of 
the disulphide bonded monomers.  
The rHDL-C L144R 190:10:2 SSEs suggested the apoA-I L144R structure was 
comprised of 100 % turns when analysed using the CONTINLL algorithm. This was 
considered an anomalous SSE as the CD spectrum (Figure 5.3) was characteristically 
α-helical.  
Therefore, the rHDL-C L144R 190:10:2 secondary structure was estimated with the 
CDSSTR algorithm. The SSE results were treated with caution due to the 
overestimation of α-helical content in the rHDL-WT 200:2 sample (Table 5.2). The 
CDSSTR SSE for lipid-bound apoA-I L144R predicted a predominantly α-helical 
protein (~43.5 %) which agreed with the characteristic spectrum (Figure 5.3). 
However, the β-strand content (~25.8 %) was relatively high compared to the rHDL-C 
WT/R173C 190:10:2 samples. Furthermore, the intensity of the CD signal -20 to 30 M-
1 cm-1 was disproportionate relative to all other samples at the same apoA-I 
concentration. This could be due to incomplete separation from lipid-free apoA-I 
L144R or a lower stability of the protein leading to precipitation or dissociation from 
the rHDL-C nanoparticles.  
5.3.1.1 CD analysis of thermal stability 
The thermal stability of the different rHDL formulations with WT and mutant proteins 
may reflect their stability and/or resistance to denaturation in vivo. The CD spectra for 
the lipid-free and rHDL bound proteins show a typical α-helical spectrum at 25°C 
(Figure 5.5). The peak minima at 208 and 222 nm decreased as the temperature 
increased. The protein structure became less α-helical and more characteristic of a 
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random coil spectrum. The isodichroic point at approximately 205 nm suggested for LF 
and rHDL bound apoA-I proteins a two-state thermal unfolding model (monophasic) 
(Figure 5.5). However, the thermal unfolding curves of the molar ellipticity (Figure 
5.6) and the first derivative of the unfolding curve at 222 nm (Figure 5.7) suggested the 
rHDL nanoparticles thermal unfolding was a three-state model (biphasic). This was in 
agreement with the findings of Giudice et al. using high resolution SRCD of rHDL-WT 
and R173C nanoparticles (Giudice et al., 2017).  
Global analysis was used to determine the melting temperature(s) (Tm’s) of the samples, 
and the unfolding curves of the molar CD at 222 nm with the corresponding first 
derivatives of the plots (Figure 5.6-5.7) were used to determine the number of 
transitions as the temperature increased. Both the unfolding curves and first derivatives 
show the raw data and the calculated global CD data. The LF protein monophasic 
unfolding curves were fitted with a Boltzmann sigmoidal fit and the rHDL protein 
unfolding curves were fitted with a BiDoseResponse double sigmoidal fit (Figure 5.6). 
The peak maxima of the first derivatives of the unfolding curves approximately 
correspond to the Tm’s determined using the Global data analysis in Table 5.4. 
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Figure 5.5. Thermal CD spectra of LF and rHDL-WT/R173C/L144R 200:2 (M/M) 
nanoparticles in rHDL buffer, pH 7.4 over the temperature range of 25 – 95°C. The 
protein concentration was 3.6 μM.  
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Figure 5.6. The thermal CD transition analyses for LF and rHDL-WT/R173C/L144R 
200:2 (M/M) samples. The unfolding curves, Δε at 222 nm: raw data (black) and fit 
(dashed red line), and Global analysis calculated fit (solid red line) (Lau and Middleton, 
2020).  
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Figure 5.7. The corresponding first derivatives of the thermal CD transition analyses 
for the LF and rHDL-WT/R173C/L144R 200:2 (M/M) samples. The raw data derivative 
(black), Global calculated data derivative (red) and polynomial fit (solid red line) (Lau 
and Middleton, 2020).  
The Tm’s determined for LF apoA-I WT and R173C are in good agreement with 
previously measured values (Table 5.4). The LF apoA-I L144R Tm showed a similar 
trend to Gkolfinopoulou et al.’s values with a lower LF apoA-I L144R Tm relative to 
apoA-I WT at the 3.6 µM protein concentration (Gkolfinopoulou et al., 2020). Overall, 
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the ~2 – 4°C difference between the LF apoA-I Tm’s suggested a minor decrease in the 
thermal stability of the solution state apoA-I mutants relative to apoA-I WT.  
Table 5.4. The observed melting temperatures of the lipid-free and rHDL-
WT/R173C/L144R 200:2 (M/M) samples compared to literature Tm’s ±standard error.  
Sample 
Observed Tm (°C) Literature Tm (°C) 
Tm 1 Tm 2 Tm 1 
apoA-I WT 55.1 ± 0.1 - 
55.3±0.5 (Del Giudice et al., 2016) 
55.9±1.4 (Petrlova et al., 2014)  
56.0 (Townsend et al., 2017) 
57.3±0.4 (Dalla-Riva et al., 2015)  
59±1.0 (Fang et al., 2003a)  
60.0 ±2.0 (Fang et al., 2003b) 
 60±1.5 (Saito et al., 2003) 
 61±1.0 (Mei and Atkinson, 2011) 
~57.5 (Gkolfinopoulou et al., 2020) 
apoA-I R173C 51.4 ± 0.1 - 
 
50.9±1.4 (Petrlova et al., 2014) 
apoA-I L144R 53.2 ± 0.1 - ~55 (Gkolfinopoulou et al., 2020) 
rHDL-WT 43.4 ± 0.3 82.9 ± 0.4 46.6±3.6 and 78.8±0.2 (Giudice et al., 2017) 
rHDL-R173C 47.0 ± 0.4 81.0 ± 0.4 
55.9±5.0 and 72.15±0.4 (Giudice et al., 
2017) 
rHDL-L144R 44.6 ± 0.2 76.3 ± 0.1 No published data 
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The rHDL apoA-I protein thermal stability in order of least stable for Tm1 was apoA-I 
WT (43.4°C) < L144R (44.6°C) < R173C (47.0°C). This could suggest structural 
changes in the protein whilst bound to lipids (Giudice et al., 2017) or some 
disassociation from the lipid nanodisc bilayer as the temperature approaches the LF 
protein Tm. The disulphide bond in the apoA-I R173C dimer could stabilise the protein 
in this first transition. In comparison, the lipid-bound apoA-I L144R was marginally 
more stable than rHDL apoA-I WT. 
The second transition at higher temperatures has been suggested to be due to 
dissociation of the protein from the lipid bilayer nanodisc (Giudice et al., 2017). This is 
supported by the loss of α-helical secondary structure (Figure 5.8) and transition to a 
denatured protein random coil type spectrum in each rHDL sample (Figure 5.5). The 
difference in the observed Tm1 and 2 values compared to Giudice et al.’s could be due 
to sample conditions such as buffer, protein concentration, particle homogeneity, or 
lipid used in rHDL formation.  
The Tm2 thermal stability in order of least stable was apoA-I L144R (76.3°C) < R173C 
(81.0°C) < WT (82.9°C). This indicated that the R173C protein may have similar 
thermal stability due to the intramolecular disulphide bond in the second transition to 
apoA-I WT in rHDL. Whereas apoA-I L144R had a lower thermal stability than both 
apoA-I R173C and apoA-I WT in rHDL nanoparticles.  
During a thermal CD experiment as the protein unfolds the number of melting 
temperatures indicates the number of protein conformations (Greenfield, 2006a). In a 
monophasic transition there are two species at 25 and 95°C respectively. In a biphasic 
thermal transition, there are three species before and after each Tm, i.e., an additional 
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intermediate species conformation. The estimated α-helical content of the protein 
conformation in each species conformation are indicated in Figure 5.8. 
 
Figure 5.8. LF and rHDL-WT/R173C/L144R 200:2 sample estimated α-helical content 
±7.7 % error using Equation [10] before and after each thermal transition. The LF 
sample species were pre- and post-Tm at 25 and 95°C, respectively. The rHDL sample 
species pre-Tm1 at 25°C, the intermediate species between Tm1 and Tm2 at 58 (WT), 63 
(R173C), and 61°C (L144R), and species post-Tm2 at 95°C. The intermediate 
temperatures indicated were the temperatures most of the protein in the sample was in 
the intermediate conformation. 
The LF apoA-I WT and mutants showed similar behaviour pre-Tm from 43 – 48 % α-
helical to 19 – 22 % post-Tm which indicated denaturation of the α-helical protein 
structure. The rHDL-WT and R173C samples were ~67 % α-helical and rHDL-L144R 
was ~48 % α-helical at 25°C pre-Tm1. The rHDL apoA-I intermediate conformations 
showed a small decrease in α-helical structure (7 – 11 %) fluctuations within the error 
range of the start conformations (Figure 5.8). After Tm2 the rHDL-WT/R173C sample 
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α-helical content decreased to ~20 % and rHDL-L144R to ~16%. This suggested the 
apoA-I protein structure dissociated from the lipids as the α-helical content was similar 
to LF apoA-I at 95°C (Figure 5.8). 
5.3.2 SS NMR apoA-I orientation in rHDL nanoparticles  
To determine the rHDL nanoparticle apoA-I protein secondary structure and orientation 
with respect to the lipids rHDL nanoparticles were prepared with [13C, 15N]-labelled 
apoA-I WT. The PEG-precipitated rHDL-WT 200:2 nanoparticles were analysed by 
CP-MAS 13C-13C dipolar correlation SS NMR spectroscopy (Figure 5.9). The chemical 
shifts for alpha, beta and backbone amide carbons are highly sensitive to secondary 
structure and can distinguish amino acids in α-helices from those in β-sheet or 
unstructured regions. The resolution of the spectrum did not provide complete 
individual cross-peak secondary structure assignment from chemical shift reference 
data (Appendix 3) (Ulrich et al., 2007; Wang and Jardetzky, 2002).  
The rHDL-WT 200:2 experimental spectrum was compared with a spectrum simulated 
from predicted chemical shifts for the predominantly α-helical structure of apoA-I in 
the model of Pourmousa et al. The similarity between the experimental and simulated 
HDL-C 200:20:2 model apoA-I WT spectra (Figure 5.9) indicated a predominantly α-
helical structure as in Figure 5.10B (Pourmousa et al., 2018). 
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Figure 5.9 The 2D 13C-13C dipolar correlation spectrum of the PEG-precipitated rHDL 
[13C]-WT 200:2 (M/M) nanoparticles. The spectrum was obtained at a frequency of 
100.13 MHz, a DARR mixing time of 100 ms, and a MAS spinning frequency at 8 kHz 
(Lau and Middleton, 2020). The HDL-C WT 200:20:2 AAMD model (Pourmousa et 
al., 2018) simulated spectra is overlaid (green contours). The apoA-I WT chemical 
shifts were predicted by submission of the simulation protein coordinates to the 
SHIFTX2 server (Han et al., 2011). The cross-peaks (dashed boxes) which are very 
sensitive to structure were identified as α-helical (blue), β-sheet (purple) and random 
coil (yellow). Cross-peaks arising from possible long-range coupling are circled (black). 
Experimental arginine possible long-range couplings, Cδ-Cγ/Cβ-Cδ (red box), and Cβ- 
Cγ (dashed red box). Adapted from (Lau and Middleton, 2020).  
In the rHDL-WT 200:2 spectra there were multiple cross-peaks in the Cα – Cβ region 
(~15 – 35 by ~15 -35 ppm), whereas the AAMD simulated spectra showed cross-peaks 
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in the central diagonal region only. Multiple amino acids (MLIQEKR) have side-chain 
cross-peak correlations in this region of the experimental spectrum. As an example the 
possible long range side-chain coupling(s) cross-peak regions for arginine are shown in 
Figure 5.9 for Cδ-Cγ/Cβ-Cδ (red box), and Cβ-Cγ (dashed red box).  
In the simulated spectrum factors such as the cross-peak intensity were not considered 
as the simulated spectra was used to predict the position of cross-peaks only. Therefore, 
the possible long-range couplings in the simulated HDL-C WT 200:20:2 apoA-I 
spectrum may not be similar to the experimental rHDL-WT 200:2 apoA-I spectrum in 
this region and does not reflect structural differences between the spectra. 
An 1H-15N PISEMA spectrum was produced from an oriented rHDL-WT 200:2 sample 
where 𝐼𝑧
𝐻𝐷𝐿 (Figure 5.10B), the principal axis of inertia of the rHDL nanoparticles, was 
predominantly parallel to B0 (see Chapter 6 section 6.3.1.1, Figure 6.8, 16 hr 
hydration). The simulated 1H-15N PISEMA spectrum of the AAMD-HDL model 
apoA-I WT was overlaid relative to the experimental rHDL-WT 200:2 spectrum 
(Figure 5.10A).  
In a 1H-15N PISEMA spectrum cross-peaks appear due to the alignment of the N-H bond 
vectors in α-helical proteins relative to the lipid bilayer normal/B0 (see Chapter 2, 
Figure 2.11) (Marassi et al., 1999; Marassi and Opella, 2000). The 1H-15N dipolar 
coupling and 15N chemical shift cross-peaks become disperse in a “wheel-like” pattern 
as the α-helix axis tilts with respect to the bilayer normal/B0, i.e. towards perpendicular 
to the bilayer normal (Marassi et al., 1999; Marassi and Opella, 2000). 
Marassi and Opella simulated 1H-15N PISEMA spectra for an α-helix containing 19 
amino acids at angles between 0 – 90° relative to the bilayer normal, similar to Figure 
2.11 (Marassi et al., 1999; Marassi and Opella, 2000). The cross-peak regions for the 
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approximate upper and lower limits of the 0 – 40° and 50 – 90° tilt angles relative to 
the bilayer normal, and either extreme at 0° or 90° are in Figure 5.10A.  
 
Figure 5.10. (A) The 1H-15N PISEMA spectrum of the oriented rHDL [15N]-WT 200:2 
(M/M) 16 hr rehydration nanoparticles oriented with 𝑰𝒛
𝑯𝑫𝑳 predominantly parallel to B0. 
The dipolar couplings were calculated for the HDL-AAMD model apoA-I WT for the 
overlaid PISEMA spectrum (green) when 𝑰𝒛
𝑯𝑫𝑳 was parallel to the applied magnetic 
field. The estimated regions (dashed boxes) for α-helices tilted relative to B0 between 0 
– 40° (blue) and 50 – 90° (red). The regions for 0° (blue) and 90° (red) solid boxes. (B) 
𝑰𝒛
𝑯𝑫𝑳/the nanodisc bilayer normal parallel to B0 with the HDL-C WT 200:20:2 AAMD 
model, with α-helices tilted with respect to B0 between 0 – 90° (blue) and perpendicular 
(~90°) relative to B0 (red). POPC headgroups (coloured by heteroatom), lipid tails 
(grey), cholesterol (purple), apoA-I termini labelled N1 C1 and N2 C2, for chain 1 and 2, 
respectively. Adapted from (Lau and Middleton, 2020).  
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The similarities between the experimental and simulated rHDL nanoparticle spectra 
cross-peaks suggested the apoA-I α-helices were predominantly perpendicular to the 
lipid bilayer nanodisc normal (Figure 5.10, red) (Lau and Middleton, 2020). This was 
reflected in the AAMD model where the majority of the α-helices in the rHDL 
nanoparticle apoA-I chains were 61% perpendicular relative to B0 (Figure 5.10B, red).  
In HDL nanoparticles the hydrophobic effect acts to stabilise the interactions between 
the hydrophobic face of the apoA-I helices and the lipid acyl tails (Shih et al., 2007a; 
Shih et al., 2007b). Additionally, interhelical interactions such as salt bridges stabilise 
the interactions between the anti-parallel apoA-I chains (Bibow et al., 2017).  
Furthermore, AAMD simulations of POPC, cholesterol, and short peptides comprised 
of 18 ELK amino acid residues exhibited different arrangements of the α-helices 
similar to the picket-fence model (Figure 1.11A) (Islam et al., 2018; Pourmousa and 
Pastor, 2018). This suggested the interhelical registry and interactions between the 
helices in the discoidal HDL apoA-I dimer are important to form the “double-belt” 
HDL model. Therefore, spectra cross-peak position changes due to further 
rearrangement of the apoA-I protein chains was not expected. 
The cross-peaks in the 0 – 40° tilt angle region (Figure 5.10A, blue) also agree with 
the tilted α-helices in the AAMD-HDL model (Figure 5.10B, blue). This suggested 
the results of these combined 2D SS NMR spectra agree with the “double-belt” model 
of apoA-I in discoidal HDL nanoparticles (Bibow et al., 2017; Pourmousa et al., 2018) 
compared to the earlier “picket-fence” model (Jonas et al., 1990; Phillips et al., 1997). 
The diagonal cross peaks (~140 – 230 ppm by ~2 – 10 kHz) in the 0 – 40° tilt angle 
region correspond to the apoA-I residues tilted with respect to B0 in both spectra 
(Figure 5.10A, blue). As the tilt angle increased towards 40° the cross-peaks shift 
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diagonally towards the right side of the blue region, i.e. towards 125 ppm. This is 
visualised in Figure 5.10B where the α-helices (blue) show varied tilt angles with 
respect to B0. 
5.3.2.1 Atheroprotective apoA-I L144R structure in rHDL nanoparticles 
Investigation of the differences between the rHDL-WT and atheroprotective apoA-I 
L144R and R173C 200:2 nanoparticle protein conformation was required. This was 
implemented by PEG-precipitation of the rHDL-L144R nanoparticles and compared to 
the rHDL-WT 2D high resolution 13C-13C dipolar correlation spectrum. The highlighted 
regions of the spectra (Figure 5.11) indicated small differences between the apoA-I WT 
and L144R protein conformations in rHDL nanoparticles (Lau and Middleton, 2020). 
This suggested the apoA-I L144R was also predominantly α-helical. However, 
differences in the chemical shifts for specific amino acids, which may indicate local 
structural differences cannot be pinpointed without selective isotope labelling of apoA-
I.  
An example of an identified residue region was alanine in the rHDL-WT and L144R 
proteins between ~53 – 58 ppm to ~16 – 19 ppm for Cα and Cβ, respectively (Li et al., 
2006; Wang and Jardetzky, 2002). This indicated the presence of alanine residues in an 
α-helical or random coil conformation (Li et al., 2006). The reference α-helical alanine 
chemical shifts are between approximately Cα at 53.9 – 55.8 ppm and Cβ at 17.2 – 19.4 
ppm. Whilst the random coil alanine shifts are at 50.9 – 54.4 ppm, and 17.8 – 20.3 ppm 
(Appendix 3) (Wang and Jardetzky, 2002). The regions indicated in Figure 5.11 
contain predominantly α-helical secondary structure residue cross-peaks. This was by 
comparison with the average chemical shifts (Appendix 3) (Wang and Jardetzky, 
2002), and to previous spectra of truncated apoA-I (MSP1) in PEG-precipitated 
nanodiscs (Li et al., 2006), and LF apoA-I WT (Townsend et al., 2017).  
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Figure 5.11. The expanded 2D 13C-13C dipolar correlation spectra of the PEG-
precipitated rHDL [13C]-WT (black) and L144R (red) 200:2 (M/M) nanoparticles. The 
spectrum was obtained at a frequency of 100.13 MHz, a DARR mixing time of 100 ms, 
and a MAS spinning frequency at 8 kHz (Lau and Middleton, 2020). The cross-peaks 
(dashed boxes) which are very sensitive to structure were identified as α-helical (blue), 
β-sheet (purple) and random coil (yellow). Cross-peaks arising from possible long-
range coupling are circled (black). 
The rHDL-L144R spectrum suggested there could be an increased mobility of residues 
such as methionines, and/or changes in the double belt interhelical registry. This was 
suggested by the absence of cross-peaks assigned to the methionine methyl groups and 
inter-residue long-range couplings (Figure 5.11, Mε) compared to the rHDL-WT 
spectrum.  
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Interestingly, the rHDL-L144R Glu carboxyl 13C chemical shifts are perturbed relative 
to rHDL-WT (Figure 5.11, Eδ). The L144R point mutation occurs in α-helix 6 (H6) of 
apoA-I in which there are multiple native acidic and basic side chains ideally placed for 
interhelical salt bridge formation (Figure 5.12A) (Borhani et al., 1997). The arginine 
residue in apoA-I L144R H6 could change the Glu-Arg and Asp-Arg salt-bridge 
patterns in H6 (Figure 5.12B).  
In the apoA-I WT Δ(1-43) crystal structure (Borhani et al., 1997) monomers are in an 
antiparallel alignment with the LL5/5 interhelical registry with α-helix 6 and 4 (H4) in 
registry with each other (see Chapter 1, Figure 1.6). In the H6/H4 alignment the L144 
sidechain is facing inwards between the respective monomers in a cluster of 
hydrophobic residues. Therefore, the apoA-I L144R mutation could pose 
conformational constraints and prevent this alignment from forming in the LL5/5 
registry.  
To visualise the possible salt bridges, the L144 residue was mutated to arginine using 
the mutagenesis feature of the PyMol software (Schrodinger, 2015) in the LL5/5 
registration of the apoA-I WT Δ(1-43) crystal structure (Borhani et al., 1997). This 
produced 25 suggested rotamer conformations in total. In this assumed LL5/5 registry 
of the apoA-I L144R dimer there was only one viable arginine rotamer which did not 
produce clashes (Figure 5.12A, right). The R144 residue is facing outwards on the 
hydrophilic face of H6 in proximity to Glu147. This could indicate the formation of a 
salt bridge between R144 and E147.  
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Figure 5.12. (A) A cross-section of apoA-I L144R H6 (chain B) and H4 (chain A). 
Left) The R144 rotamer example with spatial clashes (red discs). Right) The R144 
rotamer conformation without clashes. The residues at position 144 are Leucine (L) and 
Arginine (R), and Glutamic acid (E) at position 147. The suggested E147 and R144 salt 
bridge (orange dashed line). The approximate margin between H4/H5 and H6/H5 is 
indicated by the dashed line. The amino acid sidechains are represented by polarity: 
nonpolar (white), polar (green), acidic (red, negative charge), basic (blue, positive 
charge), and backbone atoms (grey). (B) The possible salt bridge network in apoA-I 
L144R H6 with the Glu, Asp and Arg residues labelled.  
The high resolution 2D 13C-13C dipolar correlation spectrum of apoA-I in rHDL-WT 
and R173C 200:2 nanoparticles were compared (Figure 5.13). Similar to the rHDL-
Chapter 5: ApoA-I structure in rHDL 
Sophie Lau - July 2021   253 
L144R apoA-I spectrum the spectra are broadly similar with an absence of major 
structural differences. The structural differences detected in the rHDL-bound apoA-I 
R173C protein are shown by some selective chemical shift differences such as Ala, Leu 
and Ser in the β-sheet regions (Figure 5.13). Further differences observed in the rHDL-
R173C protein spectrum were a lack of assigned cross-peaks in the Thr/Val C’-Cα/Cβ 
(~177 by 65 ppm) and P/V Cβ-Cα (~28 by 65 ppm) α-helix regions.  
Interestingly, the differences observed in the rHDL-R173C spectrum were not the same 
as the rHDL-L144R spectrum. The R173C mutation is in the apoA-I α-helix 7 (H7), 
which results in a shifted interhelical registry in the apoA-I R173C dimer due to the 
disulphide bonded “locked” conformation (Klon et al., 2000). This could explain the 
subtle structural differences in the rHDL-R173C apoA-I spectrum relative to the rHDL-
WT spectrum.  
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Figure 5.13. The expanded 2D 13C-13C dipolar correlation spectra of the PEG-
precipitated rHDL [13C]-WT (black) and R173C (red) 200:2 (M/M) nanoparticles. The 
spectrum was obtained at a frequency of 100.13 MHz, a DARR mixing time of 100 ms, 
and a MAS spinning frequency at 8 kHz (Lau and Middleton, 2020). The cross-peaks 
(dashed boxes) which are very sensitive to structure were identified as α-helical (blue), 
β-sheet (purple) and random coil (yellow). Cross-peaks arising from possible long-
range coupling are circled (black). 
Finally, the 2D 13C-13C dipolar correlation spectrum of PEG-precipitated lipid-free 
apoA-I WT was compared to the apoA-I rHDL-WT 200:2 spectrum (Figure 5.14). 
Similar to the previous spectra the structurally sensitive cross-peak regions are 
highlighted. The LF apoA-I WT and the rHDL-WT spectra are very similar with only 
small structural differences detected. Such as the Cα-Cβ cross-peaks assigned for lipid-
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free apoA-I WT for the residues Ala, Thr, Pro/Val in random coil and β-sheet regions 
(Figure 5.14).  
 
Figure 5.14. The expanded 2D 13C-13C dipolar correlation spectra of the PEG-
precipitated rHDL [13C]-WT 200:2 (M/M) nanoparticles (black) and lipid-free apoA-I 
WT (red). The spectrum was obtained at a frequency of 100.13 MHz, a DARR mixing 
time of 100 ms, and a MAS spinning frequency at 8 kHz (Lau and Middleton, 2020). 
The cross-peaks (dashed boxes) which are very sensitive to structure were identified as 
α-helical (blue), β-sheet (purple) and random coil (yellow). Cross-peaks arising from 
possible long-range coupling are circled (black). 
Another aspect to consider was whether the differences in the PEG-precipitated lipid-
free and rHDL-bound apoA-I sample spectra were due to differences in the protein side-
chain dynamics. Amino acid side-chain rotation dynamics can occur on the micro- to 
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nanosecond timescale. This can affect the CP-MAS spectra by weakening the dipolar 
coupling strengths and relative signal intensity (Matlahov and van der Wel, 2018).  
It is possible that the dynamics of the residue sidechains contributed to some of the 
small differences observed in the cross-peak regions of the lipid-free apoA-I WT 
spectrum. For example, the absence of a Pδ cross-peak for lipid-free apoA-I WT. 
Overall, the spectral differences were attributed to small structural differences as the 
cross-peak positions shifted from one site-specific secondary structure region to 
another. For example, the lipid-bound and lipid-free Thr cross-peaks were at the β-sheet 
to β-sheet/random coil regions, respectively.  
5.4 Discussion 
5.4.1 Lipid-bound apoA-I stability and secondary structure 
CD SSE and thermal stability of the rHDL 200:2 nanoparticles were compared to 
determine if there were significant differences in the structures of the apoA-I mutants 
that confers greater or lower stability on the proteins. The rHDL nanoparticles had two 
thermal transitions. Tm1 could be a result of protein to protein conformation changes, 
whereas, protein dissociation from the lipids as the protein structure becomes fully 
denatured occurs during Tm2 (Giudice et al., 2017).  
In the main protein-lipid dissociation transition the rHDL-L144R Tm2 was lower at 
76.3°C than the rHDL-WT (82.9°C) and R173C (81.0°C) 200:2 nanoparticles. The 
changes in the lipid-bound apoA-I L144R SSE -12 % α-helix and +10 % unordered 
content could contribute to the lower thermal stability (Tm2) of lipid-bound apoA-I 
L144R compared to apoA-I WT in rHDL. The reduced stability of LF and rHDL apoA-
I L144R could contribute to the different HDL metabolism and enhanced catabolism of 
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apoA-I/A-II in vivo (Gkolfinopoulou et al., 2020; Recalde et al., 2001), and the 
efficiency of in vivo lipid transfer (Lau and Middleton, 2020).  
The LF apoA-I WT, R173C and L144R transition temperatures were in good agreement 
with previously published values (Table 5.4, and refs therein). Both atheroprotective 
mutants had a lower thermal stability compared to apoA-I WT. The LF apoA-I WT and 
R173C SSE’s (α – 52, β – 6, T – 16, and U – 27 %) were similar to each other, and 
previous literature values at apoA-I concentrations close to 3.6 μM. The SSE’s for 
apoA-I WT (α – 48, β – 8, T – 19, and U – 25 %) and R173C were similar in Giudice 
et al.’s study (Giudice et al., 2017), and for WT only (α – 49, β – 6, T – 17, U - ~28 %) 
(Sparks et al., 1992a).  
Other studies estimated the α-helix content only of apoA-I WT between approximately 
40 – 54 % (Alexander et al., 2009; Del Giudice et al., 2016; Han et al., 2005; Jonas et 
al., 1989; Mei and Atkinson, 2011; Petrlova et al., 2014). Previous LF apoA-I R173C 
of mixed monomer and dimer contained 55 ±1.3 % α-helix (7.2 μM) (Petrlova et al., 
2014). The LF apoA-I R173C in this work has a lower α-helix content but this could be 
due to the lower sample concentration (3.6 μM) to avoid oligomerisation.  
The rHDL-WT 200:2 SSEs (α – 67, β – 2, T – 11, and U – 20 %) were similar to 
literature values in Table 5.5. The secondary structure changes from LF to rHDL apoA-
I WT support the “beta-clasp” model of lipid binding (see Chapter 1, section 1.6.1, 
Figure 1.9) (Lagerstedt et al., 2012; Oda et al., 2003). The LF apoA-I random coil (189-
200) and β-sheet regions (209-219) are converted to α-helix during lipid-binding 
(Lagerstedt et al., 2012; Nagao et al., 2014; Oda, 2017; Oda et al., 2003) which 
correspond to approximately -4.5 and -4.1 % decreases in respective structure content. 
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This is similar to the structural changes observed from LF WT and rHDL-WT 200:2 
observed by CD here, U is -6.3 % and β is -4.2 % (Table 5.3).  
The increase in α-helix content in apoA-I WT upon lipid binding has been widely 
observed (see Table 5.5, and refs therein). The energy to bind lipids from α-helix 
formation has been suggested to be provided by the conversion of C-terminus random 
coil and β-sheet to α-helix (Lagerstedt et al., 2012; Nagao et al., 2014; Oda, 2017; Oda 
et al., 2003; Saito et al., 2004). The N-terminal domain, residues 1 – 43, of apoA-I WT 
have been shown to become lipid-bound in larger rHDL nanoparticles (11 – 12 nm) (Li 
et al., 2004). In the AAMD-HDL model of 200:20:2 nanoparticles these residues are 
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Table 5.5. Literature SSEs of rHDL nanoparticles with approximate molar ratios and 
nanoparticle diameters (nm). Lipids are POPC or *DMPC, rHDL-R173C and L144R 








α β T U   





   
7.8 
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9.4 
10.2 
(Gu et al., 2010) 
156:2 78.0    9.6  (Silva et al., 2008) 
170:2* 65 ±3    11.6 (Fang et al., 2003a) 











(Jonas et al., 1989) 
200:20:2L144R ~57.5    ~ 8.4 – 
10.0 
(Gkolfinopoulou et 
al., 2020) 200:20:2 ~65.5    
 
The lipid-bound apoA-I R173C structure contained more residues in an ordered 
conformation (α – +7.2%, β – +17 % and -20% U) compared to rHDL-WT 
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nanoparticles. This contrasted with the rHDL-R173C 200:2 nanoparticle SSE from 
SRCD (Giudice et al., 2017). This suggested that dimeric disulphide bonded apoA-I 
R173C when lipid-bound in a “locked” shifted registry (Klon et al., 2000) may retain 
some regions with different conformations such as β-strand structure. The overall β-
strand content in the LF apoA-I WT “beta-clasp” model was ~17 % in the N- and C-
termini regions (Lagerstedt et al., 2012) suggesting potential regions of β-strand 
formation in rHDL apoA-I R173C (~19 % by CD).  
Furthermore, the rHDL-C WT and R173C 190:10:2 nanoparticles (~8.8 – 9.6 nm 
diameter) contained similar secondary content to the corresponding apoA-I 200:2 
nanoparticles. Previously, ~9.6 nm diameter rHDL-C WT 160:8:2 (M/M) nanoparticles 
examined by EPR spectroscopy detected 9 % β-strand content in apoA-I WT (Giudice 
et al., 2017; Oda et al., 2013). This is similar to the ~8.5% β-strand content observed in 
the rHDL-C WT 190:10:2 nanoparticles in this study.  
Interestingly, a recent structure-function study showed analysis of rHDL-C ~200:20:2 
(M/M) nanoparticles containing apoA-I WT or L144R with a diameter between ~ 8.4 – 
10.0 nm (Gkolfinopoulou et al., 2020). The CD α-helix content (~57.5 vs. ~65.5 %) and 
thermal stability (~70 vs. 73°C) of lipid-bound apoA-I L144R were lower than apoA-I 
WT in the rHDL-C nanoparticles, respectively (Gkolfinopoulou et al., 2020). This is 
similar to the reduced thermal stability and α-helix content determined for the rHDL-
L144R 200:2 (M/M) nanoparticles in this work. Additionally, the LF apoA-I L144R of 
~52 % α-helix content was similar to this work (~55%) (Gkolfinopoulou et al., 2020). 
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5.4.2 rHDL apoA-I SS NMR structural analyses 
This work focussed upon comparing the protein structures of apoA-I WT, R173C and 
L144R in PEG-precipitated rHDL nanoparticles detected using 2D 13C-13C dipolar CP-
MAS SS NMR.  
The 2D 13C-13C dipolar CP-MAS SS NMR spectra of rHDL-WT and L144R 
nanoparticles showed small differences between the predominantly α-helical lipid-
bound proteins (Lau and Middleton, 2020). Interestingly, the differences detected in the 
rHDL-L144R protein assigned cross-peaks, suggested an increased mobility of residues 
and the possible altering of the salt bridge network in helix 6 and/or the interhelical 
registry.  
The subtle differences in the spectra could reflect the increase in unordered (+10 %) 
and decrease in α-helical content (-12 %) in the rHDL-L144R apoA-I relative to the 
lipid-bound apoA-I WT (Lau and Middleton, 2020). The rHDL apoA-I L144R 
differences in the local structure detected by SS NMR and reduced stability indicated 
by Tm2 relative to apoA-I WT in rHDL suggest the conformation of the “double belt” 
dimer in the discoidal rHDL nanoparticles could be perturbed. Further experiments are 
required to understand if the subtle structural differences detected in lipid-bound apoA-
I L144R results in these changes.  
Another key aspect of this work was the comparison between the AAMD-HDL model 
and experimental rHDL-WT 2D 13C-13C CP-MAS correlation CP-MAS and 1H-15N 
PISEMA spectra. The AAMD-model deviates from the planar “double belt” model 
(Segrest et al., 1999) with the N- and C- terminal α-helices tilted away from the bilayer 
normal (Pourmousa et al., 2018). Cross-peaks were observed in the corresponding 
estimated regions for tilt angles between 0 – 90° from B0 in a simulated α-helical 
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spectrum (Marassi and Opella, 2000). The intensity and distribution of the experimental 
rHDL-WT and AAMD-HDL protein cross-peaks in the perpendicular α-helical region 
(~50 – 125 ppm by ~0 – 6 kHz) was greater than the cross-peaks in the parallel 
orientation region (~125 – 225 ppm by 0 – 10 kHz) (Figure 5.10). This suggested the 
protein conformation of apoA-I in the rHDL-WT 200:2 nanoparticles and AAMD-HDL 
model were similar with the α-helices predominantly perpendicular to the bilayer 
normal.  
Overall, the similarities between the two different types of SS NMR spectra supported 
the predominantly α-helical conformation and molecular belt model alignment of apoA-
I relative to the lipids. However, further evidence is required to support the 
predominantly perpendicular orientation of the apoA-I WT protein α-helices with 
respect to the lipid bilayer/B0, such as a simulated PISEMA spectrum in which the 
apoA-I protein is parallel to the bilayer normal. As well as experimental comparisons 
to oriented rHDL-WT, R173C and L144R nanoparticle protein 1H-15N PISEMA spectra 
using uniformly [15N]-labelled proteins.  
The CP-MAS spectra of apoA-I R173C in rHDL did not show the same differences as 
apoA-I L144R relative to apoA-I WT in rHDL nanoparticles. This suggested that 
although the interhelical registry of the apoA-I R173C dimer is shifted to align via H7 
through the cysteine-cysteine disulphide bond that this does not cause major structural 
differences with respect to apoA-I. The lipid-bound apoA-I R173C dimer in the shifted 
registry spectrum contained different cross-peaks assigned to the β-sheet regions for 
Leu and Ala residues. In combination with the CD SSE this suggested that apoA-I 
R173C in HDL could contain a higher β-strand content compared to apoA-I WT.  
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Similarly, the lipid-free apoA-I WT CP-MAS spectrum indicated additional cross-peaks 
assigned to β-sheet and unstructured random coil regions. The structural models of 
lipid-free apoA-I WT are predominantly α-helical (see Chapter 1, section 1.6.1) with 
regions of unstructured random coil between α-helices. In the crystal structures of 
apoA-I Δ(1-43) between H9 and H10, and in the N-terminal helical region of apoA-I 
Δ(185-243) (Borhani et al., 1997; Mei and Atkinson, 2011), and cross-linking models 
of full-length apoA-I WT (Pollard et al., 2013; Silva et al., 2005a). The β-sheet content 
has been detected in the “beta-clasp” model of lipid-free apoA-I WT (Lagerstedt et al., 
2012; Oda et al., 2003).  
This is the first direct comparison of the thermal stability and secondary structure using 
CD and solid-state NMR of rHDL nanoparticles containing apoA-I WT, or the 
atheroprotective apoA-I mutants. Overall, the CD SSEs indicated apoA-I WT, R173C 
and L144R in rHDL nanoparticles was predominantly α-helical. Surprisingly, the apoA-
I L144R protein did not increase in α-helix content when lipid bound but increased in 
unordered content. This could explain the lower thermal stability of the rHDL-L144R 
nanoparticles compared to rHDL apoA-I WT. Furthermore, the CP-MAS spectra 
comparison of precipitated rHDL-WT and L144R nanoparticles did not show major 
differences in the secondary structure. The comparisons of both experimental rHDL-
L144R and R173C protein CP-MAS spectra compared to rHDL apoA-I WT suggested 
the proteins overall contain similar predominantly α-helical conformations.  
The detection of selective differences in the structurally sensitive cross-peaks of the 
apoA-I L144R and R173C proteins in rHDL nanoparticles suggested there were subtle 
local structural differences. To identify the local differences in structure further SS 
NMR experiments are required with rHDL nanoparticles containing selectively labelled 
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proteins expressed using suitable E. coli auxotrophs (Lin et al., 2015; Monneau et al., 
2016).  
The absence of major structural differences detected in the respective apoA-I proteins 
suggested further investigation of possible morphological differences was necessary. 
For example, the rHDL nanoparticles could have different lipid and cholesterol 
distributions affecting the overall nanoparticle morphology. This was explored further 
in Chapter 6 using oriented 31P SS NMR. The rHDL nanoparticle morphology could 
affect how the particles interact with enzymes in RCT (Lau and Middleton, 2020), such 
as LCAT (Sorci-Thomas et al., 1993), CETP (Qiu et al., 2007) and cell receptors like 
ABCA1 (Sahoo et al., 2004).  
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6 rHDL nanoparticle 
morphology 
6.1 Introduction  
In the previous chapter the structure of apoA-I WT and atheroprotective apoA-I mutants 
in rHDL nanoparticles was analysed by CD and SS NMR. However, only subtle 
structural differences between the lipid-bound apoA-I WT and atheroprotective apoA-
I mutants were found. This suggested the apoA-I structure may not be the only 
component of the rHDL nanoparticles that could explain the atheroprotective rHDL 
nanoparticle functional differences, and the lipid component may also play a role.  
As discussed in Chapter 5, the experimental techniques used to study rHDL 
nanoparticle structure have focussed on the truncated apoA-I WT structure rather than 
the phospholipid or cholesterol constituents. There is also a need for techniques to 
establish the morphology of the particles, as the surface curvature could affect 
cholesterol cycling and how the rHDL nanoparticles interact with enzymes such as 
CETP (Qiu et al., 2007) in RCT. The shape of the particles modulates interactions with 
CETP and SR-B1, for example (Liadaki et al., 2000; Qiu et al., 2007). It is conceivable 
that the apoA-I mutants confer different morphologies on the HDL particles compared 
to apoA-I WT.  
TEM is used routinely to confirm the discoidal shape of rHDL nanoparticles (Bibow et 
al., 2017; Chen et al., 2009; Sparks et al., 1992b; Zhang et al., 2011) and (see Chapter 
4, Table 4.1 and refs therein). However, negative stain TEM is limited in resolution 
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and may miss subtle shape differences between rHDL nanoparticles that could have 
significant implications for the functional interactions with cholesterol cycling proteins. 
Additionally, the type of negative staining such as PTA was suggested to increase 
rouleaux formation of rHDL nanoparticles compared to uranyl formate (UF) (Zhang et 
al., 2011).  
Previous solution and SS NMR studies have focussed on the structure of truncated 
apoA-I (Bibow et al., 2017; Li et al., 2006) or the structure of nanodisc embedded 
proteins (Hagn et al., 2013; Mors et al., 2013) rather than discoidal rHDL nanoparticles 
containing full-length apoA-I WT. The truncated apoA-I Δ(1-54, 121-142) structure 
was analysed by solution-state NMR to produce high-resolution structural models of 
discoidal rHDL-like nanoparticles to increase reorientation rates (Bibow et al., 2017; 
Lau and Middleton, 2020).  
The 31P CSA provides lipid headgroup curvature information, however, this cannot be 
obtained using this high-resolution solution NMR technique due to averaging of the 31P 
CSA information from isotropic tumbling (Lau and Middleton, 2020). Under the 
applied magnetic field in solution NMR magnetic alignment of bicelles or larger 
macrodiscs (~30 nm in diameter) occurs and the 31P CSA is preserved (Park et al., 
2011). However, plasma HDL and rHDL particles have smaller diameters between ~7 
– 17 nm (Cavigiolio et al., 2008; Chen et al., 2009; Rosenson et al., 2011; Sparks et al., 
1992b) and do not align under B0 (Lau and Middleton, 2020). 
NMR structural studies of embedded membrane proteins in planar oriented 
phospholipid bilayers on glass slides is well established and has enabled the study of 
proteins associated with diseases and proteins with antibiotic activity (Bechinger et al., 
2004; Hansen et al., 2015; Hughes and Middleton, 2014; Naito, 2009; Park et al., 2012; 
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Salnikov et al., 2009; Sharma et al., 2010). An oriented planar lipid bilayer can be 
prepared with or without protein on glass slide substrates such as microscope cover slips 
(Hughes and Middleton, 2014; Nicholson et al., 1987; Park et al., 2012; Salnikov et al., 
2009; Sharma et al., 2010; Traaseth et al., 2006). The lipid/protein sample organic 
solvent is evaporated after deposition on the slides. Next the sample is rehydrated at a 
relatively high humidity and constant temperature (Naito, 2009).  
In oriented phospholipid bilayer SS NMR studies, the membrane can be oriented with 
the bilayer normal perpendicular or parallel to the applied magnetic field (Bechinger et 
al., 2004; Huster, 2014). rHDL nanoparticles can form rouleaux which are stacks of 
particles where the lipid bilayer normal (𝐼𝑧
𝐻𝐷𝐿) is parallel to the surface of the TEM grid 
which formed as a function of concentration as indicated in Chapter 4 with UA stained 
rHDL-WT 200:2 nanoparticles visualised by TEM. At the higher apoA-I concentration 
(36 µM) the rHDL-WT 200:2 nanoparticles formed rouleaux where 𝐼𝑧
𝐻𝐷𝐿  is 
perpendicular to B0. Whereas, at the lower apoA-I concentration (9 µM) 𝐼𝑧
𝐻𝐷𝐿  was 
parallel to B0 and formed discrete nanoparticles (Figure 6.1). Significantly this implied 
that the rHDL nanoparticles could adopt preferred orientations in a concentration 
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Figure 6.1. The orientations of rHDL nanoparticles on the planar TEM grid surface as 
stacks in rouleaux (left) and as discrete (right) particles, where the principal axis of 
inertia (𝑰𝒛
𝑯𝑫𝑳) of the HDL nanoparticle matrix, is oriented perpendicular and parallel 
relative to B0, respectively. The lipid headgroups (orange spheres), lipid acyl tails 
(grey), and apoA-I WT molecules (red). The AAMD-HDL WT 200:20:2 model was 
obtained from (Pourmousa et al., 2018). 
The two extreme orientations of 𝐼𝑧
𝐻𝐷𝐿  relative to the applied magnetic field of 0° 
(parallel) and 90° (perpendicular) were considered for the simulated NMR line shapes 
as the rHDL nanoparticles could adopt a completely parallel or perpendicular 
orientation on the planar glass surface. The relationship between the dynamically 
averaged lipid orientation and the 31P NMR lineshape relative to the applied magnetic 
field and how this affects the observed spectra is explained in section 6.2.3. It will be 
shown that the rHDL nanoparticles have specific orientations on the glass surface and 
that experimental and simulated 31P line shapes are highly sensitive to the surface 
curvature of the lipid cargo, which defines the overall shape of the particles.  
Furthermore, there is a distinct lack of NMR methods for determining the shape of 
rHDL nanoparticles containing full-length apoA-I or the atheroprotective apoA-I 
mutants. Therefore, this chapter focuses on analysing the novel application of oriented 
31P SS NMR for determining rHDL nanoparticle morphology. The oriented 31P SS 
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NMR of lipids in rHDL nanoparticles could provide clues to differences in the 
nanoparticle morphology or lipid distributions not evident by experimental analyses that 
have focussed on the apoA-I structure. 
6.1.1 Aims 
The aim of the work described in this chapter is: 
To compare the morphologies of the rHDL particles bearing the WT and mutant 
proteins. A 31P NMR method was developed, which exploited the ability of rHDL to 
adopt preferred orientations on glass substrates held at a fixed angle in the magnetic 
field. Previous oriented studies of lipid bilayers demonstrated the feasibility of 
examining protein and lipid orientations with 15N/13C, and 31P SS NMR, respectively 
(Bechinger et al., 2004; Das et al., 2013; Hughes and Middleton, 2014; Marassi and 
Crowell, 2003; Nakazawa et al., 2009; Salnikov et al., 2009).  
6.2 Materials and methods 
The rHDL nanoparticles characterised in this chapter were prepared as described in 
Chapter 4. The following methods for rHDL nanoparticle lipid and cholesterol 
structural characterisation are published in (Lau and Middleton, 2020).  
6.2.1 Oriented rHDL nanoparticle preparation 
The glass cover slips and dried rHDL nanoparticles on slides were prepared as described 
in Chapter 5 (see section 5.2.3). The dried samples were rehydrated at 37°C and 99 % 
humidity for various time periods (3, 4, 6 and 16 hours), and wrapped in cling film 
before NMR analysis. The human plasma HDL sample (10 mg, Merck) contained ~5 
mg protein in 150 mM NaCl, 0.01 % EDTA, pH 7.4 solution and was diluted to 1 mL 
before following the same preparation as the rHDL nanoparticle samples. 
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6.2.2 31P solid-state NMR of rHDL nanoparticles 
A Bruker Avance 400 spectrometer was used to perform the SS NMR measurements 
using an 89 mm bore magnet at a magnetic field strength of 9.3 T and a temperature of 
25°C. The stacked oriented rHDL nanoparticle sample was placed into the coil (9 x 3 x 
3 mm) of a double resonance (H/F and X, the latter tuned to 161 MHz for 31P 
observation) static flat-coil probe (Bruker), and 31P NMR measurements were collected. 
Excitation of the 31P spins was induced with a 3.5 µs 90° pulse followed by continuous 
wave proton decoupling at 20 kHz during the acquisition time period. A 2 s recycle 
delay was used and spectra contained 10 000 – 50 000 accumulated transients. 
6.2.3 31P oriented rHDL nanoparticle lineshape calculations 
6.2.3.1 Lipids in planar or spherical distributions  
This section explains the relationship between the lipid orientation and the 31P NMR 
lineshape relative to the applied magnetic field (B0) in different lipid samples and how 
this affects the observed spectra. To explain NMR lineshape calculations used in this 
work for planar and spherical lipid distributions.  
The lipid orientation within the planar bilayer relative to B0 can be detected using 
31P 
SS NMR (Huster, 2014). The chemical shift tensor components of a phospholipid are 
represented by an ellipsoid as in Figure 2.5 (see Chapter 2) where δ11 ≥ δ22 ≥ δ33 (Duer, 
2004; Nakazawa et al., 2009). The orientation dependence of the CSA for lipids in 
different samples affects the observed spectra (Figure 6.2) (Huster, 2014). The isotropic 
chemical shift (δiso) in the simulated spectrum of lipids undergoing rapid motion in 
solution show a narrow Lorentzian lineshape at ~2 ppm as the CSA components average 
to zero (Figure 6.2A) (Huster, 2014). In experimental solution NMR spectra, the 
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detected isotropic chemical shift varies dependent upon the type of phospholipid and 
lipid headgroup (Puppato et al., 2007).  
 
Figure 6.2. Simulated 31P proton decoupled NMR spectra adapted from (Huster, 2014). 
(A) Lipids in solution undergoing isotropic motion at δiso at 2 ppm (dotted line). (B) A 
planar lipid bilayer at ~30 ppm with the principal axis (bilayer normal) parallel, (C) or 
perpendicular to B0, at ~-15 ppm. (D) Lipids in a multilamellar vesicle with each 
chemical shift for all available lipid orientations in the vesicles. (E) A solid crystalline 
state lipid spectrum (Huster, 2014). (F) Rotational diffusion of a bilayer lipid (blue 
arrow) around the long molecular axis of the lipid (dashed blue line). The bilayer normal 
(red arrow), the lipid headgroups (blue) and fatty acid tails (black). (G) The principal 
axis of the rotationally averaged chemical shift tensor (red arrow) of a bilayer lipid 
relative to B0 (black arrow), separated by the angle β. 
The theoretical treatment in this work is based on previous work by Picard et al. for 
aqueous suspensions of liposomes and has been adapted for the specific case of rHDL 
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oriented on a planar substrate (Lau and Middleton, 2020; Picard et al., 1999). All 
simulations were performed using C programs written by Prof. D. Middleton. The 
simulated spectra for a 100 % planar or spherical lipid distribution were determined 
using Equations [11] and [12] of the measured lipid(s) 31P NMR frequency and the 
spectral density, respectively.  
A lipid experiences fast rotational diffusion around the long molecular axis in a lipid 
bilayer in the liquid crystalline phase state (Figure 6.2F) (Huster, 2014; Macdonald et 
al., 2013). The measured 31P NMR frequency of a rapidly rotating lipid in a bilayer can 
be described with (Picard et al., 1999): 
 𝜔 = ∆𝛿𝑎𝑣
(3𝑐𝑜𝑠2𝛽 − 1)
2
+ 𝛿𝑖𝑠𝑜 [11] 
The angle between B0 and the principal axis of the chemical shift tensor is β (Figure 
6.2G) (Picard et al., 1999). The isotropic chemical shift (δiso) is nearly zero (~2 ppm) 
for a lipid in a fluid bilayer with the corresponding rotationally averaged full CSA is 45 
ppm, and Δδav is 30 ppm (Huster, 2014; Macdonald et al., 2013). When the lipid bilayer 
normal is parallel or perpendicular to B0 the respective chemical shifts are 30 and -15 
ppm, respectively (Figure 6.2B-C) (Huster, 2014).  
A range of 31P NMR frequencies dependent on the lipid orientation(s) (i.e., angle β) can 
be observed between 30 and -15 ppm. This results in a broad powder pattern lineshape, 
e.g., as seen for a multilamellar vesicle that contains multiple lipid orientations (Figure 
6.2D) (Huster, 2014; Macdonald et al., 2013). In comparison the spectra of lipids in a 
solid crystalline state (Figure 6.2E) shows a very broad powder pattern lineshape 
(Huster, 2014). The continuous lineshape with less than three-fold symmetry is formed 
from overlapping lines at each frequency due to the presence of all available orientations 
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(Duer, 2004). This demonstrates the orientation dependence of the 31P SS NMR signal 
in phospholipids.  
Equation [12] describes the connection between the orientation distribution of the 
lipids which experience fast molecular motions and the sample molecules weighted-
average NMR frequencies (Lau and Middleton, 2020; Picard et al., 1999). These are 
known as the spectral density, S(ω), and angular distribution, P(β), and affect the NMR 
spectrum lineshape. This is defined as (Picard et al., 1999): 
 𝑆(𝜔)|𝑑𝜔| = 𝑃(𝛽)|𝑑(𝛽)| [12] 
In a liposome the lipid molecules are in a 100 % spherical distribution and a spherically-
averaged and axially symmetrical powder lineshape is produced as P(β) = sin(β) 
(Figure 6.2D) (Huster, 2014; Lau and Middleton, 2020). In comparison, β = 0° or 90° 
when a 100 % planar lipid bilayer normal (Figure 6.2B and C) is parallel or 
perpendicular to B0, respectively. The narrow Lorentzian lineshapes are observed at 30 
and -15 ppm for the 100 % parallel and perpendicular oriented lipid bilayers, 
respectively (Huster, 2014). This is a result of the limited random distribution of lipids 
about the β angles in the planar bilayers hence the term angular distribution P(β) (Lau 
and Middleton, 2020). The following calculation was used to determine the real part of 
the NMR signal as a function of time.  




  [13] 
The complex signal was Fourier transformed to produce the NMR lineshape with the 
broadening function (exp(-t/T2)) used on all calculated signals (Lau and Middleton, 
2020).  
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6.2.3.2 Calculations of expected lineshapes from the AAMD model 
A 31P NMR lineshape was simulated based on the AAMD structural model of nascent 
HDL containing POPC:cholesterol:apoA-I WT 200:20:2 (M/M) (Figure 6.3) 
(Pourmousa et al., 2018) for comparison with the lineshapes of the oriented rHDL 
nanoparticle samples. The three different types of motion the POPC molecules can 
experience within a bilayer leaflet are translational motion, local motional fluctuations, 
and as described before the rotation about the long molecular axis (Klauda et al., 2008; 
Lau and Middleton, 2020; Macdonald et al., 2013). The dominant motion of the POPC 
lipids was assumed to be the rotational diffusion about the long molecular axis i.e. angle 
β which in turn scales the 31P CSA as shown in Equation [11] (section 6.2.3.1) (Lau 
and Middleton, 2020). 
The dynamically averaged 31P NMR frequency for each lipid in the final 1 μs of a 10 
µs MD simulation trajectory was determined by calculating the average inclination 
angle (βav) of each of the 200 lipids over this time period. Previous studies have 
calculated the axial rotational diffusion coefficient (DR) of DPPC lipids in MD 
simulated fluid-phase bilayers between ~1x107 – 1.6x108 s-1 (Essmann and Berkowitz, 
1999; Klauda et al., 2008), and experimentally with electron spin resonance in 
DMPC/DMPG/cholesterol fluid membranes where the DR values had a magnitude up 
to x109 s-1 (Ge and Freed, 2011; Sanderson, 2012). Therefore, the timescale of 1 μs was 
greater than the rotational diffusion timescale of each lipid in this timeframe (Lau and 
Middleton, 2020). 
𝐼𝑧
𝐻𝐷𝐿 the principal axis of inertia of the rHDL nanoparticle lipid matrix was therefore 
assumed to be either parallel or perpendicular to B0, i.e. as separate discrete rHDL 
nanoparticles or as stacks in the rouleaux formation, respectively (Figure 6.3) (Lau and 
Middleton, 2020). 
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Figure 6.3. The orientation of the rHDL nanoparticles with 𝑰𝒛
𝑯𝑫𝑳, the principal axis of 
inertia of the HDL nanoparticle matrix, oriented perpendicular (left) and parallel (right) 
to B0, representations for stacked rouleaux or discrete nanoparticles relative to the 
planar glass surface. AAMD-HDL WT 200:20:2 model obtained from (Pourmousa et 
al., 2018). The lipid headgroups (orange spheres), lipid acyl tails (grey), and apoA-I 
WT molecules (red).  
Across a total of 64 frames in the final 1 μs of the 10 μs MD simulation the angle β in 
each frame was calculated for all POPC molecules in the 200:20:2 HDL nanoparticle. 
β is the angle between each lipid(s) principal axis of inertia (𝐼𝑧
𝑃𝑂𝑃𝐶) relative to B0 (Lau 
and Middleton, 2020). Small changes in the root mean square deviation (RMSD) occur 
in the final 1 μs of the simulation and the overall assembly is assumed to have reached 
a stable state.  
To calculate the time-averaged 31P frequency of each lipid molecule the average 
inclination angle βav over the final 1 μs was substituted into Equation [11] (Lau and 
Middleton, 2020). Another approach considered was motional averaging of the full 
CSA tensor of each lipid molecule in the HDL nanoparticle. However, the method 
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described above had greater sensitivity towards the lipid molecule(s) average 
orientations (Lau and Middleton, 2020).  
6.2.3.3 Application to the hemispheroid shape 
Picard et al.’s equation determined the density of probability for an ellipsoid (Equation 
[14]) (Picard et al., 1999). This applied to rHDL nanoparticles with lipid bilayer surface 




[sin2 𝛽 + 𝑟2 cos2 𝛽]2
  [14] 
In Equation [14] r = b/a, where a and b are the minor and major hemispheroid axis, 
respectively, indicated in Figure 6.4. When a < b the shape is an oblate hemispheroid 
and was assumed to represent the surface curvature of the lipids.  
As described previously, the rHDL nanoparticles can form rouleaux or exist as discrete 
particles on a planar surface. Therefore, the NMR lineshapes were calculated for the 
hemispheroid approximation where 𝐼𝑧
𝐻𝐷𝐿 was perpendicular or parallel to B0. The NMR 
lineshape calculations for an oblate hemispheroid with axis a parallel or perpendicular 
to B0 were different with respect to the angles available to the lipids in the nanoparticles. 
The NMR lineshape when axis a was parallel to B0 (Figure 6.4A) was calculated using 
Equations [11], [12] and [14], with summation of every angle β from 0° to 90°. The 
angle β represents the available orientations of the lipids in discrete rHDL nanoparticles 
(Lau and Middleton, 2020).  
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Figure 6.4. The hemispheroid representation of the surface curvature in an rHDL 
nanoparticle. The minor axis (a) and major axis (b) are indicated. 𝑰𝒛
𝑯𝑫𝑳 (green arrow) or 
axis a is parallel (A) or perpendicular (B) to the applied magnetic field (B0). The angles 
α and β are indicated relative to B0. Obtained from (Lau and Middleton, 2020).  
In comparison for rouleaux rHDL nanoparticles axis a is perpendicular to B0 and the 
lipids can also be oriented in a circular distribution at angle α with respect to angle β 
(Figure 6.4B). Therefore, the possible α values were from +(90°-β) to –(90°-β). All of 
the α and β angles were summated and α was substituted into Equation [14], followed 
by the use of Equations [11], and [12] to calculate the lineshape (Lau and Middleton, 
2020).  
6.2.3.4 Discoidal rHDL nanoparticle lineshape simulations  
The rHDL-C nanoparticle lineshapes were simulated with a torus discoidal shape 
approximation. This approximation contained two components, a planar lipid bilayer 
inner circular core and the surrounding outer lipids distributed in a partial torus. The 
radius of the circular core is defined as c, and the partial torus width by t (Figure 6.5A-
B) (Lau and Middleton, 2020).  
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Figure 6.5. The discoidal rHDL morphology approximation (A, B). The labels indicate 
the particle diameter d, thickness b, the partial torus width t, the radius of the planar 
core c, and the maximum tilt angle βt of the lipids in the partial torus relative to 𝑰𝒛
𝒅𝒊𝒔𝒄. 
(C) Simulated spectra when the disc normal is parallel (black) or perpendicular (red) to B0. 
The maximum angle of βt was increased from 20 to 90°. The constant value of b/d = 0.5 
was used when the diameter and thickness of the rHDL nanoparticles was assumed to be 
11 and 5.5 nm, respectively. Obtained from (Lau and Middleton, 2020). 
The lipids in the partial torus are in various orientations tilted away from 𝐼𝑧
𝐻𝐷𝐿 which 
were described by the maximum tilt angle βt. The particle diameter (d) and thickness 
(b) were 11 nm and 5.5 nm, respectively, based upon the rHDL nanoparticle TEM 
measurements in Chapter 4. The condition that the curvature of the partial torus lipids 
did not alter d or b was used (Lau and Middleton, 2020). Therefore, the inner core must 
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contract to maintain d and b, i.e., r will decrease as βt increases. This is described by 
Equation [15]. 
Equation [16] was derived in this work to describe the lipids in the partial torus, i.e., 
fraction of lipids (ft). It follows that the fraction of lipids in the core is 𝒇𝒄 = 𝟏 − 𝒇𝒕 (Lau 
and Middleton, 2020).  
 𝑓𝑡 =
𝑏(2𝛽𝑡𝑐 + 𝑏 sin 𝛽𝑡) 
2𝑐2 + 𝑏(2𝛽𝑡𝑐 + 𝑏𝑠𝑖𝑛𝛽𝑡) 
  [16] 
The density of probability of lipids in the partial torus in discrete rHDL nanoparticles, i.e. 
when 𝐼𝑧
𝐻𝐷𝐿  was parallel to B0, was calculated according to Equation [17] which was 
partially derived from Picard et al.’s equation for a full torus (Picard et al., 1999), where 0 
≤ β ≤ βt (Lau and Middleton, 2020). 
 𝑃𝑡(𝛽) = 0.5𝜋𝑏(𝑐 + 0.5𝑏 sin 𝛽)  [17] 
The angular distributions were summated for the lipids in the planar bilayer core and partial 
torus when β = 0° and 0 ≤ β ≤ βt, respectively. Equations [15], [16] and [17] were used to 
calculate the NMR lineshape of the discoidal approximated particles (Lau and Middleton, 
2020). 
For rouleaux oriented rHDL nanoparticles where 𝐼𝑧
𝐻𝐷𝐿 is oriented perpendicular to B0 a 
numerical approach was required. Separate unit vectors described the planar core and 
the partial outer torus lipid components. The β angles between these unit vectors and B0 
were used to calculate the NMR lineshape (Lau and Middleton, 2020). These 
calculations allowed the production of simulated 31P NMR spectra fittings (Figure 
 𝑐 = 0.5(𝑑 − 𝑏 sin 𝛽𝑡)   [15] 
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6.5C) for measured rHDL nanoparticle spectra that contained a similar lineshape by 
varying βt to determine the rHDL nanoparticle morphology.  
6.3 Results 
6.3.1 SS NMR of rHDL nanoparticles 
6.3.1.1 Surface curvature of lipids detection by SS NMR 
NMR spectra were simulated to determine if the 31P NMR lineshape could in principle 
be affected by the rHDL nanoparticle morphology when rHDL is oriented on a planar 
substrate. The simulated spectra used the atomic coordinates of the POPC molecules 
from the AAMD simulated model of POPC:cholesterol:apoA-I WT 200:20:2 HDL 
nanoparticle simulated for 10 μs (Pourmousa et al., 2018). The calculations used to 
determine the simulated spectra and the lipid contributions at each orientation with 
respect to B0 are discussed in section 6.2.3.2 
When the HDL model principal axis of inertia (𝐼𝑧
𝐻𝐷𝐿) was parallel to B0 (Figure 6.6B) 
the spectrum exhibits a continuous asymmetric lineshape between the upper and lower 
limits of the 31P CSA in Figure 6.6A.  
The lineshape reflects a proportion of the outer lipids that are perpendicular to B0 
(resulting in the ‘spike’ at -15 ppm) and a larger proportion of inner lipids with their 
long molecular axes distributed about the B0 axis (Lau and Middleton, 2020). When 
𝐼𝑧
𝐻𝐷𝐿 is perpendicular to B0 most of the lipids were in the perpendicular orientation at -
15 ppm with a smaller proportion towards the upper limit (Figure 6.6C). These lipid 
orientations can be observed in the AAMD model by the lipid headgroup positions 
(Figure 6.6D).  
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Figure 6.6. (A) The simulated spectra for a phospholipid bilayer with the lipid 
membrane normal parallel (black) and perpendicular (red) to B0. The simulated MD 
model lineshapes (black) and hemispheroid approximation when a/b = 0.4 (short/long 
axis) (red) when the principal axis of inertia of HDL (𝑰𝒛
𝑯𝑫𝑳) is (B) parallel or (C) 
perpendicular to B0. (D) The POPC:cholesterol:apoA-I WT 200:20:2 HDL nanoparticle 
structure after 10 μs of AAMD simulation obtained from (Pourmousa et al., 2018). 
ApoA-I molecules (red), lipid acyl chains (grey) and headgroups (orange spheres). (E) 
The hemispheroid representation of the surface curvature in an rHDL nanoparticle with 
minor axis (a), major axis (b), and 𝑰𝒛
𝑯𝑫𝑳 (green arrow). The angle β indicates the lipid 
principal axis relative to B0. Adapted from (Lau and Middleton, 2020). 
It was considered whether the lineshapes based on the HDL model could be replicated 
by assuming a hemispheroid distribution of lipid orientation, as visual inspection of the 
model shape reveals convex and concave surfaces. Simulated spectra based on the 
hemispheroid approximation (see section 6.2.3.3), with the hemispheroid parallel and 
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perpendicular relative to B0, fit the AAMD model NMR lineshapes well (Figure 6.6B-
C). This revealed that the oblate hemispheroid approximation (Figure 6.6E) was a 
suitable representation of the HDL particle lipid surface curvature (Lau and Middleton, 
2020). The normal to the tangent plane at any point on the hemispheroid surface (Figure 
6.6E) represents the average lipid molecular orientation at that position (Lau and 
Middleton, 2020; Picard et al., 1999).  
With the hemispheroid approximation it is straightforward to generate simulated 31P 
lineshapes for different surface curvatures. The orientational distribution of the lipids 
(Figure 6.7) can be related to the surface curvature of the hemispheroid by a flattening 
factor 𝑓 = 1 − 𝑎/𝑏 between 0 to 1.0, i.e. as a decreases f will increase towards 1 (Lau 
and Middleton, 2020). As the surface curvature lessens the lineshapes became narrower 
and approach the planar lipid distribution lineshapes in Figure 6.6A.  
The surface curvature lipid orientation relationship could then be applied to fit 
experimentally observed rHDL nanoparticle spectra. This is a valuable tool to determine 
if the lipid distribution in the rHDL nanoparticles contained surface curvature. 
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Figure 6.7. The simulated 31P NMR spectra lineshape oblate hemispheroid (a < b) 
approximation of the lipid surface curvature in rHDL nanoparticles. The flattening 
factor (f) was increased from a completely spherical (f = 0) to planar (f = 1.0) lipid 
distribution when axis a was parallel (red) or perpendicular (black) relative to B0. Each 
spectrum lineshape was normalised to the peak area, and across the assumed full 45 
ppm averaged POPC CSA. Obtained from (Lau and Middleton, 2020).  
6.3.1.2 31P NMR spectra of oriented rHDL nanoparticles at different hydration 
times 
The rHDL-WT 200:2 samples were deposited on glass cover slips, dried, and then 
rehydrated for different lengths of time to test how the level of hydration can affect the 
31P NMR lineshape (Figure 6.8). Two symmetrical peaks were observed at the upper 
and lower limits of the 31P CSA and indicated a mixture of particles oriented parallel 
(30 ppm) and perpendicular to (-15 ppm) to B0. The best fits of the experimental spectra 
were Lorentzian lineshapes at the upper and lower limits of the CSA. Therefore, a fitting 
factor of 1.0 and the ratio (rp) of particles either parallel or perpendicular to B0 were 
used to fit the experimental peaks.  
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As the hydration time increased (3-16 hrs) the proportion of parallel to perpendicular 
oriented nanoparticles increased (as signified by the ratio of the peak areas), and the 
peak width became narrower (Lau and Middleton, 2020). This suggests that longer 
hydration times favour the formation of discrete (parallel to B0) rather than rouleaux 
stacked (perpendicular to B0) rHDL nanoparticles as the hydration level increased. An 
increased amount of moisture in the sample, after 16 hours, may have reduced the CSA 
indicated by the decrease in the separation between the two peaks to ~41 ppm. This 
could reflect an increase in the lipid mobility in the rHDL nanoparticles (Lau and 
Middleton, 2020). 
 
Figure 6.8. 31P NMR spectra of rHDL-WT 200:2 nanoparticles at 3 mM POPC 
concentration with a hydration time of 3, 4, 5 and 16 hours at 37°C. The best fits (red) 
of the spectra are Lorentzian lineshapes considered as a ratio (rp) of planar (f = 1.0) 
nanoparticles either parallel or perpendicular to B0. Optimisation of the linewidths and 
peak areas was used to determine the best fits, and the peak areas were proportional to 
rp. Adapted from (Lau and Middleton, 2020).  
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6.3.1.3 Atheroprotective apoA-I rHDL morphology 
Oriented 31P NMR rHDL 200:2 nanoparticle spectra, in triplicate to assess the 
reproducibility of the sample preparation, were obtained for separate samples 
containing either apoA-I WT, R173C or L144R. The sample lipid concentration was 
lower to try and form predominantly discrete rHDL nanoparticles, i.e., oriented with 
𝐼𝑧
𝐻𝐷𝐿  parallel to B0. Initial observations indicated the rHDL-WT (Figure 6.9) and 
R173C (Figure 6.10) lineshapes were distributions of nanoparticles oriented either 
parallel or perpendicular to B0. The spectra were fitted with the planar bilayer 
morphology Lorentzian lineshape fitting with a value of f = 1.0, and a varied rp value 
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Figure 6.9. The oriented 31P NMR spectra of rHDL-WT 200:2 nanoparticles. The 
POPC concentration after dialysis was ~0.76 mM. Each sample (#1-3) was rehydrated 
for 4 hours at 37°C. The experimental spectra (black) and simulated Lorentzian best fits 
(red). The fitting criteria included the f values, rp ratio, and line broadening. The * 
indicates an additional peak not seen in any other spectrum and possibly from smaller, 
micellar-like structures.  
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Figure 6.10. The oriented 31P NMR spectra of rHDL-R173C 200:2 (M/M) 
nanoparticles. The POPC concentration after dialysis was ~0.15 mM. Each sample was 
rehydrated for 4 hours at 37°C. The experimental spectra (black) and simulated 
Lorentzian best fits (red). The fitting criteria included the f values, rp ratio, and line 
broadening. 
The rHDL-L144R lineshape (Figure 6.11) was significantly different from the results 
above and were more indicative of the lipid surface curvature seen in the MD model, as 
represented by the hemispheroid approximation. The f factor values of 0.5 and 0.6 
indicated the lipid surface curvature of the rHDL-L144R nanoparticles was not a planar 
bilayer nanodisc as in Figure 6.7.  
Although not clearly delineated as in the previous spectra, the lineshapes are consistent 
with two orientations of the particles, as before. Maxima occur at the two edges of the 
spectra, but some intensity is also present across the entire CSA range. Comparisons 
with simulated spectra of a mixture hemispheroid distributions in the two orientations, 
indicate that a larger proportion of rHDL-R173C nanoparticles formed rouleaux as 
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indicated by the lower rp values. The rHDL-L144R rp values were higher than both 
rHDL-WT and R173C nanoparticles indicating the morphology of the particles resulted 
in less rouleaux formation (Lau and Middleton, 2020).  
 
Figure 6.11. The oriented 31P NMR spectra of rHDL-L144R 200:2 (M/M) 
nanoparticles. The POPC concentration after dialysis was ~0.70 mM. Each sample was 
rehydrated for 4 hours at 37°C. The experimental spectra (black) and simulated 
hemispheroid approximation best fits (red), and a broadening of 200 Hz was applied to 
the rHDL-L144R spectra. The fitting criteria included the f values, rp ratio, and line 
broadening.  
The application of these fitting functions to the NMR lineshapes of the oriented 31P 
NMR spectrum has allowed the determination of similarities and differences in the 
rHDL nanoparticle morphology. The lipid surface curvature difference in the rHDL-
L144R nanoparticle morphology could suggest a physical basis for the atheroprotective 
properties of this mutant (Lau and Middleton, 2020).  
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6.3.1.4 Oriented rHDL-C WT nanoparticles 31P NMR analysis 
To determine if cholesterol affected the NMR lineshape, samples were prepared at the 
POPC:cholesterol:apoA-I WT molar ratios indicated in Figure 6.12. Each sample 
contained 10 mol % cholesterol relative to the total POPC content. The curvature of the 
lower limit lipid distribution peak at -15 ppm increased as the lipid:cholesterol:apoA-I 
WT molar ratio increased (160:16:2 to 300:30:2) (Lau and Middleton, 2020). The 
lineshape distribution between the upper limit (30 ppm) and lower limit (-15 ppm) 
shows a change in the distribution of lipids in the rHDL nanoparticles relative to B0. In 
the samples containing cholesterol the curvature increased towards the upper limit and 
the lineshape is quite distinct from that of a planar lipid distribution or a hemispheroid 
approximation. Another model was therefore sought to explain this observation.  
A new fitting model was used for the spectra of rHDL nanoparticles containing 
cholesterol (Figure 6.12A) referred to as the torus disc distribution. In this model the 
planar lipid bilayer circular core is surrounded by lipids in a partial torus (Figure 6.5). 
The increase in the lipid content resulted in the outer lipids being moved further from 
the lipid bilayer normal, i.e. as βt increased in the partial torus (Lau and Middleton, 
2020). Summation of the 𝐼𝑧
𝑑𝑖𝑠𝑐  components was used to calculate the torus disc 
experimental spectra fittings when 𝐼𝑧
𝑑𝑖𝑠𝑐 was oriented parallel or perpendicular to B0 
(see section 6.2.3.4, Figure 6.5C) (Lau and Middleton, 2020).  
Additionally, a comparative spectrum of POPC:apoA-I WT 300:2 nanoparticles in 
Figure 6.12B fitted the torus disc morphology without cholesterol. This suggested the 
morphology occurs when the total lipid concentration is increased. The rHDL 
nanoparticle lipid surface area may increase to adapt to the increased number of lipid 
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molecules which could reduce the exposure of the outer lipids to the aqueous medium 
(Lau and Middleton, 2020).  
 
Figure 6.12. (A) The experimental (black) 31P NMR spectra of rHDL-C WT 
nanoparticles at the molar ratios indicated. The lipid concentration was 3 mM and 
samples were rehydrated for 4 hours at 37°C. The torus disc model simulated fitted 
spectra (red). The maximum tilt angle of the lipids in the torus is indicated by βt. (B) 
rHDL-WT 300:2 nanoparticle 31P NMR spectrum (black) without cholesterol fitted with 
the torus disc distribution (red). (C) Unfractionated human plasma HDL 31P NMR 
spectrum (black) fitted with the hemispheroid approximation (red). Adapted from (Lau 
and Middleton, 2020). 
Furthermore, the spectrum of unfractionated human plasma HDL was fitted with the 
combined parameters in equal proportions of the hemispheroid morphology 
approximation and a 100 % spherical distribution. The morphology sensitive technique 
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was able to detect the presence of spherical mature and flatter nascent discoidal HDL 
particles (Lau and Middleton, 2020).  
The possibility that the observed spectra were comprised of a superimposed powder 
spectrum and an oriented spectrum was considered. The rHDL nanoparticle 
morphology models were chosen with respect to the observed experimental spectra. For 
example, the rHDL-WT 200:20:2 nanoparticle spectra for the AAMD simulated 
spectrum fitted with the hemispheroid approximation model (Figure 6.6B) and the 
observed spectrum fitted with the torus disc model (Figure 6.12A).  
The different rHDL morphology models explained the differences in the observed 
lineshape curvature. Whereas a superimposed powder and oriented spectra would not 
account for this. For example, the lineshape curvature in Figure 6.12 rHDL-C 
nanoparticles spectra shifted towards the upper limit (~30 ppm) and was not accounted 
for by the hemispheroid or the planar morphology fittings.  
6.4 Discussion 
6.4.1 Discoidal rHDL nanoparticle morphology 
The 31P NMR lineshape of oriented rHDL nanoparticles is sensitive to the alignment of 
lipids within the rHDL nanoparticles with respect to B0. Application of calculated 
fittings produced three distinct models of discoidal rHDL nanoparticle morphology, 
described as the hemispheroid approximation and planar disc (Picard et al., 1999), and 
the torus disc models (Lau and Middleton, 2020). Whilst other models may also 
describe the observed phenomena, the key finding of this work is that 31P NMR is a 
useful new tool to assess the morphological differences between HDL preparations, 
either from reconstituted samples or from human plasma.  
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Another facet of this approach was the production of simulated NMR lineshapes using 
the AAMD-HDL 200:20:2 model (Pourmousa et al., 2018). This demonstrated how 
computational HDL models could be combined with or compared to experimental 
results using the 31P SS NMR morphology tool.  
In terms of the different rHDL nanoparticles in this study. The rHDL-WT and R173C 
200:2 nanoparticles had a planar disc morphology. This fits the predominant discoidal 
HDL model in the literature of a planar lipid nanodisc surrounded by a belt of apoA-I 
(Bibow et al., 2017; Segrest et al., 1999; Sparks et al., 1992b). The rHDL-L144R 200:2 
nanoparticle lineshape is consistent with greater lipid surface curvature, which may be 
approximated by a hemispheroid distribution of lipid orientations. The overall lipid 
surface curvature was similar to the AAMD-HDL 200:20:2 simulated model 
(Pourmousa et al., 2018). In Chapter 5, the 2D 13C-13C CP-MAS correlation and 1H-
15N PISEMA spectra of the rHDL nanoparticles apoA-I spectra supported the 
predominantly α-helical conformation and molecular belt model alignment of apoA-I 
relative to the lipids (section 5.3.2, Figure 5.9-5.10).  
In the AAMD-HDL model the apoA-I molecules are not strictly perpendicular to the 
bilayer normal to adapt to the lipid-protein circumference mismatch (Figure 6.6D), 
which causes bending of the lipid nanodisc to maintain contact between the lipid leaflets 
forming a convex and a concave face (Lau and Middleton, 2020; Pourmousa et al., 
2018). The simulated lineshapes for the AAMD-HDL model, i.e. the lipid orientations, 
can be represented by the hemispheroid approximation, reflecting the lipid surface 
curvature in both orientations when 𝐼𝑧
𝐻𝐷𝐿 is parallel or perpendicular relative to B0 (Lau 
and Middleton, 2020). 
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The absence of distortion from planarity of the lipid bilayer nanodisc suggested the 
lipids in the disc morphology of the rHDL-WT and R173C nanoparticles are sufficiently 
relaxed (Lau and Middleton, 2020). In comparison, the rHDL-L144R lipid surface 
curvature was represented by the hemispheroid approximation which suggested these 
nanoparticles have a convex and concave face. This surface curvature of the particles 
could have resulted in a higher proportion of discrete particles on the planar surface as 
indicated by the larger rp values, i.e., the ratio of particles with 𝐼𝑧
𝐻𝐷𝐿  parallel: 
perpendicular relative to B0.  
The hemispheroid rHDL-L144R nanoparticle morphology lipid surface curvature could 
explain the reduced thermal stability at Tm2 and the different estimated secondary 
structure content of apoA-I L144R in rHDL, +10 % unordered and -12 % α-helical 
relative to rHDL-WT, determined by CD, when compared to the relaxed lipids in the 
planar disc rHDL-WT and R173C morphologies. The rHDL-WT and R173C apoA-I 
proteins also had a similar Tm2 at 82.9°C and 81°C, respectively, which suggested a 
similar stability of the proteins in the rHDL 200:2 nanoparticles, possibly related to the 
planar disc morphology.  
In Chapter 4, the rHDL-L144R 200:2 DLS diameter measurement was significantly 
smaller at ~6.2 nm compared to ~11.3 nm for the rHDL-WT nanoparticles. The rHDL-
L144R DLS diameter was considerably less than the rHDL-WT and L144R estimated 
NDGGE hydrodynamic diameter (~8.6 – 10.1 nm) and the TEM diameter of dried 
particles (~11 nm). The hydrodynamic diameter of non-spherical particles can be 
overestimated when measured using DLS, i.e., the non-spherical planar disc rHDL-WT 
morphology, which calculates the diameter based upon an ideal spherical particle 
morphology (Eiser, 2014; Lau and Middleton, 2020). The 31P NMR tool detected the 
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
294  Sophie Lau - July 2021 
rHDL-L144R hemispheroid morphology where the lipid surface curvature approaches 
that of an ideal spherical particle. This could explain the diameter measurement 
discrepancy, with the DLS measurement representing the actual rHDL-L144R particle 
diameter (Lau and Middleton, 2020).  
In the last model, the rHDL-C WT nanoparticles containing 10 mol % cholesterol had 
a torus disc morphology. In comparison to the previous models the outer lipids move 
away from the bilayer normal as the particle cholesterol and lipid content increased (Lau 
and Middleton, 2020). This was observed in the 31P NMR spectra line shape as a change 
in the lower limit (-15 ppm) peak curvature shifted towards the upper limit as the lipid 
and cholesterol content increased. The narrower Lorentzian line shapes of the rHDL-
WT and R173C planar disc morphology and rHDL-L144R hemispheroid morphology 
line shapes shifted peak orientations towards the upper limit were distinct from the 
rHDL-C spectra lineshapes. A key feature of the rHDL-C WT torus disc morphology is 
the possibility of allowing for molecular crowding as the lipid content increases 
allowing for an increased lipid surface area to prevent exposure of the outer lipid 
hydrophobic acyl tails to the aqueous medium (Lau and Middleton, 2020). 
6.4.2 Summary 
This is the first application of oriented 31P SS NMR to determine the morphology of 
rHDL nanoparticles. As well as a direct comparison between the rHDL-WT, R173C 
and L144R nanoparticle morphologies. The development of this technique has 
diversified the techniques used to characterise rHDL nanoparticles morphology. As it 
is necessary to use multiple approaches when characterising rHDL nanoparticle 
structure as seen by the differing measured diameters. The different morphologies 
identified here could reflect the dynamic nature of in vivo nascent discoidal HDL 
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nanoparticles. This in turn could affect how the particles interact with enzymes in RCT 
(Lau and Middleton, 2020), such as LCAT (Sorci-Thomas et al., 1993), CETP (Qiu et 
al., 2007) and cell receptors like ABCA1 (Sahoo et al., 2004). The functional aspects of 
the respective rHDL nanoparticles are explored further and discussed in Chapters 7 
and 8.  
Significantly, the proof of concept unfractionated human plasma HDL sample 
demonstrated how this morphology detection tool could be used to analyse fractionated 
HDL cardiovascular disease patient samples (Lau and Middleton, 2020). Furthermore, 
the morphological detection could be applied to experimental assays such as HDL 
particles formed in vitro (Duong et al., 2006).  
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7 Further investigations 
7.1 Introduction  
The work in this chapter lays the foundation for future work in analysing the rHDL 
nanoparticles function and structure computationally and experimentally. Preliminary 
coarse-grained MD simulations have examined the conditions required for self-
assembly simulations of rHDL nanoparticles containing full-length apoA-I WT and 
R173C. In addition, experimental cellular assays have been developed to assess the 
capability of WT apoA-I and mutants to facilitate cholesterol efflux in vitro. Finally, 
the amyloidogenic potential of apoA-I WT and mutants are assessed.  
7.1.1 Molecular dynamics simulations of HDL nanoparticles 
Molecular dynamics simulations can be used to produce models of HDL nanoparticles. 
There are different types of MD simulations that can be combined with experimental 
data (see Chapter 1, section 1.6.2) and have been reviewed comprehensively (Pan and 
Segrest, 2016; Pourmousa and Pastor, 2018). The work in this chapter has focussed on 
coarse-grained MD simulations. The major advantage of CGMD simulations is the 
prolonged timescales, e.g. 10 - 42 µs (Debnath and Schäfer, 2015; Shih et al., 2007a), 
that can be sampled due to the 4 to 1 atom mapping in the MARTINI force field 
(Marrink et al., 2007; Monticelli et al., 2008).  
The structure of apoA-I WT in CGMD HDL self-assembly simulations has focussed 
upon truncated apoA-I WT Δ(1 – 43), Δ(1 – 54) and Δ(1 – 65) also known as MSP1, 
MSP1 Δ(1 – 11) and MSP1Δ(1 – 22), respectively (Debnath and Schäfer, 2015; Shih et 
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al., 2006; Shih et al., 2007a; Shih et al., 2007b). The CGMD simulations observed the 
self-assembly process of HDL nanoparticles over timescales up to 10.0 µs (Shih et al., 
2007a) and 42 µs (Figure 7.1A) (Debnath and Schäfer, 2015). Interestingly, Debnath 
and Schäfer utilised a feature in GROMACS (Abraham et al., 2015) called the 
backmapping algorithm which converts a CG structure to an all-atom model (Debnath 
and Schäfer, 2015; Rzepiela et al., 2010). The resultant AAMD structure was simulated 
for 500 ns and demonstrated the stability of the converted structure containing the 
truncated apoA-I proteins and lipids (Figure 7.1B).  
 
Figure 7.1. (A) The self-assembly CGMD simulation of a HDL nanoparticle containing 
160 DMPC lipids (green acyl chains, gold spheres headgroups), and two apoA-I Δ(1 – 
65) monomers (red, blue) at the start (0 µs) and end (42 µs) of the simulation. (B) The 
final structure of a backmapped AAMD simulated HDL nanoparticle for 500 ns. 
Obtained and adapted from (Debnath and Schäfer, 2015). 
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There was limited time in which to focus on the computational aspects of this work. 
Therefore, initial simulations aimed to produce HDL nanoparticles through self-
assembly following a similar methodology to Shih et al. and Debnath and Schäfer. The 
previous CGMD self-assembly HDL simulations used truncated apoA-I WT therefore 
this work aimed to establish self-assembly of HDL nanoparticles containing full-length 
apoA-I WT and mutants. The CGMD assembled HDL nanoparticle structural models 
would provide further comparison between apoA-I WT and the atheroprotective 
mutants. To determine if structural differences are related to the atheroprotective apoA-
I mutant function.  
7.1.2 Macrophage cholesterol efflux 
A key stage in atherosclerosis is the formation of foam cells leading to the development 
of atherosclerotic plaques (see section 1.1). Foam cells are macrophages that contain 
lipoprotein derived cholesterol and CEs (Libby et al., 2011; Tabas, 2010; Tabas et al., 
2007).  
Macrophages contain three different cell receptors involved in cholesterol efflux known 
as ABCA1, ABCG1, and SR-B1 (Shen et al., 2018). In RCT LF apoA-I and lipid-poor 
pre-β-HDL particles interact with ABCA1 initiating the major pathway for cellular lipid 
and cholesterol efflux (Sahoo et al., 2004; Sankaranarayanan et al., 2011; von 
Eckardstein et al., 2001). Mature HDL nanoparticles interact with the macrophage cell 
receptors SR-B1 and ABCG1 to mediate cholesterol efflux through passive diffusion 
and unidirectional efflux, respectively (Shen et al., 2018). 
The significant pathogenicity of cholesterol accumulation in atherosclerotic plaque 
macrophages highlights the importance of understanding this stage in RCT (Libby et 
al., 2011; Lusis, 2000). In vitro cholesterol efflux assays from cholesterol-loaded 
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macrophages could provide insight into the effectiveness of the cholesterol acceptors 
containing apoA-I WT or the atheroprotective mutants in mediating cholesterol efflux.  
The efflux of cholesterol from cells has been widely monitored using radiolabelled [3H]- 
or [14C]-cholesterol with cholesterol acceptors such as lipid-free apoA-I and rHDL 
containing apoA-I WT or R173C (Calabresi et al., 1999; Daniil et al., 2013; 
Sankaranarayanan et al., 2011; Zhu et al., 2005). Sankaranarayanan et al. demonstrated 
the effective use of BODIPY-cholesterol (Figure 7.2A) fluorescence detection as an 
alternative to radiolabelled cholesterol in a simplified ABCA1-mediated cholesterol 
efflux assay (Sankaranarayanan et al., 2011). Murine J774 macrophages loaded with 
BODIPY-cholesterol were incubated with lipid-free apoA-I WT or human HDL3 as 
cholesterol acceptors (Sankaranarayanan et al., 2011). The ABCA1-mediated efflux 
was determined by the difference between BODIPY-cholesterol efflux from J774 
macrophages incubated with or without cAMP prior to incubation with cholesterol 
acceptors (Sankaranarayanan et al., 2011). 
 
Figure 7.2. The structure of (A) BODIPY-cholesterol and (B) BODIPY-cholesteryl 
ester (-CE). The BODIPY fluorophore motif is circled (green). 
The BODIPY-cholesterol efflux from murine J774 macrophages was measured by 
fluorescence detection in the filtered media rather than retained cholesterol in the cells 
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(Sankaranarayanan et al., 2011). In comparison, Liu et al. adapted the use of BODIPY-
cholesterol for flow cytometry with BODIPY-cholesterol loaded THP-1 monocytes 
(Liu et al., 2014). Flow cytometry is a versatile technique that can detect and separate 
cells from cellular debris through laser light scattering and fluorescent molecule 
detection (McKinnon, 2018).  
In this work preliminary experiments explored the experimental conditions for 
evaluating the cholesterol acceptor mediated efflux of BODIPY-CE (Figure 7.2B) from 
THP-1 macrophages using flow cytometry.  
7.1.3 Amyloidogenic properties of apoA-I 
This work aimed to compare the amyloidogenic potential of WT and mutant apoA-I. 
This may be a reason for the atheroprotective properties of the mutants.  
ApoA-I can become amyloidogenic in pro-inflammatory conditions such as an acidic 
pH, in the presence of glycosaminoglycans (GAGs), including heparin, and oxidation 
of methionine residues (Ramella et al., 2011; Townsend et al., 2017; Wong et al., 2010). 
In atherosclerosis this results in deposition of misfolded aggregated apoA-I WT in the 
form of amyloid fibrils or apoA-I peptide fragments in atherosclerotic plaques 
(Mucchiano et al., 2001; Ramella et al., 2011; Rocken et al., 2006).  
Heparin is a GAG polysaccharide comprised of linear chains containing the subunits L-
iduronic acid 2-sulphate (IdoA,2S) and D-glucosamine N,6-sulphated (GlcNS,6S) 
(Figure 7.3A) (Casu et al., 2015; McLaurin et al., 1999). GAGs have been detected in 
atherosclerotic plaque deposits (Ramella et al., 2011; Teoh et al., 2011), and in other 
amyloidogenic protein deposits (Cohlberg et al., 2002; McLaurin et al., 1999). 
Interestingly, GAGs were suggested to aid amyloid-β peptide fibril formation by acting 
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as a supporting frame (McLaurin et al., 1999). Heparin is required for rapid fibril 
formation by apoA-I. 
 
Figure 7.3. (A) The disaccharide unit of heparin containing the sequential subunits 
[IdoA2SO3-GlcNS,6SO3], adapted from (Casu et al., 2015). (B) The structure of ThT, 
a cationic fluorescent dye. The planar segments are outlined by the dashed boxes and 
can rotate about the C-C bond indicated with the arrow. Adapted from (Biancalana and 
Koide, 2010). C) An example ThT fluorescence assay of apoA-I WT (7 µM) with varied 
molar ratios of apoA-I: heparin 1:0.1 – 1:5 at pH 4. Arrow indicates the addition of HCl 
to change the pH to 4.0. Obtained from (Townsend et al., 2017). 
The widely used thioflavin T (ThT) (Figure 7.3B) binding assay was used to detect the 
formation of amyloid fibrils in vitro (Khurana et al., 2005; LeVine, 1993). An increase 
in ThT fluorescence is observed when ThT binds to amyloid fibrils (LeVine, 1993). For 
example, apoA-I incubated with heparin under acidic conditions showed an enhanced 
rate of fibril formation indicated by the increased ThT fluorescence (Figure 7.3C) 
(Townsend et al., 2017). In this work, the ThT assay was used as a starting point to 
determine if the LF atheroprotective mutants were less likely to form amyloid fibrils.  
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7.1.4 Aims 
The following aims of this chapter are described here: 
1. To produce HDL nanoparticle structures containing full-length apoA-I WT or 
apoA-I R173C with coarse-grained molecular dynamics simulations. To provide 
further structural comparisons between apoA-I WT and mutants in HDL 
nanoparticles.  
2. To use flow cytometry to monitor the cholesterol efflux from BODIPY-CE 
loaded THP-1 macrophages mediated by apoA-I and rHDL nanoparticles. The 
development towards the cholesterol efflux assay method is key to 
understanding if the rHDL bearing atheroprotective apoA-I mutants have a 
greater cholesterol efflux capacity.  
3. To begin to assess the susceptibility of the atheroprotective apoA-I mutants to 
form amyloid fibrils. ApoA-I WT under the appropriate conditions can become 
amyloidogenic and contribute to the formation of atherosclerotic plaques 
(Arciello et al., 2016; Townsend et al., 2017).  
7.2 Materials and methods 
7.2.1 Molecular dynamics simulations 
VMD (Humphrey et al., 1996) and PyMol (Schrodinger, 2015) software were used to 
produce figures and visualise trajectories. The production run simulations were run on 
the High-End Computing Cluster (HEC, Lancaster University, UK). 
7.2.1.1 Full-length apoA-I structure 
The full-length apoA-I structures were kindly produced by Dr. E. Hughes using 
Modeller 9.18 (Webb and Sali, 2016) to produce 5 model structures for apoA-I WT and 
with mutated residues L144R and R173C for the respective apoA-I mutants. The 
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alignment sequences used the truncated apoA-I Δ(1-43) (PDB 1AV1) (Borhani et al., 
1997) crystal structure and the N-terminal residues 3 – 42 of the full-length solution 
SANS apoA-I structures (PDB 3K2S) (Wu et al., 2009). The protein structure model 
was selected with the lowest Discrete Optimised Protein Energy (DOPE) score (Shen 
and Sali, 2006).  
7.2.1.2 Self-assembly molecular dynamics simulations 
The following methods were adapted from (Debnath and Schäfer, 2015; Shih et al., 
2007a; Shih et al., 2007b). The Martini FF version 2.2 (de Jong et al., 2013; Marrink et 
al., 2007; Monticelli et al., 2008) was used. The CG POPC, water and ion topology files 
were obtained from the Martini download source 
(http://cgmartini.nl/index.php/downloads) (Marrink, 2004; Wassenaar et al., 2015).  
To form the apoA-I R173C dimer, the apoA-I R173C monomers were oriented anti-
parallel with the cysteine residue sulphydryl groups 0.85 nm apart. The atomistic apoA-
I protein structures were coarse-grained using the martinize.py script (de Jong et al., 
2013). DSSP (Joosten et al., 2011; Kabsch and Sander, 1983) was used to assign the 
backbone secondary structure. The secondary structure of the protein backbone was 
predominantly α-helical as in the PDB structures (Borhani et al., 1997; Mei and 
Atkinson, 2011; Wu et al., 2009).  
The CG protein was placed in the centre of a cubic box 1 nm from the box edge. Energy 
minimisation (EM) was performed with the steepest descent algorithm with up to 1000 
steps in vacuo. Next 160 CG POPC lipids were added to the simulation box randomly 
followed by a second EM in vacuo under the same conditions. The system was solvated 
with CG water beads and EM. The first system contained the apoA-I R173C dimer 
(1074 CG beads), 160 POPC lipids (1920 CG beads), 31117 water beads and 16 Na+ 
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ion CG beads in a cubic box (16 x 16 x 16 nm). The second system contained the apoA-
I WT Δ(1-43) chain A and B monomers (898 CG beads), 160 POPC lipids (1920 CG 
beads), 23049 water beads and 12 Na+ beads in a cubic box (14.6 x 14.6 x 14.6 nm).  
The molecular dynamics parameters (mdp) were adapted from the recommendations of 
de Jong et al. (de Jong et al., 2016) for the CGMD NVT, NPT, and production run 
ensembles. A 20 fs integration time step was used throughout these stages. Each system 
was equilibrated to 320 K (NVT) for 1 ns. This was followed by 1 ns NPT equilibrations 
until the average pressure was ~1 bar. In the NVT and NPT equilibrations the protein 
was under position restraints. The temperature coupling time constant (τT) was 1 ps with 
the v-rescale thermostat (Bussi et al., 2007). The pressure coupling time constant (τP) 
was 4 ps with a compressibility of 3x10-5 bar-1 for the isotropic Berendsen barostat 
conditions (Berendsen et al., 1984; Debnath and Schäfer, 2015).  
The Coulomb electrostatics were treated with reaction-field electrostatics (Fukuda and 
Nakamura, 2012) with a cut-off of 1.2 nm, a relative dielectric screening constant (εrel) 
of 15, and the reaction-field dielectric constant was set to infinity (Barnoud and 
Monticelli, 2015; de Jong et al., 2016). The Coulomb potential was shifted smoothly to 
zero between 0 – 1.2 nm (Debnath and Schäfer, 2015). The LJ potential was smoothly 
decreased between 0.9 – 1.2 nm to zero with the vdW-modifier force-switch (Barnoud 
and Monticelli, 2015; Debnath and Schäfer, 2015). The Verlet cutoff scheme was used 
with a 1.4 nm cutoff and the neighbour list updated every 20 steps (de Jong et al., 2016; 
Debnath and Schäfer, 2015). Periodic boundary conditions were used in each direction 
(x, y, z).  
The dynamic production MD run was simulated without position restraints on the 
protein from the NPT equilibrated system with coordinates saved every 0.5 ns. The 
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simulation progress was monitored to determine if it was necessary to the total time of 
10 μs. The apoA-I R173C and WT Δ(1-43) simulations were stopped at ~6.6 and 8.9 
μs, respectively, as the protein conformation did not alter significantly after the initial 
self-assembly into “HDL-like” nanoparticles.  
7.2.2 Cholesterol efflux 
The following methods for the BODIPY-CE efflux assay were adapted from (Liu et al., 
2014; Sankaranarayanan et al., 2011). The following experiments were performed with 
the helpful guidance of Dr. S. Allinson (Biomedical and Life Sciences, Lancaster 
University, UK).  
7.2.2.1 THP-1 cell culture and differentiation into THP-1 macrophages 
The human THP-1 monocytes were generously gifted by Dr. L. Unterholzner and kindly 
initially cultured by PhD student Rebecca Barker (Biomedical and Life Sciences, 
Lancaster University, UK) from frozen cell stocks. The cell culture products were 
purchased from Thermo Fisher Scientific from Gibco® unless indicated otherwise. 
The cell culture experiments, and preparation of sterile solutions were performed under 
sterile conditions in a laminar air flow hood. The THP-1 monocytes were grown in 
suspension in 75 cm2 flasks at 37°C in 5% CO2 in air (standard conditions). The cell 
culture media per 500 mL contained RPMI 1640 medium with 2 mM L-glutamine 
supplemented with 10 % (v/v) heat-inactivated foetal calf serum (FCS) and 100 
units/mL penicillin and 100 ug/mL streptomycin (PS). The cells were split 1:2 or 3 (v/v) 
with fresh media approximately every 2 – 3 days to prevent the cell density rising above 
1 x106 cells/mL.  
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Just prior to THP-1 monocyte differentiation microscope cover slips were placed into 
the sample wells for confocal microscopy. The THP-1 cells were counted with a 
haemocytometer and added to a final cell density of 6 x105 cells/mL per well in a 12 
well plate with a maximum volume of 2 mL. Phorbol 12-myristate 13-acetate (PMA) 
(stock 1 mg/mL) was added to each well to a final concentration of 100 ng/mL and 
incubated for 48 hours under standard conditions to differentiate the cells to THP-1 
macrophages. The differentiation of the cells was checked using a microscope as the 
THP-1 macrophages become adherent.  
7.2.2.2 Preparation of the BODIPY-CE complex 
Prior to incubation with the THP-1 macrophages the BODIPY-CE complex was 
prepared (Sankaranarayanan et al., 2011). MEM media, pH 7.4 supplemented with 10 
mM HEPES was prepared by the syringe filter-sterilisation (0.22 µm) of 5 mL 1 M 
HEPES into 495 mL MEM media. The methyl-β-cyclodextrin (m-β-CD, Sigma) 20 mM 
stock solution was prepared by dissolving 211.5 mg of m-β-CD in 8 mL of MEM-
HEPES.  
A concentrated 109.4 mM stock solution of cholesterol (42.3 mg in 1 mL CHCl3) was 
prepared in a 5 mL amber glass vial with a PTFE-lined lid (Avanti®). The BODIPY® 
FL C12 cholesteryl ester (BODIPY-CE, Invitrogen™), 1 mg was dissolved in 1.27 mL 
of CHCl3 to produce a stock concentration of 1 mM and transferred to a 5 mL amber 
glass vial with a PTFE-lined lid (Avanti®) wrapped in foil.  
The cholesterol and BODIPY-CE were aliquoted into a foil wrapped 25 mL round-
bottomed flask and dried under N2 in the dark to form a thin film and remove the organic 
solvent. The film was dried under a high vacuum for at least 4 hours before 
resuspension. M-β-CD (20 mM) in MEM-HEPES (4 mL) was added to resuspend the 
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dried film. The appropriate volumes of stock solutions were added at the respective 
stages to the final concentrations of BODIPY-CE/m-β-CD (BD-CE complex) of 
0.05/0.2/20 mM. The BODIPY-CE was complexed with m-β-CD to increase the 
solubility in the cell culture media (Sankaranarayanan et al., 2011).  
The BD-CE complex was sonicated at 37°C in a bath sonicator for 30 minutes. After 
sonication the BD-CE complex was incubated at 37°C with shaking for 3 hours and 
filter-sterilised with a 0.45 µm syringe filter. If the BD-CE complex was not used 
immediately it was stored at 4°C. Just prior to use the complex was sonicated under the 
same conditions as before and diluted with an equal volume of sterile MEM-HEPES 
media containing 2 ug/mL Sandoz 58-035 (Sigma) acyl-coenzyme A:cholesterol 
acyltransferase (ACAT) inhibitor (100 µg/mL stock in DMSO). The ACAT inhibitor is 
present in the MEM-HEPES media from this point forward at a final concentration of 
1 ug/mL. The final molar concentrations of BODIPY-CE/cholesterol/m-β-CD were 
0.025/0.1/10 mM.  
7.2.2.3 THP-1 macrophage BODIPY-CE uptake 
After THP-1 macrophage differentiation the RPMI cell culture media was removed, and 
the cells were washed with 1 mL of MEM-HEPES media. The cells were incubated 
under standard conditions for 1 hour with 2 mL per well of MEM-HEPES media 
containing the BD-CE complex (0.025/0.1/10 mM) and ACAT inhibitor at the final 
concentrations described above. The labelling media was removed, and the THP-1 
macrophages were washed with 2 mL of MEM-HEPES media per well to remove the 
BD-CE complex not taken up into the cells. Next, the cells were incubated under 
standard conditions with RPMI containing 2 mg/mL fatty-acid free bovine serum 
albumin (BSA), 1 µg/mL Sandoz ACAT inhibitor, and ± 0.3 mM cAMP for 18 hours. 
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This will be referred to as the equilibration period. The cells were washed with MEM-
HEPES before cholesterol acceptor incubation.  
7.2.2.4 Incubation with cholesterol acceptors 
The cholesterol acceptors in MEM-HEPES media were added to the cells at the 
concentrations described below with a total volume of 2 mL per well. The control wells 
contained THP-1 macrophages ±BD-CE complex without cholesterol acceptors. During 
the efflux incubation periods the controls were incubated with media only. The lipid-
free apoA-I WT, R173C and L144R were lyophilised, resuspended in MEM-HEPES 
and filter-sterilised (0.22 µm) before addition to each well. The conditions tested are 
described in the next section.  
After incubation with the respective cholesterol acceptors the cells were washed with 2 
mL of MEM-HEPES media. Accutase® solution (Sigma) 0.55 mL was added to each 
well and the plate was incubated under standard conditions for 10 minutes. The solution 
was gently pipetted across the surface to ensure the cells were detached fully. The 
detached cells were transferred to individual round-bottomed flow cytometry tubes and 
kept on ice closed with parafilm until analysis. The cells in Accutase solution were 
directly analysed by flow cytometry as the solution contained Dulbecco’s PBS (0.2 g/L 
KCl, 0.2 g/L KH2PO4, 8 g/L NaCl, and 1.15 g/L Na2HPO4), and 0.5 mM EDTA·4Na 
and 3 mg/L phenol red.  
7.2.2.5 Flow cytometry 
The CytoFlex flow cytometer (Beckman Coulter) and the CytExpert software 
(Beckman Coulter) were used for sample measurements and analysis. The sample flow 
rate was 60 µL/min and a total of 10000 events per sample were recorded. Initially, to 
determine the gating used for the THP-1 macrophages the cell nuclei were stained with 
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NUCLEAR-ID® Red DNA stain (Enzo life Sciences), at a 500-fold dilution in the 
resuspended cell media.  
The BODIPY-CE has an excitation and emission maxima of ~502 nm and 511 nm, 
respectively. The respective excitation and emission peak ranges are between ~460 – 
512 nm and ~500 – 570 nm, respectively (Fluorescence SpectraViewer, ThermoFisher 
Scientific). The fluorescence was recorded for each sample and shown in the PC5.5 and 
FITC channel ranges for the nuclear DNA stain (Enzo) and the BODIPY-CE, 
respectively. The DNA stain excitation and emission maxima are at ~566 and 650 nm 
(Enzo), respectively. The respective excitation and emission peak ranges are between 
~450 – 650 nm, and 600 – 700 nm (Enzo).  
The forward scatter (FSC) and side scatter (SSC) area plots were used to determine the 
THP-1 macrophage cell population gating (P2/P3) and separated the cellular debris 
(P1). The FSC-Width (FSC-W) vs. FSC area (FSC-A) plots in P2/P3 were used to 
confirm most of the compound fluorescence was measured in singlet cells. The nuclear 
dye (PC5.5-A) and BODIPY-CE (FITC-A) fluorescence area was compared using 
histograms between samples in P2/P3. A correlation area dot plot between the PC5.5 
and FITC fluorescence detection was also included.  
The percentage of BODIPY-CE retained in the cells after incubation was initially 
calculated using: 
  % 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 𝑟𝑒𝑡𝑎𝑖𝑛𝑒𝑑 =  
𝑀𝐹𝐼𝑎𝑐𝑐.
𝑀𝐹𝐼𝑛𝑜 𝑎𝑐𝑐.
∙ 100 [18] 
The mean fluorescence intensity (MFI) of the BODIPY-CE detected in flow cytometry 
in cells incubated with (MFIacc.) and without cholesterol acceptors (MFIno acc.). The 
background MFI of cells without BODIPY-CE was subtracted from each MFI before 
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the % cholesterol retained was calculated. Therefore, the % cholesterol efflux = 100 - 
% cholesterol retained. This was similar to the method used by Liu et al. (Liu et al., 
2014). 
The control samples were THP-1 macrophages incubated ± BD-CE complex only, and 
±0.3 mM cAMP in the equilibration period. Initial control samples contained the nuclei 
staining dye to gate the THP-1 macrophages. The apoA-I WT concentration range was 
tested at the following concentrations 10, 25, 50 and 100 µg/mL. The apoA-I WT and 
atheroprotective apoA-I mutants cholesterol efflux were tested at the excess 
concentrations of 120 and 600 µg/mL and incubated for 8 and 24 hours with the 
BODIPY-CE loaded cells at each concentration. To develop a method and establish 
background controls the effect of cAMP in the equilibration period before incubation 
with a cholesterol acceptor, and the background level of efflux without acceptors at 0, 
1, 2, 4, 8 and 24 hours were tested.  
In the final experiment comparing apoA-I WT and the atheroprotective apoA-I mutants 
as described above the cholesterol efflux was also calculated similar to 
Sankaranarayanan et al. (Sankaranarayanan et al., 2011). Before each MFI value was 
used the background (BGD) fluorescence of THP-1 cells without the BD-CE complex 
was subtracted. Additional control samples were included of BODIPY-CE loaded THP-
1 macrophages without cholesterol acceptors measured at 0 (MFIt0), 8 and 24 (MFIno 
acc.) hrs post-equilibration period to calculate the BGD efflux as follows: 
 𝐵𝐺𝐷 𝑒𝑓𝑓𝑙𝑢𝑥 % =  
𝑀𝐹𝐼𝑛𝑜 𝑎𝑐𝑐.
𝑀𝐹𝐼𝑡0
∙ 100 [19] 
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The % cholesterol efflux was calculated with Equation [20]: 
 
% 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 𝑒𝑓𝑓𝑙𝑢𝑥
= 100 − (
𝑀𝐹𝐼𝑎𝑐𝑐.
𝑀𝐹𝐼𝑡0
∙ 100) − 𝐵𝐺𝐷 𝑒𝑓𝑓𝑙𝑢𝑥 
[20] 
The background efflux was subtracted for the respective 8 and 24 hr incubation periods, 
respectively.  
7.2.2.6 Fluorescence microscopy 
The microscope cover slips placed into the wells prior to THP-1 macrophage 
differentiation were removed from the wells after BD-CE complex uptake. The adherent 
cells were washed with 1 mL PBS and fixed in 4 % (v/v) paraformaldehyde for 20 
minutes. Next the cells were washed with 1 mL of PBS and a droplet of DAPI was used 
to stain the cell DNA and mount the cover slips onto microscope slides. The slides were 
stored at 4°C. Initially, the THP-1 macrophages were viewed after incubation with the 
BD-CE complex with an Axiovert 35 fluorescence microscope (Zeiss) with the 
transmission and FITC channels.  
The LSM 880 AxioObserver confocal microscope (Zeiss) and Zeiss software was used 
to confirm if the cells contained the BD-CE complex. The samples were viewed with 
the objective lens Plan-Apochromat dry 40x magnification/0.95 Korr, with the laser at 
488 nm at 10 – 12.7 % power. The BODIPY-CE and DAPI stained nuclei fluorescence 
excitation/emission wavelengths are 488/541 and 405/447 nm, respectively. The images 
were viewed using the ZEN Lite (Zeiss) and FIJI (Schindelin et al., 2012) software.  
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7.2.3 Thioflavin T fluorescence assay 
The following methods for the ThT fluorescence assay were adapted from (Townsend 
et al., 2017). The samples and stock solutions were prepared in McIlvaine buffer (165 
mM Na2HPO4 and 17.6 mM citrate) at pH 7.0. The ThT (Sigma-Aldrich) and heparin 
([IdoA(2S)-GlcNS(6S)] > 70 %, Iduron) stock solutions were prepared to a final 
concentration of 1 mM. The average MW of heparin was ~14 – 15 kDa. The lipid-free 
apoA-I WT/R173C/L144R stocks were prepared at concentrations > 72 µM.  
The ThT assay fluorescence measurements used the FlexStation 3 microplate reader 
(Molecular Devices) and a 96-well clear bottomed black walled plate (Nunc®). The 
sample wells (n = 6) contained a total volume of 200 µL, with 7.2 µM apoA-I, 20 µM 
ThT, at pH 7.0 or pH ~4.6 ± 14.4 µM heparin. The control samples (n = 6) were ThT 
only and apoA-I WT/R173C/L144R without ThT.  
The wavelengths used for ThT excitation and emission were 430 and 480 nm, 
respectively. A constant temperature of 37°C was used throughout the assay. The 
fluorescence readings were taken every minute with agitation every 30 seconds, and 10 
seconds before the measurement was taken. The baseline fluorescence of all samples 
was established for 10 minutes at pH 7.0. After 10 minutes 2.6 µL of concentrated 37 
% HCl was added to the relevant sample wells to decrease the pH to <5.0.  
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7.3 Results 
7.3.1 Self-assembly G MD simulations 
The CGMD simulations of 160 POPC lipids with full-length apoA-I R173C dimer and 
two apoA-I WT Δ(1-43) monomers are described in sections 7.3.1.1 and 7.3.1.2 
respectively.  
7.3.1.1 ApoA-I R173C CGMD simulation 
Initially, before starting the CGMD simulation setup the apoA-I R173C dimer was 
prepared. The modelled all atom full-length apoA-I R173C structure monomers were 
oriented anti-parallel with the cysteine residue sulfhydryl groups in α-helix 7 (H7) 
approximately 8.5 Å apart (Figure 7.4A). The H7 representations show the reduced 
number of atoms in the CG representation (Figure 7.4B vs. C). The disulphide bond 
was formed when the AA structure was converted to the CG structure (Figure 7.4B to 
C). The disulphide bond was relaxed to ~2.4 Å during energy minimisation in vacuo 
before further setup of the CGMD system.  
After the addition of 160 POPC lipids, 16 Na+ ions and solvation with water the system 
was equilibrated to a temperature and pressure of 323 K and 1 bar, respectively. The 
apoA-I R173C dimer CGMD system (Figure 7.5, 0 ns) was simulated for a total time 
of 6.6 µs. The POPC molecules aggregated and formed micelles during the equilibration 
stages and the dynamics run due to the hydrophobic effect.  
Further interactions driven by the hydrophobic effect occurred between the lipids and 
amphipathic protein α-helices within 105 ns (Figure 7.5). Interestingly, the termini α-
helices (red, blue) acted as “anchors” for the lipids and were originally extended 
outwards before joining the overall elongated lipid micelle/bilayer (Figure 7.5, 5 – 95 
ns).  
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Figure 7.4. The all-atom anti-parallel full-length apoA-I R173C monomers orientations 
prior to disulphide bond formation, chain 1 and 2. The secondary structure is as 
described in Chapter 1, section 1.6, Figure 1.5–1.6. The N-termini (N) G* helix (blue), 
and the α-helices are coloured as H1 (yellow), H2 (orange), H3 (light orange), H4 
(green), H5 (purple), H6 (brown), H7 (violet), H8 (light brown), H9 (light green) and 
the C-termini H10 (C, red). H7 in the all-atom (A) and coarse-grained (B) 
representations. The respective monomer cysteine residues were positioned ~8.5 Å 
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Figure 7.5. Snapshots of timepoints (0, 5, 95 and 105 ns) during the 6.6 µs self-
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The POPC lipids were in an approximate elongated bilayer disc shape between ~138 ns 
to 6.6 µs (Figure 7.6). The overall final “HDL-like” nanoparticle conformation was 
approximately 12.9 nm x 6.8 nm in diameter with a thickness between 4.3 – 4.6 nm.  
The apoA-I R173C dimer chains 1 and 2 (Figure 7.4) did not wrap around the POPC 
bilayer to form an interhelical registry, except at the position of the disulphide bond in 
H7 (Figure 7.6). The apoA-I R173C chain 1 primarily formed interhelical interactions 
within the same chain and folded back at H5/6 (Figure 7.6D) to form the N- and C-
termini α-helix cluster (Figure 7.6A). Chain 2 did not wrap around the bilayer 
completely due to self-association between the N-terminal region and H2/3 (Figure 
7.6B-C).  
The apoA-I R173C dimer interacted predominantly with the lipid acyl tails whilst 
exposed POPC areas without the protein contained the POPC headgroups facing 
outwards (Figure 7.6C). Furthermore, the relative mean standard deviation (RMSD) 
and radius of gyration of the apoA-I R173C dimer during the simulation indicated 
relatively small changes in the protein conformation after the incorporation of the POPC 
lipids into the bilayer (~138 ns) (Appendix 4).  
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Figure 7.6. The full-length dimeric apoA-I R173C with 160 POPC lipids self-assembly HDL CGMD simulation final conformation (A-D) side-
views and (E-F) top views at ~6.6 µs. The apoA-I R173C dimer helices are coloured as in Figure 7.4. The POPC headgroups are blue and acyl 
tails are silver. The labels for chain 1 α-helices are underlined to distinguish these from chain 2 α-helices in the apoA-I R173C dimer.  
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7.3.1.2 Self-assembly apoA-I WT Δ(1-43) CGMD simulation 
A control CGMD simulation of the apoA-I WT Δ(1-43) crystal structure (Borhani et 
al., 1997) and 160 POPC lipids under the same conditions as above was performed 
(Figure 7.7). To determine if the MD parameters used could reproduce results similar 
to previous nanodisc simulations with truncated apoA-I WT (Debnath and Schäfer, 
2015; Shih et al., 2007b).  
 
Figure 7.7. Snapshots of timepoints (0, 30, 255 and 375 ns) during the 8.9 µs self-
assembly simulation of two apoA-I WT Δ(1-43) monomers with 160 POPC lipids, the 
CGMD WT simulation. 
The starting conformation of the apoA-I WT Δ(1-43) monomer chains A and B at 0 ns 
were as in Chapter 1, Figure 1.6 (Borhani et al., 1997). In the apoA-I WT Δ(1-43) 
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CGMD simulation the POPC molecules interacted with the monomer residues through 
the hydrophobic effect. The protein monomer conformations remained similar up to 375 
ns (Figure 7.7), e.g., at 255 ns the C-termini of chain A interacted with H1 of chain B 
and vice versa. At 375 ns chain A is wrapped around the outside in a V-shape as the C-
termini helices (Figure 7.7, red) of both monomers and chain B H1 (Figure 7.7, 
yellow) folded back to allow the POPC micelle to form an elongated bilayer with a 
micellar end containing all of the lipids. The inter- and intrahelical interactions are more 
clearly observed in the final conformation of the “HDL-like” nanoparticle (Figure 
7.8A) at 8.9 µs. The nanoparticle was approximately 11.9 x 9.1 – 9.9 nm, with a 
thickness between 4.2 – 5.1 nm.  
The H5/H5 registry of the apoA-I WT Δ(1-43) crystal structure was disrupted at ~40 ns 
when POPC molecules separated the chains. At ~6.5 µs chain B began to move back 
towards the chain A H5 which brought the helices into close proximity (Figure 7.8D). 
The CGMD simulation did not achieve a conformation similar to the “double belt” 
model as chain B was folded back across the planar face of the POPC lipid bilayer 
(Figure 7.8E and H). The apoA-I WT Δ(1-43) CG monomer backbone conformation 
changes were observed in the RMSD and radius of gyration (Appendix 4). The protein 
was not wrapped around the lipid bilayer therefore the final conformation contained 
exposed areas of the lipid bilayer with some lipids facing outwards (Figure 7.8B-C).  
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Figure 7.8. WT CGMD conformation at 8.9 µs. The apoA-I Δ(1-43) chains A and B (Borhani et al., 1997) with 160 POPC lipids self-assembly 
HDL CGMD simulation final conformation (A-F) side-views and (G-H) top views at ~8.9 µs. The α-helices are coloured as in Figure 7.4. The 
POPC headgroups are blue and acyl tails are silver. The labels for chain A α-helices are underlined to distinguish these from the chain B α-helices.  
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7.3.2 BODIPY-cholesteryl ester uptake 
The following sections describe the different sample conditions used in the THP-1 
macrophage BODIPY-CE uptake and efflux flow cytometry assay.  
7.3.2.1 Fluorescence microscopy 
Initially the THP-1 macrophage uptake of the BD-CE complex was tested using a 
standard fluorescence microscope (data not shown). There was some photobleaching of 
the cells during imaging, therefore confocal microscopy was used to confirm the uptake 
of BODIPY cholesterol. The incubated THP-1 macrophages showed intake of the BD-
CE complex detected as bright green fluorescence spots in the cytoplasm as lipid 
droplets (Ghosh et al., 2010) or close to/in the cell membrane (Figure 7.9B-C). This 
suggested the THP-1 macrophage incubation conditions with the BODIPY-
CE/cholesterol/m-β-CD complex (0.025/0.1/10 mM) were successful for flow 
cytometry.  
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Figure 7.9. THP-1 macrophages incubated without the BD-CE complex (A) and with 
the BD-CE complex (B) imaged under the same conditions. (C) Another example of 
cells incubated with the BD-CE complex. The sample was viewed under different 
microscope settings to enhance the fluorescence detected. The scale bar represents 20 
µm. The different confocal microscope channels shown (left to right) are the non-
fluorescent transmission, FITC (493 – 589 nm) for BODIPY-CE detection, and the 
DAPI-stained nuclei channel (410 – 483 nm), with a final overlay of the FITC and DAPI 
channel images.  
7.3.2.2 Flow cytometry of BODIPY-CE in THP-1 macrophages 
To further confirm the intake of the BD-CE complex into THP-1 macrophages flow 
cytometry was used. The preliminary flow cytometry experiment examined the 
difference in fluorescence between THP-1 macrophages incubated with and without the 
BD-CE complex. The fluorescence was detected after the 18 hour incubation period.  
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The THP-1 macrophages (P2) were separated from cellular debris (P1) with the gating 
in Figure 7.10A-B. After data collection analysis of the FSC-width versus FSC-A 
showed the majority of the cells which contributed to the fluorescence detected in P2 
were singlets in the indicated regions (Figure 7.10A-B). The greater fluorescence 
detected in the THP-1 macrophages (Figure 7.10C, FITC-A) clearly indicated the cells 
with BODIPY-CE retained the fluorophore. Furthermore, the correlation between the 
nuclear staining dye (PC5.5-A) and the FITC-A BODIPY-CE detected fluorescence 
indicated the P2 gated cells contained both fluorescent compounds (Figure 7.10C). The 
background fluorescence of the THP-1 only cells in the FITC region did not overlap 
significantly with the BODIPY-CE fluorescence detected. 
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
324  Sophie Lau - July 2021 
 
Figure 7.10. Flow cytometry of THP-1 macrophages ±BD-CE after a 4-hr incubation in media. A total of 10000 events (P1+ P2) were recorded. 
(A, B) In the FSC vs. SSC area plots the cells were gated in P2 (blue) and separated from the cell debris in P1 (purple). P1 and P2 are shown in the 
corresponding post-gated FSC-W vs. FSC-A dot plots with the doublet region circled. (C) The fluorescence histograms and dye correlation plot 
for cells -BD-CE complex (red) and +BD-CE complex (green) for the nuclear dye (PC5.5-A), and the BODIPY-CE (FITC-A). 
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7.3.3 Development of the BODIPY-CE efflux assay 
Next, BD-CE loaded THP-1 macrophages were incubated with lipid-free apoA-I WT at 
various protein concentrations to determine if apoA-I could mediate cholesterol efflux 
from the cells (Figure 7.11).  
Interestingly, the cells incubated without cAMP showed no cholesterol efflux until a 
10-fold increase in apoA-I WT concentration with only 4 % efflux overall. The 
relatively large ~20 – 32 % cholesterol efflux in the samples incubated with cAMP 
before incubation with apoA-I WT for 4 hours suggested the media and time period 
were suitable for cholesterol efflux detection. Additionally, the cholesterol efflux at 
concentrations of apoA-I WT above 25 µg/mL appeared to plateau at approximately 25 
% cholesterol efflux (Figure 7.11). However, the results for each sample required 
repeats to determine if the controls for the background cholesterol efflux and 
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Figure 7.11. The % cholesterol efflux calculated with Equation [18] of BODIPY-CE 
from THP-1 macrophages. After loading with BODIPY-CE the cells were incubated in 
RPMI media containing 2 mg/mL fatty-acid free BSA, 1 µg/mL ACAT inhibitor, ±0.3 
mM cAMP. Then the cells were incubated with LF apoA-I WT at 10, 25, 50, and 100 
µg/mL concentrations (n = 1) for 4 hours. The cells were gated as previously described.  
The establishment of controls for background cholesterol efflux was explored further. 
The average MFI of BODIPY-CE loaded THP-1 macrophages was measured over 
various time points (Figure 7.12) after the cells were equilibrated in media ±cAMP.  
The gating strategy in flow cytometry was altered to use the gating in the FSC-width 
vs. FSC-A plot due to the different distribution of cells from previous P2 gating used 
(Figure 7.12A). The MFI and cholesterol efflux were determined for cells loaded with 
BODIPY-CE equilibrated in media ±cAMP followed by incubation in media without 
apoA-I WT (Figure 7.12B-C).  
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Figure 7.12. (A) An example of the flow cytometry gating used to determine the MFI 
of 10000 events collected in P3 (n = 1) of BODIPY-CE loaded THP-1 macrophages 
incubated without a cholesterol acceptor at various timepoints. At time 0 hrs the 
BODIPY-CE loaded THP-1 macrophages had been equilibrated for 18 hrs in media 
±cAMP. The (B) MFI and (C) background efflux were calculated with Equation [19] 
for various timepoints to determine the extent of background cholesterol efflux.  
The background efflux present in the THP-1 macrophages indicated the need for 
separate control cells for different time points. In contrast, the majority of the cells 
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
328  Sophie Lau - July 2021 
incubated with cAMP before media only appeared to retain the BODIPY-CE overall. 
Therefore, the efflux experiment with apoA-I WT and the atheroprotective mutants 
equilibration period included cAMP and the cholesterol acceptor incubation time 
periods of 8 and 24 hours.  
Finally, a pilot experiment of cholesterol efflux from cells incubated with apoA-I WT 
or the atheroprotective mutants in excess protein concentrations were tested by flow 
cytometry (Figure 7.14). The cholesterol efflux was calculated as in previous 
experiments with Equation [18] (Figure 7.14A), and with the background cholesterol 
efflux calculated separately with Equations [19] and [20]. The difference in the control 
samples used for calculating the cholesterol efflux in the protocol can be more clearly 
identified in Figure 7.13.  
 
Figure 7.13. The stages of the BD-CE efflux from the THP-1 macrophages protocol. 
The points are identified for the control cells (MFIno acc.) used to calculate the cholesterol 
efflux with Equation [18] (green), and the second approach for calculating the 
background cholesterol efflux with Equation [19] (blue). 
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Using Equation [18] to calculate the cholesterol efflux when the cells were incubated 
with lipid-free apoA-I WT and L144R showed cholesterol efflux, but most 
measurements had large standard deviations (Figure 7.14A). The apoA-I L144R 600 
µg/mL showed similar (~18 %) cholesterol efflux at both incubation periods. This 
suggested the excess concentration of protein saturated the available cholesterol efflux. 
The difference between the 8 and 24 hr incubation apoA-I WT cholesterol efflux values, 
i.e., 600 µg/mL apoA-I WT at 5.7 ±12.0 % (24 hrs), 14.3 ±14.5 % (8 hrs) and 32.5 ±8.8 
% at 120 µg/mL (24 hrs), suggested the results were inconsistent as both concentrations 
of apoA-I were in excess. Therefore, there could be discrepancies in the protocol or in 
the cholesterol efflux calculation. 
 
Figure 7.14. The average % cholesterol efflux ±standard deviation (n = 2) of BODIPY-
CE loaded THP-1 macrophages incubated with apo WT, R173C and L144R for 8 and 
24 hours. The cholesterol efflux was calculated using (A) Equation [18] and (B) 
Equations [19] and [20]. The cells were gated in flow cytometry as described (Figure 
7.12), 10000 events were recorded in P3. Separate controls without LF apoA-I were 
used for the MFIno acc. at 8 and 24 hours. The apoA-I R173C samples at both 
concentrations and time points presented with no cholesterol efflux (not shown).  
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Consequently, the background cholesterol efflux was calculated separately using 
Equation [19] and the t0 MFI was measured after the 18-hr equilibration period of the 
THP-1 macrophages containing the BD-CE complex (Figure 7.13, Figure 7.14B). The 
background efflux for the 8 and 24 hr samples incubated were relatively large at 29.9 
±22.9 % and 55.6 ±12.5 % respectively. The background efflux contradicted the 
previous lack of background efflux detected (Figure 7.12C) which suggested the 
background efflux was not consistent. Equation [18] assumed the background efflux 
was relatively small during the incubation period (Figure 7.13) which caused an 
overestimation of the cholesterol efflux as the background efflux of cells incubated 
without cholesterol acceptors was not considered (Figure 7.14A).  
After the background efflux was subtracted, the ~16.3 ±4.4 % cholesterol efflux to 
apoA-I WT in the 24 hr incubated sample with lipid-free apoA-I WT was similar to the 
previously observed value of ~15 % [3H]-cholesterol from J774 macrophages 
(Sankaranarayanan et al., 2011). Hence, the calculation for cholesterol efflux using 
Equations [19] and [20] was suitable. The large standard deviations suggested repeats 
were necessary.  
Additionally, the background efflux was greater than the efflux observed resulting in 
no detection of cholesterol efflux for the samples which showed 0 % cholesterol efflux 
and LF apoA-I R173C (Figure 7.14). This suggested a shorter timeframe would be 
suitable for further experiments to limit the amount of background cholesterol efflux.  
Overall, this suggested the methodology required further optimisation and repeats to 
determine if the lipid-free and rHDL-bound atheroprotective mutants have a greater 
capability to mediate cholesterol efflux relative to apoA-I WT.  
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7.3.4 ThT fluorescence assay of lipid-free apoA-I 
A ThT fluorescence assay was used to determine if the lipid-free atheroprotective apoA-
I mutants aggregated with and without heparin at pH 7 and 4.6. The control samples of 
ThT only, and each protein in the absence of ThT did not show any increase in 
fluorescence over the timescale observed (Appendix 4). Immediately after the sample 
conditions were acidified each protein showed an increased ThT fluorescence in the 
presence of heparin (Figure 7.15A). This suggested that amyloid fibril formation could 
be induced in the atheroprotective apoA-I mutants and apoA-I WT. The overall average 
total fluorescence was similar for each protein at ~220 – 240 A.U. (Figure 7.15B) which 
suggested the level of aggregation and ThT binding was similar for each protein.  
 
Figure 7.15. A) ThT fluorescence of 7.2 µM apoA-I WT, apoA-I R173C and apoA-I 
L144R in McIlvaine buffer at pH 7.0 and pH ~4.6 ± 14.4 µM heparin (n = 6). B) The 
average total fluorescence over 10 minutes (Initial) and over 60 minutes (Final).  
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7.4 Discussion 
7.4.1 Self-assembly CGMD simulations 
The CGMD simulations of the apoA-I R173C dimer and apoA-I WT Δ(1-43) monomers 
with POPC lipids did not produce a final HDL nanoparticle morphology similar to the 
“double belt” model. In this work the apoA-I R173C chain 1 and 2 N-termini helices 
were self-associated with the respective H1 and/or the H2/H3 of each chain (Figure 
7.6A-B). This could have affected the propensity of the protein chain to wrap around 
the elongated lipid bilayer formed. In the future it could be relevant to repeat the CGMD 
self-assembly simulations to determine if the lipid-free apoA-I starting structure was 
suitable and if the protein self-association occurs in multiple repeats.  
However, in the model described below of a 9.6 nm discoidal HDL R173C nanoparticle 
the N-termini residues 1-65 are folded back at residue G39 (Gursky et al., 2013). In this 
work residue G39 is in Figure 7.6B (grey, residues 34 – 43) and does not appear to act 
as a defined residue specific “hinge region” but does fold with H1 to allow the N-termini 
fold back and self-associate. Gursky et al. have produced apoA-I R173C “double-belt” 
discoidal HDL nanoparticle models based upon the apoA-I WT Δ(185-243) and C-
terminal residues of apoA-I Δ(1-43) crystal structures combined with cross-linking data 
(Gursky et al., 2013). The AAMD equilibration of a preformed bilayer nanodisc of 178 
POPC lipids and a “double-belt” model of the apoA-I R173C dimer remained stable 
throughout a 15 ns equilibration period of a 9.6 nm HDL R173C nanoparticle (Gursky 
et al., 2013).  
Hence, the removal of the N-terminal region may not be necessary but further 
refinement of the starting structure of the apoA-I R173C dimer is required such as the 
method used by Gursky et al. (Gursky et al., 2013). Another aspect of their method used 
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a more biased starting conformation with a preformed “belt-like” structure of the apoA-
I R173C dimer and lipid nanodisc (Gursky et al., 2013).  
Overall, in both CGMD simulations a relatively energetically stable state was observed 
in the “HDL-like” nanoparticles with only minor tertiary protein conformation changes 
after the initial self-assembly and incorporation of the lipids into a bilayer/micellar 
arrangement. This occurred very early in each simulation at ~140 and ~375 ns which 
suggested the starting protein conformation could require further refinement. For 
example, utilising a model based upon the higher resolution crystal structure of apoA-I 
WT Δ(185-243) (Gursky et al., 2013; Mei and Atkinson, 2011). As well as, using 
different starting lipid conformations such as micellar, random or as a preformed 
nanodisc (Debnath and Schäfer, 2015; Gursky et al., 2013; Shih et al., 2006; Shih et al., 
2007a; Shih et al., 2007b). 
In this work the CGMD simulations demonstrated the hydrophobic effect in self-
assembly of the “HDL-like” nanoparticles and the interactions between the amphipathic 
α-helices of the respective apoA-I proteins and the phospholipids.  
During the course of this work Pourmousa et al. produced the multi-microsecond (10 – 
20 µs) AAMD simulation models of the HDL nanoparticles containing 
POPC:cholesterol:apoA-I WT 200:20:2 and 160:24:2 (M/M) (Chapter 1, Figure 1.15). 
The atomistic definition allowed for secondary structure changes and tertiary apoA-I 
structural conformation rearrangements (Pourmousa et al., 2018). Importantly, the 
simulations required the long timescales of 10 – 20 µs to converge suggesting future 
AAMD simulations should use similar timescales (Pourmousa et al., 2018). 
Consequently, the oriented 31P NMR HDL nanoparticle morphology characterisation 
utilised the atomistic HDL nanoparticle models (Chapter 6). Furthermore, some of the 
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details provided by the AAMD simulations are required to show the rHDL nanoparticles 
self-assemble.  
A comparative AAMD HDL 200:20:2 nanoparticle 10 µs simulation with an initial 
uneven apoA-I double-belt became kinetically trapped and produced a different final 
HDL apoA-I conformation with a statistically equivalent average shape to the model 
used in Chapter 6 (Pourmousa and Pastor, 2018). This demonstrated the starting 
conformation of apoA-I was highly important and suggested further research is required 
to produce different starting conformations of the apoA-I mutants.  
Overall, due to the limited success and time available for the CGMD simulations further 
work was not explored. There are several enhanced sampling options discussed by 
Pourmousa and Pastor (Pourmousa and Pastor, 2018) available for producing different 
apoA-I conformations such as replica exchange MD (Sugita and Okamoto, 1999) or the 
use of MDSA for HDL nanoparticle simulations (Jones et al., 2011). These could be 
explored in future work. 
Little is known about the apoA-I L144R mutant monomer or dimer arrangements in 
discoidal rHDL nanoparticles. The residue L144 could be mutated in both monomers 
of the full-length apoA-I WT dimer in the 200:20:2 HDL nanoparticle model 
(Pourmousa et al., 2018) to provide a framework for testing a shifted monomer to 
monomer registry. Furthermore, chemical cross-linking experiments combined with 
mass spectrometry of apoA-I L144R in discoidal rHDL nanoparticles could provide 
specific structural constraints to support different monomer registries such as LL5/5 or 
LL5/2 for apoA-I WT (Silva et al., 2005b). Overall, future AAMD simulations 
combined with experimental data would provide residue specific structural information.  
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7.4.2 Evaluation of the BODIPY-CE efflux assay 
This work explored the use of BODIPY-CE to monitor efflux to ApoA-I WT and 
mutants from THP-1 macrophages. The use of confocal microscopy and flow cytometry 
to detect the fluorescently labelled BODIPY-CE inside THP-1 macrophages showed 
that the conditions for cellular uptake were successful (Liu et al., 2014; 
Sankaranarayanan et al., 2011).  
Initially the cholesterol efflux was examined for LF apoA-I WT concentrations between 
10 – 100 µg/mL. The efflux was mainly observed for cells equilibrated with cAMP and 
did not increase significantly at protein concentrations above 25 µg/mL. Previously, LF 
apoA-I ABCA1-mediated cholesterol efflux plateaued above ~10 µg/mL protein 
concentration (Sankaranarayanan et al., 2011). However, it became apparent that further 
controls are necessary for calculating the cholesterol efflux such as background efflux. 
As well as the effect of cAMP on ABCA1-mediated cholesterol efflux in THP-1 
macrophages.  
In the limited time available for the functional studies BODIPY-CE efflux from THP-1 
macrophages was compared between LF apoA-I WT and the atheroprotective apoA-I 
mutants at two excess concentrations. Although efflux was observed in the apoA-I WT 
and L144R 8 hr incubation period samples the measurements contained large standard 
deviations. Furthermore, efflux was not detected for the apoA-I R173C samples which 
was unexpected compared to previous studies of LF apoA-I and rHDL-R173C 
nanoparticles (Calabresi et al., 1999; Zhu et al., 2005).  
Taken together this suggested the assay conditions required further testing to produce 
reproducible and reliable results. In future work the cholesterol efflux calculations 
which included the background efflux as controls and the equilibration period t0 MFI 
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(Equations [19]-[20], Figure 7.14B) could be used to provide a more reliable efflux 
calculation. 
Further experimental conditions were not tested due to the limited time available. 
However, there are several factors which require further research and understanding 
before examining the cholesterol efflux of different apoA-I bearing cholesterol 
acceptors.  
Notably, the use of BODIPY-CE rather than BODIPY-cholesterol could have affected 
the efflux observed. Further research after experiments indicated that in macrophages 
CE’s require hydrolysis into fatty acids and cholesterol by cholesterol ester hydrolase 
before free cholesterol efflux (Ghosh et al., 2010). This suggested the detection of the 
fluorophore in the THP-1 macrophages in the cells could be due to retained BODIPY-
tagged fatty acids or BODIPY-CE molecules (Solanko et al., 2016). Additionally, the 
ABCA1-mediated cholesterol efflux from THP-1 macrophages can be regulated by an 
intracellular macrophage liver X receptor agonist not cAMP (Costet et al., 2000; Kiss 
et al., 2005; Yano et al., 2016).  
Overall, further research was required to determine accurate cholesterol efflux values 
from cholesterol loaded THP-1 macrophages. An analysis of the limitations in the 
methodology suggested changes in the fluorophore used and ABCA1 up-regulation 
compound were necessary. As well as appropriate controls and cholesterol efflux 
calculations in the flow cytometry fluorescence detection. This is essential to compare 
the cholesterol efflux properties of LF or rHDL-bound apoA-I mutants in the search for 
clues in determining how the apoA-I mutants could be atheroprotective.  
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7.4.3 Amyloidogenic potential of the atheroprotective apoA-I mutants 
The increased ThT fluorescence of each apoA-I protein under amyloidogenic conditions 
suggested the atheroprotective mutants were similarly susceptible to aggregation 
compared to apoA-I WT. The lack of an increase in ThT fluorescence in samples at pH 
7.0 with and without heparin was similar to previous studies for apoA-I WT and R173C 
(Petrlova et al., 2014; Townsend et al., 2017). The apoA-I samples did not increase in 
fluorescence over the timescale measured (60 minutes) at pH 4.6. This difference could 
be due to sample incubation before fluorescence measurements were taken (Ramella et 
al., 2011; Townsend et al., 2017). As shown previously, aggregation is enhanced by the 
presence of heparin at acidic pH consistent with proinflammatory conditions.  
These initial results suggest that resistance to amyloid formation is unlikely to be a 
major reason for the atheroprotective properties of apoA-I R173C or L144R. 
The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
338  Sophie Lau - July 2021 
8 Discussion and future work 
Overall, the research in this thesis aimed to investigate the structural and functional 
properties of rHDL nanoparticles containing apoA-I WT, R173C or L144R, to 
understand how the atheroprotective apoA-I mutants could affect reverse cholesterol 
transport and atherosclerosis.  
8.1 ApoA-I mutant protein expression 
In this work the apoA-I R173C and L144R point mutations in the apoA-I WT (E2D) 
PNFXex vector were produced using SLIM-PCR. The recombinant atheroprotective 
mutants were expressed with the previously established apoA-I WT (E2D) expression 
methods (Oda et al., 2001; Ryan et al., 2003; Townsend, 2016). Both mutations were 
confirmed with gene sequencing and ESI-TOF MS confirmed the correct molecular 
weight for the apoA-I L144R mutant only.  
A key step in the apoA-I R173C protein expression was the identification of the apoA-
I C173 post-translational modification, the glutathione adduct (Sengupta and 
Udgaonkar, 2017). In this work, the apoA-I R173C protein after his-tag cleavage was 
incubated with a reducing agent (TCEP) to cleave the glutathione adduct. Upon removal 
of TCEP monomeric and dimeric disulphide bonded apoA-I R173C formed, and the 
correct MW’s were confirmed by SEC separation followed by ESI-TOF MS.  
Overall, the average yield of the apoA-I mutants was suitable for routine expression and 
formation of rHDL nanoparticles. The expression of recombinant apoA-I L144R and 
R173C enabled the formation of rHDL-R173C and rHDL-L144R nanoparticles for the 
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first direct comparison of both mutants to rHDL-WT nanoparticles. In particular, 
isotopically labelled [13C, 15N]-apoA-I WT, R173C and L144R were expressed which 
allowed for solid-state NMR studies in Chapter 5. The expression yields for the 
atheroprotective mutants rHDL nanoparticle production at ~32 mg/L of culture media 
was in excess for analysing the samples using CD and 31P oriented SS NMR. However, 
significant scaling of the [13C, 15N]-labelled apoA-I R173C and WT recombinant 
protein expressions were required for the 2D 13C-13C dipolar correlation spectra analysis 
of lipid-bound apoA-I. It was important to establish the expression of both full-length 
apoA-I mutants to produce discoidal rHDL nanoparticles containing apoA-I that reflects 
the structural features of plasma HDL.  
The primary limitation of the apoA-I R173C expression was precipitation of the protein 
during the removal of the glutathione moiety. Therefore, further work could explore the 
optimisation of the apoA-I R173C TCEP reduction protocol and subsequent apoA-I 
R173C dimer formation. This could be achieved by limiting the protein concentration 
to < 0.1 mg/mL in the TCEP reduction to prevent precipitation due to oligomerisation. 
As apoA-I R173C could behave similarly to apoA-I WT and form concentration 
dependent oligomers (Davidson et al., 1996; Giudice et al., 2017; Oda, 2017; Petrlova 
et al., 2016). After TCEP removal this would require subsequent concentration of the 
sample by spin concentration or lyophilisation. Another option would be addition of a 
buffer additive such as salts like 0.15 M NaCl (Bagby et al., 2001) to increase the apoA-
I R173C solubility in solution during TCEP reduction and removal by dialysis.  
Further work for both apoA-I L144R and R173C proteins could be to increase the 
expression yield (~30 mg/mL) to that of apoA-I WT, up to 100 mg/mL. This could be 
achieved by changing the E. coli competent cell type to a different strain such as 
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BL21(DE3) Tuner™ (Novagen) to induce IPTG concentration dependent protein 
expression (Khlebnikov and Keasling, 2002; Rosano and Ceccarelli, 2014).  
8.2 rHDL nanoparticle production  
Initially, rHDL-WT 200:2 nanoparticles were prepared using the sodium cholate 
dialysis method (Jonas, 1986) and two different methods for size fractionation were 
compared, SEC and density-based UTC. Density-based UTC was chosen as the method 
to isolate the major rHDL-WT nanoparticle population with a diameter between 8.6 – 
9.8 nm according to NDGGE. Both types of density-based UTC fractionation separated 
the rHDL nanoparticles from lipid-free apoA-I and SG-UTC had the highest yield of 
the major rHDL-WT particles. Therefore, the rHDL nanoparticles were prepared via 
detergent-mediated dialysis followed by primarily SG-UTC. Importantly, this 
established a method for analysing the rHDL nanoparticles apoA-I secondary structure 
with circular dichroism and solid-state NMR.  
It would be useful to optimise the yield of rHDL nanoparticle production. The yield of 
~32 % was comparable to an rHDL-C purification (~33%) (Cavigiolio et al., 2008). 
However, this yield is below 50 % and results in apoA-I protein loss. It would be 
advantageous to increase the yield of rHDL nanoparticles to avoid loss of recombinant 
apoA-I and for further characterisation. In particular labelled protein expressions for SS 
NMR analyses are expensive so minimising protein loss could be included in future 
work.  
Reconstituted HDL-R173C and L144R nanoparticles were produced at the 200:2 molar 
ratio for a direct comparison to the rHDL-WT nanoparticles. Reconstituted HDL-C WT 
nanoparticles were prepared at POPC:apoA-I WT molar ratios between 160:16:2 – 
300:30:2, with respective diameter ranges according to NDGGE between 8.7 – 9.3 nm 
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and 9.3 – 10.1 nm. rHDL-C R173C nanoparticles were prepared at the 
POPC:cholesterol:apoA-I 190:10:2 molar ratio. Whilst the rHDL-C L144R 
nanoparticles were prepared at the 190:10:2 and 200:20:2 molar ratios.  
NDGGE was used to determine the major particle population hydrodynamic diameter 
range of each type of rHDL, and rHDL-C nanoparticles produced. The differences 
between the hydrodynamic measurements according to NDGGE and DLS suggested 
further investigation was required to understand the rHDL nanoparticle structure, 
specifically, the rHDL-L144R 200:2 nanoparticles.  
This work focussed on rHDL nanoparticles similar to plasma HDL nanoparticles of a 
similar size (see Chapter 4, section 4.1.4, Table 4.1, and references therein). The 
rHDL nanoparticles with and without cholesterol were produced containing apoA-I 
WT, R173C or L144R, with comparable major particle population diameters according 
to NDGGE between ~8.6 – 10.1 nm, and without the presence of lipid-free apoA-I. The 
production of similar size distributions of rHDL nanoparticles containing apoA-I 
R173C or L144R allowed for molecular level structural comparisons to rHDL-WT 
nanoparticles, specifically the lipid, cholesterol, and apoA-I organisation.  
Regardless of producing reasonably homogeneous rHDL nanoparticle populations for 
structural and functional characterisation, the size fractionation of the rHDL 
nanoparticles could be improved. This could be achieved with more rigorous fraction 
selection, i.e., a smaller fraction volume, or sequential Fl-UTC followed by SG-UTC 
(Chen et al., 2009). Another method has used KBr ultracentrifugation to remove lipid-
free apoA-I followed by size-exclusion chromatography which produced fractionated 
rHDL-C nanoparticle populations with a smaller SD as measured by TEM (Cavigiolio 
et al., 2008).  
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Further size measurements of rHDL nanoparticles containing apoA-I R173C and 
L144R with the nanodisc face perpendicular to the TEM grid are required. This could 
use the protocol established in this work such as the rHDL-WT 200:2 nanoparticles at 
the 9 µM protein concentration which suggested concentration dependent rouleaux 
formation, or with the optimised negative stain uranyl formate protocol (Zhang et al., 
2011). It became apparent that multiple size measurement techniques are required to 
determine the rHDL nanoparticle size as the hydrodynamic diameter measurements 
differed from each other (NDGGE, DLS) or dried negatively stained nanoparticles 
(TEM).  
8.3 rHDL nanoparticle structure 
After the production of rHDL nanoparticles was established the analysis of the apoA-I 
secondary structure, lipid and cholesterol organisation was performed using circular 
dichroism and solid-state NMR.  
8.3.1 The structure of apoA-I in rHDL nanoparticles 
The average secondary structure and thermal stability of apoA-I in rHDL nanoparticles 
was determined using circular dichroism combined with secondary structure estimation. 
The apoA-I L144R and R173C mutants had a lower thermal stability relative to apoA-
I WT in rHDL nanoparticles. The difference in melting temperatures suggested minor 
structural differences in the atheroprotective mutants respective secondary structures. 
Overall, the thermal stability and secondary structure estimations of lipid-free and 
rHDL-bound apoA-I proteins were similar to current literature values (see Chapter 5, 
section 5.3.1.1, Table 5.4).  
The average α-helical content increased in lipid-bound apoA-I WT and R173C which 
has similar SSEs overall. Surprisingly, the rHDL apoA-I L144R SSE had an α-helical 
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content similar to lipid-free apoA-I L144R and an increased estimation of unordered 
content relative to apoA-I WT and R173C in rHDL. Therefore, high-resolution SS 
NMR spectra of isotopically labelled apoA-I in rHDL nanoparticles were obtained to 
further identify structural differences.  
This is the first study that has directly compared the full-length protein conformations 
of apoA-I L144R and R173C mutants to apoA-I WT rHDL nanoparticles and the 
utilisation of solid-state NMR to examine structural differences in both apoA-I mutants.  
The high-resolution 13C-13C CP MAS spectra of uniformly labelled apoA-I mutants in 
rHDL nanoparticles confirmed subtle structural differences between the apoA-I 
structure of both mutants relative to apoA-I WT and each other.  
The multi-microsecond AAMD model of the nascent discoidal HDL-WT 200:20:2 
nanoparticle (Pourmousa et al., 2018) was used as comparison to the rHDL 
nanoparticles in this work. The AAMD “double-belt” model showed the tertiary 
conformation of apoA-I WT was not rigidly planar when wrapped around the bilayer 
nanodisc, with the terminal domains moved away from being perpendicular to the 
nanodisc bilayer normal (Pourmousa et al., 2018).  
Similarities were observed in the PEG-precipitated rHDL-WT 200:2 and simulated 
HDL-C WT 200:20:2 nanoparticle (Pourmousa et al., 2018) 2D 13C-13C dipolar 
correlation and the PISEMA spectra cross-peaks. This suggested the apoA-I WT 
conformation in the rHDL-WT nanoparticles was similar to the 200:20:2 HDL model 
with apoA-I predominantly perpendicular to the phospholipid bilayer nanodisc normal 
(Lau and Middleton, 2020). However, this requires further evidence as discussed in 
Chapter 5. To confirm the orientation of the apoA-I α-helices relative to the nanodisc 
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phospholipid bilayer normal a simulated PISEMA spectrum where the apoA-I helices 
are parallel to the bilayer normal could be produced.  
The absence of large structural differences in the secondary structure of rHDL-bound 
apoA-I R173C and L144R did not immediately suggest why there are functional 
differences or lack of atherosclerosis incidence in carriers of the respective mutations.  
A recent functional study showed a ~70 % and ~40 % reduction in LCAT activation 
and SR-B1 mediated cholesterol efflux by rHDL-C L144R 200:20:2 nanoparticles 
compared to rHDL-C WT nanoparticles (Gkolfinopoulou et al., 2020). This supported 
the reduced LCAT activation detected in a mouse model (Haase et al., 2011). Whilst 
the ABCG1-mediated cholesterol efflux was similar between the rHDL-C WT and 
L144R nanoparticles (Gkolfinopoulou et al., 2020).  
Therefore, the minor structural differences detected in this work could be related to the 
reduced rHDL-L144R nanoparticle function in LCAT activation and SR-B1-mediated 
cholesterol efflux as the L144R mutation is located in helix 6, residues 143-164 which 
are associated with LCAT activation (Gkolfinopoulou et al., 2020; Haase et al., 2011; 
Sorci-Thomas et al., 1993).  
Perhaps, the reduced LCAT activity in apoA-I L144R carriers is related to a shifted 
interhelical registry between the two monomers in discoidal HDL nanoparticles. This 
would be similar to the apoA-I R173C dimer shifted registry in discoidal HDL due to 
the intermonomer disulphide bond (Klon et al., 2000), which was suggested to 
contribute to reduced LCAT activation with rHDL-C R173C nanoparticles (Calabresi 
et al., 1997a).  
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Different subtle structural differences were detected when the rHDL-WT 200:2 2D 13C-
13C dipolar correlation spectra was compared to the respective rHDL-L144R and rHDL-
R173C spectrum. This suggested there are different apoA-I structural conformational 
changes in each apoA-I mutant relative to apoA-I WT and each other. Further 
experiments are suggested below that could identify the residue-specific structural 
differences in the apoA-I mutants with respect to apoA-I WT in rHDL nanoparticles. 
This would enhance our understanding of how the HDL nanoparticle functions in RCT 
could be affected by structural changes in the rHDL apoA-I conformation.  
To resolve the subtle structural differences detected in apoA-I of the rHDL-R173C and 
rHDL-L144R nanoparticles further SS NMR studies to obtain residue-specific cross-
peaks for secondary structure assignment in high-resolution 2D 13C-13C dipolar 
correlation spectra are required. This would require selective isotope labelling of 
specific residue methyl groups such as valine, leucine, and threonine, produced by 
expressing recombinant apoA-I in E. coli auxotrophs (Lin et al., 2015; Lin et al., 2011; 
Monneau et al., 2016).  
The limitation of CD secondary structure estimation is that it addressed only average 
global secondary structure conformational changes. To elucidate additional lipid-bound 
apoA-I dimer structural information, in particular for apoA-I L144R, chemical cross-
linking combined with MS could reveal inter- and intramolecular cross-links between 
apoA-I monomers in rHDL nanoparticles as demonstrated with discoidal rHDL-WT 
(Silva et al., 2005b) and rHDL-R173C nanoparticles (Bhat et al., 2010). This could 
provide evidence to determine if the apoA-I L144R mutant dimer retains or has a 
different interhelical registry compared to apoA-I WT in discoidal rHDL. This could 
lead to the development of a proposed model for dimeric apoA-I L144R in different 
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sized discoidal rHDL nanoparticles as previously demonstrated with apoA-I WT and 
R173C (Bhat et al., 2010; Gursky et al., 2013; Silva et al., 2005b).  
8.3.1.1 rHDL nanoparticle morphology 
The subtle structural differences in the rHDL apoA-I protein structure, according to CD 
and PEG-precipitated rHDL SSNMR spectra, suggested there could be other reasons 
for the functional differences observed in carriers of the apoA-I mutations. The work in 
Chapter 6 described the development and optimisation of a novel technique to detect 
three distinct morphologies of rHDL nanoparticles using 31P oriented SS NMR (Lau 
and Middleton, 2020). This expanded upon the theory developed by Picard et al. for 
determining the shape of an oriented phospholipid bilayer for an ellipsoid or bicelle 
using 31P SS NMR spectra (Picard et al., 1999).  
This is significant as it has provided detailed information about the surface curvature of 
the phospholipid headgroups, and in turn the lipid distribution in three discoidal rHDL 
nanoparticle morphologies. The rHDL-WT and R173C 200:2 nanoparticles had a planar 
disc morphology like the “double-belt” model of discoidal HDL (Segrest et al., 1999).  
The “discoidal” rHDL-L144R 200:2 broad asymmetric lineshape fit the hemispheroid 
approximation, in which the lipid surface curvature approaches an ideal spherical 
particle, with a concave and convex face of the nanodisc. This is supported by the 
200:20:2 AAMD HDL-C model which has concave and convex nanodisc faces 
(Pourmousa et al., 2018). As demonstrated by simulating lineshapes for the AAMD 
200:20:2 HDL model in this work, this technique can provide an experimental detection 
of the rHDL morphology to compare to proposed variations of the planar “double-belt” 
model of nanoparticles. For example, smaller “saddle-shaped” particles at component 
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molar ratios <160:±24:2, which were supported by TEM only, to confirm the 
computational structures (Catte et al., 2006; Gu et al., 2010; Pourmousa et al., 2018).  
The differences in the morphologies could explain the variation in the size 
measurements of the rHDL nanoparticles. The small rHDL-L144R hydrodynamic 
diameter (~6.5 nm) according to DLS may more accurately reflect the nanoparticle 
diameter due to surface curvature of the lipid nanodisc. Whereas, the planar disc rHDL-
WT and R173C nanoparticle diameters could be overestimated with a spherical particle 
approximation (Eiser, 2014).  
This is a new tool which can assess the morphological differences of rHDL 
nanoparticles prepared with atheroprotective apoA-I R173C or L144R. Significantly, 
the morphological detection technique could be used to assess the nanoparticle 
morphology in clinical plasma HDL samples, as demonstrated with an unfractionated 
plasma HDL sample.  
Future work could expand to the cholesterol component of the rHDL-C nanoparticles, 
with isotopically [13C]-labelled cholesterol to detect the orientation of cholesterol 
molecules in oriented rHDL-C nanoparticles to determine the cholesterol distribution. 
This could aid the understanding of how cholesterol is incorporated into the discoidal 
rHDL nanoparticles. For example, in the rHDL-C WT torus disc morphology the outer 
lipids are angled further from the bilayer normal due to an increased lipid and 
cholesterol content. It would be interesting to see if rHDL-C nanoparticles containing 
apoA-I L144R or R173C at similar component molar ratios showed a similar torus disc 
morphology. If the morphology of rHDL-C mutant particles was different this could 
reflect differences in lipid transfer (Lau and Middleton, 2020), enhanced 
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accessibility/availability of cholesterol for enzymes such as CETP or SR-B1 (Liadaki 
et al., 2000; Qiu et al., 2007).  
The technique could be applied to the morphology of rHDL ±cholesterol and each 
apoA-I variant of different rHDL and plasma HDL size populations between 5 – 17 nm 
in diameter (Cavigiolio et al., 2008; Rosenson et al., 2011). A comprehensive 
comparison of various sizes and compositions would provide morphological similarities 
and differences between rHDL-WT, R173C and L144R nanoparticles. Future work with 
respect to the functional implications of structural differences is described in the 
following section.  
8.4 Molecular dynamics, cholesterol efflux and 
amyloidogenicity 
The future work for the computational and functional experiments were suggested in 
Chapter 7, therefore further suggestions are briefly discussed here. The conditions for 
self-assembly CGMD simulations containing full-length apoA-I R173C or apoA-I WT 
were examined and required improvement.  
Further work could involve testing simulation setups such as a biased simulation setup 
with a preformed phospholipid nanodisc and a more planar restricted apoA-I Δ(1-43) 
(Borhani et al., 1997) conformation (Siuda and Tieleman, 2015). As well as, the 
refinement of, or alternative models of the starting full-length protein structure based 
upon the higher resolution apoA-I WT Δ(185-243) crystal structure (Mei and Atkinson, 
2011). The molecular dynamics parameters could be tested by attempting to reproduce 
a control self-assembly CGMD simulation of 160 DMPC phospholipids and two apoA-
I Δ(1-65) monomers (Debnath and Schäfer, 2015). 
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The rHDL-mediated cholesterol efflux assay required further improvements as 
described in Chapter 7. The in vitro cholesterol efflux could assess the cholesterol 
influx with HepG2 cells (Zhiping et al., 2003) from BODIPY-CE loaded rHDL 
nanoparticles with flow cytometry and confocal microscopy.  
The ThT assay of lipid-free apoA-I WT and the atheroprotective mutants suggested the 
mutants were not resistant to amyloid fibril formation under conditions mimicking a 
proinflammatory environment. Dysfunctional HDL nanoparticles can form when apoA-
I is oxidised by myeloperoxidase in atherosclerotic plaques (Nicholls et al., 2005). 
Specifically, apoA-I methionine oxidation of apoA-I occurs in atherogenic conditions 
and results in oxidised lipid-free apoA-I WT amyloid fibril formation (Townsend et al., 
2017).  
In rHDL containing plasma apoA-I WT nanoparticles oxidation of apoA-I methionine 
residues resulted in reduced particle stability (Jayaraman et al., 2008). Further 
experiments could compare the resistance of the apoA-I mutants to oxidation, or the 
stability of oxidised apoA-I mutants in rHDL nanoparticles compared to oxidised apoA-
I. The rHDL nanoparticle structural stability could be determined with thermal CD and 
ThT assays of both lipid-free and rHDL-bound apoA-I proteins (Jayaraman et al., 2008; 
Townsend et al., 2017).  
8.5 Summary 
In conclusion, this work has compared the structure of rHDL nanoparticles containing 
full-length apoA-I WT, R173C or L144R with a focussed approach using circular 
dichroism and SS NMR to examine the protein, lipid, and cholesterol constituents. The 
apoA-I secondary structure characterisation of the respective apoA-I mutant 
nanoparticles detected structural differences compared to rHDL-WT nanoparticles. 
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This suggested there are structural differences in apoA-I, the major HDL protein, that 
could have functional consequences in RCT.  
This work has established a sensitive novel method for determining three different 
rHDL nanoparticle morphologies using 31P oriented SS NMR. This has allowed for 
direct experimental observation of the lipid distribution in rHDL nanoparticles which 
were not detected by conventional TEM. Importantly, this included a plasma HDL 
sample which could be fractionated in the future to analyse the morphology of clinical 
plasma samples.  
There are many questions to be answered to gain a greater understanding of the low 
incidence of atherosclerosis in carriers of the mutants and inform atherosclerosis 
treatment, with several avenues for further structural and functional studies of rHDL 
nanoparticles containing apoA-I L144R or R173C.  
Recent literature has suggested improvements to the approach of rHDL-infusion 
therapy (Darabi et al., 2016; Kingwell et al., 2014). This could include the use of rHDL 
nanoparticles as a molecular drug carrier for combined therapeutic treatment with rHDL 
containing drugs such as statins (Duivenvoorden et al., 2014; Lau et al., 2019). This 
could also be applied to drug molecules that can treat other diseases in the body as rHDL 
nanoparticles are well-tolerated in the body as demonstrated by clinical trials (Darabi et 
al., 2016; Kingwell et al., 2014; Simonsen, 2016). This could also include changing the 
lipid content to obtain protective functions such as anti-oxidative and anti-inflammatory 
effects (Darabi et al., 2016).  
Reverse cholesterol transport is a complex system which involves a variety of cell 
receptors and enzymes (Fisher et al., 2012; von Eckardstein et al., 2001). Therefore, a 
direct comparison of the atheroprotective apoA-I mutants in rHDL with rHDL-WT 
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nanoparticles will require further testing to compare their interactions with enzymes in 
RCT, such as LCAT (Calabresi et al., 1997a; Sorci-Thomas et al., 1993), CETP (Qiu et 
al., 2007) and cell receptors such as ABCA1 (Sahoo et al., 2004; Sankaranarayanan et 
al., 2011). 
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Appendices 
Appendix 1 
The cDNA and amino acid sequences of recombinant human apoA-I. A) The his6-tag 
(purple) and first 3 amino acid residues of the apoA-I sequence without the E2D 
mutation (Oda et al., 2001), the ellipses refer to the continued sequence in (B) from the 
4th residue. The 2nd amino acid residue is indicated in green. B) The apoA-I (E2D) 
sequence (Ryan et al., 2003), adapted from (Townsend, 2016). The E2D mutated 
residue and formic acid his-tag cleavage site (D/P) (green), L144 (blue), R173C (red), 
underlined new restriction endonuclease sites (solid), and optimised E. coli abundance 
codons (dashed). The superscript numbers indicate the amino acid residue number in 
the full-length apoA-I WT protein. 
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The pBluescript KS (+) plasmid (2958 bp) was discontinued (Addgene), therefore the 
pBluescript II KS (+) plasmid map (2961 bp) obtained from Addgene is shown with the 
cloning/expression region (bp 598-826) obtained from Agilent.  
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Original gene sequencing data before translation to amino acid sequence using ExPASy 
translate tool.  
The re-isolated and sequenced apoA-I R173C plasmid from (Townsend, 2016). 
Nucleotide BLAST® results compared to apoA-I WT (E2D) sequence 477/579 
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The pre- and post- his-tag cleavage gels for apoA-I R173C and L144R showing the 
cropped, duplicate sample and empty lanes removed.  
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Appendix 2 
Original data of mass % of NaBr in solution and the corresponding densities (g/mL) 
from the Handbook of Chemistry and Physics (Haynes, 2010). 
Mass (%) Density (g/mL) Mass (%) Density (g/mL) 
0.5 1.0021 16 1.1352 
1 1.006 18 1.1546 
2 1.0139 20 1.1745 
3 1.0218 22 1.1951 
4 1.0298 24 1.2163 
5 1.038 26 1.2382 
6 1.0462 28 1.2608 
7 1.0546 30 1.2842 
8 1.063 32 1.3083 
9 1.0716 34 1.3333 
10 1.0803 36 1.3592 
12 1.0981 38 1.386 








The Structure-Function Relationship of Atheroprotective ApoA-I Mutants in High-Density Lipoproteins 
384  Sophie Lau - July 2021 
The NaBr mass (%) and the corresponding density (g/mL) original data (Haynes, 2010) 
and linearly interpolated values using Origin 2018 software. 
 
NaBr SG-UTC density solutions (g/mL) and the corresponding mass (%) and mass in 
grams for a 10 mL total volume. 
Density (g/mL) NaBr Mass (%) NaBr Mass (g) 
1.0404 5.2879 0.5288 
1.0952 11.6717 1.1672 
1.1513 17.6566 1.7657 
1.2125 23.6414 2.3641 
1.3037 31.6212 3.1621 
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Appendix 3 
The average chemical shifts of amino acids by secondary structure. Data obtained and 
table adapted from (Wang and Jardetzky, 2002). β-strand (β), random coil (RC), α-helix 
(α). 13Cα and 
13Cβ, and 
13C’ are the labelled carbon atoms in the amino acid R group, 
and the polypeptide backbone, respectively.  
Amino 
acid 
13Cα 13Cβ 13C’ 
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Appendix 4 
ApoA-I R173C dimer RMSD CGMD ~6.6 µs (A) RMSD of the protein backbone with 
a least-squares fit to the equilibrated protein backbone. (B) The radius of gyration of 
the protein in the CGMD simulation. 
 
 
ApoA-I WT Δ(1-43) chains A and B RMSD CGMD ~8.9 µs (A) RMSD of the protein 
backbone with a least-squares fit to the equilibrated protein backbone. (B) The radius 
of gyration of the protein in the CGMD simulation. 
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ThT Fluorescence assay controls: ThT only, apoA-I WT, R173C and L144R without 
ThT in McIlvaine buffer, pH 7.0.  
 
 
